<!DOCTYPE drug_guide PUBLIC "-//ES//DTD drug_guide DTD version 3.1//EN//XML" "Y:\WWW1\tools\Drugs\3_1_drug.dtd">
<drug_guide isbn="9780323448260">
	<alpha letter="m">
		<monograph id="1" status="active">
			<mono_name>macitentan</mono_name>
			<info>
				<pronunciation>(ma′si-ten′tan)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x210">Opsumit</tradename>
				</tradenames>
				<class type="func"> Antihypertensive</class>
				<class type="chem"> Vasodilator/endothelin receptor antagonist</class>
				<class type="preg">Pregnancy category <preg cat="X">X</preg></class>
			</info>
			<section type="actions" id="sidelem4x32">
				<sec_title>Action:</sec_title>
				<para>Prevents the binding of ET-1, to ETA and ETB receptors on human pulmonary arterial smooth muscle</para>
			</section>
			<section type="uses" id="sidelem4x37">
				<sec_title>Uses:</sec_title>
				<para>Pulmonary arterial hypertension; WHO Group 1 to delay disease progression</para>
			</section>
			<section type="contra" id="sidelem4x42">
				<sec_title>Contraindications:</sec_title>
				<para>Pregnancy (<preg cat="X">X</preg>), breastfeeding, hypersensitivity</para>
				<section type="none" id="sidelem4x47">
					<section type="none" id="sidelem4x48">
						<sec_title>Precautions:</sec_title>
						<para> Anemia, hepatic disease, pulmonary edema</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x53">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x61">
					<label>•</label>
					<sec_title>Adult<route> PO</route></sec_title>
					<para>
						<list id="lidelem4x61">
							<item>
								<label>•</label>
								<para> 10 mg/day</para>
							</item>
						</list>
					</para>
				</section>
				<section type="none" id="sidelem4x65">
					<section type="none" id="sidelem4x66">
						<sec_title>Available forms:</sec_title>
						<para> Tabs 10 mg</para>
					</section>
					<section type="none" id="sidelem4x71">
						<sec_title>Administer:</sec_title>
						<para>
							<list id="lidelem4x75">
								<item>
									<label>•</label>
									<para>Do not break, crush, chew tabs, without regard to food; if a dose is missed, then take when remember to (do not take more than one tab per day)</para>
								</item>
								<item>
									<label>•</label>
									<para>Do not discontinue abruptly</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x86">
				<sec_title>Side effects:</sec_title>
				<section type="none" id="sidelem4x89">
					<section type="none" id="sidelem4x90">
						<sec_title>CNS:</sec_title>
						<para> Headache</para>
					</section>
					<section type="none" id="sidelem4x95">
						<sec_title>GI:</sec_title>
						<para> Hepatotoxicity</para>
					</section>
					<section type="none" id="sidelem4x100">
						<sec_title>GU:</sec_title>
						<para> Decreased sperm counts</para>
					</section>
					<section type="none" id="sidelem4x105">
						<sec_title>HEMA:</sec_title>
						<para> Anemia</para>
					</section>
					<section type="none" id="sidelem4x110">
						<sec_title>RESP:</sec_title>
						<para> Pharyngitis, pulmonary edema, bronchitis</para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x115">
				<sec_title>Pharmacokinetics</sec_title>
				<para>Rapidly absorbed, peak 2 hr, protein binding 99%, metabolized by CYP3A4, CYP2C19, terminal half-life 15 hr, effective half-life 9 hr</para>
			</section>
			<section type="interactions" id="sidelem4x120">
				<sec_title>Interactions</sec_title>
				<para>
					<emphasis style="bold">Increase:</emphasis> Macitentan effect CYP3A4 inhibitors</para>
				<section type="none" id="sidelem4x127">
					<section type="none" id="sidelem4x128">
						<sec_title>Drug/Herb</sec_title>
						<para>
							<list id="lidelem4x132">
								<item>
									<label>•</label>
									<para>Need for macitentan dosage change: St. John’s wort, ephedra (ma huang)</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
			<section type="considerations" id="sidelem4x138">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x141">
					<section type="none" id="sidelem4x142">
						<sec_title>Assess:</sec_title>
						<section type="none" id="sidelem4x150">
							<label>•</label>
							<sec_title>Pulmonary status</sec_title>
							<para>
								<list id="lidelem4x150">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Pulmonary status:</emphasis> improvement in breathing, ability to exercise; pulmonary edema that may indicate veno-occlusive disease</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x157">
							<label>•</label>
							<sec_title>Blood studies</sec_title>
							<para>
								<list id="lidelem4x157">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Blood studies:</emphasis> CBC with differential; Hct, Hgb may be decreased</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x164">
							<label>•</label>
							<sec_title>Liver function tests</sec_title>
							<para>
								<list id="lidelem4x164">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Liver function tests:</emphasis> AST, ALT, bilirubin
<bbw>Assess pregnancy status before giving this product; pregnancy (X), do not breastfeed</bbw>
</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x177">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x181">
								<item>
									<label>•</label>
									<para>Therapeutic response: decrease in B/P, decreased shortness of breath</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x187">
						<sec_title>Teach patient/family:</sec_title>
						<para>
							<list id="lidelem4x192">
								<item>
									<label>•</label>
									<para>The importance of complying with dosage schedule, even if feeling better
<bbw>To notify if pregnancy is planned or suspected (if pregnant, product will need to be discontinued, pregnancy test done monthly); to use 2 contraception methods while taking this product</bbw>
</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x206">
								<item>
									<label>•</label>
									<para>Not to use OTC products including herbs and supplements, unless approved by prescriber</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x211">
								<item>
									<label>•</label>
									<para>To report to prescriber immediately: dizziness, faintness, chest pain, palpitations, uneven or rapid heart rate, headache, edema, weight gain</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x216">
								<item>
									<label>•</label>
									<para>Do not split, crush, or chew tabs; if a dose is missed, take as soon as remembered (do not take more than one tab per day); there are many drug interactions</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x225">
							<label>•</label>
							<sec_title>
								<route>The signs and symptoms of hepatotoxicity</route>
							</sec_title>
						</section>
					</section>
				</section>
			</section>
		</monograph>
<monograph id="2" status="active">
			<mono_name>mafenide topical</mono_name>
			<section type="none" id="sidelem4x231">
				<para>See <see refid="tra">Appendix B</see></para>
			</section>
		</monograph>
<monograph id="2" status="active">
			<mono_name>MAGNESIUM SALTS</mono_name>
			<info>
				<tradenames>
					<tradename id="tnidelem4x2380"/>
				</tradenames>
			</info>
		</monograph>
<monograph id="1" status="active" ha="yes">
			<mono_name> magnesium sulfate (<emphasis style="smallcaps">otc</emphasis>, Rx)</mono_name>
			<info>
				<class type="func"> Electrolyte; anticonvulsant; saline laxative, antacid</class>
				<class type="preg">Pregnancy category <preg cat="A">A</preg></class>
			</info>
			<section type="actions" id="sidelem4x290">
				<sec_title>Action:</sec_title>
				<para>Increases osmotic pressure, draws fluid into colon, neutralizes HCl</para>
			</section>
			<section type="uses" id="sidelem4x295">
				<sec_title>Uses:</sec_title>
				<para>Constipation, dyspepsia; bowel preparation before surgery or exam; anticonvulsant for preeclampsia, eclampsia (magnesium sulfate); electrolyte; cardiac glycoside-induced arrhythmias, nutritional supplement</para>
				<section type="none" id="sidelem4x300">
					<section type="none" id="sidelem4x301">
						<sec_title>Unlabeled uses:</sec_title>
						<para> <emphasis style="italic">Magnesium sulfate:</emphasis> persistent pulmonary hypertension of the newborn (PPHN), cardiac arrest, CPR, digitoxin/digoxin toxicity, premature labor, seizure prophylaxis, status asthmaticus, torsades de pointes, ventricular fibrillation/tachycardia</para>
					</section>
				</section>
			</section>
			<section type="contra" id="sidelem4x309">
				<sec_title>Contraindications:</sec_title>
				<para>Hypersensitivity, abdominal pain, nausea/vomiting, obstruction, acute surgical abdomen, rectal bleeding, heart block, myocardial damage</para>
				<section type="none" id="sidelem4x315">
					<section type="none" id="sidelem4x316">
						<sec_title>Precautions:</sec_title>
						<para> Pregnancy (<preg cat="A">A</preg>); (B) (magnesium sulfate), renal/cardiac disease</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x321">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x324">
					<section type="none" id="sidelem4x325">
						<sec_title>Laxative</sec_title>
						<section type="none" id="sidelem4x333">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x333">
									<item>
										<label>•</label>
										<para> (milk of magnesia) 15-60 ml at bedtime</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x340">
							<label>•</label>
							<sec_title>Adult and child &gt;12 yr<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x340">
									<item>
										<label>•</label>
										<para> (magnesium sulfate) 15 g in 8 oz water;  (concentrated milk of magnesia) 5-30 ml;  (magnesium citrate) 5-10 oz at bedtime</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x353">
							<label>•</label>
							<sec_title>Child 2-6 yr<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x353">
									<item>
										<label>•</label>
										<para> (milk of magnesia) 5-15 ml/day</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x357">
						<sec_title>Prevention of magnesium deficiency</sec_title>
						<section type="none" id="sidelem4x365">
							<label>•</label>
							<sec_title>Adult and child ≥10 yr<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x365">
									<item>
										<label>•</label>
										<para> (male) 350-400 mg/day; (female) 280-300 mg/day; (breastfeeding) 335-350 mg/day; (pregnancy) 320 mg/day</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x372">
							<label>•</label>
							<sec_title>Child 8-10 yr<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x372">
									<item>
										<label>•</label>
										<para> 170 mg/day</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x379">
							<label>•</label>
							<sec_title>Child 4-7 yr<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x379">
									<item>
										<label>•</label>
										<para> 120 mg/day</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x383">
						<sec_title>Magnesium sulfate deficiency</sec_title>
						<section type="none" id="sidelem4x391">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x391">
									<item>
										<label>•</label>
										<para> 200-400 mg in divided doses tid-qid;  1 g q6hr × 4 doses;  5 g (severe)</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x404">
							<label>•</label>
							<sec_title>Child 6-12 yr<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x404">
									<item>
										<label>•</label>
										<para> 3-6 mg/kg/day in divided doses tid-qid</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x408">
						<sec_title>Preeclampsia/eclampsia (magnesium sulfate)</sec_title>
						<section type="none" id="sidelem4x416">
							<label>•</label>
							<sec_title>Adult<route> IM/IV</route></sec_title>
							<para>
								<list id="lidelem4x416">
									<item>
										<label>•</label>
										<para> 4-5 g IV infusion; with 5 g  in each gluteus, then 5 g q4hr or 4 g  then 1-3 g/hr  max 40 g/day or 20 g/48 hr in severe renal disease</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x429">
						<sec_title>Persistent pulmonary hypertension of the newborn (PPHN) in mechanically ventilated neonates (unlabeled)</sec_title>
						<section type="none" id="sidelem4x437">
							<label>•</label>
							<sec_title>Premature infants &gt;33 wk and term neonates</sec_title>
							<para>
								<list id="lidelem4x437">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Premature infants &gt;33 wk and term neonates:</emphasis> (magnesium sulfate) 200 mg/kg over 20-30 min, then  20-150 mg/kg/hr to maintain blood magnesium levels at 3.5-5.5 mmol/L</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x444">
						<sec_title>Status asthmaticus (unlabeled)</sec_title>
						<section type="none" id="sidelem4x452">
							<label>•</label>
							<sec_title>Adult<route> IV</route></sec_title>
							<para>
								<list id="lidelem4x452">
									<item>
										<label>•</label>
										<para> (magnesium sulfate) 2 g</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x459">
							<label>•</label>
							<sec_title>Child<route> IV INFUSION</route></sec_title>
							<para>
								<list id="lidelem4x459">
									<item>
										<label>•</label>
										<para> (PALS) (magnesium sulfate) 25-50 mg/kg diluted in D<emphasis style="inf">5</emphasis>W, given over 10-20 min, max 2 g/dose</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x466">
						<sec_title>Premature labor (unlabeled)</sec_title>
						<section type="none" id="sidelem4x474">
							<label>•</label>
							<sec_title>Adult<route> IV INFUSION</route></sec_title>
							<para>
								<list id="lidelem4x474">
									<item>
										<label>•</label>
										<para> (magnesium sulfate) 4-6 g given as a loading dose over 20-30 min, then 2-4 g/hr  use infusion pump until contractions cease; continue infusion at lowest dose over 12-24 hr;  (magnesium chloride/gluconate/oxide) 648-1200 mg/day elemental magnesium in divided doses</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x484">
						<sec_title>Torsades de pointes/cardiac dysrhythmias with hypomagnesemia (unlabeled)</sec_title>
						<section type="none" id="sidelem4x492">
							<label>•</label>
							<sec_title>Adult<route> IV</route></sec_title>
							<para>
								<list id="lidelem4x492">
									<item>
										<label>•</label>
										<para> (magnesium sulfate) use ACLS guidelines or 1-2 g in 50-100 ml D<emphasis style="inf">5</emphasis>W given over 5-20 min in emergent cases or over 5-60 min</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x499">
						<sec_title>Available forms:</sec_title>
						<para> <emphasis style="bold">Chloride:</emphasis> sus rel tabs 535 mg (64 mg Mg); enteric tabs 833 mg (100 mg Mg); <emphasis style="bold">citrate:</emphasis> oral sol 240-, 296-, 300-ml bottles (77 mEq/100 ml); <emphasis style="bold">gluconate:</emphasis> tabs 500 mg; liquid 54 mg/5 ml; <emphasis style="bold">oxide:</emphasis> tabs 400 mg; caps 140 mg; <emphasis style="bold">hydroxide:</emphasis> liq 400 mg/5 ml; concentration liq 800 mg/5 ml; chew tabs 300, 600 mg; <emphasis style="bold">sulfate:</emphasis> 500 mg/ml; premixed infusion 1 g/100 ml, 2 g/100 ml, 4 g/50 ml, 4 g/100 ml, 20 g/500 ml, 40 g/1000 ml</para>
					</section>
					<section type="none" id="sidelem4x522">
						<sec_title>Administer:</sec_title>
						<section type="none" id="sidelem4x525">
							<sec_title>PO route</sec_title>
							<para>
								<list id="lidelem4x530">
									<item>
										<label>•</label>
										<para>With 8 oz water</para>
									</item>
								</list>
							</para>
							<para>
								<list id="lidelem4x535">
									<item>
										<label>•</label>
										<para>Refrigerate magnesium citrate before giving</para>
									</item>
								</list>
							</para>
							<para>
								<list id="lidelem4x540">
									<item>
										<label>•</label>
										<para>Shake susp before using as antacid at least 2 hr after meals</para>
									</item>
								</list>
							</para>
							<para>
								<list id="lidelem4x545">
									<item>
										<label>•</label>
										<para>Tablets should be chewed thoroughly before patient swallows; give 4 oz of water afterward</para>
									</item>
								</list>
							</para>
							<section type="none" id="sidelem4x553">
								<label>•</label>
								<sec_title>Laxative</sec_title>
								<para>
									<list id="lidelem4x553">
										<item>
											<label>•</label>
											<para>
												<emphasis style="bold">Laxative:</emphasis> give on empty stomach</para>
										</item>
									</list>
								</para>
							</section>
						</section>
						<section type="none" id="sidelem4x557">
							<sec_title>IM route (magnesium sulfate)</sec_title>
							<para>
								<list id="lidelem4x561">
									<item>
										<label>•</label>
										<para>Give deeply in gluteal site</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x567">
							<sec_title>IV route (magnesium sulfate)</sec_title>
							<para>
								<list id="lidelem4x571">
									<item>
										<label>•</label>
										<para>Only when calcium gluconate available for magnesium toxicity</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x577">
							<sec_title>Direct IV route</sec_title>
							<para>
								<list id="lidelem4x581">
									<item>
										<label>•</label>
										<para>Dilute 50% sol to ≤20%, give at ≤150 mg/min</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x587">
							<sec_title>Continuous IV INFUSION route</sec_title>
							<para>
								<list id="lidelem4x591">
									<item>
										<label>•</label>
										<para>May dilute to 20% sol, infuse over 3 hr</para>
									</item>
									<item>
										<label>•</label>
										<para>IV at less than 125 mg/kg/hr; circulatory collapse may occur; use INFUSION pump</para>
									</item>
								</list>
							</para>
							<para>
								<emphasis style="bold">Y-site compatibilities:</emphasis> Acyclovir, aldesleukin, alemtuzumab, alfentanil, amifostine, amikacin, aminocaproic acid, argatroban, arsenic trioxide, ascorbic acid injection, asparaginase, atenolol, atosiban, atracurium, atropine, azithromycin, aztreonam, benztropine, bivalirudin, bleomycin, bumetanide, buprenorphine, butorphanol, calcium gluconate, cangrelor, CARBOplatin, carmustine, caspofungin, cefotaxime, cefoTEtan, cefOXitin, cefTAZidime, ceftizoxime, cephapirin, chloramphenicol, chlorproMAZINE, cimetidine, cisatracurium, CISplatin, clindamycin, clonidine, codeine, cyanocobalamin, cyclophosphamide, cytarabine, DACTINomycin, DAPTOmycin, DAUNOrubicin liposome, DAUNOrubicin, dexmedetomidine, dexrazoxane, digoxin, diltiazem, dimenhyDRINATE, diphenhydrAMINE, DOBUTamine, DOCEtaxel, dolasetron, DOPamine, doripenem, doxacurium chloride, DOXOrubicin liposomal, doxycycline, enalaprilat, ePHEDrine, EPINEPHrine, epoetin alfa, eptifibatide, ertapenem, esmolol, etoposide, etoposide phosphate, famotidine, fenoldopam, fentaNYL, fluconazole, fludarabine, fluorouracil, folic acid (as sodium salt), foscarnet, gallium, gatifloxacin, gemcitabine, gemtuzumab, gentamicin, glycopyrrolate, granisetron, heparin, HYDROmorphone, hydrOXYzine, IDArubicin, ifosfamide, imipenem-cilastatin, insulin (regular), irinotecan, isoproterenol, kanamycin, ketamine, ketorolac, labetalol, lactated ringer’s injection, lepirudin, leucovorin, lidocaine, linezolid, LORazepam, mannitol, mechlorethamine, mesna, metaraminol, methotrexate, methyldopate, metoclopramide, metoprolol, metroNIDAZOLE, micafungin, midazolam, milrinone, minocycline, mitoMYcin, mitoXANtrone, mivacurium, morphine, moxifloxacin, multiple vitamins injection, mycophenolate mofetil, nafcillin, nalbuphine, nesiritide, netilmicin, niCARdipine, nitroglycerin, nitroprusside, norepinephrine, octreotide, ondansetron, oxaliplatin, oxytocin, PACLitaxel, palonosetron, pamidronate, pancuronium, papaverine, PEMEtrexed, penicillin G potassium/sodium, pentazocine, PENTobarbital, PHENobarbital, phentolamine, phenylephrine, piperacillin, piperacillin tazobactam, polymyxin B, potassium acetate/chloride, procainamide, prochlorperazine, promethazine, propranolol, protamine, pyridoxine, quiNIDine, quinupristin-dalfopristin, ranitidine, remifentanil, ringer’s injection, riTUXimab, rocuronium, sargramostim, sodium acetate/bicarbonate, succinylcholine, SUFentanil, tacrolimus, telavancin, teniposide, theophylline, thiamine, thiotepa, ticarcillin, ticarcillin-clavulanate, tigecycline, tirofiban, TNA (3-in-1), tobramycin, tolazoline, topotecan, TPN (2-in-1), trastuzumab, urokinase, vancomycin, vasopressin, vecuronium, verapamil, vinBLAStine, vinCRIStine, vinorelbine, vitamin B complex with C, voriconazole, zoledronic acid</para>
						</section>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x608">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x611">
					<section type="none" id="sidelem4x612">
						<sec_title>CNS:</sec_title>
						<para> Muscle weakness, flushing, sweating, confusion, sedation, depressed reflexes, <emphasis style="bold">flaccid paralysis,</emphasis> hypothermia</para>
					</section>
					<section type="none" id="sidelem4x620">
						<sec_title>CV:</sec_title>
						<para> Hypotension, heart block, <emphasis style="bold">circulatory collapse,</emphasis> vasodilation</para>
					</section>
					<section type="none" id="sidelem4x628">
						<sec_title>GI:</sec_title>
						<para> <emphasis style="italic">Nausea, vomiting, anorexia, cramps,</emphasis> diarrhea</para>
					</section>
					<section type="none" id="sidelem4x636">
						<sec_title>HEMA:</sec_title>
						<para> Prolonged bleeding time</para>
					</section>
					<section type="none" id="sidelem4x641">
						<sec_title>META:</sec_title>
						<para> Electrolyte, fluid imbalances</para>
					</section>
					<section type="none" id="sidelem4x646">
						<sec_title>RESP:</sec_title>
						<para> Respiratory depression/paralysis</para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x651">
				<sec_title>Pharmacokinetics</sec_title>
				<section type="none" id="sidelem4x654">
					<section type="none" id="sidelem4x655">
						<sec_title>PO:</sec_title>
						<para> Onset 1-2 hr</para>
					</section>
					<section type="none" id="sidelem4x660">
						<sec_title>IM:</sec_title>
						<para> Onset 1 hr, duration 4 hr</para>
					</section>
					<section type="none" id="sidelem4x665">
						<sec_title>IV:</sec_title>
						<para> Duration <emphasis style="sup">1</emphasis>/<emphasis style="inf">2</emphasis> hr</para>
						<para>Excreted by kidney, effective anticonvulsant serum levels 2.5-7.5 mEq/L</para>
					</section>
				</section>
			</section>
			<section type="interactions" id="sidelem4x678">
				<sec_title>Interactions</sec_title>
				<para>
					<emphasis style="bold">Increase:</emphasis> effect of neuromuscular blockers</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> hypotension—antihypertensives, calcium channel blockers</para>
				<para>
					<emphasis style="bold">Decrease:</emphasis> absorption of tetracyclines, fluoroquinolones, nitrofurantoin</para>
				<para>
					<emphasis style="bold">Decrease:</emphasis> effect of digoxin</para>
			</section>
			<section type="considerations" id="sidelem4x697">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x700">
					<section type="none" id="sidelem4x701">
						<sec_title>Assess:</sec_title>
						<section type="none" id="sidelem4x709">
							<label>•</label>
							<sec_title>Laxative</sec_title>
							<para>
								<list id="lidelem4x709">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Laxative:</emphasis> cause of constipation; lack of fluids, bulk, exercise; cramping, rectal bleeding, nausea, vomiting; product should be discontinued</para>
									</item>
								</list>
							</para>
						</section>
						<para>
							<list id="lidelem4x714">
								<item>
									<para>
										<emphasis alert="nurse">Eclampsia: seizure precautions, B/P, ECG (magnesium sulfate); magnesium toxicity: thirst, confusion, decrease in reflexes; I&amp;O ratio; check for decrease in urinary output</emphasis>
									</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x719">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x723">
								<item>
									<label>•</label>
									<para>Therapeutic response: decreased constipation; absence of seizures (eclampsia), normal serum calcium levels</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x729">
						<sec_title>Teach patient/family:</sec_title>
						<para>
							<list id="lidelem4x733">
								<item>
									<label>•</label>
									<para>Not to use laxatives for long-term therapy because bowel tone will be lost</para>
								</item>
								<item>
									<label>•</label>
									<para>That chilling improves taste of magnesium citrate</para>
								</item>
								<item>
									<label>•</label>
									<para>To shake suspension well</para>
								</item>
								<item>
									<label>•</label>
									<para>Not to give at bedtime as a laxative, may interfere with sleep; that MOM is usually given at bedtime</para>
								</item>
								<item>
									<label>•</label>
									<para>To give citrus fruit after administering to counteract unpleasant taste</para>
								</item>
								<item>
									<label>•</label>
									<para>About reason for product, expected results</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
		</monograph>
<monograph id="2" status="active">
			<mono_name>mannitol (Rx)</mono_name>
			<info>
				<pronunciation>(man′i-tole)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x7691">Osmitrol</tradename>
					<tradename id="tnidelem4x7690">Resectisol</tradename>
				</tradenames>
				<class type="func"> Diuretic, osmotic</class>
				<class type="chem"> Hexahydric alcohol</class>
				<class type="preg">Pregnancy category <preg cat="C">C</preg></class>
			</info>
			<section type="actions" id="sidelem4x779">
				<sec_title>Action:</sec_title>
				<para>Acts by increasing osmolarity of glomerular filtrate, which inhibits reabsorption of water and electrolytes and increases urinary output</para>
			</section>
			<section type="uses" id="sidelem4x784">
				<sec_title>Uses:</sec_title>
				<para>Edema; promotion of systemic diuresis in cerebral edema; decrease in intraocular/intracranial pressure; improved renal function in acute renal failure, chemical poisoning, urinary bladder irrigation, kidney transplant</para>
				<section type="none" id="sidelem4x791">
					<section type="none" id="sidelem4x792">
						<sec_title>Unlabeled uses:</sec_title>
						<para> Traumatic brain injury</para>
					</section>
				</section>
			</section>
			<section type="contra" id="sidelem4x797">
				<sec_title>Contraindications:</sec_title>
				<para>Active intracranial bleeding, hypersensitivity, anuria, severe pulmonary congestion, edema, severe dehydration, progressive heart, renal failure, acute MI, aneurysm, stroke</para>
				<section type="none" id="sidelem4x802">
					<section type="none" id="sidelem4x803">
						<sec_title>Precautions:</sec_title>
						<para> Pregnancy (<preg cat="C">C</preg>), breastfeeding, geriatric patients, dehydration, severe renal disease, CHF, electrolyte imbalances</para>
						<para>
							<bbw>Acute bronchospasm asthma</bbw>
						</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x818">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x821">
					<section type="none" id="sidelem4x822">
						<sec_title>Oliguria, prevention</sec_title>
						<section type="none" id="sidelem4x830">
							<label>•</label>
							<sec_title>Adult<route> IV</route></sec_title>
							<para>
								<list id="lidelem4x830">
									<item>
										<label>•</label>
										<para> after initial test dose; if urine output is 30-50 ml/hr × 2 hr, give 20-100 g over a 24-hr period of 15% or 20% sol</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x834">
						<sec_title>Oliguria, treatment</sec_title>
						<section type="none" id="sidelem4x842">
							<label>•</label>
							<sec_title>Adult<route> IV</route></sec_title>
							<para>
								<list id="lidelem4x842">
									<item>
										<label>•</label>
										<para> after initial test dose; give balance of 50 g of a 20% sol over 1 hr then 5% via  to maintain output at 50 ml/hr</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x852">
							<label>•</label>
							<sec_title>Child (unlabeled)<route> IV</route></sec_title>
							<para>
								<list id="lidelem4x852">
									<item>
										<label>•</label>
										<para> 0.5-2 g/kg as 15%-20% sol, run over 30-60 min; maintenance 0.25-0.5 g/kg q4-6hr</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x856">
						<sec_title>Edema</sec_title>
						<section type="none" id="sidelem4x864">
							<label>•</label>
							<sec_title>Adult<route> IV</route></sec_title>
							<para>
								<list id="lidelem4x864">
									<item>
										<label>•</label>
										<para> after test dose, use product 10%-20% at a rate of 25-75 ml/hr; give loop diuretics before mannitol</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x871">
							<label>•</label>
							<sec_title>Child (unlabeled)<route> IV</route></sec_title>
							<para>
								<list id="lidelem4x871">
									<item>
										<label>•</label>
										<para> 0.5-2 g/kg of 15%-20% mannitol over 2-6 hr</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x875">
						<sec_title>Intraocular pressure</sec_title>
						<section type="none" id="sidelem4x883">
							<label>•</label>
							<sec_title>Adult<route> IV</route></sec_title>
							<para>
								<list id="lidelem4x883">
									<item>
										<label>•</label>
										<para> 1.5-2 g/kg of 15%-20% sol over 30-60 min</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x887">
						<sec_title>ICP</sec_title>
						<section type="none" id="sidelem4x895">
							<label>•</label>
							<sec_title>Adult<route> IV</route></sec_title>
							<para>
								<list id="lidelem4x895">
									<item>
										<label>•</label>
										<para> 1-2 g/kg, then 0.25-1 g/kg q4hr</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x899">
						<sec_title>Diuresis with drug intoxication</sec_title>
						<section type="none" id="sidelem4x907">
							<label>•</label>
							<sec_title>Adult and child &gt;12 yr</sec_title>
							<para>
								<list id="lidelem4x907">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Adult and child &gt;12 yr:</emphasis> 5%-25% sol continuously up to 200 g  while maintaining 100-500 ml urine output/hr</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x914">
						<sec_title>Kidney transplant</sec_title>
						<section type="none" id="sidelem4x922">
							<label>•</label>
							<sec_title>Adult donor<route> IV</route></sec_title>
							<para>
								<list id="lidelem4x922">
									<item>
										<label>•</label>
										<para> 12.5 g before nephrectomy, with adequate hydration, may repeat. <emphasis style="bold">Recipient:</emphasis> 50 g before revascularization</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x929">
						<sec_title>Traumatic brain injury (unlabeled)</sec_title>
						<section type="none" id="sidelem4x937">
							<label>•</label>
							<sec_title>Adult<route> IV</route></sec_title>
							<para>
								<list id="lidelem4x937">
									<item>
										<label>•</label>
										<para> 1.4 g/kg before neurosurgery with fluid replacement</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x941">
						<sec_title>Available forms:</sec_title>
						<para> Inj 5%, 10%, 15%, 20%, 25%; GU irrigation: 5%</para>
					</section>
					<section type="none" id="sidelem4x946">
						<sec_title>Administer:</sec_title>
						<section type="none" id="sidelem4x949">
							<sec_title>Intermittent/continuous IV route</sec_title>
							<para>
								<list id="lidelem4x954">
									<item>
										<label>•</label>
										<para>Precipitate may occur with PVC</para>
									</item>
								</list>
							</para>
							<para>
								<list id="lidelem4x959">
									<item>
										<label>•</label>
										<para>Change IV set q24hr</para>
									</item>
								</list>
							</para>
							<para>
								<list id="lidelem4x964">
									<item>
										<label>•</label>
										<para>May warm solution to dissolve crystals</para>
									</item>
								</list>
							</para>
							<para>
								<list id="lidelem4x969">
									<item>
										<label>•</label>
										<para>In 15%-25% sol with filter; rapid infusion may worsen CHF; warm in hot water, shake to dissolve, use in-line filter, do not give as direct injection</para>
									</item>
								</list>
							</para>
							<para>
								<list id="lidelem4x974">
									<item>
										<label>•</label>
										<para>Monitor for infiltration</para>
									</item>
								</list>
							</para>
							<section type="none" id="sidelem4x982">
								<label>•</label>
								<sec_title>
									<route>Test dose</route>
								</sec_title>
								<para>
									<list id="lidelem4x982">
										<item>
											<label>•</label>
											<para> with severe oliguria, 0.2 g/kg over 3-5 min; if continued oliguria, give 2nd test dose; if no response, reassess patient</para>
										</item>
									</list>
								</para>
							</section>
							<para>
								<emphasis style="bold">Y-site compatibilities:</emphasis> Acetaminophen, acyclovir, aldesleukin, alemtuzumab, amifostine, amikacin, ampicillin, asparaginase, atropine, aztreonam, bivalirudin, bumetanide, calcium gluconate, caspofungin, ceFAZolin, cefotaxime, cefOXitin, cefTAZidime, ceftizoxime, chloramphenicol, cimetidine, cisatracurium, clindamycin, DAPTOmycin, dexmedetomidine, digoxin, diltiazem, diphenhydrAMINE, DOBUTamine, DOCEtaxel, DOPamine, DOXOrubicin liposome, doxycycline, enalaprilat, EPINEPHrine, ertapenem, esmolol, famotidine, fenoldopam, fentaNYL, fluconazole, fludarabine, gentamicin, granisetron, heparin, HYDROmorphone, hydrOXYzine, IDArubicin, imipenem/cilastatin, insulin, isoproterenol, ketorolac, labetalol, levofloxacin, lidocaine, linezolid, LORazepam, meperidine, metoclopramide, metoprolol, metroNIDAZOLE, micafungin, midazolam, milrinone, morphine, nafcillin, niCARdipine, nitroglycerin, nitroprusside, norepinephrine, ondansetron, oxaliplatin, PACLitaxel, palonosetron, pantoprazole, penicillin G potassium, phenylephrine, piperacillin/tazobactam, potassium chloride, procainamide, prochlorperazine, promethazine, propofol, propranolol, protamine, quinupristin/dalfopristin, ranitidine, remifentanil, sargramostim, sodium bicarbonate, tacrolimus, thiotepa, ticarcillin/clavulanate, tirofiban, tobramycin, trimethoprim/sulfamethoxazole, vancomycin, vasopressin, verapamil, vincristine, vit B complex with C, voriconazole, zoledronic acid</para>
						</section>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x992">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x995">
					<section type="none" id="sidelem4x996">
						<sec_title>CNS:</sec_title>
						<para> <emphasis style="italic">Dizziness, headache,</emphasis><emphasis style="bold">seizures, rebound increased ICP,</emphasis> confusion</para>
					</section>
					<section type="none" id="sidelem4x1006">
						<sec_title>CV:</sec_title>
						<para> Edema, thrombophlebitis, hypo/hypertension, <emphasis style="bold">tachycardia,</emphasis> angina-like chest pains, fever, chills, <emphasis style="bold">CHF, circulatory overload,</emphasis> PVCs</para>
					</section>
					<section type="none" id="sidelem4x1017">
						<sec_title>EENT:</sec_title>
						<para> Loss of hearing, blurred vision, nasal congestion, decreased intraocular pressure</para>
					</section>
					<section type="none" id="sidelem4x1022">
						<sec_title>ELECT:</sec_title>
						<para> Fluid, electrolyte imbalances, <emphasis style="italic">acidosis,</emphasis> electrolyte loss, dehydration, hypo/hyperkalemia</para>
					</section>
					<section type="none" id="sidelem4x1030">
						<sec_title>GI:</sec_title>
						<para> <emphasis style="italic">Nausea, vomiting,</emphasis> dry mouth, diarrhea</para>
					</section>
					<section type="none" id="sidelem4x1038">
						<sec_title>GU:</sec_title>
						<para> Marked diuresis, urinary retention, thirst</para>
					</section>
					<section type="none" id="sidelem4x1043">
						<sec_title>RESP:</sec_title>
						<para> Pulmonary congestion, <emphasis style="italic">cough,</emphasis> dyspnea</para>
					</section>
					<section type="none" id="sidelem4x1051">
						<sec_title>INTEG:</sec_title>
						<para> Injection-site reaction</para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x1056">
				<sec_title>Pharmacokinetics</sec_title>
				<section type="none" id="sidelem4x1059">
					<section type="none" id="sidelem4x1060">
						<sec_title>IV:</sec_title>
						<para> Onset 1-3 hr for diuresis, <emphasis style="sup">1</emphasis>/<emphasis style="inf">2</emphasis>-1 hr for intraocular pressure, 15 min for cerebrospinal fluid; duration 4-8 hr for intraocular pressure, 3-8 hr for cerebrospinal fluid; excreted in urine; half-life 100 min</para>
					</section>
				</section>
			</section>
			<section type="interactions" id="sidelem4x1071">
				<sec_title>Interactions</sec_title>
				<para>
					<emphasis style="bold">Increase:</emphasis> elimination of mannitol—lithium</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> excretion of salicylates, barbiturates, imipramine, bromides</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> hypokalemia—arsenic trioxide, cardiac glycosides, levomethadyl</para>
				<section type="none" id="sidelem4x1086">
					<section type="none" id="sidelem4x1087">
						<sec_title>Drug/Lab Test</sec_title>
						<para>
							<emphasis style="bold">Interference:</emphasis> inorganic phosphorus, ethylene glycol</para>
					</section>
				</section>
			</section>
			<section type="considerations" id="sidelem4x1094">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x1097">
					<section type="none" id="sidelem4x1098">
						<sec_title>Assess:</sec_title>
						<para>
							<list id="lidelem4x1103">
								<item>
									<label>•</label>
									<para>Weight, I&amp;O daily to determine fluid loss; effect of product may be decreased if used daily; output hourly prn</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x1108">
								<item>
									<label>•</label>
									<para>B/P lying, standing; postural hypotension may occur</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x1113">
								<item>
									<label>•</label>
									<para>Electrolytes: potassium, sodium, chloride; include BUN, CBC, serum creatinine, blood pH, ABGs, CVP, PAP</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x1121">
							<label>•</label>
							<sec_title>Metabolic acidosis</sec_title>
							<para>
								<list id="lidelem4x1121">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Metabolic acidosis:</emphasis> drowsiness, restlessness</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x1128">
							<label>•</label>
							<sec_title>Hypokalemia</sec_title>
							<para>
								<list id="lidelem4x1128">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Hypokalemia:</emphasis> postural hypotension, malaise, fatigue, tachycardia, leg cramps, weakness, or hyperkalemia</para>
									</item>
								</list>
							</para>
						</section>
						<para>
							<list id="lidelem4x1132">
								<item>
									<label>•</label>
									<para>Rashes, temperature daily</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x1137">
								<item>
									<label>•</label>
									<para>Confusion, especially in geriatric patients; take safety precautions if needed</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x1142">
								<item>
									<label>•</label>
									<para>Hydration including skin turgor, thirst, dry mucous membranes, provide adequate fluids</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x1150">
							<label>•</label>
							<sec_title>
								<route>(increased intraocular pressure);</route>
							</sec_title>
							<para>
								<list id="lidelem4x1150">
									<item>
										<label>•</label>
										<para>Blurred vision, pain in eyes before, during treatment  neurologic checks, intracranial pressure during treatment </para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x1157">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x1161">
								<item>
									<label>•</label>
									<para>Therapeutic response: improvement in edema of feet, legs, sacral area daily if medication being used with CHF; decreased intraocular pressure, prevention of hypokalemia, increased excretion of toxic substances; decreased ICP</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x1167">
						<sec_title>Teach patient/family:</sec_title>
						<para>
							<list id="lidelem4x1171">
								<item>
									<label>•</label>
									<para>To rise slowly from lying or sitting position</para>
								</item>
								<item>
									<label>•</label>
									<para>About the reason for, method of treatment</para>
								</item>
								<item>
									<label>•</label>
									<para>To report signs of electrolyte imbalance, confusion, pain at injection site, hearing loss, blurred vision</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
		</monograph>
<monograph id="3" status="active">
			<mono_name>maraviroc (Rx)</mono_name>
			<info>
				<pronunciation>(mah-rav′er-rock)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x11980">Selzentry</tradename>
				</tradenames>
				<class type="func"> Antiretroviral</class>
				<class type="chem"> Fusion inhibitor, CCR5-receptor antagonist</class>
				<class type="preg">Pregnancy category <preg cat="B">B</preg></class>
			</info>
			<section type="actions" id="sidelem4x1208">
				<sec_title>Action:</sec_title>
				<para>Interferes with entry into HIV-1 by inhibiting the fusion of the virus and the cell membrane</para>
			</section>
			<section type="uses" id="sidelem4x1213">
				<sec_title>Uses:</sec_title>
				<para>CCR5-tropic HIV in combination with other antiretroviral agents for treating experienced patients</para>
			</section>
			<section type="contra" id="sidelem4x1218">
				<sec_title>Contraindications:</sec_title>
				<para>Hypersensitivity, dialysis, renal impairment</para>
				<section type="none" id="sidelem4x1223">
					<section type="none" id="sidelem4x1224">
						<sec_title>Precautions:</sec_title>
						<para> Pregnancy (<preg cat="B">B</preg>), Asian patients, breastfeeding, renal/hepatic/cardiac disease, electrolyte imbalance, dehydration, immune reconstitution syndrome, infection, MI, orthostatic hypotension, children, geriatric patients, Graves’ disease, Guillain-Barré syndrome, polymyositis</para>
						<para>
							<bbw>Hepatitis, fever, serious rash</bbw>
						</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x1239">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x1242">
					<section type="none" id="sidelem4x1243">
						<sec_title>Those not taking any CYP3A inducers/inhibitors</sec_title>
						<section type="none" id="sidelem4x1251">
							<label>•</label>
							<sec_title>Adult/adolescent ≥16 yr<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x1251">
									<item>
										<label>•</label>
										<para> 300 mg bid</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x1255">
						<sec_title>Those taking CYP3A4 inhibitors with/without a CYP3A inducer</sec_title>
						<section type="none" id="sidelem4x1263">
							<label>•</label>
							<sec_title>Adult/adolescent ≥16 yr<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x1263">
									<item>
										<label>•</label>
										<para> 150 mg bid</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x1267">
						<sec_title>Those taking CYP3A4 inducers without a strong CYP3A inhibitor</sec_title>
						<section type="none" id="sidelem4x1275">
							<label>•</label>
							<sec_title>Adult/adolescent ≥16 yr<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x1275">
									<item>
										<label>•</label>
										<para> 600 mg bid</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x1279">
						<sec_title>Renal dose</sec_title>
						<section type="none" id="sidelem4x1287">
							<label>•</label>
							<sec_title>Adult<route> PO ≤30 ml/min, reduce dose to 150 mg bid</route></sec_title>
						</section>
					</section>
					<section type="none" id="sidelem4x1290">
						<sec_title>Available forms:</sec_title>
						<para> Tabs 150, 300 mg</para>
					</section>
					<section type="none" id="sidelem4x1295">
						<sec_title>Administer:</sec_title>
						<para>
							<list id="lidelem4x1299">
								<item>
									<label>•</label>
									<para>May give without regard to meals, with 8 oz water; swallow whole; do not crush, chew, break</para>
								</item>
								<item>
									<label>•</label>
									<para>Store at room temperature</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x1310">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x1313">
					<section type="none" id="sidelem4x1314">
						<sec_title>CV:</sec_title>
						<para> <emphasis style="bold">MI, cardiac ischemia, orthostatic hypotension</emphasis></para>
					</section>
					<section type="none" id="sidelem4x1321">
						<sec_title>CNS:</sec_title>
						<para> Dizziness, depression, <emphasis style="bold">viral meningitis,</emphasis> disturbances in consciousness, peripheral neuropathy, paresthesia, dysesthesia, fever</para>
					</section>
					<section type="none" id="sidelem4x1329">
						<sec_title>EENT:</sec_title>
						<para> Gingival hyperplasia, visual changes</para>
					</section>
					<section type="none" id="sidelem4x1334">
						<sec_title>GI:</sec_title>
						<para> Diarrhea, constipation, dyspepsia, <emphasis style="bold">pseudomembranous colitis, hepatotoxicity</emphasis></para>
					</section>
					<section type="none" id="sidelem4x1341">
						<sec_title>INTEG:</sec_title>
						<para> Rash, urticaria, pruritus, folliculitis</para>
					</section>
					<section type="none" id="sidelem4x1346">
						<sec_title>MS:</sec_title>
						<para> Joint pain, leg pain, muscle cramps</para>
					</section>
					<section type="none" id="sidelem4x1351">
						<sec_title>RESP:</sec_title>
						<para> Cough, upper respiratory tract infection, sinusitis, bronchitis, pneumonia, <emphasis style="bold">bronchospasm, obstruction,</emphasis> dyspnea</para>
					</section>
					<section type="none" id="sidelem4x1359">
						<sec_title>SYST:</sec_title>
						<para> Herpes virus, <emphasis style="bold">lipodystrophy, malignancy</emphasis></para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x1366">
				<sec_title>Pharmacokinetics</sec_title>
				<para>Metabolized by P450 system; CYP3A metabolism; excreted 20% urine, 76% feces; protein binding 76%; terminal half-life 14-18 hr</para>
			</section>
			<section type="interactions" id="sidelem4x1371">
				<sec_title>Interactions</sec_title>
				<para>
					<emphasis style="bold">Increase:</emphasis> maraviroc levels—CYP3A inhibitors (amiodarone, aprepitant, chloramphenicol, clarithromycin, conivaptan, cycloSPORINE, dalfopristin, danazol, diltiazem, erythromycin, estradiol, fluconazole, fluvoxaMINE, imatinib, isoniazid, itraconazole, ketoconazole, miconazole, nefazodone, niCARdipine, propoxyphene, RU-486, tamoxifen, telithromycin, troleandomycin, verapamil, voriconazole, zafirlukast); reduce dose</para>
				<para>
					<emphasis style="bold">Decrease:</emphasis> maraviroc levels—CYP3A4 inducers (efavirenz, aminoglutethimide, barbiturates, bexaroten, bosentan, carBAMazepine, dexamethasone, griseofulvin, modafinil, nafcillin, OXcarbazepine, phenytoin, fosphenytoin, rifabutin, rifampin, rifapentine, topiramate, tipranavir); increase dose</para>
				<section type="none" id="sidelem4x1384">
					<section type="none" id="sidelem4x1385">
						<sec_title>Drug/Herb</sec_title>
						<para>
							<list id="lidelem4x1389">
								<item>
									<label>•</label>
									<para>Decreased maraviroc effect: St. John’s wort</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x1395">
						<sec_title>Drug/Food</sec_title>
						<para>
							<list id="lidelem4x1399">
								<item>
									<label>•</label>
									<para>High-fat meal decreases absorption 33%</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x1405">
						<sec_title>Drug/Lab Test</sec_title>
						<section type="none" id="sidelem4x1411">
							<sec_title>Increase</sec_title>
							<para>
								<list id="lidelem4x1411">
									<item>
										<para>
											<emphasis style="bold">Increase:</emphasis> AST, ALT, bilirubin, amylase, lipase</para>
									</item>
								</list>
							</para>
						</section>
					</section>
				</section>
			</section>
			<section type="considerations" id="sidelem4x1415">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x1418">
					<section type="none" id="sidelem4x1419">
						<sec_title>Assess:</sec_title>
						<section type="none" id="sidelem4x1427">
							<label>•</label>
							<sec_title>HIV</sec_title>
							<para>
								<list id="lidelem4x1427">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">HIV:</emphasis> CD<emphasis style="inf">4</emphasis>, T-cell count, plasma HIV RNA, CCR5-tropic HIV-1; assess for changes in symptoms, other infections during treatment</para>
									</item>
								</list>
							</para>
						</section>
						<para>
							<list id="lidelem4x1434">
								<item>
									<label>•</label>
									<para>Renal studies: serum creatinine</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x1439">
								<item>
									<label>•</label>
									<para>Bowel pattern before, during treatment</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x1447">
							<label>•</label>
							<sec_title>Allergies</sec_title>
							<para>
								<list id="lidelem4x1447">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Allergies:</emphasis> skin eruptions: rash, urticaria, itching; discontinue product
<bbw>
												<emphasis alert="lifethreat">Hepatitis/hepatotoxicity:</emphasis> dark urine; abdominal pain, vomiting; yellowing of skin, eyes; hepatomegaly; discontinue product; monitor liver function tests; serious rash, fever, eosinophilia, or elevated IgE before hepatotoxicity may occur</bbw>
</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x1462">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x1466">
								<item>
									<label>•</label>
									<para>Therapeutic response: improvement in CD4, viral load, T-cell count</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x1472">
						<sec_title>Teach patient/family:</sec_title>
						<para>
							<list id="lidelem4x1477">
								<item>
									<label>•</label>
									<para>To take as prescribed; if dose is missed, to take as soon as remembered up to 1 hr before next dose; not to double dose; that product does not cure condition, should not be shared with others</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x1482">
								<item>
									<label>•</label>
									<para>That product does not cure infection, just controls symptoms and does not prevent infecting others</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x1488">
								<item>
									<para>
										<emphasis alert="nurse">To report sore throat, fever, fatigue (may indicate superinfection); yellow skin/eyes, abdominal pain, vomiting (hepatitis); itching, SOB (allergic reaction)</emphasis>
									</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x1493">
								<item>
									<label>•</label>
									<para>That product must be taken in equal intervals around the clock to maintain blood levels for duration of therapy</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x1498">
								<item>
									<label>•</label>
									<para>To avoid all OTC products unless approved by prescriber</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x1503">
								<item>
									<label>•</label>
									<para>To avoid driving, other hazardous activities until reaction is known; that dizziness may occur</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x1508">
								<item>
									<label>•</label>
									<para>To make position changes slowly to prevent postural hypotension</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x1516">
							<label>•</label>
							<sec_title>
								<route>not to breastfeed</route>
							</sec_title>
							<para>
								<list id="lidelem4x1516">
									<item>
										<label>•</label>
										<para>To notify prescriber if pregnancy is planned or suspected; </para>
									</item>
								</list>
							</para>
						</section>
					</section>
				</section>
			</section>
		</monograph>
<monograph id="4" status="active">
			<mono_name>mebendazole (Rx)</mono_name>
			<info>
				<tradenames>
					<tradename id="tnidelem4x15230">This drug has been discontinued.</tradename>
				</tradenames>
				<class type="func"> Anthelmintic</class>
				<class type="preg">Pregnancy category <preg cat="C">C</preg></class>
			</info>
			<section type="actions" id="sidelem4x1535">
				<sec_title>Action:</sec_title>
				<para>Inhibits glucose uptake, degeneration of cytoplasmic microtubules in the cell; interferes with absorption, secretory function</para>
			</section>
			<section type="uses" id="sidelem4x1540">
				<sec_title>Uses:</sec_title>
				<para>Pinworms, roundworms, hookworms, whipworms, thread-worms, pork tapeworms, dwarf tapeworms, beef tapeworms, hydatid cyst</para>
			</section>
			<section type="contra" id="sidelem4x1545">
				<sec_title>Contraindications:</sec_title>
				<para>Hypersensitivity</para>
				<section type="none" id="sidelem4x1550">
					<section type="none" id="sidelem4x1551">
						<sec_title>Precautions:</sec_title>
						<para> Pregnancy (<preg cat="C">C</preg>) (1st trimester), breastfeeding, children &lt;2 yr, Crohn’s disease, hepatic disease, inﬂammatory bowel disease, ulcerative colitis</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x1556">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x1564">
					<label>•</label>
					<sec_title>Adult and child &gt;2 yr<route> PO</route></sec_title>
					<para>
						<list id="lidelem4x1564">
							<item>
								<label>•</label>
								<para> 100 mg as a single dose (pinworms) or bid ×3 days (whipworms, roundworms, or hookworms); course may be repeated in 3 wk if needed</para>
							</item>
						</list>
					</para>
				</section>
				<section type="none" id="sidelem4x1568">
					<section type="none" id="sidelem4x1569">
						<sec_title>Available forms:</sec_title>
						<para> Tabs 100 mg</para>
					</section>
					<section type="none" id="sidelem4x1574">
						<sec_title>Administer:</sec_title>
						<para>
							<list id="lidelem4x1578">
								<item>
									<label>•</label>
									<para>May be crushed, chewed, swallowed whole, mixed with food</para>
								</item>
								<item>
									<label>•</label>
									<para>PO after meals to avoid GI symptoms</para>
								</item>
								<item>
									<label>•</label>
									<para>Second course after 3 wk if needed; usually recommended</para>
								</item>
								<item>
									<label>•</label>
									<para>Store in tight container</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x1600">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x1603">
					<section type="none" id="sidelem4x1604">
						<sec_title>CNS:</sec_title>
						<para> Dizziness, fever, headache, <emphasis style="bold">seizures (rare)</emphasis></para>
					</section>
					<section type="none" id="sidelem4x1611">
						<sec_title>GI:</sec_title>
						<para> Transient diarrhea, abdominal pain, nausea, vomiting, constipation, hepatitis</para>
					</section>
					<section type="none" id="sidelem4x1616">
						<sec_title>INTEG:</sec_title>
						<para> Rash</para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x1621">
				<sec_title>Pharmacokinetics</sec_title>
				<section type="none" id="sidelem4x1624">
					<section type="none" id="sidelem4x1625">
						<sec_title>PO:</sec_title>
						<para> Peak <emphasis style="sup">1</emphasis>/<emphasis style="inf">2</emphasis>-7 hr; excreted in feces primarily (metabolites), small amount in urine (unchanged); highly bound to plasma proteins 95%</para>
					</section>
				</section>
			</section>
			<section type="interactions" id="sidelem4x1636">
				<sec_title>Interactions</sec_title>
				<para>
					<emphasis style="bold">Decrease:</emphasis> mebendazole effect—carBAMazepine, hydantoins</para>
				<section type="none" id="sidelem4x1643">
					<section type="none" id="sidelem4x1644">
						<sec_title>Drug/Food</sec_title>
						<para>
							<emphasis style="bold">Increase:</emphasis> absorption—high-fat meal</para>
					</section>
				</section>
			</section>
			<section type="considerations" id="sidelem4x1651">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x1654">
					<section type="none" id="sidelem4x1655">
						<sec_title>Assess:</sec_title>
						<para>
							<list id="lidelem4x1659">
								<item>
									<label>•</label>
									<para>Stools during entire treatment; specimens must be sent to lab while still warm, also 1-3 wk after treatment is completed</para>
								</item>
								<item>
									<label>•</label>
									<para>For allergic reaction: rash (rare)</para>
								</item>
								<item>
									<label>•</label>
									<para>For diarrhea during expulsion of worms; avoid self-contamination with patient’s feces</para>
								</item>
								<item>
									<label>•</label>
									<para>For infection in other family members, since infection from person to person is common</para>
								</item>
								<item>
									<label>•</label>
									<para>Blood studies: AST, ALT, alk phos, BUN, CBC during treatment</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x1685">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x1689">
								<item>
									<label>•</label>
									<para>Therapeutic response: expulsion of worms and 3 negative stool cultures after completion of treatment</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x1695">
						<sec_title>Teach patient/family:</sec_title>
						<para>
							<list id="lidelem4x1699">
								<item>
									<label>•</label>
									<para>Proper hygiene after BM, including hand-washing technique; tell patient to avoid putting fingers in mouth; clean fingernails</para>
								</item>
								<item>
									<label>•</label>
									<para>That infected person should sleep alone; not to shake bed linen, change bed linen daily, wash in hot water, change and wash undergarments daily</para>
								</item>
								<item>
									<label>•</label>
									<para>To clean toilet daily with disinfectant (green soap solution)</para>
								</item>
								<item>
									<label>•</label>
									<para>The need for compliance with dosage schedule, duration of treatment</para>
								</item>
								<item>
									<label>•</label>
									<para>To wear shoes, wash all fruits and vegetables well before eating; use commercial fruit/vegetable cleaner</para>
								</item>
								<item>
									<label>•</label>
									<para>That all members of the family should be treated (pinworms)</para>
								</item>
								<item>
									<label>•</label>
									<para>To report jaundice, liver pain</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
		</monograph>
<monograph id="5" status="active">
			<mono_name>mecasermin (Rx)</mono_name>
			<info>
				<pronunciation>(mec-a′sir-men)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x17400">Increlex</tradename>
				</tradenames>
				<class type="func"> Biologic response modifier; insulin-like growth factor</class>
				<class type="preg">Pregnancy category <preg cat="C">C</preg></class>
			</info>
			<section type="actions" id="sidelem4x1746">
				<sec_title>Action:</sec_title>
				<para>Stimulates growth; IGF-1 is the principal hormonal mediator of statural growth; GH binds to its receptor in the liver and other tissues</para>
			</section>
			<section type="uses" id="sidelem4x1751">
				<sec_title>Uses:</sec_title>
				<para>Growth failure in children with severe primary insulin-like growth factor-1 (IGF-1) deficiency (primary IGFD) or with growth hormone (GH) gene deletion who have developed neutralizing antibodies to GH</para>
				<section type="none" id="sidelem4x1756">
					<section type="none" id="sidelem4x1757">
						<sec_title>Unlabeled uses:</sec_title>
						<para> ALS</para>
					</section>
				</section>
			</section>
			<section type="contra" id="sidelem4x1762">
				<sec_title>Contraindications:</sec_title>
				<para>Hypersensitivity, benzyl alcohol, closed epiphyses, active/suspected neoplasia, IV use</para>
				<section type="none" id="sidelem4x1767">
					<section type="none" id="sidelem4x1768">
						<sec_title>Precautions:</sec_title>
						<para> Pregnancy (<preg cat="C">C</preg>), breastfeeding, children &lt;2 yr, diabetes mellitus, hypothyroidism, lymphoid tissue hypertrophy, increased intracranial pressure, malnutrition, scoliosis, sleep apnea</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x1773">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x1781">
					<label>•</label>
					<sec_title>Child ≥2 yr<route> SUBCUT</route></sec_title>
					<para>
						<list id="lidelem4x1781">
							<item>
								<label>•</label>
								<para> 0.04-0.08 mg/kg (40-80 mcg/kg) bid; if well tolerated for 1 wk, may increase by 0.04 mg/kg/dose, max 0.12 mg/kg bid</para>
							</item>
						</list>
					</para>
				</section>
				<section type="none" id="sidelem4x1785">
					<section type="none" id="sidelem4x1786">
						<sec_title>Available forms:</sec_title>
						<para> Inj 10 mg/ml</para>
					</section>
					<section type="none" id="sidelem4x1791">
						<sec_title>Administer:</sec_title>
						<section type="none" id="sidelem4x1794">
							<sec_title>SUBCUT route</sec_title>
							<para>
								<list id="lidelem4x1798">
									<item>
										<label>•</label>
										<para>Give within 20 min of meal or snack; do not give if unable to eat or if vomiting</para>
									</item>
									<item>
										<label>•</label>
										<para>Rotate inj site; use sterile, disposable syringe/needles; use small-volume syringe for accurate measurement; if using syringe (units), convert to mg/kg (weight [kg] × dose [mg/kg] × 1 ml/mg × 100 units/1 ml = units/injection)</para>
									</item>
									<item>
										<label>•</label>
										<para>Do not double dose if a dose is missed</para>
									</item>
									<item>
										<label>•</label>
										<para>Store in refrigerator before opening, avoid freezing; after opening, stable for 30 days after initial vial entry, store in refrigerator; do not use if particulate matter is present, avoid direct light, do not use after expiration date</para>
									</item>
								</list>
							</para>
						</section>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x1821">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x1824">
					<section type="none" id="sidelem4x1825">
						<sec_title>CNS:</sec_title>
						<para> Headache, <emphasis style="bold">seizures,</emphasis> dizziness, cardiac valvulopathy, <emphasis style="bold">increased intracranial pressure</emphasis></para>
					</section>
					<section type="none" id="sidelem4x1835">
						<sec_title>CV:</sec_title>
						<para> Cardiac murmur</para>
					</section>
					<section type="none" id="sidelem4x1840">
						<sec_title>EENT:</sec_title>
						<para> Ear pain, otitis media, abnormal tympanometry, papilledema, visual impairment, tonsillar hypertrophy, sinusitis</para>
					</section>
					<section type="none" id="sidelem4x1845">
						<sec_title>ENDO:</sec_title>
						<para> <emphasis style="bold">Hypoglycemia, ketosis, hypothyroidism, hypercholesterolemia, hypertriglyceridemia</emphasis></para>
					</section>
					<section type="none" id="sidelem4x1852">
						<sec_title>INTEG:</sec_title>
						<para> Pruritus, urticaria, <emphasis style="bold">anaphylaxis, angioedema</emphasis></para>
					</section>
					<section type="none" id="sidelem4x1859">
						<sec_title>GI:</sec_title>
						<para> Vomiting, nausea</para>
					</section>
					<section type="none" id="sidelem4x1864">
						<sec_title>HEMA:</sec_title>
						<para> Thymus hypertrophy, lymphadenopathy</para>
					</section>
					<section type="none" id="sidelem4x1869">
						<sec_title>MISC:</sec_title>
						<para> Bruising, lipohypertrophy, inj-site reaction</para>
					</section>
					<section type="none" id="sidelem4x1874">
						<sec_title>MS:</sec_title>
						<para> Arthralgia, joint pain, slipped upper femoral epiphysis</para>
					</section>
					<section type="none" id="sidelem4x1879">
						<sec_title>RESP:</sec_title>
						<para> Snoring, <emphasis style="bold">apnea</emphasis></para>
					</section>
					<section type="none" id="sidelem4x1886">
						<sec_title>SYST:</sec_title>
						<para> <emphasis style="bold">Antibodies to growth hormone, secondary malignancy</emphasis></para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x1893">
				<sec_title>Pharmacokinetics</sec_title>
				<para>Bioavailability almost 100%, metabolized in liver/kidney, half-life 5.8 hr</para>
			</section>
			<section type="interactions" id="sidelem4x1898">
				<sec_title>Interactions</sec_title>
				<para>
					<emphasis style="bold">Increase:</emphasis> hypoglycemia—antidiabetics, corticosteroids</para>
				<para>
					<emphasis style="bold">Decrease:</emphasis> growth suppression possible—psychostimulants</para>
			</section>
			<section type="considerations" id="sidelem4x1909">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x1912">
					<section type="none" id="sidelem4x1913">
						<sec_title>Assess:</sec_title>
						<para>
							<list id="lidelem4x1918">
								<item>
									<label>•</label>
									<para>Monitor preprandial glucose at beginning of treatment and until well tolerated</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x1923">
								<item>
									<label>•</label>
									<para>By funduscopic exam at beginning and periodically during treatment</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x1931">
							<label>•</label>
							<sec_title>
								<route>Allergic reactions;</route>
							</sec_title>
							<para>
								<list id="lidelem4x1931">
									<item>
										<label>•</label>
										<para> if present, interrupt treatment and notify prescriber</para>
									</item>
								</list>
							</para>
						</section>
						<para>
							<list id="lidelem4x1935">
								<item>
									<label>•</label>
									<para>Growth rate of child at intervals during treatment</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x1943">
							<label>•</label>
							<sec_title>Serious skin disorders<route> angioedema, anaphylaxis</route></sec_title>
						</section>
					</section>
					<section type="none" id="sidelem4x1946">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x1950">
								<item>
									<label>•</label>
									<para>Therapeutic response: growth in children</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x1956">
						<sec_title>Teach patient/family:</sec_title>
						<para>
							<list id="lidelem4x1960">
								<item>
									<label>•</label>
									<para>That treatment may continue for years; that regular assessments are required</para>
								</item>
								<item>
									<label>•</label>
									<para>To avoid hazardous activities, driving within 2-3 hr of dosing</para>
								</item>
								<item>
									<label>•</label>
									<para>About correct administration, needle disposal, rotation of injection sites</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
		</monograph>
<monograph id="6" status="active">
			<mono_name>meclizine (<emphasis style="smallcaps">otc</emphasis>, Rx)</mono_name>
			<info>
				<pronunciation>(mek′li-zeen)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x19842">Antivert</tradename>
					<tradename id="tnidelem4x19841">Bonine</tradename>
					<tradename id="tnidelem4x19840">Dramamine Less Drowsy Formula</tradename>
				</tradenames>
				<class type="func"> Antiemetic, antihistamine, anticholinergic</class>
				<class type="chem"> H-receptor antagonist, piperazine derivative</class>
				<class type="preg">Pregnancy category <preg cat="B">B</preg></class>
			</info>
			<section type="actions" id="sidelem4x1997">
				<sec_title>Action:</sec_title>
				<para>Acts centrally by blocking chemoreceptor trigger zone, which in turn acts on vomiting center</para>
			</section>
			<section type="uses" id="sidelem4x2002">
				<sec_title>Uses:</sec_title>
				<para>Vertigo, motion sickness</para>
			</section>
			<section type="contra" id="sidelem4x2007">
				<sec_title>Contraindications:</sec_title>
				<para>Hypersensitivity to cyclizines</para>
				<section type="none" id="sidelem4x2012">
					<section type="none" id="sidelem4x2013">
						<sec_title>Precautions:</sec_title>
						<para> Pregnancy (<preg cat="B">B</preg>), breastfeeding, children, geriatric patients, closed-angle glaucoma, prostatic hypertrophy, hepatic/renal disease, urinary retention, GI obstruction, contact lenses</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x2018">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x2021">
					<section type="none" id="sidelem4x2022">
						<sec_title>Vertigo</sec_title>
						<section type="none" id="sidelem4x2030">
							<label>•</label>
							<sec_title>Adult/adolescent<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x2030">
									<item>
										<label>•</label>
										<para> 25-100 mg/day in divided doses</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x2034">
						<sec_title>Motion sickness</sec_title>
						<section type="none" id="sidelem4x2042">
							<label>•</label>
							<sec_title>Adult/adolescent<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x2042">
									<item>
										<label>•</label>
										<para> 25-50 mg 1 hr before traveling, repeat dose q24hr prn</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x2047">
						<sec_title>Available forms:</sec_title>
						<para> Tabs 12.5, 25, 50 mg</para>
					</section>
					<section type="none" id="sidelem4x2052">
						<sec_title>Administer:</sec_title>
						<section type="none" id="sidelem4x2055">
							<sec_title>PO route</sec_title>
							<para>
								<list id="lidelem4x2060">
									<item>
										<label>•</label>
										<para>May give without regard to food</para>
									</item>
								</list>
							</para>
							<section type="none" id="sidelem4x2068">
								<label>•</label>
								<sec_title>Chew tab</sec_title>
								<para>
									<list id="lidelem4x2068">
										<item>
											<label>•</label>
											<para>
												<emphasis style="bold">Chew tab:</emphasis> give without regard to water or may be swallowed whole with water</para>
										</item>
									</list>
								</para>
							</section>
							<para>
								<list id="lidelem4x2072">
									<item>
										<label>•</label>
										<para>Lowest possible dose for geriatric patients; anticholinergic effects</para>
									</item>
								</list>
							</para>
						</section>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x2077">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x2080">
					<section type="none" id="sidelem4x2081">
						<sec_title>CNS:</sec_title>
						<para> <emphasis style="italic">Drowsiness,</emphasis> fatigue, restlessness, headache, insomnia</para>
					</section>
					<section type="none" id="sidelem4x2089">
						<sec_title>CV:</sec_title>
						<para> Hypotension</para>
					</section>
					<section type="none" id="sidelem4x2094">
						<sec_title>EENT:</sec_title>
						<para> Dry mouth, blurred vision</para>
					</section>
					<section type="none" id="sidelem4x2099">
						<sec_title>GI:</sec_title>
						<para> Nausea, anorexia, constipation, increased appetite</para>
					</section>
					<section type="none" id="sidelem4x2104">
						<sec_title>GU:</sec_title>
						<para> Urinary retention</para>
					</section>
					<section type="none" id="sidelem4x2109">
						<sec_title>SYST:</sec_title>
						<para> <emphasis style="bold">Anaphylaxis</emphasis></para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x2116">
				<sec_title>Pharmacokinetics</sec_title>
				<section type="none" id="sidelem4x2119">
					<section type="none" id="sidelem4x2120">
						<sec_title>PO:</sec_title>
						<para> Onset 1 hr, duration 8-24 hr, half-life 6 hr</para>
					</section>
				</section>
			</section>
			<section type="interactions" id="sidelem4x2125">
				<sec_title>Interactions</sec_title>
				<para>
					<emphasis style="bold">Increase:</emphasis> sedation—CYP2D6, inhibitors</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> anticholinergic effects—other antihistamines, atropine, antidepressants, phenothiazines</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> effect of alcohol, opioids, other CNS depressants</para>
				<section type="none" id="sidelem4x2140">
					<section type="none" id="sidelem4x2141">
						<sec_title>Drug/Lab Test</sec_title>
						<para>
							<emphasis style="bold">False negative:</emphasis> allergy skin testing (allergen extracts)</para>
					</section>
				</section>
			</section>
			<section type="considerations" id="sidelem4x2148">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x2151">
					<section type="none" id="sidelem4x2152">
						<sec_title>Assess:</sec_title>
						<section type="none" id="sidelem4x2160">
							<label>•</label>
							<sec_title>Vertigo/motion sickness</sec_title>
							<para>
								<list id="lidelem4x2160">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Vertigo/motion sickness:</emphasis> nausea, vomiting after 1 hr; assess vertigo periodically</para>
									</item>
								</list>
							</para>
						</section>
						<para>
							<list id="lidelem4x2165">
								<item>
									<para>
										<emphasis alert="nurse">Signs of toxicity of other products, masking of symptoms of disease: brain tumor, intestinal obstruction</emphasis>
									</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x2170">
								<item>
									<label>•</label>
									<para>Observe for drowsiness, dizziness, level of consciousness</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x2175">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x2179">
								<item>
									<label>•</label>
									<para>Therapeutic response: absence of dizziness, vomiting</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x2185">
						<sec_title>Teach patient/family:</sec_title>
						<para>
							<list id="lidelem4x2189">
								<item>
									<label>•</label>
									<para>That a false-negative result may occur with skin testing for allergies; that these procedures should not be scheduled for ≤4 days after discontinuing use</para>
								</item>
								<item>
									<label>•</label>
									<para>To avoid hazardous activities, activities requiring alertness because dizziness may occur; to request assistance with ambulation</para>
								</item>
								<item>
									<label>•</label>
									<para>To avoid alcohol, other depressants; not to breastfeed, report severe side effects</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
		</monograph>
<monograph id="7" status="active">
			<mono_name>medroxyPROGESTERone (Rx)</mono_name>
			<info>
				<pronunciation>(me-drox′ee-proe-jess′te-rone)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x22103">Depo-Provera</tradename>
					<tradename id="tnidelem4x22102">Depo-sub Q Provera</tradename>
					<tradename id="tnidelem4x22101">
						<country code="CAN">Gen-Medroxy </country>
					</tradename>
					<tradename id="tnidelem4x22100">Provera</tradename>
				</tradenames>
				<class type="func"> Antineoplastic, hormone, contraceptive</class>
				<class type="chem"> Progesterone derivative</class>
				<class type="preg">Pregnancy category <preg cat="X">X</preg></class>
			</info>
			<section type="confusion" id="sidelem4x2223">
				<para>
					<confusion>
						<tradename id="tnidelem4x22230">medroxyPROGESTERone</tradename>
						<drug type="generic" refid="idelem4x22230">methylPREDNISolone</drug>
					</confusion>
				</para>
			</section>
			<section type="actions" id="sidelem4x2230">
				<sec_title>Action:</sec_title>
				<para>Inhibits secretion of pituitary gonadotropins, which prevents follicular maturation and ovulation; antineoplastic action against endometrial cancer</para>
			</section>
			<section type="uses" id="sidelem4x2235">
				<sec_title>Uses:</sec_title>
				<para>Uterine bleeding (abnormal); secondary amenorrhea; prevention of endometrial changes associated with estrogen replacement therapy (ERT); contraceptive; inoperable, recurrent, metastatic endometrial/renal cancer</para>
				<section type="none" id="sidelem4x2240">
					<section type="none" id="sidelem4x2241">
						<sec_title>Unlabeled uses:</sec_title>
						<para> Hot flashes; symptoms of menopause; paraphilia (men); hot flashes (men) with prostate cancer</para>
					</section>
				</section>
			</section>
			<section type="contra" id="sidelem4x2246">
				<sec_title>Contraindications:</sec_title>
				<para>Pregnancy (<preg cat="X">X</preg>), hypersensitivity, reproductive cancer, genital bleeding (abnormal, undiagnosed), missed abortion, stroke, cerebrovascular disease, cervical cancer, hepatic disease, uterine/vaginal cancer</para>
				<para>
					<bbw>Breast cancer, MI, stroke, thromboembolic disease, thrombophlebitis</bbw>
				</para>
				<section type="none" id="sidelem4x2262">
					<section type="none" id="sidelem4x2263">
						<sec_title>Precautions:</sec_title>
						<para> Breastfeeding, hypertension, asthma, blood dyscrasias, gallbladder disease, CHF, diabetes mellitus, bone disease, depression, migraine headache, seizure disorders, renal/hepatic disease, family history of cancer of breast or reproductive tract, bone mineral density loss, ocular disorders, AIDS/HIV, alcoholism, children, hyperlipidemia</para>
						<para>
							<bbw>Cardiac disease, dementia, osteoporosis</bbw>
						</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x2278">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x2281">
					<section type="none" id="sidelem4x2282">
						<sec_title>Secondary amenorrhea</sec_title>
						<section type="none" id="sidelem4x2290">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x2290">
									<item>
										<label>•</label>
										<para> 5-10 mg/day × 5-10 days</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x2294">
						<sec_title>Uterine bleeding</sec_title>
						<section type="none" id="sidelem4x2302">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x2302">
									<item>
										<label>•</label>
										<para> 5-10 mg/day × 5-10 days starting on 16th or 21st day of menstrual cycle</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x2306">
						<sec_title>With ERT</sec_title>
						<section type="none" id="sidelem4x2314">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x2314">
									<item>
										<label>•</label>
										<para> 5-10 mg daily × 10-14 or more days/mo (sequential estrogen); 2.5-5 mg daily (continuous estrogen)</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x2318">
						<sec_title>Contraceptive</sec_title>
						<section type="none" id="sidelem4x2326">
							<label>•</label>
							<sec_title>Adult<route> IM</route></sec_title>
							<para>
								<list id="lidelem4x2326">
									<item>
										<label>•</label>
										<para> (contraceptive inj) 150 mg q12wk;  (depot SUBCUT Provera 104 inj) 104 mg q3mo</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x2333">
						<sec_title>Endometrial/renal cancer</sec_title>
						<section type="none" id="sidelem4x2341">
							<label>•</label>
							<sec_title>Adult<route> IM</route></sec_title>
							<para>
								<list id="lidelem4x2341">
									<item>
										<label>•</label>
										<para> 400 mg-1 g (using 400 mg/ml depot inj susp) weekly</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x2345">
						<sec_title>Hot flashes/symptoms of menopause (unlabeled)</sec_title>
						<section type="none" id="sidelem4x2353">
							<label>•</label>
							<sec_title>Adult (female)<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x2353">
									<item>
										<label>•</label>
										<para> 20 mg/day;  150 mg monthly</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x2360">
						<sec_title>Hot flashes (men) in prostate cancer (unlabeled)</sec_title>
						<section type="none" id="sidelem4x2368">
							<label>•</label>
							<sec_title>Adult (male)<route> IM</route></sec_title>
							<para>
								<list id="lidelem4x2368">
									<item>
										<label>•</label>
										<para> Depot 150 or 400 mg</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x2372">
						<sec_title>Available forms:</sec_title>
						<para> Tabs 2.5, 5, 10 mg; inj susp, 150, 400 mg/ml; depot-SUBCUT inj: 104 mg/0.65 ml</para>
					</section>
					<section type="none" id="sidelem4x2377">
						<sec_title>Administer:</sec_title>
						<para>
							<list id="lidelem4x2381">
								<item>
									<label>•</label>
									<para>Store in dark area</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x2387">
							<sec_title>PO route</sec_title>
							<para>
								<list id="lidelem4x2391">
									<item>
										<label>•</label>
										<para>Give without regard to food</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x2397">
							<sec_title>IM route</sec_title>
							<para>
								<list id="lidelem4x2401">
									<item>
										<label>•</label>
										<para>Visually inspect particulate matter and discoloration before use</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x2407">
							<sec_title>Depo-Provera contraceptive injection suspension</sec_title>
							<para>
								<list id="lidelem4x2411">
									<item>
										<label>•</label>
										<para>IM only, <emphasis style="italic">never</emphasis> IV</para>
									</item>
									<item>
										<label>•</label>
										<para>Instruct patient on risks and warnings associated with hormonal contraceptives (see Patient Information)</para>
									</item>
									<item>
										<label>•</label>
										<para>The possibility of pregnancy should be excluded before giving the first dose of medroxyPROGESTERone or whenever &gt;14 wk has passed since the last dose</para>
									</item>
									<item>
										<label>•</label>
										<para>Do not dilute</para>
									</item>
									<item>
										<label>•</label>
										<para>Shake vigorously immediately before administration</para>
									</item>
									<item>
										<label>•</label>
										<para>Inject deeply into the gluteal or deltoid muscle; aspirate before injection to avoid injection into a blood vessel</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x2445">
							<sec_title>Depo-Provera sterile aqueous suspension, preserved</sec_title>
							<para>
								<list id="lidelem4x2449">
									<item>
										<label>•</label>
										<para>IM only, <emphasis style="italic">never</emphasis> IV</para>
									</item>
									<item>
										<label>•</label>
										<para>Instruct patient on risks and warnings associated with progestin use (see Patient Information)</para>
									</item>
									<item>
										<label>•</label>
										<para>Shake vigorously immediately before use</para>
									</item>
									<item>
										<label>•</label>
										<para>When multidose vials are used, take special care to prevent contamination</para>
									</item>
									<item>
										<label>•</label>
										<para>Inject deeply into the gluteal or deltoid muscle; aspirate before injection</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x2478">
							<sec_title>SUBCUT route</sec_title>
							<para/>
						</section>
						<section type="none" id="sidelem4x2482">
							<sec_title>Depo-subQ provera 104 contraceptive injection suspension <emphasis style="bold">
									<emphasis style="italic">only</emphasis>
								</emphasis></sec_title>
							<para>
								<list id="lidelem4x2489">
									<item>
										<label>•</label>
										<para>For subcut only, <emphasis style="italic">never</emphasis> give IM or IV</para>
									</item>
									<item>
										<label>•</label>
										<para>Instruct patient on risks and warnings associated with hormonal contraceptives (see Patient Information)</para>
									</item>
									<item>
										<label>•</label>
										<para>Shake vigorously for at least 1 min before use</para>
									</item>
									<item>
										<label>•</label>
										<para>Inject the entire contents of the prefilled syringe subcut into the anterior thigh or abdomen, avoiding bony areas and the umbilicus; gently grasp and squeeze a large area of skin in the chosen injection area, ensuring that the skin is pulled away from the body; insert the needle at a 45-degree angle; inject until the syringe is empty; this usually requires 5-7 sec; following use, press lightly on the injection site with a clean cotton pad for a few seconds; do not rub the area</para>
									</item>
								</list>
							</para>
						</section>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x2513">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x2516">
					<section type="none" id="sidelem4x2517">
						<sec_title>CNS:</sec_title>
						<para> Dizziness, headache, migraines, depression, fatigue, nervousness</para>
					</section>
					<section type="none" id="sidelem4x2523">
						<sec_title>CV:</sec_title>
						<para> Hypotension, thrombophlebitis, edema, <emphasis style="bold">thromboembolism, stroke, PE, MI</emphasis></para>
					</section>
					<section type="none" id="sidelem4x2530">
						<sec_title>EENT:</sec_title>
						<para> Diplopia</para>
					</section>
					<section type="none" id="sidelem4x2535">
						<sec_title>GI:</sec_title>
						<para> <emphasis style="italic">Nausea,</emphasis> vomiting, anorexia, cramps, increased weight, <emphasis style="bold">cholestatic jaundice,</emphasis> abdominal pain</para>
					</section>
					<section type="none" id="sidelem4x2546">
						<sec_title>GU:</sec_title>
						<para> Amenorrhea, cervical erosion, breakthrough bleeding, dysmenorrhea, vaginal candidiasis, breast changes, <emphasis style="italic">gynecomastia, testicular atrophy, impotence,</emphasis> endometriosis, <emphasis style="bold">spontaneous abortion,</emphasis> vaginitis, libido increased/decreased</para>
					</section>
					<section type="none" id="sidelem4x2557">
						<sec_title>INTEG:</sec_title>
						<para> Rash, urticaria, acne, hirsutism, alopecia, oily skin, seborrhea, purpura, melasma, photosensitivity, injection-site reaction</para>
					</section>
					<section type="none" id="sidelem4x2562">
						<sec_title>META:</sec_title>
						<para> Hyperglycemia</para>
					</section>
					<section type="none" id="sidelem4x2567">
						<sec_title>MS:</sec_title>
						<para> Decreased bone density</para>
					</section>
					<section type="none" id="sidelem4x2572">
						<sec_title>SYST:</sec_title>
						<para> <emphasis style="bold">Angioedema, anaphylaxis</emphasis></para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x2579">
				<sec_title>Pharmacokinetics</sec_title>
				<section type="none" id="sidelem4x2582">
					<section type="none" id="sidelem4x2583">
						<sec_title>PO:</sec_title>
						<para> Duration 3-5 days; <emphasis style="bold">IM</emphasis> duration 3-4 months; excreted in urine and feces; metabolized in liver</para>
					</section>
				</section>
			</section>
			<section type="interactions" id="sidelem4x2591">
				<sec_title>Interactions</sec_title>
				<para>
					<emphasis style="bold">Decrease:</emphasis> medroxyPROGESTERone action—aminoglutethimide, carBAMazepine, phenytoins, PHENobarbital, rifampin</para>
				<para>
					<emphasis style="bold">Decrease:</emphasis> bone mineral density—anticoagulants, corticosteroids</para>
				<section type="none" id="sidelem4x2602">
					<section type="none" id="sidelem4x2603">
						<sec_title>Drug/Lab Test</sec_title>
						<para>
							<emphasis style="bold">Increase:</emphasis> LFTs, HDL, triglycerides, coagulation tests</para>
						<para>
							<emphasis style="bold">Decrease:</emphasis> GTT</para>
					</section>
				</section>
			</section>
			<section type="considerations" id="sidelem4x2614">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x2617">
					<section type="none" id="sidelem4x2618">
						<sec_title>Assess:</sec_title>
						<para>
							<list id="lidelem4x2623">
								<item>
									<label>•</label>
									<para>Pelvic exam, Pap smear before treatment, periodically</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x2629">
								<item>
									<para>
										<emphasis alert="nurse">Severe allergic reaction, angioedema; have EPINEPHrine and rescusitative equipment available</emphasis>
									</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x2634">
								<item>
									<label>•</label>
									<para>Weight daily; notify prescriber of weekly weight gain &gt;5 lb; bone mineral density</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x2639">
								<item>
									<label>•</label>
									<para>B/P at beginning of treatment and periodically</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x2644">
								<item>
									<label>•</label>
									<para>I&amp;O ratio; be alert for decreasing urinary output, increasing edema</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x2649">
								<item>
									<label>•</label>
									<para>Hepatic studies: ALT, AST, bilirubin periodically during long-term therapy</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x2654">
								<item>
									<label>•</label>
									<para>Edema, hypertension, cardiac symptoms, jaundice</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x2659">
								<item>
									<label>•</label>
									<para>Mental status: affect, mood, behavioral changes, depression
<bbw>This product should not be given to those with breast cancer, MI, stroke, thromboembolic disorders</bbw>
</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x2676">
							<label>•</label>
							<sec_title>Bone mineral density loss</sec_title>
							<para>
								<list id="lidelem4x2676">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Bone mineral density loss:</emphasis> in those taking anticoagulants, corticosteroids with Depo-Provera or Depo-sub Q Provera
<bbw>Use of product shown to increase dementia in women ≥65 yr old; use may increase osteoporosis in long-term treatment; those who smoke also at greater risk; adequate calcium and vit D should be taken</bbw>
</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x2689">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x2693">
								<item>
									<label>•</label>
									<para>Therapeutic response: decreased abnormal uterine bleeding, absence of amenorrhea</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x2699">
						<sec_title>Teach patient/family:</sec_title>
						<para>
							<list id="lidelem4x2704">
								<item>
									<label>•</label>
									<para>To avoid sunlight or to use sunscreen; photosensitivity can occur</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x2710">
								<item>
									<para>
										<emphasis alert="nurse">To report breast lumps, vaginal bleeding, edema, jaundice, dark urine, clay-colored stools, dyspnea, headache, blurred vision, abdominal pain, sudden change in speech/coordination, numbness or stiffness in legs, chest pain; males to report impotence, gynecomastia</emphasis>
									</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x2718">
							<label>•</label>
							<sec_title>
								<route>To report suspected pregnancy (X); fertility returns 6-12 mo after discontinuing</route>
							</sec_title>
						</section>
					</section>
				</section>
			</section>
		</monograph>
<monograph id="8" status="active" ha="yes">
			<mono_name> megestrol (Rx)</mono_name>
			<info>
				<pronunciation>(me-jess′trole)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x27381">Megace</tradename>
					<tradename id="tnidelem4x27380">Megace ES</tradename>
				</tradenames>
				<class type="func"> Antineoplastic hormone</class>
				<class type="chem"> Progestin</class>
				<class type="preg">Pregnancy category <preg cat="D">D</preg></class>
			</info>
			<section type="confusion" id="sidelem4x2748">
				<para>
					<confusion>
						<tradename id="tnidelem4x27480">Megace</tradename>
						<drug type="generic" refid="idelem4x27480">Reglan</drug>
					</confusion>
				</para>
			</section>
			<section type="actions" id="sidelem4x2752">
				<sec_title>Action:</sec_title>
				<para>Affects endometrium with antiluteinizing effect; thought to bring about cell death, stimulates appetite by unknown action</para>
			</section>
			<section type="uses" id="sidelem4x2757">
				<sec_title>Uses:</sec_title>
				<para>Breast, endometrial cancer; cachexia, anorexia, weight loss with AIDS</para>
				<section type="none" id="sidelem4x2762">
					<section type="none" id="sidelem4x2763">
						<sec_title>Unlabeled uses:</sec_title>
						<para> Hot flashes in women (menopause), unexplained weight loss in geriatric patients, endometriosis, endometrial cancer, breast cancer (metastatic)</para>
					</section>
				</section>
			</section>
			<section type="contra" id="sidelem4x2768">
				<sec_title>Contraindications:</sec_title>
				<para>Pregnancy (<preg cat="D">D</preg>) tabs, (X) susp; hypersensitivity</para>
				<section type="none" id="sidelem4x2773">
					<section type="none" id="sidelem4x2774">
						<sec_title>Precautions:</sec_title>
						<para> Diabetes, thrombosis, adrenal insufficiency</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x2779">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x2782">
					<section type="none" id="sidelem4x2783">
						<sec_title>Endometrial/ovarian carcinoma</sec_title>
						<section type="none" id="sidelem4x2791">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x2791">
									<item>
										<label>•</label>
										<para> 40-320 mg/day in divided doses</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x2795">
						<sec_title>Breast carcinoma</sec_title>
						<section type="none" id="sidelem4x2803">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x2803">
									<item>
										<label>•</label>
										<para> 40 mg qid or 160 mg/day</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x2807">
						<sec_title>Cachexia (AIDS)</sec_title>
						<section type="none" id="sidelem4x2815">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x2815">
									<item>
										<label>•</label>
										<para> 800 mg/day (oral susp) or 625 mg/day (ES)</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x2819">
						<sec_title>Hot flashes (unlabeled)</sec_title>
						<section type="none" id="sidelem4x2827">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x2827">
									<item>
										<label>•</label>
										<para> 20 mg bid</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x2831">
						<sec_title>Metastatic endometrial cancer</sec_title>
						<section type="none" id="sidelem4x2839">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x2839">
									<item>
										<label>•</label>
										<para> 40-320 mg/day in divided doses × ≥2 mo</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x2843">
						<sec_title>Available forms:</sec_title>
						<para> Tabs 20, 40 mg; oral susp 40, 125 mg/ml</para>
					</section>
					<section type="none" id="sidelem4x2848">
						<sec_title>Administer:</sec_title>
						<para>
							<list id="lidelem4x2852">
								<item>
									<label>•</label>
									<para>Oral susp for AIDS patients; shake well</para>
								</item>
								<item>
									<label>•</label>
									<para>Tablets for carcinoma</para>
								</item>
								<item>
									<label>•</label>
									<para>Without regard to food</para>
								</item>
								<item>
									<label>•</label>
									<para>Store in tight container at room temperature</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x2873">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x2876">
					<section type="none" id="sidelem4x2877">
						<sec_title>CNS:</sec_title>
						<para> Mood swings, insomnia, fever, lethargy, depression</para>
					</section>
					<section type="none" id="sidelem4x2882">
						<sec_title>CV:</sec_title>
						<para> <emphasis style="bold">Thrombophlebitis, thromboembolism,</emphasis> hypertension</para>
					</section>
					<section type="none" id="sidelem4x2890">
						<sec_title>ENDO:</sec_title>
						<para> Adrenal insufficiency</para>
					</section>
					<section type="none" id="sidelem4x2895">
						<sec_title>GI:</sec_title>
						<para> Nausea, vomiting, diarrhea, abdominal cramps, weight gain, flatus, indigestion</para>
					</section>
					<section type="none" id="sidelem4x2900">
						<sec_title>GU:</sec_title>
						<para> Gynecomastia, fluid retention, hypercalcemia, vaginal bleeding, discharge, impotence, decreased libido, menstruation disorders</para>
					</section>
					<section type="none" id="sidelem4x2905">
						<sec_title>INTEG:</sec_title>
						<para> Alopecia, rash, pruritus, purpura, itching, sweating</para>
					</section>
					<section type="none" id="sidelem4x2910">
						<sec_title>META:</sec_title>
						<para> Hyperglycemia</para>
					</section>
					<section type="none" id="sidelem4x2915">
						<sec_title>MISC:</sec_title>
						<para> Tumor flare</para>
					</section>
					<section type="none" id="sidelem4x2920">
						<sec_title>RESP:</sec_title>
						<para> Dyspnea</para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x2925">
				<sec_title>Pharmacokinetics</sec_title>
				<section type="none" id="sidelem4x2928">
					<section type="none" id="sidelem4x2929">
						<sec_title>PO:</sec_title>
						<para> Half-life 13-105 hr; metabolized in liver; excreted in feces, urine, breast milk; food increases bioavailability of oral sol</para>
					</section>
				</section>
			</section>
			<section type="interactions" id="sidelem4x2934">
				<sec_title>Interactions</sec_title>
				<section type="none" id="sidelem4x2942">
					<label>•</label>
					<sec_title>
						<route>Do not use with dofetilide</route>
					</sec_title>
				</section>
				<para>
					<emphasis style="bold">Decrease:</emphasis> megestrol effect—antidiabetics</para>
				<section type="none" id="sidelem4x2949">
					<section type="none" id="sidelem4x2950">
						<sec_title>Drug/Lab Test</sec_title>
						<para>
							<emphasis style="bold">Increase:</emphasis> glucose</para>
					</section>
				</section>
			</section>
			<section type="considerations" id="sidelem4x2957">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x2960">
					<section type="none" id="sidelem4x2961">
						<sec_title>Assess:</sec_title>
						<para>
							<list id="lidelem4x2966">
								<item>
									<label>•</label>
									<para>PSA levels in men (prostate cancer); blood glucose, LFTs, serum calcium, weight</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x2971">
								<item>
									<label>•</label>
									<para>Effects of alopecia on body image; feelings about body changes</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x2976">
								<item>
									<label>•</label>
									<para>Frequency of stools, characteristics: cramping, acidosis, signs of dehydration (rapid respirations, poor skin turgor, decreased urine output, dry skin, restlessness, weakness)</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x2981">
								<item>
									<label>•</label>
									<para>Anorexia, nausea, vomiting, constipation, weakness, loss of muscle tone</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x2988">
								<item>
									<para>
										<emphasis alert="nurse">Thrombophlebitis: Homans’ sign, edema; pain in calf, thigh; notify prescriber immediately</emphasis>
									</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x2993">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x2997">
								<item>
									<label>•</label>
									<para>Therapeutic response: decreased tumor size, spread of malignancy; weight gain in AIDS patients; resolved dysfunctional uterine bleeding</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x3003">
						<sec_title>Teach patient/family:</sec_title>
						<para>
							<list id="lidelem4x3008">
								<item>
									<label>•</label>
									<para>To report vaginal bleeding</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x3013">
								<item>
									<label>•</label>
									<para>That nonhormonal contraception should be used during and for 4 mo after treatment; pregnancy (D) tabs, (X) susp</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x3018">
								<item>
									<label>•</label>
									<para>That gynecomastia, alopecia can occur; reversible after discontinuing treatment</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x3024">
								<item>
									<para>
										<emphasis alert="nurse">To recognize signs of fluid retention, thromboemboli; to report these immediately</emphasis>
									</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x3029">
								<item>
									<label>•</label>
									<para>To monitor blood glucose if diabetic</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
		</monograph>
<monograph id="9" status="active" ha="yes">
			<mono_name> melphalan (Rx)</mono_name>
			<info>
				<pronunciation>(mel′fa-lan)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x30410">Alkeran</tradename>
				</tradenames>
				<class type="func"> Antineoplastic, alkylating agent</class>
				<class type="chem"> Nitrogen mustard</class>
				<class type="preg">Pregnancy category <preg cat="D">D</preg></class>
			</info>
			<section type="confusion" id="sidelem4x3051">
				<para>
					<confusion>
						<tradename id="tnidelem4x30510">melphalan</tradename>
						<drug type="generic" refid="idelem4x30510">Myleran</drug>
					</confusion>
				</para>
			</section>
			<section type="actions" id="sidelem4x3055">
				<sec_title>Action:</sec_title>
				<para>Responsible for cross-linking DNA strands, thereby leading to cell death; activity is not cell-cycle–phase specific</para>
			</section>
			<section type="uses" id="sidelem4x3060">
				<sec_title>Uses:</sec_title>
				<para>Multiple myeloma, advanced ovarian cancer</para>
				<section type="none" id="sidelem4x3065">
					<section type="none" id="sidelem4x3066">
						<sec_title>Unlabeled uses:</sec_title>
						<para> Breast, testicular, prostate carcinoma; osteogenic sarcoma, amyloidosis, chronic myelogenous leukemia, non-Hodgkin’s lymphoma, pediatric rhabdomyosarcoma, stem cell transplant, bone marrow ablation, AML, myelodysplastic syndrome</para>
					</section>
				</section>
			</section>
			<section type="contra" id="sidelem4x3071">
				<sec_title>Contraindications:</sec_title>
				<para>Pregnancy (<preg cat="D">D</preg>), breastfeeding</para>
				<para>
					<bbw>Hypersensitivity to this product</bbw>
				</para>
				<section type="none" id="sidelem4x3086">
					<section type="none" id="sidelem4x3087">
						<sec_title>Precautions:</sec_title>
						<para> Children, radiation therapy, infections, renal disease</para>
						<para>
							<bbw>Bone marrow depression, secondary malignancy, radiation therapy; requires an experienced clinician</bbw>
						</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x3102">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x3105">
					<section type="none" id="sidelem4x3106">
						<sec_title>Multiple myeloma</sec_title>
						<section type="none" id="sidelem4x3114">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x3114">
									<item>
										<label>•</label>
										<para> 6 mg daily × 2-3 wk, adjust dose based on blood counts or 10 mg daily × 7-10 days</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x3121">
							<label>•</label>
							<sec_title>Adult<route> IV INFUSION</route></sec_title>
							<para>
								<list id="lidelem4x3121">
									<item>
										<label>•</label>
										<para> 16 mg/m<emphasis style="sup">2</emphasis>, reduce with renal insufficiency, give over 15-20 min, give at 2-wk intervals × 4 doses, then at 4-wk intervals</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x3128">
						<sec_title>Ovarian carcinoma</sec_title>
						<section type="none" id="sidelem4x3136">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x3136">
									<item>
										<label>•</label>
										<para> 200 mcg/kg/day × 5 days q4-5wk</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x3140">
						<sec_title>Available forms:</sec_title>
						<para> Tabs 2 mg, powder for inj 50 mg</para>
					</section>
					<section type="none" id="sidelem4x3145">
						<sec_title>Administer:</sec_title>
						<para>
							<list id="lidelem4x3149">
								<item>
									<label>•</label>
									<para>Antiemetic 30-60 min before product to prevent vomiting</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x3155">
							<sec_title>PO route</sec_title>
							<para>
								<list id="lidelem4x3159">
									<item>
										<label>•</label>
										<para>Give on empty stomach</para>
									</item>
									<item>
										<label>•</label>
										<para>Protect from light; store refrigerated</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x3170">
							<sec_title>Intermittent IV INFUSION route</sec_title>
							<para>
								<list id="lidelem4x3174">
									<item>
										<label>•</label>
										<para>Use gloves during administration; if skin exposure occurs, wash immediately with soap and water; use cytotoxic handling procedures</para>
									</item>
									<item>
										<label>•</label>
										<para>Give after reconstituting with 10 ml diluent provided (5 mg/ml); shake, dilute dose with 0.9% NaCl (≤0.45 mg/ml); give within 1 hr, run over ≥15-20 min; degrading of product occurs rapidly; make sure infusion is completed in time specified</para>
									</item>
								</list>
							</para>
							<para>
								<emphasis style="bold">Y-site compatibilities:</emphasis> Acyclovir, amikacin, aminophylline, ampicillin, aztreonam, bleomycin, bumetanide, buprenorphine, butorphanol, calcium gluconate, CARBOplatin, carmustine, ceFAZolin, cefepime, cefoperazone, cefotaxime, cefoTEtan, cefTAZidime, ceftizoxime, cefTRIAXone, cefuroxime, cimetidine, CISplatin, clindamycin, cyclophosphamide, cytarabine, dacarbazine, DACTINomycin, DAUNOrubicin, dexamethasone, diphenhy-drAMINE, DOXOrubicin, doxycycline, droperidol, enalaprilat, etoposide, famotidine, floxuridine, fluconazole, flu-darabine, fluorouracil, furosemide, gallium, ganciclovir, gentamicin, grani-setron, haloperidol, heparin, hydrocortisone, hydrocortisone sodium phosphate, HYDROmorphone, hydrOXYzine, IDArubicin, ifosfamide, imipenem-cilastatin, LORazepam, mannitol, mechlorethamine, meperidine, mesna, methotrexate, methylPREDNISolone, metoclopramide, metroNIDAZOLE, miconazole, minocycline, mitoMYcin, mitoXANtrone, morphine, nalbuphine, netilmicin, ondansetron, pentostatin, piperacillin, plicamycin, potassium chloride, prochlorperazine, promethazine, ranitidine, sodium bicarbonate, streptozocin, teniposide, thiotepa, ticarcillin, ticarcillin/clavulanate, tobramycin, trimethoprim-sulfamethoxazole, vancomycin, vinBLAStine, vinCRIStine, vinorelbine, zidovudine</para>
						</section>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x3191">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x3194">
					<section type="none" id="sidelem4x3195">
						<sec_title>GI:</sec_title>
						<para> <emphasis style="italic">Nausea, vomiting,</emphasis> stomatitis, diarrhea, <emphasis style="bold">hepatotoxicity</emphasis></para>
					</section>
					<section type="none" id="sidelem4x3205">
						<sec_title>GU:</sec_title>
						<para> Amenorrhea, hyperuricemia, gonadal suppression, hyperuricemia</para>
					</section>
					<section type="none" id="sidelem4x3210">
						<sec_title>HEMA:</sec_title>
						<para> <emphasis style="bold">Thrombocytopenia, neutropenia, leukopenia,</emphasis> anemia</para>
					</section>
					<section type="none" id="sidelem4x3218">
						<sec_title>INTEG:</sec_title>
						<para> Rash, urticaria, alopecia, pruritus, necrosis, extravasation</para>
					</section>
					<section type="none" id="sidelem4x3223">
						<sec_title>RESP:</sec_title>
						<para> <emphasis style="bold">Fibrosis, dysplasia,</emphasis> dyspnea, pneumonitis</para>
					</section>
					<section type="none" id="sidelem4x3231">
						<sec_title>SYST:</sec_title>
						<para> <emphasis style="bold">Anaphylaxis,</emphasis> allergic reactions, <emphasis style="bold">secondary malignancies,</emphasis> edema</para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x3242">
				<sec_title>Pharmacokinetics</sec_title>
				<para>Metabolized in liver, excreted in urine, half-life 2 hr, protein binding ≤30%-90%</para>
			</section>
			<section type="interactions" id="sidelem4x3247">
				<sec_title>Interactions</sec_title>
				<para>
					<list id="lidelem4x3251">
						<item>
							<label>•</label>
							<para>Avoid administration of sargramostim, GM-CSF, filgrastim, G-CSF 24 hr before or 24 hr after product</para>
						</item>
					</list>
				</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> toxicity—antineoplastics, radiation</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> pulmonary toxicity—carmustine</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> renal failure risk—cycloSPORINE</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> enterocolitis risk—nalidixic acid</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> bleeding risk—NSAIDs, anticoagulants, salicylates, thrombolytics, platelet inhibitors</para>
				<para>
					<emphasis style="bold">Decrease:</emphasis> antibody response—live virus vaccines</para>
				<section type="none" id="sidelem4x3281">
					<section type="none" id="sidelem4x3282">
						<sec_title>Drug/Lab Test</sec_title>
						<para>
							<emphasis style="bold">Decrease:</emphasis> Hgb, RBC, WBC, platelets</para>
						<para>
							<emphasis style="bold">False-positive:</emphasis> Direct Coombs’ test</para>
					</section>
				</section>
			</section>
			<section type="considerations" id="sidelem4x3293">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x3296">
					<section type="none" id="sidelem4x3297">
						<sec_title>Assess:</sec_title>
						<para>
							<bbw>
								<emphasis alert="lifethreat">Bone marrow depression:</emphasis> Full nadir 2-3 wk; CBC, differential, platelet count weekly; notify prescriber, withhold product if WBC is &lt;3000/mm3 or platelet count is &lt;100,000/mm3; notify prescriber; recovery usually occurs in 6 wk</bbw>
						</para>
						<para>
							<list id="lidelem4x3319">
								<item>
									<label>•</label>
									<para>Renal studies: BUN, serum uric acid before, during therapy</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x3324">
								<item>
									<label>•</label>
									<para>I&amp;O ratio; report fall in urine output to 30 ml/hr</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x3332">
							<label>•</label>
							<sec_title>Infection</sec_title>
							<para>
								<list id="lidelem4x3332">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Infection:</emphasis> fever, cough, temperature, chills, sore throat; notify prescriber</para>
									</item>
								</list>
							</para>
						</section>
						<para>
							<list id="lidelem4x3336">
								<item>
									<label>•</label>
									<para>Hepatic studies before, during therapy (bilirubin, AST, ALT, LDH) as needed; jaundiced skin and sclera, dark urine, clay-colored stools, itchy skin, abdominal pain, fever, diarrhea</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x3344">
							<label>•</label>
							<sec_title>Bleeding</sec_title>
							<para>
								<list id="lidelem4x3344">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Bleeding:</emphasis> hematuria, guaiac, bruising or petechiae, mucosa or orifices q8hr</para>
									</item>
								</list>
							</para>
						</section>
						<para>
							<list id="lidelem4x3348">
								<item>
									<label>•</label>
									<para>Buccal cavity q8hr for dryness, sores, ulceration, white patches, oral pain, bleeding, dysphagia</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x3353">
								<item>
									<label>•</label>
									<para>Local irritation, pain, burning, discoloration at inj site</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x3361">
							<label>•</label>
							<sec_title>Hyperuricemia</sec_title>
							<para>
								<list id="lidelem4x3361">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Hyperuricemia:</emphasis> joint pain, edema, increased uric acid, increase fluids to &gt;2 L unless contraindicated, monitor uric acid levels</para>
									</item>
								</list>
							</para>
						</section>
						<para>
							<list id="lidelem4x3367">
								<item>
									<para>
										<emphasis alert="nurse">Severe allergic reaction: rash, pruritus, urticaria, purpuric skin lesions, itching, flushing; assess allergy to chlorambucil; cross-sensitivity may occur</emphasis>
									</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x3372">
								<item>
									<label>•</label>
									<para>Increase fluid intake to 2-3 L/day to prevent urate deposits, calculi formation</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x3377">
								<item>
									<label>•</label>
									<para>Rinsing of mouth tid-qid with water, club soda; brushing of teeth bid-tid with soft brush or cotton-tipped applicators for stomatitis; use unwaxed dental floss</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x3382">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x3386">
								<item>
									<label>•</label>
									<para>Therapeutic response: decreased tumor size, spread of malignancy</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x3392">
						<sec_title>Teach patient/family:</sec_title>
						<para>
							<list id="lidelem4x3397">
								<item>
									<label>•</label>
									<para>That usually sterility, amenorrhea occur; reversible after discontinuing treatment</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x3402">
								<item>
									<label>•</label>
									<para>To avoid foods with citric acid, hot or rough texture</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x3407">
								<item>
									<label>•</label>
									<para>To report any bleeding, white spots, or ulcerations in mouth to prescriber; to examine mouth daily</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x3412">
								<item>
									<label>•</label>
									<para>To report signs of infection: fever, sore throat, flulike symptoms</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x3420">
							<label>•</label>
							<sec_title>
								<route>To report suspected pregnancy; to use contraception during treatment; pregnancy (D)</route>
							</sec_title>
						</section>
						<para>
							<list id="lidelem4x3423">
								<item>
									<label>•</label>
									<para>To report signs of anemia: fatigue, headache, faintness, SOB, irritability, nausea/vomiting, dehydration, decreased urine output</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x3428">
								<item>
									<label>•</label>
									<para>To avoid use of aspirin products, NSAIDs, alcohol</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
		</monograph>
<monograph id="10" status="active">
			<mono_name>memantine (Rx)</mono_name>
			<info>
				<pronunciation>(me-man′teen)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x34382">
						<country code="CAN">Ebixa </country>
					</tradename>
					<tradename id="tnidelem4x34381">Namenda</tradename>
					<tradename id="tnidelem4x34380">Namenda XR</tradename>
				</tradenames>
				<class type="func"> Anti-Alzheimer agent</class>
				<class type="chem"> NMDA receptor antagonist</class>
				<class type="preg">Pregnancy category <preg cat="B">B</preg></class>
			</info>
			<section type="actions" id="sidelem4x3451">
				<sec_title>Action:</sec_title>
				<para>Antagonist action of CNS NMDA receptors that may contribute to the symptoms of Alzheimer’s disease</para>
			</section>
			<section type="uses" id="sidelem4x3456">
				<sec_title>Uses:</sec_title>
				<para>Moderate to severe dementia in Alzheimer’s disease</para>
				<section type="none" id="sidelem4x3461">
					<section type="none" id="sidelem4x3462">
						<sec_title>Unlabeled uses:</sec_title>
						<para> Vascular dementia, acquired pendular nystagmus</para>
					</section>
				</section>
			</section>
			<section type="contra" id="sidelem4x3467">
				<sec_title>Contraindications:</sec_title>
				<para>Children, hypersensitivity</para>
				<section type="none" id="sidelem4x3472">
					<section type="none" id="sidelem4x3473">
						<sec_title>Precautions:</sec_title>
						<para> Pregnancy (<preg cat="B">B</preg>), breastfeeding, renal disease, GU conditions that raise urine pH, seizures, severe hepatic disease, renal failure</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x3478">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x3486">
					<label>•</label>
					<sec_title>Adult<route> PO</route></sec_title>
					<para>
						<list id="lidelem4x3486">
							<item>
								<label>•</label>
								<para> 5 mg/day, may increase dose in 5-mg increments ≥1 wk intervals over a 3-wk period; recommended target dose as 10 mg bid; at wk 4; ext rel 7 mg daily, increased by 7 mg ≥1 wk up to target dose of 28 mg daily</para>
							</item>
						</list>
					</para>
				</section>
				<section type="none" id="sidelem4x3490">
					<section type="none" id="sidelem4x3491">
						<sec_title>Available forms:</sec_title>
						<para> Tabs 5, 10 mg; tab titration pak 5, 10 mg; oral sol 2 mg/ml (10 mg/5 ml); cap ext rel 7, 14, 21, 28 mg</para>
					</section>
					<section type="none" id="sidelem4x3496">
						<sec_title>Administer:</sec_title>
						<para>
							<list id="lidelem4x3501">
								<item>
									<label>•</label>
									<para>Can be taken without regard to meals</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x3506">
								<item>
									<label>•</label>
									<para>Twice a day if dose &gt;5 mg</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x3511">
								<item>
									<label>•</label>
									<para>Dosage adjusted to response no more than q1wk</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x3519">
							<label>•</label>
							<sec_title>Ext rel caps</sec_title>
							<para>
								<list id="lidelem4x3519">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Ext rel caps:</emphasis> do not crush, chew, divide; swallow whole or open and sprinkle on applesauce</para>
									</item>
								</list>
							</para>
						</section>
						<para>
							<list id="lidelem4x3523">
								<item>
									<label>•</label>
									<para>When switching from immediate release product, begin the ext rel the day after the last dose of immediate release product. Those on 10 mg bid should be switched to ext rel 28 mg daily</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x3531">
							<label>•</label>
							<sec_title>
								<route>Oral sol</route>
							</sec_title>
							<para>
								<list id="lidelem4x3531">
									<item>
										<label>•</label>
										<para> using device provided; remove dosing syringe, green cap, plastic tube from plastic; attach tube to green cap; open cap by pushing down on cap, turning counterclockwise; remove unscrewed cap; remove seal from bottle, discard; insert plastic tube fully into bottle, screw green cap tightly onto bottle by turning cap clockwise; keeping bottle upright on table, remove lid; with plunger fully depressed, insert tip of syringe into cap; while holding syringe, gently pull up on plunger; remove syringe; invert syringe, slowly press plunger to level that removes large air bubbles; keep plunger in inverted position; few small air bubbles may be present</para>
									</item>
								</list>
							</para>
						</section>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x3535">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x3538">
					<section type="none" id="sidelem4x3539">
						<sec_title>CNS:</sec_title>
						<para> <emphasis style="italic">Dizziness, confusion,</emphasis> somnolence, headache, hallucinations, <emphasis style="bold">stroke,</emphasis> insomnia, depression, anxiety</para>
					</section>
					<section type="none" id="sidelem4x3550">
						<sec_title>CV:</sec_title>
						<para> Hypertension, <emphasis style="bold">heart failure, CHF</emphasis></para>
					</section>
					<section type="none" id="sidelem4x3557">
						<sec_title>GI:</sec_title>
						<para> Vomiting, constipation</para>
					</section>
					<section type="none" id="sidelem4x3562">
						<sec_title>HEMA:</sec_title>
						<para> Anemia</para>
					</section>
					<section type="none" id="sidelem4x3568">
						<sec_title>INTEG:</sec_title>
						<para> Rash</para>
					</section>
					<section type="none" id="sidelem4x3573">
						<sec_title>MISC:</sec_title>
						<para> Back pain, fatigue, pain, influenza-like symptoms</para>
					</section>
					<section type="none" id="sidelem4x3578">
						<sec_title>RESP:</sec_title>
						<para> Coughing, dyspnea</para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x3583">
				<sec_title>Pharmacokinetics</sec_title>
				<para>Rapidly absorbed PO, 44% protein binding, very little metabolism, 57%-82% excreted unchanged in urine, terminal elimination half-life 60-80 hr</para>
			</section>
			<section type="interactions" id="sidelem4x3588">
				<sec_title>Interactions</sec_title>
				<para>
					<emphasis style="bold">Increase/decrease:</emphasis> both products: hydrochlorothiazide, triamterene, cimetidine, quiNIDine, ranitidine, nicotine</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> effect—levodopa, some ergots</para>
				<para>
					<emphasis style="bold">Decrease:</emphasis> clearance of memantine—products that make urine alkaline (sodium bicarbonate, carbonic anhydrase inhibitors)<list id="lidelem4x3603">
						<item>
							<label>•</label>
							<para>Use cautiously with amantadine, dextromethorphan, ketamine; reaction unknown</para>
						</item>
					</list></para>
				<section type="none" id="sidelem4x3609">
					<section type="none" id="sidelem4x3610">
						<sec_title>Drug/Lab Test</sec_title>
						<para>
							<emphasis style="bold">Increase:</emphasis> alkaline phosphatase</para>
					</section>
				</section>
			</section>
			<section type="considerations" id="sidelem4x3617">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x3620">
					<section type="none" id="sidelem4x3621">
						<sec_title>Assess:</sec_title>
						<section type="none" id="sidelem4x3629">
							<label>•</label>
							<sec_title>Alzheimer’s dementia</sec_title>
							<para>
								<list id="lidelem4x3629">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Alzheimer’s dementia:</emphasis> affect, mood, behavioral changes; hallucinations, confusion, attention, orientation, memory; monitor serum creatinine</para>
									</item>
								</list>
							</para>
						</section>
						<para>
							<list id="lidelem4x3633">
								<item>
									<label>•</label>
									<para>Provide assistance with ambulation during beginning therapy; dizziness may occur</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x3638">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x3642">
								<item>
									<label>•</label>
									<para>Therapeutic response: decrease in confusion, improved mood, maintenance of function, even with no improvement in symptoms</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x3648">
						<sec_title>Teach patient/family:</sec_title>
						<para>
							<list id="lidelem4x3652">
								<item>
									<label>•</label>
									<para>To report side effects: restlessness, psychosis, visual hallucinations, stupor, LOC; may indicate overdose</para>
								</item>
								<item>
									<label>•</label>
									<para>To use product exactly as prescribed; that product not a cure; to avoid alcohol, nicotine</para>
								</item>
								<item>
									<label>•</label>
									<para>To use oral sol dispenser</para>
								</item>
								<item>
									<label>•</label>
									<para>To avoid OTC, herbal products unless approved by prescriber</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
		</monograph>
<monograph id="11" status="active" ha="yes">
			<mono_name> meperidine (Rx)</mono_name>
			<info>
				<pronunciation>(me-per′i-deen)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x36801">Demerol</tradename>
					<tradename id="tnidelem4x36800">Meperitab</tradename>
				</tradenames>
				<class type="func"> Opioid analgesic</class>
				<class type="chem"> Phenylpiperidine derivative</class>
				<class type="preg">Pregnancy category <preg cat="C">C</preg></class>
				<class type="schedule">Controlled Substance Schedule <schedule num="2">II</schedule></class>
			</info>
			<section type="confusion" id="sidelem4x3692">
				<para>
					<confusion>
						<tradename id="tnidelem4x36920">meperidine</tradename>
						<drug type="generic" refid="idelem4x36920">HYDROmorphone/meprobamate/morphine</drug>
					</confusion>
				</para>
			</section>
			<section type="actions" id="sidelem4x3699">
				<sec_title>Action:</sec_title>
				<para>Depresses pain impulse transmission at the spinal cord level by interacting with opioid receptors</para>
			</section>
			<section type="uses" id="sidelem4x3704">
				<sec_title>Uses:</sec_title>
				<para>Moderate to severe pain preoperatively, postoperatively, general anesthesia maintenance, sedation induction</para>
				<section type="none" id="sidelem4x3709">
					<section type="none" id="sidelem4x3710">
						<sec_title>Unlabeled uses:</sec_title>
						<para> Obstetric/regional analgesic, acute severe headache/migraine, shaking chills induced by IV amphotericin B or postoperative shivering</para>
					</section>
				</section>
			</section>
			<section type="contra" id="sidelem4x3715">
				<sec_title>Contraindications:</sec_title>
				<para>Hypersensitivity, severe respiratory insufficiency, MAOI therapy</para>
				<section type="none" id="sidelem4x3720">
					<section type="none" id="sidelem4x3721">
						<sec_title>Precautions:</sec_title>
						<para> Pregnancy (<preg cat="C">C</preg>), breastfeeding, children, geriatric patients, addictive personality, increased intracranial pressure, respiratory depression, renal/hepatic disease, seizure disorder, abrupt discontinuation, chronic pain, cardiac disease, adrenal insufficiency, alcoholism, angina, anticoagulant therapy, asthma, atrial flutter, biliary tract disease, bladder obstruction, cardiac dysrhythmias, COPD, CNS depression, coagulopathy, constipation, cor pulmonale, dehydration, diarrhea, driving, epidural use, geriatric patients, GI obstruction, head trauma, heart failure, hypotension, hypothyroidism, ileus, IBS, IM/intrathecal/IV use, labor, myxedema, thrombocytopenia</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x3727">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x3730">
					<section type="none" id="sidelem4x3731">
						<sec_title>Moderate to severe pain</sec_title>
						<section type="none" id="sidelem4x3739">
							<label>•</label>
							<sec_title>Adult<route> PO/SUBCUT/IM</route></sec_title>
							<para>
								<list id="lidelem4x3739">
									<item>
										<label>•</label>
										<para> 50-150 mg q3-4hr prn</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x3746">
							<label>•</label>
							<sec_title>Child<route> PO/SUBCUT/IM</route></sec_title>
							<para>
								<list id="lidelem4x3746">
									<item>
										<label>•</label>
										<para> 1-1.8 mg/kg q3-4hr prn, max single dose 150 mg</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x3750">
						<sec_title>Labor analgesia</sec_title>
						<section type="none" id="sidelem4x3758">
							<label>•</label>
							<sec_title>Adult<route> SUBCUT/IM</route></sec_title>
							<para>
								<list id="lidelem4x3758">
									<item>
										<label>•</label>
										<para> 50-100 mg given when contractions regularly spaced, repeat q1-3hr prn</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x3762">
						<sec_title>Preoperatively</sec_title>
						<section type="none" id="sidelem4x3770">
							<label>•</label>
							<sec_title>Adult<route> IM/SUBCUT</route></sec_title>
							<para>
								<list id="lidelem4x3770">
									<item>
										<label>•</label>
										<para> 50-100 mg 30-90 min before surgery</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x3777">
							<label>•</label>
							<sec_title>Child<route> IM/SUBCUT</route></sec_title>
							<para>
								<list id="lidelem4x3777">
									<item>
										<label>•</label>
										<para> 1-2.2 mg/kg 30-90 min before surgery, max 100 mg</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x3781">
						<sec_title>Shaking chills (unlabeled)</sec_title>
						<section type="none" id="sidelem4x3789">
							<label>•</label>
							<sec_title>Adult<route> IV</route></sec_title>
							<para>
								<list id="lidelem4x3789">
									<item>
										<label>•</label>
										<para> 25-50 mg as a single dose</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x3796">
							<label>•</label>
							<sec_title>Child/adolescent<route> IV</route></sec_title>
							<para>
								<list id="lidelem4x3796">
									<item>
										<label>•</label>
										<para> 0.35-1 mg/kg, max adult dose</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x3800">
						<sec_title>Renal dose</sec_title>
						<section type="none" id="sidelem4x3808">
							<label>•</label>
							<sec_title>
								<route>Avoid or modify dose</route>
							</sec_title>
						</section>
					</section>
					<section type="none" id="sidelem4x3811">
						<sec_title>Available forms:</sec_title>
						<para> Inj 10, 25, 50, 75, 100 mg/ml; tabs 50, 100 mg; oral sol 50 mg/5 ml</para>
					</section>
					<section type="none" id="sidelem4x3816">
						<sec_title>Administer:</sec_title>
						<section type="none" id="sidelem4x3819">
							<sec_title>PO route</sec_title>
							<para>
								<list id="lidelem4x3824">
									<item>
										<label>•</label>
										<para>May give with food or milk to decrease GI irritation</para>
									</item>
								</list>
							</para>
							<section type="none" id="sidelem4x3832">
								<label>•</label>
								<sec_title>Oral liquid</sec_title>
								<para>
									<list id="lidelem4x3832">
										<item>
											<label>•</label>
											<para>
												<emphasis style="bold">Oral liquid:</emphasis> dilute in 4 oz water</para>
										</item>
									</list>
								</para>
							</section>
							<para>
								<list id="lidelem4x3836">
									<item>
										<label>•</label>
										<para>Store in light-resistant container at room temperature</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x3841">
							<sec_title>IM/SUBCUT route</sec_title>
							<para>
								<list id="lidelem4x3845">
									<item>
										<label>•</label>
										<para>Patient should remain recumbent for 1 hr after IM/SUBCUT route</para>
									</item>
									<item>
										<label>•</label>
										<para>With antiemetic for nausea, vomiting</para>
									</item>
									<item>
										<label>•</label>
										<para>When pain beginning to return; determine dosage interval by patient response</para>
									</item>
									<item>
										<label>•</label>
										<para>In gradually decreasing dose after long-term use; withdrawal symptoms may occur</para>
									</item>
									<item>
										<label>•</label>
										<para>Inject IM into large muscle mass; IM preferred route for multiple inj</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x3871">
							<sec_title>Direct IV route</sec_title>
							<para>
								<list id="lidelem4x3875">
									<item>
										<label>•</label>
										<para>Dilute to concentration of 10 mg/ml with sterile water for inj or NS</para>
									</item>
									<item>
										<label>•</label>
										<para>Inject slowly ≤25 mg/min</para>
									</item>
									<item>
										<label>•</label>
										<para>Have emergency equipment and opiate antagonist on hand</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x3891">
							<sec_title>Continuous IV INFUSION route</sec_title>
							<para>
								<list id="lidelem4x3895">
									<item>
										<label>•</label>
										<para>Dilute to concentration of 1 mg/ml</para>
									</item>
									<item>
										<label>•</label>
										<para>Infuse using infusion pump</para>
									</item>
								</list>
							</para>
							<para>
								<emphasis style="bold">Syringe compatibilities:</emphasis> Acetaminophen, butorphanol, chlorproMAZINE, cimetidine, dimenhyDRINATE, diphenhydrAMINE, droperidol, fentaNYL, glycopyrrolate, hydrOXYzine, ketamine, metoclopramide, midazolam, ondansetron, pentazocine, perphenazine, prochlorperazine, promazine, ranitidine, scopolamine</para>
							<para>
								<emphasis style="bold">Y-site compatibilities:</emphasis> Abelcet, acetaminophen, amifostine, amikacin, anidulafungin, atenolol, aztreonam, bumetanide, ceFAZolin, cefotaxime, cefOXitin, cefTAZidime, ceftizoxime, cefTRIAXone, cefuroxime, cisatracurium, cladribine, clindamycin, diltiazem, diphenhydrAMINE, DOBUTamine, DOPamine, DOXOrubicin HCL, doxycycline, droperidol, erythromycin, famotidine, filgrastim, fluconazole, fludarabine, gallium, gentamicin, granisetron, hydrocortisone, insulin (regular), kanamycin, labetalol, lidocaine, methyldopate, melphalan, metoclopramide, metoprolol, metroNIDAZOLE, ondansetron, oxytocin, PACLitaxel, penicillin G potassium, piperacillin, potassium chloride, propofol, propranolol, ranitidine, remifentanil, sargramostim, teniposide, thiotepa, ticarcillin, ticarcillin/clavulanate, tobramycin, vancomycin, verapamil, vinorelbine</para>
						</section>
						<section type="none" id="sidelem4x3914">
							<sec_title>Continuous intrathecal INFUSION route</sec_title>
							<para>
								<list id="lidelem4x3918">
									<item>
										<label>•</label>
										<para>Use controlled infusion device; implantable controlled microinfusion device used for highly concentrated infusion; monitor for several days after implantation</para>
									</item>
									<item>
										<label>•</label>
										<para>Filling of infusion reservoir should only be done by those fully qualified</para>
									</item>
									<item>
										<label>•</label>
										<para>To prevent pain, depletion of reservoir should be avoided</para>
									</item>
								</list>
							</para>
						</section>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x3934">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x3937">
					<section type="none" id="sidelem4x3938">
						<sec_title>CNS:</sec_title>
						<para> <emphasis style="italic">Drowsiness, dizziness, confusion, headache, sedation, euphoria,</emphasis><emphasis style="bold">increased intracranial pressure, seizures,</emphasis> serotonin syndrome</para>
					</section>
					<section type="none" id="sidelem4x3948">
						<sec_title>CV:</sec_title>
						<para> Palpitations, bradycardia, hypotension, change in B/P, tachycardia (IV)</para>
					</section>
					<section type="none" id="sidelem4x3954">
						<sec_title>EENT:</sec_title>
						<para> Tinnitus, blurred vision, miosis, diplopia, depressed corneal reflex</para>
					</section>
					<section type="none" id="sidelem4x3959">
						<sec_title>GI:</sec_title>
						<para> Nausea, vomiting, anorexia, constipation, cramps, biliary spasm, paralytic ileus</para>
					</section>
					<section type="none" id="sidelem4x3964">
						<sec_title>GU:</sec_title>
						<para> Urinary retention, dysuria</para>
					</section>
					<section type="none" id="sidelem4x3969">
						<sec_title>INTEG:</sec_title>
						<para> Rash, urticaria, bruising, flushing, diaphoresis, pruritus</para>
					</section>
					<section type="none" id="sidelem4x3974">
						<sec_title>RESP:</sec_title>
						<para> <emphasis style="bold">Respiratory depression</emphasis></para>
					</section>
					<section type="none" id="sidelem4x3981">
						<sec_title>SYST:</sec_title>
						<para> <emphasis style="bold">Anaphylaxis</emphasis></para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x3988">
				<sec_title>Pharmacokinetics</sec_title>
				<para>Metabolized by liver (to active/inactive metabolites), excreted by kidneys; crosses placenta, excreted in breast milk; half-life 3-4 hr; toxic by-product accumulation can result from regular use or renal disease; protein binding 65%-75%</para>
				<section type="none" id="sidelem4x3993">
					<section type="none" id="sidelem4x3994">
						<sec_title>PO:</sec_title>
						<para> Onset 15 min, peak 1.5 hr, duration 2-4 hr, absorption 50%</para>
					</section>
					<section type="none" id="sidelem4x3999">
						<sec_title>SUBCUT/IM:</sec_title>
						<para> Onset 10 min, peak 30-60 min, duration 2-4 hr, well absorbed</para>
					</section>
					<section type="none" id="sidelem4x4004">
						<sec_title>IV:</sec_title>
						<para> Onset immediate, peak 5-7 min, duration 2 hr</para>
					</section>
				</section>
			</section>
			<section type="interactions" id="sidelem4x4009">
				<sec_title>Interactions</sec_title>
				<para>
					<emphasis alert="nurse">May cause fatal reaction: MAOIs, procarbazine</emphasis>
				</para>
				<para>
					<emphasis alert="lifethreat">Increase: serotonin syndrome, neuroleptic malignant syndrome, SSRIs, SNRIs, serotonin-receptor agonists</emphasis>
				</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> effects with other CNS depressants, alcohol, opioids, sedative/hypnotics, antipsychotics, skeletal muscle relaxants</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> adverse reactions—protease inhibitor antiretrovirals</para>
				<para>
					<emphasis style="bold">Decrease:</emphasis> meperidine effect—phenytoin</para>
				<section type="none" id="sidelem4x4032">
					<section type="none" id="sidelem4x4033">
						<sec_title>Drug/Herb</sec_title>
						<para>
							<emphasis style="bold">Increase:</emphasis> CNS depression—St. John’s wort</para>
					</section>
					<section type="none" id="sidelem4x4040">
						<sec_title>Drug/Lab Test</sec_title>
						<para>
							<emphasis style="bold">Increase:</emphasis> amylase, lipase</para>
					</section>
				</section>
			</section>
			<section type="considerations" id="sidelem4x4047">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x4050">
					<section type="none" id="sidelem4x4051">
						<sec_title>Assess:</sec_title>
						<section type="none" id="sidelem4x4059">
							<label>•</label>
							<sec_title>Pain</sec_title>
							<para>
								<list id="lidelem4x4059">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Pain:</emphasis> location, type, character; give product before pain becomes extreme; reassess after 60 min (IM, SUBCUT, PO) and 5-10 min (IV)</para>
									</item>
								</list>
							</para>
						</section>
						<para>
							<list id="lidelem4x4063">
								<item>
									<label>•</label>
									<para>Renal function before initiating therapy; poor renal function can lead to accumulation of toxic metabolite and seizures</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x4068">
								<item>
									<label>•</label>
									<para>I&amp;O ratio; check for decreasing output; may indicate urinary retention</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x4073">
								<item>
									<label>•</label>
									<para>For constipation; increase fluids, bulk in diet; give stimulant laxatives if needed</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x4078">
								<item>
									<label>•</label>
									<para>CNS changes: dizziness, drowsiness, hallucinations, euphoria, LOC, pupil reactions with chronic or high-dose use</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x4083">
								<item>
									<label>•</label>
									<para>Allergic reactions: rash, urticaria</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x4089">
								<item>
									<para>
										<emphasis alert="nurse">Respiratory dysfunction: depression, character, rate, rhythm; notify prescriber if respirations are &lt;12/min</emphasis>
									</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x4094">
								<item>
									<label>•</label>
									<para>CNS stimulation: with chronic or high doses</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x4099">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x4103">
								<item>
									<label>•</label>
									<para>Therapeutic response: decrease in pain</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x4109">
						<sec_title>Teach patient/family:</sec_title>
						<para>
							<list id="lidelem4x4113">
								<item>
									<label>•</label>
									<para>To report any symptoms of CNS changes, allergic reactions</para>
								</item>
								<item>
									<label>•</label>
									<para>That physical dependency may result from extended use; use should be short-term only</para>
								</item>
								<item>
									<label>•</label>
									<para>That drowsiness, dizziness may occur</para>
								</item>
								<item>
									<label>•</label>
									<para>That withdrawal symptoms may occur: nausea, vomiting, cramps, fever, faintness, anorexia</para>
								</item>
								<item>
									<label>•</label>
									<para>To make position changes slowly; orthostatic hypotension can occur</para>
								</item>
								<item>
									<label>•</label>
									<para>To avoid OTC medications, alcohol unless directed by prescriber</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
		</monograph>
<monograph id="12" status="active" ha="yes">
			<mono_name> mercaptopurine (6-MP) (Rx)</mono_name>
			<info>
				<pronunciation>(mer-kap-toe-pyoor′een)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x41591">Purinethol</tradename>
					<tradename id="tnidelem4x41590">Purixan</tradename>
				</tradenames>
				<class type="func"> Antineoplastic-antimetabolite</class>
				<class type="chem"> Purine analog</class>
				<class type="preg">Pregnancy category <preg cat="D">D</preg></class>
			</info>
			<section type="actions" id="sidelem4x4169">
				<sec_title>Action:</sec_title>
				<para>Inhibits purine metabolism at multiple sites, which inhibits DNA and RNA synthesis; specific for S phase of cell cycle</para>
			</section>
			<section type="uses" id="sidelem4x4176">
				<sec_title>Uses:</sec_title>
				<para>Acute lymphocytic leukemia</para>
				<section type="none" id="sidelem4x4181">
					<section type="none" id="sidelem4x4182">
						<sec_title>Unlabeled uses:</sec_title>
						<para> Ulcerative colitis, Crohn’s disease</para>
					</section>
				</section>
			</section>
			<section type="contra" id="sidelem4x4187">
				<sec_title>Contraindications:</sec_title>
				<para>Pregnancy (<preg cat="D">D</preg>), breastfeeding, patients with prior product resistance, hypersensitivity</para>
				<section type="none" id="sidelem4x4192">
					<section type="none" id="sidelem4x4193">
						<sec_title>Precautions:</sec_title>
						<para> Renal/hepatic disease, tumor lysis syndrome, dental disease, herpes, radiation therapy, leukopenia, thrombocytopenia, anemia, requires an experienced clinician, secondary malignancy, infection, hypocalcemia, hyperuricemia, hyperphosphatemia, hyperkalemia</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x4198">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x4201">
					<section type="none" id="sidelem4x4202">
						<sec_title>Acute lymphocytic leukemia</sec_title>
						<section type="none" id="sidelem4x4210">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x4210">
									<item>
										<label>•</label>
										<para> 2.5-5 mg/kg/day or 80-100 mg/m<emphasis style="sup">2</emphasis>/day, maintenance 1.5-2.5 mg/kg/day</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x4220">
							<label>•</label>
							<sec_title>Child<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x4220">
									<item>
										<label>•</label>
										<para> 2.5-5 mg/kg/day, maintenance 1.5-2.5 mg/kg/day or 70-100 mg/m<emphasis style="sup">2</emphasis>/day</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x4227">
						<sec_title>Crohn’s disease/ulcerative colitis (unlabeled)</sec_title>
						<section type="none" id="sidelem4x4235">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x4235">
									<item>
										<label>•</label>
										<para> 1.5-2 mg/kg/day</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x4239">
						<sec_title>Available forms:</sec_title>
						<para> Tabs 50 mg; susp 2000 mg/100 ml</para>
					</section>
					<section type="none" id="sidelem4x4244">
						<sec_title>Administer:</sec_title>
						<para>
							<list id="lidelem4x4249">
								<item>
									<label>•</label>
									<para>Store in tightly closed container in cool environment</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x4254">
								<item>
									<label>•</label>
									<para>Give product after evening meal, before bedtime, on an empty stomach</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x4262">
							<label>•</label>
							<sec_title>Suspension</sec_title>
							<para>
								<list id="lidelem4x4262">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Suspension:</emphasis> Shake well, wash syringe with warm, soapy water, rinse, move plunger up and down several times, use only after dry; after opening, use within 6 wk</para>
									</item>
								</list>
							</para>
						</section>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x4266">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x4269">
					<section type="none" id="sidelem4x4270">
						<sec_title>CNS:</sec_title>
						<para> Weakness</para>
					</section>
					<section type="none" id="sidelem4x4275">
						<sec_title>GI:</sec_title>
						<para> <emphasis style="italic">Nausea, vomiting, anorexia, diarrhea, stomatitis,</emphasis><emphasis style="bold">hepatotoxicity</emphasis> (high doses), jaundice, gastritis, <emphasis style="bold">pancreatitis</emphasis></para>
					</section>
					<section type="none" id="sidelem4x4287">
						<sec_title>GU:</sec_title>
						<para> <emphasis style="bold">Renal failure,</emphasis> hyperuricemia, <emphasis style="bold">oliguria,</emphasis> crystalluria, <emphasis style="bold">hematuria</emphasis></para>
					</section>
					<section type="none" id="sidelem4x4300">
						<sec_title>HEMA:</sec_title>
						<para> <emphasis style="bold">Thrombocytopenia, leukopenia, myelosuppression, anemia</emphasis></para>
					</section>
					<section type="none" id="sidelem4x4307">
						<sec_title>INTEG:</sec_title>
						<para> <emphasis style="italic">Rash,</emphasis> dry skin, urticaria, alopecia</para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x4315">
				<sec_title>Pharmacokinetics</sec_title>
				<para>Incompletely absorbed when taken orally, metabolized in liver, excreted in urine, peak 1-2 hr, terminal half-life 47 min (adult), 21 min (child)</para>
			</section>
			<section type="interactions" id="sidelem4x4320">
				<sec_title>Interactions</sec_title>
				<para>
					<emphasis alert="lifethreat">Increase: effects of mercaptopurine—allopurinol, avoid use or decrease dose</emphasis>
				</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> effects—radiation or other antineoplastics, immunosuppressants</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> bone marrow depression—azaTHIOprine, sulfamethoxazole-trimethoprim, avoid concurrent use</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> anticoagulant action—anticoagulants, NSAIDs, thrombolytics, platelet inhibitors, salicylates</para>
				<para>
					<emphasis style="bold">Decrease:</emphasis> antibodies—live virus vaccines</para>
				<para>
					<emphasis alert="lifethreat">Decrease: TPMT, rapid bone marrow suppression—balzalazide, olsalazine, mesalamine, sulfaSALAzine, use cautiously</emphasis>
				</para>
			</section>
			<section type="considerations" id="sidelem4x4345">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x4348">
					<section type="none" id="sidelem4x4349">
						<sec_title>Assess:</sec_title>
						<para>
							<list id="lidelem4x4355">
								<item>
									<para>
										<emphasis alert="nurse">Bone marrow suppression: CBC, differential, platelet count weekly; withhold product at first sign of abnormally large decrease in blood counts, unless bone marrow aplasia is the goal</emphasis>
									</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x4363">
							<label>•</label>
							<sec_title>Thiopurine methyltransferase (TPMT) deficiency<route> individuals are prone to rapid bone marrow suppression; dosage reduction may be required in homozygous-TPMT-deficient persons</route></sec_title>
						</section>
						<section type="none" id="sidelem4x4369">
							<label>•</label>
							<sec_title>Tumor lysis syndrome<route> monitor for increased potassium, uric acid, phosphate, decreased urine output, calcium</route></sec_title>
						</section>
						<para>
							<list id="lidelem4x4372">
								<item>
									<label>•</label>
									<para>Renal studies: BUN, serum uric acid, urine CCr, electrolytes before, during therapy</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x4377">
								<item>
									<label>•</label>
									<para>I&amp;O ratio; report fall in urine output to &lt;30 ml/hr</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x4382">
								<item>
									<label>•</label>
									<para>Monitor temperature; fever may indicate beginning infection; no rectal temperature</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x4391">
							<label>•</label>
							<sec_title>Hepatotoxicity<route> Hepatic studies before, during therapy</route></sec_title>
						</section>
						<section type="none" id="sidelem4x4397">
							<label>•</label>
							<sec_title>Bleeding</sec_title>
							<para>
								<list id="lidelem4x4397">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Bleeding:</emphasis> hematuria, guaiac, bruising, petechiae, mucosa or orifices, avoid IM inj if platelets are low; blood transfusions may be needed</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x4404">
							<label>•</label>
							<sec_title>Stomatitis</sec_title>
							<para>
								<list id="lidelem4x4404">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Stomatitis:</emphasis> buccal cavity for dryness, sores, ulceration, white patches, oral pain, bleeding, dysphagia</para>
									</item>
								</list>
							</para>
						</section>
						<para>
							<list id="lidelem4x4408">
								<item>
									<label>•</label>
									<para>Increase fluid intake to 2-3 L/day to prevent urate deposits, calculi formation, unless contraindicated</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x4413">
								<item>
									<label>•</label>
									<para>Rinsing of mouth tid-qid with water, club soda; brushing of teeth bid-tid with soft brush or cotton-tipped applicators for stomatitis; use unwaxed dental floss</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x4418">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x4422">
								<item>
									<label>•</label>
									<para>Therapeutic response: decreased size of tumor, spread of malignancy</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x4428">
						<sec_title>Teach patient/family:</sec_title>
						<para>
							<list id="lidelem4x4433">
								<item>
									<label>•</label>
									<para>To avoid foods with citric acid, hot or rough texture for stomatitis; to report stomatitis: any bleeding, white spots, ulcerations in mouth; to examine mouth daily, report symptoms</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x4441">
							<label>•</label>
							<sec_title>Pregnancy<route> that contraceptive measures recommended during therapy (D); to avoid breastfeeding</route></sec_title>
						</section>
						<para>
							<list id="lidelem4x4444">
								<item>
									<label>•</label>
									<para>To drink 10-12 8-oz glasses of fluid/day</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x4452">
							<label>•</label>
							<sec_title>
								<route>To notify prescriber of fever, chills, sore throat, nausea, vomiting, anorexia, diarrhea, bleeding, bruising, all of which may indicate blood dyscrasias/infection</route>
							</sec_title>
						</section>
						<para>
							<list id="lidelem4x4455">
								<item>
									<label>•</label>
									<para>To report signs of infection: fever, sore throat, flulike symptoms</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x4460">
								<item>
									<label>•</label>
									<para>To report signs of anemia: fatigue, headache, faintness, SOB, irritability</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x4465">
								<item>
									<label>•</label>
									<para>To report bleeding; to avoid use of razors, commercial mouthwash</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x4470">
								<item>
									<label>•</label>
									<para>To avoid use of aspirin products, NSAIDs</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x4475">
								<item>
									<label>•</label>
									<para>To take entire dose at one time</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
		</monograph>
<monograph id="13" status="active">
			<mono_name>meropenem (Rx)</mono_name>
			<info>
				<pronunciation>(mer-oh-pen′em)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x44850">Merrem</tradename>
				</tradenames>
				<class type="func"> Antiinfective—miscellaneous</class>
				<class type="chem"> Carbapenem</class>
				<class type="preg">Pregnancy category <preg cat="B">B</preg></class>
			</info>
			<section type="actions" id="sidelem4x4495">
				<sec_title>Action:</sec_title>
				<para>Bactericidal; interferes with cell-wall replication of susceptible organisms</para>
			</section>
			<section type="uses" id="sidelem4x4500">
				<sec_title>Uses:</sec_title>
				<para>
					<emphasis style="italic">Acinetobacter</emphasis> sp., <emphasis style="italic">Aeromonas hydrophila, Bacteroides distasonis, Bacteroides fragilis, Bacteroides ovatus, Bacteroides thetaiotaomicron, Bacteroides uniformis, Bacteroides ureolyticus, Bacteroides vulgatus, Campylobacter jejuni, Citrobacter diversus, Citrobacter freundii, Clostridium difficile, Clostridium perfringens, Enterobacter cloacae, Enterococcus faecalis, Escherichia coli, Eubacterium lentum, Fusobacterium</emphasis> sp., <emphasis style="italic">Haemophilus influenzae</emphasis> (beta-lactamase negative), <emphasis style="italic">Haemophilus influenzae</emphasis> (beta-lactamase positive), <emphasis style="italic">Hafnia alvei, Klebsiella oxytoca, Klebsiella pneumoniae, Moraxella catarrhalis, Morganella morganii, Neisseria meningitidis, Pasteurella multocida, Peptostreptococcus</emphasis> sp., <emphasis style="italic">Porphyromonas asaccharolytica, Prevotella bivia, Prevotella intermedia, Prevotella melaninogenica, Propionibacterium acnes, Proteus mirabilis, Proteus vulgaris, Pseudomonas aeruginosa, Salmonella</emphasis> sp., <emphasis style="italic">Serratia marcescens, Shigella</emphasis> sp., <emphasis style="italic">Staphylococcus aureus</emphasis> (MSSA), <emphasis style="italic">Staphylococcus epidermidis, Streptococcus agalactiae</emphasis> (group B streptococci), <emphasis style="italic">Streptococcus pneumoniae, Streptococcus pyogenes</emphasis> (group A beta-hemolytic streptococci), <emphasis style="italic">Viridans streptococci, Yersinia enterocolitica;</emphasis> appendicitis, bacteremia, intraabdominal infections, meningitis, peritonitis, skin/skin structure infections</para>
				<section type="none" id="sidelem4x4537">
					<section type="none" id="sidelem4x4538">
						<sec_title>Unlabeled uses:</sec_title>
						<para> Febrile, neutropenic, community-acquired pneumonia</para>
					</section>
				</section>
			</section>
			<section type="contra" id="sidelem4x4544">
				<sec_title>Contraindications:</sec_title>
				<para>Hypersensitivity to this product, carbapenems, hypersensitivity to cephalosporins, penicillins</para>
				<section type="none" id="sidelem4x4549">
					<section type="none" id="sidelem4x4550">
						<sec_title>Precautions:</sec_title>
						<para> Pregnancy (<preg cat="B">B</preg>), breastfeeding, geriatric patients, renal disease, seizure disorder, gram-negative infection, hypersensitivity to pneumonia</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x4555">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x4558">
					<section type="none" id="sidelem4x4559">
						<sec_title>Intraabdominal infections (complicated appendicitis, peritonitis)</sec_title>
						<section type="none" id="sidelem4x4567">
							<label>•</label>
							<sec_title>Adult/child/adolescent &gt;50 kg<route> IV</route></sec_title>
							<para>
								<list id="lidelem4x4567">
									<item>
										<label>•</label>
										<para> 1 g q8hr or adult 500 mg q6hr</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x4574">
							<label>•</label>
							<sec_title>Infant ≥3 mo/child/adolescent ≤50 kg<route> IV</route></sec_title>
							<para>
								<list id="lidelem4x4574">
									<item>
										<label>•</label>
										<para> 20 mg/kg q8hr</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x4581">
							<label>•</label>
							<sec_title>Term neonates/infants &lt;3 mo (unlabeled)<route> IV</route></sec_title>
							<para>
								<list id="lidelem4x4581">
									<item>
										<label>•</label>
										<para> 30 mg/kg/dose q8hr</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x4585">
						<sec_title>Extended dose (3-hr infusion) (unlabeled)</sec_title>
						<section type="none" id="sidelem4x4593">
							<label>•</label>
							<sec_title>Adult<route> IV</route></sec_title>
							<para>
								<list id="lidelem4x4593">
									<item>
										<label>•</label>
										<para> 1 g over 3 hr, q8hr</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x4597">
						<sec_title>Complicated skin and skin structure infections</sec_title>
						<section type="none" id="sidelem4x4605">
							<label>•</label>
							<sec_title>Adult/adolescents/child &gt;50 kg<route> IV</route></sec_title>
							<para>
								<list id="lidelem4x4605">
									<item>
										<label>•</label>
										<para> 500 mg q8hr over 15-30 min</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x4612">
							<label>•</label>
							<sec_title>Infants ≥3 mo/children/adolescents ≤50 kg<route> IV</route></sec_title>
							<para>
								<list id="lidelem4x4612">
									<item>
										<label>•</label>
										<para> 10 mg/kg q8hr over 15-30 min</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x4616">
						<sec_title>Bacterial meningitis</sec_title>
						<section type="none" id="sidelem4x4624">
							<label>•</label>
							<sec_title>Adult/child/adolescent &gt;50 g<route> IV</route></sec_title>
							<para>
								<list id="lidelem4x4624">
									<item>
										<label>•</label>
										<para> 2 g q8hr</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x4631">
							<label>•</label>
							<sec_title>Infant/child/adolescent ≤50 kg<route> IV</route></sec_title>
							<para>
								<list id="lidelem4x4631">
									<item>
										<label>•</label>
										<para> 40 mg/kg q8hr</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x4635">
						<sec_title>Renal disease</sec_title>
						<section type="none" id="sidelem4x4643">
							<label>•</label>
							<sec_title>Adult<route> IV CCr 26-50 ml/min, give dose q12hr; CCr 10-25 ml/min, give 1/2 dose q12hr; CCr &lt;10 ml/min, give 1/2 dose q24hr</route></sec_title>
						</section>
					</section>
					<section type="none" id="sidelem4x4658">
						<sec_title>Febrile neutropenia (unlabeled)</sec_title>
						<section type="none" id="sidelem4x4666">
							<label>•</label>
							<sec_title>Adult<route> IV</route></sec_title>
							<para>
								<list id="lidelem4x4666">
									<item>
										<label>•</label>
										<para> 1 g q8hr</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x4670">
						<sec_title>Community-acquired pneumonia (CAP) (unlabeled)</sec_title>
						<section type="none" id="sidelem4x4678">
							<label>•</label>
							<sec_title>Adult<route> IV</route></sec_title>
							<para>
								<list id="lidelem4x4678">
									<item>
										<label>•</label>
										<para> 1 g q8hr with ciprofloxacin/levaquin or with aminoglycoside plus fluoroquinolone</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x4682">
						<sec_title>Available forms:</sec_title>
						<para> Powder for inj 500 mg, 1 g</para>
					</section>
					<section type="none" id="sidelem4x4687">
						<sec_title>Administer:</sec_title>
						<para>
							<list id="lidelem4x4691">
								<item>
									<label>•</label>
									<para>After C&amp;S is taken</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x4697">
							<sec_title>Direct IV route</sec_title>
							<para>
								<list id="lidelem4x4701">
									<item>
										<label>•</label>
										<para>Reconstitute 500-mg or 1-g vials with 10, 20 ml of sterile water for inj, respectively; shake to dissolve; let stand until clear (average concentration 50 mg/ml); reconstituted sol may be stored for 3 hr at room temperature or for 13 hr refrigerated; inject up to 1 g in 5-20 ml over 3-5 min</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x4707">
							<sec_title>Intermittent IV INFUSION route</sec_title>
							<para>
								<list id="lidelem4x4711">
									<item>
										<label>•</label>
										<para>Vials may be directly reconstituted with compatible infusion fluid (NS, D<emphasis style="inf">5</emphasis>W) to 2.5-50 mg/ml; vials with NS can be stored 2 hr at room temperature or for ≤18 hr refrigerated, (D<emphasis style="inf">5</emphasis>W solutions) may be stored for up to 1 hr at room temperature or ≤15 hr refrigerated; infuse over 15-30 min</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x4723">
							<sec_title>Continuous IV INFUSION (unlabeled)</sec_title>
							<section type="none" id="sidelem4x4731">
								<label>•</label>
								<sec_title>3 g/day continuous IV infusion</sec_title>
								<para>
									<list id="lidelem4x4731">
										<item>
											<label>•</label>
											<para>
												<emphasis style="bold">3 g/day continuous IV infusion:</emphasis> Constitute a 1-g vial according to manufacturer recommendations; further dilute in 50 ml or 250 ml of NS and run over 8 hr; for continuous infusion, administer a new infusion bag q8hr</para>
										</item>
									</list>
								</para>
							</section>
							<section type="none" id="sidelem4x4738">
								<label>•</label>
								<sec_title>4 g/day continuous IV infusion</sec_title>
								<para>
									<list id="lidelem4x4738">
										<item>
											<label>•</label>
											<para>
												<emphasis style="bold">4 g/day continuous IV infusion:</emphasis> Constitute a 1-g vial according to manufacturer recommendations; further dilute in 100 ml of NS and administer over 6 hr; for continuous infusion, administer a new infusion bag q6hr</para>
										</item>
									</list>
								</para>
							</section>
							<section type="none" id="sidelem4x4745">
								<label>•</label>
								<sec_title>3 g/day IV continuous infusion in ambulatory infusion pump with freezer packs</sec_title>
								<para>
									<list id="lidelem4x4745">
										<item>
											<label>•</label>
											<para>
												<emphasis style="bold">3 g/day IV continuous infusion in ambulatory infusion pump with freezer packs:</emphasis> Reconstitute 1-g vial according to manufacturer recommendations by adding 20 ml of NS into each vial; add 3 g (60 ml) to a 100 ml medication cassette reservoir and bring the final volume to 100 ml (final concentration, 30 mg/ml) run over 24 hr</para>
										</item>
									</list>
								</para>
							</section>
							<para>
								<emphasis style="bold">Y-site compatibilities:</emphasis> Alemtuzumab, aminocaproic acid, aminophylline, anidulafungin, argatroban, atenolol, atropine, azithromycin, bivalirudin, bleomycin, CARBOplatin, carmustine, caspofungin, cimetidine, CISplatin, cyclophosphamide, cycloSPORINE, cytarabine, DACTINomycin, DAPTOmycin, dexamethasone, dexmedetomidine, dexrazoxane, digoxin, diltiazem, diphenhydrAMINE, DOCEtaxel, doxacurium, DOXOrubicin liposomal, enalaprilat, eptifibatide, etoposide, etoposide phosphate, fluconazole, fludarabine, fluorouracil, foscarnet, furosemide, gallium, gatifloxacin, gemcitabine, gemtuzumab, gentamicin, granisetron, heparin sodium, HYDROmorphone, ifosfamide, insulin, regular, irinotecan, lepirudin, leucovorin, linezolid injection, LORazepam, mechlorethamine, methotrexate, metoclopramide, metroNIDAZOLE, milrinone, mitoXANtrone, morphine, nesiritide, norepinephrine, octreotide, oxaliplatin, oxytocin, PACLitaxel, palonosetron, pamidronate, pancuronium, PEMEtrexed, PHENobarbital, potassium acetate/chloride, rocuronium, teniposide, thiotepa, tigecycline, tirofiban, TNA (3-in-1) total nutrient admixture, vancomycin, vasopressin, vecuronium, vinBLAStine, vinCRIStine, vinorelbine, voriconazole, zoledronic acid</para>
						</section>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x4755">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x4758">
					<section type="none" id="sidelem4x4759">
						<sec_title>CNS:</sec_title>
						<para> <emphasis style="bold">Seizures,</emphasis> dizziness, weakness, <emphasis style="italic">headache,</emphasis> insomnia, agitation, confusion, drowsiness</para>
					</section>
					<section type="none" id="sidelem4x4770">
						<sec_title>CV:</sec_title>
						<para> Hypotension, tachycardia</para>
					</section>
					<section type="none" id="sidelem4x4775">
						<sec_title>ENDO:</sec_title>
						<para> Hypoglycemia</para>
					</section>
					<section type="none" id="sidelem4x4780">
						<sec_title>GI:</sec_title>
						<para> Diarrhea, nausea, vomiting, <emphasis style="bold">pseudomembranous colitis, hepatitis,</emphasis> glossitis, jaundice</para>
					</section>
					<section type="none" id="sidelem4x4788">
						<sec_title>INTEG:</sec_title>
						<para> <emphasis style="italic">Rash,</emphasis> urticaria, <emphasis style="italic">pruritus,</emphasis> pain at inj site, phlebitis, erythema at inj site</para>
					</section>
					<section type="none" id="sidelem4x4799">
						<sec_title>RESP:</sec_title>
						<para> Dyspnea, hyperventilation</para>
					</section>
					<section type="none" id="sidelem4x4804">
						<sec_title>SYST:</sec_title>
						<para> <emphasis style="bold">Anaphylaxis, Stevens-Johnson syndrome, angioedema</emphasis></para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x4811">
				<sec_title>Pharmacokinetics</sec_title>
				<section type="none" id="sidelem4x4814">
					<section type="none" id="sidelem4x4815">
						<sec_title>IV:</sec_title>
						<para> Onset immediate, peak dose dependent, half-life 1 hr, excreted unchanged in urine (70%)</para>
					</section>
				</section>
			</section>
			<section type="interactions" id="sidelem4x4820">
				<sec_title>Interactions</sec_title>
				<para>
					<emphasis style="bold">Increase:</emphasis> meropenem plasma levels—probenecid</para>
				<para>
					<emphasis style="bold">Decrease:</emphasis> effect of valproic acid</para>
				<section type="none" id="sidelem4x4831">
					<section type="none" id="sidelem4x4832">
						<sec_title>Drug/Lab Test</sec_title>
						<para>
							<emphasis style="bold">Increase:</emphasis> AST, ALT, LDH, BUN, alk phos, bilirubin, creatinine</para>
						<para>
							<emphasis style="bold">Decrease:</emphasis> prothrombin time</para>
						<para>
							<emphasis style="bold">False positive:</emphasis> direct Coombs’ test</para>
					</section>
				</section>
			</section>
			<section type="considerations" id="sidelem4x4847">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x4850">
					<section type="none" id="sidelem4x4851">
						<sec_title>Assess:</sec_title>
						<para>
							<list id="lidelem4x4856">
								<item>
									<label>•</label>
									<para>Sensitivity to carbapenem antibiotics, penicillins, cephalosporins</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x4861">
								<item>
									<label>•</label>
									<para>Renal disease: lower dose may be required; monitor serum creatinine/BUN before, during therapy</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x4869">
							<label>•</label>
							<sec_title>Pseudomembranous colitis<route> bowel pattern daily; if severe diarrhea, fever, abdominal pain, fatigue occurs, product should be discontinued</route></sec_title>
						</section>
						<section type="none" id="sidelem4x4875">
							<label>•</label>
							<sec_title>Infection<route> temperature, sputum, characteristics of wound before, during, and after treatment</route></sec_title>
						</section>
						<para>
							<list id="lidelem4x4879">
								<item>
									<para>
										<emphasis alert="nurse">Allergic reactions, anaphylaxis: rash, laryngeal edema, wheezing, urticaria, pruritus; may occur immediately or several days after therapy begins; identify if there has been hypersensitivity to penicillins, cephalosporins, beta-lactams, cross-sensitivity may occur</emphasis>
									</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x4887">
							<label>•</label>
							<sec_title>Seizures<route> may occur in those with brain lesions, seizure disorder, bacterial meningitis, or renal disease; stop product, notify prescriber if seizures occur</route></sec_title>
						</section>
						<section type="none" id="sidelem4x4893">
							<label>•</label>
							<sec_title>Overgrowth of infection<route> perineal itching, fever, malaise, redness, pain, swelling, drainage, rash, diarrhea, change in cough, sputum</route></sec_title>
						</section>
					</section>
					<section type="none" id="sidelem4x4896">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x4900">
								<item>
									<label>•</label>
									<para>Therapeutic response: negative C&amp;S; absence of symptoms and signs of infection</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x4906">
						<sec_title>Teach patient/family:</sec_title>
						<section type="none" id="sidelem4x4914">
							<label>•</label>
							<sec_title>Pseudomembranous colitis<route> to report severe diarrhea</route></sec_title>
						</section>
						<para>
							<list id="lidelem4x4917">
								<item>
									<label>•</label>
									<para>To report sore throat, bruising, bleeding, joint pain; may indicate blood dyscrasias (rare)</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x4925">
							<label>•</label>
							<sec_title>To report overgrowth of infection<route> black, furry tongue; vaginal itching; foul-smelling stools; seizures</route></sec_title>
						</section>
						<para>
							<list id="lidelem4x4928">
								<item>
									<label>•</label>
									<para>To avoid breastfeeding; product is excreted in breast milk</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
		</monograph>
<monograph id="14" status="active">
			<mono_name>mesalamine, 5-ASA (Rx)</mono_name>
			<info>
				<pronunciation>(mez-al′a-meen)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x49447">Apriso</tradename>
					<tradename id="tnidelem4x49446">Asacol</tradename>
					<tradename id="tnidelem4x49445">Asacol HD</tradename>
					<tradename id="tnidelem4x49444">Canasa</tradename>
					<tradename id="tnidelem4x49443">Delzicol</tradename>
					<tradename id="tnidelem4x49442">Lialda</tradename>
					<tradename id="tnidelem4x49441">Pentasa</tradename>
					<tradename id="tnidelem4x49440">
						<country code="CAN">Rowasa</country>
					</tradename>
				</tradenames>
				<class type="func"> GI antiinflammatory</class>
				<class type="chem"> 5-Aminosalicylic acid</class>
				<class type="preg">Pregnancy category <preg cat="B">B</preg></class>
			</info>
			<section type="confusion" id="sidelem4x4956">
				<para>
					<confusion>
						<tradename id="tnidelem4x49560">Asacol</tradename>
						<drug type="generic" refid="idelem4x49560">Ansaid/Os-Cal</drug>
					</confusion>
				</para>
			</section>
			<section type="actions" id="sidelem4x4960">
				<sec_title>Action:</sec_title>
				<para>May diminish inflammation by blocking cyclooxygenase, inhibiting prostaglandin production in colon; local action only</para>
			</section>
			<section type="uses" id="sidelem4x4965">
				<sec_title>Uses:</sec_title>
				<para>Mild to moderate active distal ulcerative colitis, proctitis</para>
				<section type="none" id="sidelem4x4970">
					<section type="none" id="sidelem4x4971">
						<sec_title>Unlabeled uses:</sec_title>
						<para> Crohn’s disease</para>
					</section>
				</section>
			</section>
			<section type="contra" id="sidelem4x4976">
				<sec_title>Contraindications:</sec_title>
				<para>Hypersensitivity to this product or salicylates, 5-aminosalicylates</para>
				<section type="none" id="sidelem4x4981">
					<section type="none" id="sidelem4x4982">
						<sec_title>Precautions:</sec_title>
						<para> Pregnancy (<preg cat="B">B</preg>), breastfeeding, children, geriatric patients, renal disease, sulfite sensitivity, pyloric stenosis, GI obstruction</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x4987">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x4990">
					<section type="none" id="sidelem4x4991">
						<sec_title>Treatment of ulcerative colitis</sec_title>
						<section type="none" id="sidelem4x4999">
							<label>•</label>
							<sec_title>Adult<route> RECT</route></sec_title>
							<para>
								<list id="lidelem4x4999">
									<item>
										<label>•</label>
										<para> 60 ml (4 g) at bedtime, retained for 8 hr × 3-6 wk;  2.4-4.8 g/day × 8 wk;  1.6 g × 6 wk;  1 g qid up to 8 wk;  500 mg bid retained for 1-3 hr × 3-6 wk until remission, may increase tid if needed; del rel cap (Delzicol) 800 mg tid × 6 wk</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x5015">
						<sec_title>Maintenance of remission</sec_title>
						<section type="none" id="sidelem4x5023">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x5023">
									<item>
										<label>•</label>
										<para> (del rel tab: Asacol) 800 mg bid or 400 mg qid;  (del rel cap: Apriso) 1500 mg (4 caps) each <emphasis style="smallcaps">am</emphasis>;  (del rel tab: Lialda) 2.4 g (2 tabs) daily with meal; del rel cap (Delzicol) 800 mg bid</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x5036">
						<sec_title>Available forms:</sec_title>
						<para> Rectal susp 4 g/60 ml (Rowasa); ext rel tab 500 mg; ext rel cap 250, 500 mg (Pentasa); 0.375 g (Apriso); del rel tab 400 mg (Asacol), 800 mg (Asacol HD); del rel tab (Lialda) 1.2 g; rectal supp 1000 mg (Canasa); del rel cap (Delzicol) 400 mg</para>
					</section>
					<section type="none" id="sidelem4x5041">
						<sec_title>Administer:</sec_title>
						<section type="none" id="sidelem4x5044">
							<sec_title>PO route</sec_title>
							<para>
								<list id="lidelem4x5049">
									<item>
										<label>•</label>
										<para>Swallow tabs whole; do not break, crush, or chew tabs</para>
									</item>
								</list>
							</para>
							<section type="none" id="sidelem4x5057">
								<label>•</label>
								<sec_title>Lialda</sec_title>
								<para>
									<list id="lidelem4x5057">
										<item>
											<label>•</label>
											<para>
												<emphasis style="bold">Lialda:</emphasis> take with meal</para>
										</item>
									</list>
								</para>
							</section>
							<section type="none" id="sidelem4x5064">
								<label>•</label>
								<sec_title>Apriso caps</sec_title>
								<para>
									<list id="lidelem4x5064">
										<item>
											<label>•</label>
											<para>
												<emphasis style="bold">Apriso caps:</emphasis> take without regard to meals in <emphasis style="smallcaps">am</emphasis></para>
										</item>
									</list>
								</para>
							</section>
							<section type="none" id="sidelem4x5073">
								<label>•</label>
								<sec_title>Delzicol caps</sec_title>
								<para>
									<list id="lidelem4x5073">
										<item>
											<label>•</label>
											<para>
												<emphasis style="bold">Delzicol caps:</emphasis> give ≥1 hr before a meal or 2 hr after a meal</para>
										</item>
									</list>
								</para>
							</section>
						</section>
						<section type="none" id="sidelem4x5077">
							<sec_title>Rectal suspension</sec_title>
							<para>
								<list id="lidelem4x5081">
									<item>
										<label>•</label>
										<para>Product should be given at bedtime, retained until morning (8 hr); empty bowel before insertion, shake well</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x5087">
							<sec_title>Rectal suppository</sec_title>
							<para>
								<list id="lidelem4x5091">
									<item>
										<label>•</label>
										<para>Moisten before insertion; suppository should be retained for 1-3 hr</para>
									</item>
								</list>
							</para>
						</section>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x5097">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x5100">
					<section type="none" id="sidelem4x5101">
						<sec_title>CNS:</sec_title>
						<para> <emphasis style="italic">Headache, fever, dizziness,</emphasis> insomnia, asthenia, weakness, fatigue</para>
					</section>
					<section type="none" id="sidelem4x5109">
						<sec_title>CV:</sec_title>
						<para> Pericarditis, myocarditis, chest pain, palpitations</para>
					</section>
					<section type="none" id="sidelem4x5114">
						<sec_title>EENT:</sec_title>
						<para> Sore throat, cough, pharyngitis, rhinitis</para>
					</section>
					<section type="none" id="sidelem4x5119">
						<sec_title>GI:</sec_title>
						<para> <emphasis style="italic">Cramps, gas, nausea, diarrhea,</emphasis> rectal pain, constipation</para>
					</section>
					<section type="none" id="sidelem4x5127">
						<sec_title>GU:</sec_title>
						<para> <emphasis style="bold">Nephrotoxicity, interstitial nephritis</emphasis></para>
					</section>
					<section type="none" id="sidelem4x5134">
						<sec_title>INTEG:</sec_title>
						<para> <emphasis style="italic">Rash, itching,</emphasis> acne</para>
					</section>
					<section type="none" id="sidelem4x5142">
						<sec_title>SYST:</sec_title>
						<para> <emphasis style="italic">Flulike symptoms, malaise,</emphasis> back pain, peripheral edema, leg and joint pain, arthralgia, dysmenorrhea, <emphasis style="bold">anaphylaxis,</emphasis> acute intolerance syndrome</para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x5153">
				<sec_title>Pharmacokinetics</sec_title>
				<section type="none" id="sidelem4x5156">
					<section type="none" id="sidelem4x5157">
						<sec_title>RECT:</sec_title>
						<para> Primarily excreted in feces but some in urine as metabolite; half-life 1 hr, metabolite half-life 5-10 hr</para>
					</section>
				</section>
			</section>
			<section type="interactions" id="sidelem4x5162">
				<sec_title>Interactions</sec_title>
				<section type="none" id="sidelem4x5170">
					<label>•</label>
					<sec_title>
						<route>Do not give H2 blockers with Apriso</route>
					</sec_title>
				</section>
				<para>
					<emphasis alert="lifethreat">Increase: nephrotoxicity—NSAIDs</emphasis>
				</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> action, adverse reactions of azaTHIOprine, mercaptopurine</para>
				<para>
					<emphasis style="bold">Decrease:</emphasis> mesalamine absorption—lactulose, antacids</para>
				<para>
					<emphasis style="bold">Decrease:</emphasis> effect of—warfarin</para>
				<section type="none" id="sidelem4x5192">
					<section type="none" id="sidelem4x5193">
						<sec_title>Drug/Lab Test</sec_title>
						<para>
							<emphasis style="bold">Increase:</emphasis> AST, ALT, alk phos, LDH, GGTP, amylase, lipase</para>
					</section>
				</section>
			</section>
			<section type="considerations" id="sidelem4x5200">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x5203">
					<section type="none" id="sidelem4x5204">
						<sec_title>Assess:</sec_title>
						<section type="none" id="sidelem4x5212">
							<label>•</label>
							<sec_title>
								<route>Allergy to salicylates, sulfonamides;</route>
							</sec_title>
							<para>
								<list id="lidelem4x5212">
									<item>
										<label>•</label>
										<para> if allergic reactions occur, discontinue product</para>
									</item>
								</list>
							</para>
						</section>
						<para>
							<list id="lidelem4x5216">
								<item>
									<label>•</label>
									<para>Renal studies: BUN, creatinine before, periodically during treatment; renal toxicity may occur</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x5224">
							<label>•</label>
							<sec_title>Bowel disorders</sec_title>
							<para>
								<list id="lidelem4x5224">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Bowel disorders:</emphasis> cramps, gas, nausea, diarrhea, rectal pain; if severe, product should be discontinued</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x5228">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x5232">
								<item>
									<label>•</label>
									<para>Therapeutic response: absence of pain, bleeding from GI tract, decrease in number of diarrhea stools</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x5238">
						<sec_title>Teach patient/family:</sec_title>
						<para>
							<list id="lidelem4x5242">
								<item>
									<label>•</label>
									<para>That usual course of therapy is 3-6 wk</para>
								</item>
								<item>
									<label>•</label>
									<para>To shake bottle well (rectal susp)</para>
								</item>
								<item>
									<label>•</label>
									<para>About method of rectal administration</para>
								</item>
								<item>
									<label>•</label>
									<para>To inform prescriber of GI symptoms</para>
								</item>
								<item>
									<label>•</label>
									<para>To report abdominal cramping, pain, diarrhea with blood, headache, fever, rash, chest pain; product should be discontinued</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
		</monograph>
<monograph id="15" status="active" ha="yes">
			<mono_name> metFORMIN (Rx)</mono_name>
			<info>
				<pronunciation>(met-for′min)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x52754">Fortamet</tradename>
					<tradename id="tnidelem4x52753">Glucophage</tradename>
					<tradename id="tnidelem4x52752">Glucophage XR</tradename>
					<tradename id="tnidelem4x52751">Glumetza</tradename>
					<tradename id="tnidelem4x52750">Riomet</tradename>
				</tradenames>
				<class type="func"> Antidiabetic, oral</class>
				<class type="chem"> Biguanide</class>
				<class type="preg">Pregnancy category <preg cat="B">B</preg></class>
			</info>
			<section type="actions" id="sidelem4x5285">
				<sec_title>Action:</sec_title>
				<para>Inhibits hepatic glucose production and increases sensitivity of peripheral tissue to insulin</para>
			</section>
			<section type="uses" id="sidelem4x5290">
				<sec_title>Uses:</sec_title>
				<para>Type 2 diabetes mellitus</para>
				<section type="none" id="sidelem4x5295">
					<section type="none" id="sidelem4x5296">
						<sec_title>Unlabeled uses:</sec_title>
						<para> Precocious puberty or early-normal onset of puberty to delay menarche; polycystic ovary syndrome, infertility</para>
					</section>
				</section>
			</section>
			<section type="contra" id="sidelem4x5301">
				<sec_title>Contraindications:</sec_title>
				<para>Creatinine ≥1.5 mg/ml (males); diabetic ketoacidosis, metabolic acidosis, renal failure, radiographic contrast use</para>
				<section type="none" id="sidelem4x5306">
					<section type="none" id="sidelem4x5307">
						<sec_title>Precautions:</sec_title>
						<para> Pregnancy (<preg cat="B">B</preg>), breastfeeding, geriatric patients, previous hypersensitivity, thyroid disease, CHF, type 1 diabetes mellitus, hepatic disease; creatinine ≥1.4 (females); alcoholism; cardiopulmonary disease; acidemia; acute MI; cardiogenic shock; renal disease, heart failure</para>
						<para>
							<bbw>History of lactic acidosis</bbw>
						</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x5322">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x5325">
					<section type="none" id="sidelem4x5326">
						<sec_title>Type 2 diabetes mellitus</sec_title>
						<section type="none" id="sidelem4x5334">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x5334">
									<item>
										<label>•</label>
										<para> 500 mg bid or 850 mg/day initially, then 500 mg weekly or 850 mg q2wk up to 2000 mg/day in divided doses with morning meal, with dosage increased every other wk, max 2550 mg/day,  (Glucophage XR) 500 mg daily with evening meal, may increase by 500 mg per wk, max 2000 mg/day; (Glumetza) 1000 mg daily with food, preferably with <emphasis style="smallcaps">pm</emphasis> meal, may increase by 500 mg per wk, max 2000 mg daily; (Fortamet) 500-1000 mg daily with <emphasis style="smallcaps">pm</emphasis> meal, may increase by 500 mg per wk, max 2550 mg daily; regular rel or oral sol 2000-2500 mg/day for ext rel tab, depending on formulation</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x5350">
							<label>•</label>
							<sec_title>Geriatric<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x5350">
									<item>
										<label>•</label>
										<para> Use lowest effective dose</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x5354">
						<sec_title>To delay early menarche and to prolong pubertal growth with early onset of puberty (unlabeled)</sec_title>
						<section type="none" id="sidelem4x5362">
							<label>•</label>
							<sec_title>Child 8-9 yr<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x5362">
									<item>
										<label>•</label>
										<para> 825 mg/day with <emphasis style="smallcaps">pm</emphasis> meal</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x5369">
						<sec_title>To delay clinical puberty and early menarche in precocious puberty (unlabeled)</sec_title>
						<section type="none" id="sidelem4x5377">
							<label>•</label>
							<sec_title>Child &gt;6 yr<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x5377">
									<item>
										<label>•</label>
										<para> 425 mg/day with <emphasis style="smallcaps">pm</emphasis> meal</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x5384">
						<sec_title>Polycystic ovary syndrome/infertility related to hyperinsulinemia secondary to polycystic ovary syndrome (unlabeled)</sec_title>
						<section type="none" id="sidelem4x5392">
							<label>•</label>
							<sec_title>Adult (female)<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x5392">
									<item>
										<label>•</label>
										<para> 500 mg tid</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x5397">
						<sec_title>Available forms:</sec_title>
						<para> Tabs 500, 850, 1000 mg; ext rel tab 500, 850, 1000 mg; oral sol 500 mg/5 ml</para>
					</section>
					<section type="none" id="sidelem4x5402">
						<sec_title>Administer:</sec_title>
						<section type="none" id="sidelem4x5405">
							<sec_title>PO route</sec_title>
							<section type="none" id="sidelem4x5413">
								<label>•</label>
								<sec_title>Immediate rel product</sec_title>
								<para>
									<list id="lidelem4x5413">
										<item>
											<label>•</label>
											<para>
												<emphasis style="bold">Immediate rel product:</emphasis> twice a day given with meals to decrease GI upset, and provide the best absorption; immediate rel tabs crushed, mixed with meal, fluids for patients with difficulty swallowing</para>
										</item>
									</list>
								</para>
							</section>
							<section type="none" id="sidelem4x5420">
								<label>•</label>
								<sec_title>
									<route>Ext rel product</route>
								</sec_title>
								<para>
									<list id="lidelem4x5420">
										<item>
											<label>•</label>
											<para> may also be taken as single dose; titrate slowly to therapeutic response, side effect tolerance</para>
										</item>
									</list>
								</para>
							</section>
							<para>
								<list id="lidelem4x5424">
									<item>
										<label>•</label>
										<para>Ext rel tabs: do not chew, break, crush</para>
									</item>
								</list>
							</para>
						</section>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x5429">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x5432">
					<section type="none" id="sidelem4x5433">
						<sec_title>CNS:</sec_title>
						<para> <emphasis style="italic">Headache, weakness, dizziness, drowsiness,</emphasis> tinnitus, fatigue, vertigo, <emphasis style="italic">agitation</emphasis></para>
					</section>
					<section type="none" id="sidelem4x5443">
						<sec_title>ENDO:</sec_title>
						<para> <emphasis style="bold">Lactic acidosis,</emphasis> hypoglycemia</para>
					</section>
					<section type="none" id="sidelem4x5451">
						<sec_title>GI:</sec_title>
						<para> <emphasis style="italic">Nausea, vomiting, diarrhea,</emphasis> heartburn, anorexia, metallic taste</para>
					</section>
					<section type="none" id="sidelem4x5459">
						<sec_title>HEMA:</sec_title>
						<para> <emphasis style="bold">Thrombocytopenia,</emphasis> decreased vit B<emphasis style="inf">12</emphasis> levels</para>
					</section>
					<section type="none" id="sidelem4x5470">
						<sec_title>INTEG:</sec_title>
						<para> Rash</para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x5475">
				<sec_title>Pharmacokinetics</sec_title>
				<para>Excreted by kidneys unchanged 35%-50%, half-life 6 hr, peak 2-3 hr (immediate release); 7 hr (ext release); 2<emphasis style="sup">1</emphasis>/<emphasis style="inf">2</emphasis> hr (solution)</para>
			</section>
			<section type="interactions" id="sidelem4x5486">
				<sec_title>Interactions</sec_title>
				<section type="none" id="sidelem4x5494">
					<label>•</label>
					<sec_title>
						<route>Do not give with radiologic contrast media; may cause renal failure</route>
					</sec_title>
				</section>
				<section type="none" id="sidelem4x5500">
					<label>•</label>
					<sec_title>
						<route>Do not use with dofetilide; may cause lactic acidosis</route>
					</sec_title>
				</section>
				<para>
					<emphasis style="bold">Increase:</emphasis> digoxin levels—digoxin</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> metFORMIN level—cimetidine, digoxin, morphine, procainamide, quiNIDine, ranitidine, triamterene, vancomycin</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> hyperglycemia—calcium channel blockers, corticosteroids, estrogens, oral contraceptives, phenothiazines, sympathomimetics, diuretics, phenytoin, β-blockers</para>
				<section type="none" id="sidelem4x5515">
					<section type="none" id="sidelem4x5516">
						<sec_title>Drug/Herb</sec_title>
						<para>
							<emphasis style="bold">Increase:</emphasis> hyperglycemia—glucosamine</para>
						<para>
							<emphasis style="bold">Increase:</emphasis> hypoglycemia—garlic, green tea, horse chestnut</para>
					</section>
					<section type="none" id="sidelem4x5527">
						<sec_title>Drug/Lab Test</sec_title>
						<para>
							<emphasis style="bold">Decrease:</emphasis> vit B<emphasis style="inf">12</emphasis></para>
					</section>
				</section>
			</section>
			<section type="considerations" id="sidelem4x5536">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x5539">
					<section type="none" id="sidelem4x5540">
						<sec_title>Assess:</sec_title>
						<section type="none" id="sidelem4x5548">
							<label>•</label>
							<sec_title>
								<route>Hypoglycemic reactions</route>
							</sec_title>
							<para>
								<list id="lidelem4x5548">
									<item>
										<label>•</label>
										<para> (sweating, weakness, dizziness, anxiety, tremors, hunger); hyperglycemic reactions soon after meals; these occur rarely with product, may occur when product combined with sulfonylureas</para>
									</item>
								</list>
							</para>
						</section>
						<para>
							<list id="lidelem4x5552">
								<item>
									<label>•</label>
									<para>CBC (baseline, q3mo) during treatment; check LFTs periodically, AST, LDH, renal studies: BUN, creatinine during treatment; glucose, A1c; folic acid, vit B<emphasis style="inf">12</emphasis> q1-2yr</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x5563">
							<label>•</label>
							<sec_title>Surgery<route> product should be discontinued temporarily for surgical procedures when patient is NPO or if contrast media is used, resume when patient is eating</route></sec_title>
						</section>
					</section>
					<section type="none" id="sidelem4x5577">
						<sec_title>Perform/provide:</sec_title>
						<para>
							<list id="lidelem4x5581">
								<item>
									<label>•</label>
									<para>Conversion from other oral hypoglycemic agents; change may be made without gradual dosage change; monitor serum glucose, urine ketones tid during conversion</para>
								</item>
								<item>
									<label>•</label>
									<para>Store in tight container in cool environment</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x5592">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x5596">
								<item>
									<label>•</label>
									<para>Therapeutic response: decrease in polyuria, polydipsia, polyphagia; clear sensorium; absence of dizziness; stable gait; blood glucose, A1c at normal level</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x5602">
						<sec_title>Teach patient/family:</sec_title>
						<para>
							<bbw>
								<emphasis alert="lifethreat">Lactic acidosis:</emphasis> hyperventilation, fatigue, malaise, chills, myalgia, somnolence; to notify prescriber immediately; stop product</bbw>
						</para>
						<para>
							<list id="lidelem4x5618">
								<item>
									<label>•</label>
									<para>To regularly self-monitor blood glucose with blood-glucose meter</para>
								</item>
								<item>
									<label>•</label>
									<para>About signs, symptoms of hypo/hyperglycemia; what to do about each (rare)</para>
								</item>
								<item>
									<label>•</label>
									<para>That product must be continued on daily basis; about consequences of discontinuing product abruptly</para>
								</item>
								<item>
									<label>•</label>
									<para>To avoid OTC medications, alcohol unless approved by prescriber</para>
								</item>
								<item>
									<label>•</label>
									<para>That diabetes is a lifelong illness; that product is not a cure, only controls symptoms</para>
								</item>
								<item>
									<label>•</label>
									<para>To carry emergency ID and glucagon emergency kit</para>
								</item>
								<item>
									<label>•</label>
									<para>That Glucophage XR tab may appear in stool</para>
								</item>
								<item>
									<label>•</label>
									<para>To take with meals; not to break, crush, chew ext rel product</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
		</monograph>
<monograph id="16" status="active" ha="yes">
			<mono_name> methadone (Rx)</mono_name>
			<info>
				<pronunciation>(meth′a-done)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x56662">Dolophine</tradename>
					<tradename id="tnidelem4x56661">
						<country code="CAN">Metadol </country>
					</tradename>
					<tradename id="tnidelem4x56660">Methadose</tradename>
				</tradenames>
				<class type="func"> Opioid analgesic</class>
				<class type="chem"> Synthetic diphenylheptane derivative</class>
				<class type="preg">Pregnancy category <preg cat="C">C</preg></class>
				<class type="schedule">Controlled Substance Schedule <schedule num="2">II</schedule></class>
			</info>
			<section type="confusion" id="sidelem4x5681">
				<para>
					<confusion>
						<tradename id="tnidelem4x56810">methadone</tradename>
						<drug type="generic" refid="idelem4x56810">methylphenidate</drug>
					</confusion>
				</para>
			</section>
			<section type="actions" id="sidelem4x5685">
				<sec_title>Action:</sec_title>
				<para>Depresses pain impulse transmission at the spinal cord level by interacting with opioid receptors; produces CNS depression</para>
			</section>
			<section type="uses" id="sidelem4x5690">
				<sec_title>Uses:</sec_title>
				<para>Severe pain, opioid withdrawal</para>
				<section type="none" id="sidelem4x5695">
					<section type="none" id="sidelem4x5696">
						<sec_title>Unlabeled uses:</sec_title>
						<para> Bone pain</para>
					</section>
				</section>
			</section>
			<section type="contra" id="sidelem4x5701">
				<sec_title>Contraindications:</sec_title>
				<para>Hypersensitivity to this product or chlorobutanol (inj); asthma, ileus</para>
				<para>
					<bbw>Respiratory depression</bbw>
				</para>
				<section type="none" id="sidelem4x5716">
					<section type="none" id="sidelem4x5717">
						<sec_title>Precautions:</sec_title>
						<para> Pregnancy (<preg cat="C">C</preg>), breastfeeding, children &lt;18 yr, geriatric patients, addictive personality, increased intracranial pressure, MI (acute), severe heart disease, respiratory depression, pulmonary/renal/hepatic disease, respiratory insufficiency, torsades de pointes, COPD, seizures</para>
						<para>
							<bbw>QT prolongation, pain, substance abuse, potential for overdose, poisoning, accidental exposure</bbw>
						</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x5732">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x5735">
					<section type="none" id="sidelem4x5736">
						<sec_title>Severe pain</sec_title>
						<section type="none" id="sidelem4x5744">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x5744">
									<item>
										<label>•</label>
										<para> 2.5 mg q8-12hr in opioid-naive, titrate;  2.5-10 mg q8-12hr in opioid-naive</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x5751">
						<sec_title>Opioid withdrawal</sec_title>
						<section type="none" id="sidelem4x5759">
							<label>•</label>
							<sec_title>Adult including pregnant woman</sec_title>
							<para>
								<list id="lidelem4x5759">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Adult including pregnant woman:</emphasis> 20-30 mg initially unless low opioid tolerance expected; additional 5-10 mg q2-4hr as needed after initial dose; if symptoms continue, may give for ≤5 days</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x5763">
						<sec_title>Renal/hepatic disease</sec_title>
						<section type="none" id="sidelem4x5771">
							<label>•</label>
							<sec_title>Adult<route> may need to be modified</route></sec_title>
						</section>
					</section>
					<section type="none" id="sidelem4x5774">
						<sec_title>Available forms:</sec_title>
						<para> Inj 10 mg/ml; tabs 5, 10 mg; oral sol 5, 10 mg/5 ml; 10 mg/ml (concentrate); dispersible tabs 40 mg</para>
					</section>
					<section type="none" id="sidelem4x5779">
						<sec_title>Administer:</sec_title>
						<section type="none" id="sidelem4x5782">
							<sec_title>PO route</sec_title>
							<para>
								<list id="lidelem4x5786">
									<item>
										<label>•</label>
										<para>When using during a methadone maintenance program, use only PO according to NATA guidelines</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x5792">
							<sec_title>IM route</sec_title>
							<para>
								<list id="lidelem4x5796">
									<item>
										<label>•</label>
										<para>Rotating inj sites, give deep in large muscle mass (IM)</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x5802">
							<sec_title>SUBCUT route</sec_title>
							<para>
								<list id="lidelem4x5806">
									<item>
										<label>•</label>
										<para>Pain and induration may occur at site</para>
									</item>
								</list>
							</para>
						</section>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x5812">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x5815">
					<section type="none" id="sidelem4x5816">
						<sec_title>CNS:</sec_title>
						<para> <emphasis style="italic">Drowsiness, dizziness, confusion, headache, sedation,</emphasis> euphoria, <emphasis style="bold">seizures</emphasis></para>
					</section>
					<section type="none" id="sidelem4x5826">
						<sec_title>CV:</sec_title>
						<para> Palpitations, bradycardia, change in B/P, <emphasis style="bold">cardiac arrest, shock,</emphasis> hypotension, <emphasis style="bold">torsades de pointes, QT prolongation</emphasis></para>
					</section>
					<section type="none" id="sidelem4x5836">
						<sec_title>EENT:</sec_title>
						<para> Tinnitus, blurred vision, miosis, diplopia</para>
					</section>
					<section type="none" id="sidelem4x5842">
						<sec_title>GI:</sec_title>
						<para> <emphasis style="italic">Nausea, vomiting, anorexia, constipation, cramps,</emphasis> biliary tract spasm</para>
					</section>
					<section type="none" id="sidelem4x5850">
						<sec_title>GU:</sec_title>
						<para> Increased urinary output, dysuria, urinary retention, impotence</para>
					</section>
					<section type="none" id="sidelem4x5855">
						<sec_title>INTEG:</sec_title>
						<para> <emphasis style="italic">Rash,</emphasis> urticaria, bruising, flushing, diaphoresis, pruritus</para>
					</section>
					<section type="none" id="sidelem4x5863">
						<sec_title>RESP:</sec_title>
						<para> <emphasis style="bold">Respiratory depression, respiratory arrest</emphasis></para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x5870">
				<sec_title>Pharmacokinetics</sec_title>
				<para>Metabolized by liver; excreted by kidneys; crosses placenta; excreted in breast milk; half-life 2-3 hr, extended interval with continued dosing; 90% bound to plasma proteins</para>
				<section type="none" id="sidelem4x5875">
					<section type="none" id="sidelem4x5876">
						<sec_title>PO:</sec_title>
						<para> Onset 30-60 min, peak 1-1.5 hr, duration 6-8 hr, cumulative 22-48 hr; PO half as active as INJ</para>
					</section>
					<section type="none" id="sidelem4x5881">
						<sec_title>SUBCUT/IM:</sec_title>
						<para> Onset 10-20 min, peak 1<emphasis style="sup">1</emphasis>/<emphasis style="inf">2</emphasis>-2 hr, duration 4-6 hr, cumulative 22-48 hr</para>
					</section>
				</section>
			</section>
			<section type="interactions" id="sidelem4x5892">
				<sec_title>Interactions</sec_title>
				<para>
					<list id="lidelem4x5898">
						<item>
							<para>
								<emphasis alert="nurse">Unpredictable reactions: MAOIs; do not use together</emphasis>
							</para>
						</item>
					</list>
				</para>
				<section type="none" id="sidelem4x5906">
					<label>•</label>
					<sec_title>
						<route>Do not use within 2 wk of selegiline</route>
					</sec_title>
				</section>
				<para>
					<emphasis style="bold">Increase:</emphasis> effects with other CNS depressants—alcohol, opiates, sedative/hypnotics, antipsychotics, skeletal muscle relaxants</para>
				<para>
					<emphasis alert="lifethreat">Increase: toxicity—CYP3A4 inhibitors (aprepitant, antiretroviral protease inhibitors, clarithromycin, danazol, delavirdine, diltiazem, erythromycin, fluconazole, FLUoxetine, fluroxamine, imatinib, ketoconazole, mibefradil, nefazodone, telithromycin, voriconazole)</emphasis>
				</para>
				<para>
					<emphasis alert="lifethreat">Increase: QT prolongation—class IA antiarrhythmics (disopyramide, procainamide, quiNIDine), class III antiarrhythmics (amiodarone, dofetilide, ibutilide, sotalol), astemizole, arsenic trioxide, cisapride, chloroquine, clarithromycin, levomethadye, pentamidine, some phenothiazines, pimozide, terfenadine</emphasis>
				</para>
				<para>
					<emphasis style="bold">Decrease:</emphasis> analgesia—rifampin, phenytoin, nalbuphine, pentazine</para>
				<para>
					<emphasis style="bold">Decrease:</emphasis> methadone effect—CYP3A4 inducers (barbiturates, bosentan, carBAMazepine, efavirenz, phenytoins, nevirapine, rifabutin, rifampin), withdrawal symptoms may occur</para>
				<section type="none" id="sidelem4x5927">
					<section type="none" id="sidelem4x5928">
						<sec_title>Drug/Food</sec_title>
						<para>
							<list id="lidelem4x5932">
								<item>
									<label>•</label>
									<para>Avoid use with grapefruit juice</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x5938">
						<sec_title>Drug/Herb</sec_title>
						<para>
							<list id="lidelem4x5942">
								<item>
									<label>•</label>
									<para>Avoid use with St. John’s wort; withdrawal may result</para>
								</item>
							</list>
						</para>
						<para>
							<emphasis style="bold">Increase:</emphasis> CNS depression—chamomile, hops, kava, valerian</para>
					</section>
					<section type="none" id="sidelem4x5952">
						<sec_title>Drug/Lab Test</sec_title>
						<para>
							<emphasis style="bold">Increase:</emphasis> amylase, lipase</para>
					</section>
				</section>
			</section>
			<section type="considerations" id="sidelem4x5959">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x5962">
					<section type="none" id="sidelem4x5963">
						<sec_title>Assess:</sec_title>
						<section type="none" id="sidelem4x5971">
							<label>•</label>
							<sec_title>Pain</sec_title>
							<para>
								<list id="lidelem4x5971">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Pain:</emphasis> type, location, intensity, grimacing before, 1<emphasis style="sup">1</emphasis>/<emphasis style="inf">2</emphasis>-2 hr after administration; use pain scoring</para>
									</item>
								</list>
							</para>
						</section>
						<para>
							<list id="lidelem4x5981">
								<item>
									<label>•</label>
									<para>I&amp;O ratio; check for decreasing output; may indicate urinary retention</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x5986">
								<item>
									<label>•</label>
									<para>CNS changes: dizziness, drowsiness, hallucinations, euphoria, LOC, pupil reaction</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x5994">
							<para>
								<list id="lidelem4x5994">
									<item>
										<label>•</label>
										<para>Allergic reactions: rash, urticaria
<bbw>
												<emphasis alert="lifethreat">Respiratory dysfunction:</emphasis> respiratory depression, character, rate, rhythm; notify prescriber if respirations are &lt;10/min</bbw>

<bbw>
												<emphasis alert="lifethreat">QT prolongation:</emphasis> may be dose related or use with other products that increase QT</bbw>

<bbw>Accidental exposure: make sure product is not accessible to children, pets</bbw>

<bbw>Overdose, poisoning: advise persons involved in correct use</bbw>

<bbw>Substance abuse: may occur but has less psychological dependence than other opiate agonists</bbw>
</para>
									</item>
								</list>
							</para>
						</section>
						<para>
							<list id="lidelem4x6045">
								<item>
									<label>•</label>
									<para>Opioid detoxification: no analgesia occurs, only prevention of withdrawal symptoms
<bbw>B/P, pulse, ECG; hypotension, palpitations may occur</bbw>
</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x6060">
								<item>
									<label>•</label>
									<para>Bowel changes, bulk, fluids, laxatives should be used for constipation</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x6065">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x6069">
								<item>
									<label>•</label>
									<para>Therapeutic response: decrease in pain, successful opioid withdrawal</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x6075">
						<sec_title>Teach patient/family:</sec_title>
						<para>
							<list id="lidelem4x6080">
								<item>
									<label>•</label>
									<para>To report any symptoms of CNS changes, allergic reactions</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x6085">
								<item>
									<label>•</label>
									<para>That physical dependency may result from extended use</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x6091">
								<item>
									<para>
										<emphasis alert="nurse">That withdrawal symptoms may occur: nausea, vomiting, cramps, fever, faintness, anorexia</emphasis>
									</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x6096">
								<item>
									<label>•</label>
									<para>To maintain proper hydration; to avoid alcohol use</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x6101">
								<item>
									<label>•</label>
									<para>To avoid use with other products without approval of prescriber; many drug interactions</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
		</monograph>
<monograph id="17" status="active">
			<mono_name>methimazole (Rx)</mono_name>
			<info>
				<pronunciation>(meth-im′a-zole)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x61190">Tapazole</tradename>
				</tradenames>
				<class type="func"> Thyroid hormone antagonist (antithyroid)</class>
				<class type="chem"> Thioamide</class>
				<class type="preg">Pregnancy category <preg cat="D">D</preg></class>
			</info>
			<section type="confusion" id="sidelem4x6129">
				<para>
					<confusion>
						<tradename id="tnidelem4x61290">methimazole</tradename>
						<drug type="generic" refid="idelem4x61290">metoprolol/minoxidil</drug>
					</confusion>
				</para>
			</section>
			<section type="uses" id="sidelem4x6143">
				<sec_title>Uses:</sec_title>
				<para>Hyperthyroidism, preparation for thyroidectomy</para>
			</section>
			<section type="contra" id="sidelem4x6148">
				<sec_title>Contraindications:</sec_title>
				<para>Pregnancy (<preg cat="D">D</preg>), breastfeeding, hypersensitivity</para>
				<section type="none" id="sidelem4x6153">
					<section type="none" id="sidelem4x6154">
						<sec_title>Precautions:</sec_title>
						<para> Infection, bone marrow suppression, hepatic disease, bleeding disorders</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x6159">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x6162">
					<section type="none" id="sidelem4x6163">
						<sec_title>Hyperthyroidism</sec_title>
						<section type="none" id="sidelem4x6171">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x6171">
									<item>
										<label>•</label>
										<para> 15 mg/day (mild hyperthyroidism); 30-40 mg/day (moderate to severe); 60 mg/day (severe); maintenance 5-15 mg/day; may be divided</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x6178">
							<label>•</label>
							<sec_title>Child<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x6178">
									<item>
										<label>•</label>
										<para> 0.4 mg/kg/day in divided doses q8hr; continue until euthyroid; maintenance dose 0.2 mg/kg/day in divided doses q8hr, max 30 mg/24 hr; may be divided</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x6182">
						<sec_title>Preparation for thyroidectomy</sec_title>
						<section type="none" id="sidelem4x6190">
							<label>•</label>
							<sec_title>Adult and child<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x6190">
									<item>
										<label>•</label>
										<para> same as above; iodine may be added × 10 days before surgery</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x6194">
						<sec_title>Thyrotoxic crisis</sec_title>
						<section type="none" id="sidelem4x6202">
							<label>•</label>
							<sec_title>Adult and child<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x6202">
									<item>
										<label>•</label>
										<para> same as hyperthyroidism with iodine and propranolol</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x6206">
						<sec_title>Available forms:</sec_title>
						<para> Tabs 5, 10, 20 mg</para>
					</section>
					<section type="none" id="sidelem4x6211">
						<sec_title>Administer:</sec_title>
						<para>
							<list id="lidelem4x6215">
								<item>
									<label>•</label>
									<para>With meals to decrease GI upset</para>
								</item>
								<item>
									<label>•</label>
									<para>At same time each day to maintain product level</para>
								</item>
								<item>
									<label>•</label>
									<para>Lowest dose that relieves symptoms; discontinue before RAIU</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x6231">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x6234">
					<section type="none" id="sidelem4x6235">
						<sec_title>CNS:</sec_title>
						<para> <emphasis style="italic">Drowsiness, headache, vertigo, fever,</emphasis> paresthesias, neuritis</para>
					</section>
					<section type="none" id="sidelem4x6243">
						<sec_title>ENDO:</sec_title>
						<para> <emphasis style="italic">Enlarged thyroid</emphasis></para>
					</section>
					<section type="none" id="sidelem4x6250">
						<sec_title>GI:</sec_title>
						<para> <emphasis style="italic">Nausea, diarrhea, vomiting,</emphasis><emphasis style="bold">jaundice, hepatitis,</emphasis> loss of taste</para>
					</section>
					<section type="none" id="sidelem4x6260">
						<sec_title>GU:</sec_title>
						<para> <emphasis style="bold">Nephritis</emphasis></para>
					</section>
					<section type="none" id="sidelem4x6267">
						<sec_title>HEMA:</sec_title>
						<para> <emphasis style="bold">Agranulocytosis, leukopenia, thrombocytopenia, hypothrombinemia, lymphadenopathy,</emphasis> bleeding, vasculitis</para>
					</section>
					<section type="none" id="sidelem4x6275">
						<sec_title>INTEG:</sec_title>
						<para> <emphasis style="italic">Rash, urticaria, pruritus, alopecia, hyperpigmentation,</emphasis> lupuslike syndrome</para>
					</section>
					<section type="none" id="sidelem4x6283">
						<sec_title>MS:</sec_title>
						<para> Myalgia, arthralgia, nocturnal muscle cramps</para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x6288">
				<sec_title>Pharmacokinetics</sec_title>
				<para>Onset rapid; peak 30-60 min; half-life 5-13 hr; excreted in urine, breast milk; crosses placenta</para>
			</section>
			<section type="interactions" id="sidelem4x6293">
				<sec_title>Interactions</sec_title>
				<para>
					<emphasis style="bold">Increase:</emphasis> bone marrow depression—radiation, antineoplastic agents</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> response to digoxin</para>
				<para>
					<emphasis style="bold">Decrease:</emphasis> effectiveness—amiodarone, potassium iodide</para>
				<para>
					<emphasis style="bold">Decrease:</emphasis> anticoagulant effect—warfarin</para>
				<section type="none" id="sidelem4x6313">
					<section type="none" id="sidelem4x6314">
						<sec_title>Drug/Lab Test</sec_title>
						<para>
							<emphasis style="bold">Increase:</emphasis> PT, AST, ALT, alk phos</para>
					</section>
				</section>
			</section>
			<section type="considerations" id="sidelem4x6321">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x6324">
					<section type="none" id="sidelem4x6325">
						<sec_title>Assess:</sec_title>
						<section type="none" id="sidelem4x6333">
							<label>•</label>
							<sec_title>Hyperthyroidism</sec_title>
							<para>
								<list id="lidelem4x6333">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Hyperthyroidism:</emphasis> palpitation, nervousness, loss of hair, insomnia, heat intolerance, weight loss, diarrhea</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x6340">
							<label>•</label>
							<sec_title>Hypothyroidism</sec_title>
							<para>
								<list id="lidelem4x6340">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Hypothyroidism:</emphasis> constipation, dry skin, weakness, fatigue, headache, intolerance to cold, weight gain; adjustment may be needed</para>
									</item>
								</list>
							</para>
						</section>
						<para>
							<list id="lidelem4x6344">
								<item>
									<label>•</label>
									<para>Pulse, B/P, temperature</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x6349">
								<item>
									<label>•</label>
									<para>I&amp;O ratio; check for edema: puffy hands, feet, periorbits; these indicate hypothyroidism</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x6354">
								<item>
									<label>•</label>
									<para>Weight daily; same clothing, scale, time of day</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x6359">
								<item>
									<label>•</label>
									<para>T<emphasis style="inf">3</emphasis>, T<emphasis style="inf">4</emphasis>, which are increased; serum TSH, which is decreased; free thyroxine index, which is increased if dosage too low; discontinue product 3-4 wk before RAIU</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x6371">
								<item>
									<para>
										<emphasis alert="nurse">Blood dyscrasias: CBC, leukopenia, thrombocytopenia, agranulocytosis; if these occur, product should be discontinued and other treatment initiated; may occur at higher doses</emphasis>
									</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x6379">
							<label>•</label>
							<sec_title>Hypersensitivity</sec_title>
							<para>
								<list id="lidelem4x6379">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Hypersensitivity:</emphasis> rash, enlarged cervical lymph nodes; product may have to be discontinued</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x6386">
							<label>•</label>
							<sec_title>Hypoprothrombinemia</sec_title>
							<para>
								<list id="lidelem4x6386">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Hypoprothrombinemia:</emphasis> bleeding, petechiae, ecchymosis</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x6393">
							<label>•</label>
							<sec_title>Clinical response</sec_title>
							<para>
								<list id="lidelem4x6393">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Clinical response:</emphasis> after 3 wk should include increased weight; decreased T<emphasis style="inf">4</emphasis>, pulse</para>
									</item>
								</list>
							</para>
						</section>
						<para>
							<list id="lidelem4x6401">
								<item>
									<para>
										<emphasis alert="nurse">Bone marrow suppression: sore throat, fever, fatigue</emphasis>
									</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x6406">
								<item>
									<label>•</label>
									<para>Increased fluids to 3-4 L/day unless contraindicated</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x6411">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x6415">
								<item>
									<label>•</label>
									<para>Therapeutic response: weight gain, decreased pulse, decreased T<emphasis style="inf">4</emphasis>, B/P</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x6424">
						<sec_title>Teach patient/family:</sec_title>
						<section type="none" id="sidelem4x6432">
							<label>•</label>
							<sec_title>
								<route>Not to breastfeed</route>
							</sec_title>
						</section>
						<para>
							<list id="lidelem4x6435">
								<item>
									<label>•</label>
									<para>To take pulse daily</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x6440">
								<item>
									<label>•</label>
									<para>To report redness, swelling, sore throat, mouth lesions, fever, which indicate blood dyscrasias</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x6445">
								<item>
									<label>•</label>
									<para>To keep graph of weight, pulse, mood</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x6450">
								<item>
									<label>•</label>
									<para>To avoid OTC products, seafood that contains iodine, other iodine products</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x6455">
								<item>
									<label>•</label>
									<para>Not to discontinue product abruptly because thyroid crisis may occur; stress patient response</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x6460">
								<item>
									<label>•</label>
									<para>That response may take several months if thyroid is large</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x6468">
							<label>•</label>
							<sec_title>Symptoms and signs of overdose</sec_title>
							<para>
								<list id="lidelem4x6468">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Symptoms and signs of overdose:</emphasis> periorbital edema, cold intolerance, mental depression</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x6475">
							<label>•</label>
							<sec_title>Symptoms of inadequate dose</sec_title>
							<para>
								<list id="lidelem4x6475">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Symptoms of inadequate dose:</emphasis> tachycardia, diarrhea, fever, irritability</para>
									</item>
								</list>
							</para>
						</section>
						<para>
							<list id="lidelem4x6479">
								<item>
									<label>•</label>
									<para>To take medication as prescribed; not to skip or double dose</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
		</monograph>
<monograph id="18" status="active" ha="yes">
			<mono_name> methotrexate (Rx)</mono_name>
			<info>
				<pronunciation>(meth-oh-trex′ate)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x64911">Rheumatrex</tradename>
					<tradename id="tnidelem4x64910">Trexall</tradename>
				</tradenames>
				<class type="func"> Antineoplastic-antimetabolite (vesicant)</class>
				<class type="chem"> Folic acid antagonist</class>
				<class type="preg">Pregnancy category <preg cat="X">X</preg></class>
			</info>
			<section type="confusion" id="sidelem4x6501">
				<para>
					<confusion>
						<tradename id="tnidelem4x65010">methotrexate</tradename>
						<drug type="generic" refid="idelem4x65010">metolazone/mitoXANtrone</drug>
					</confusion>
				</para>
			</section>
			<section type="actions" id="sidelem4x6505">
				<sec_title>Action:</sec_title>
				<para>Inhibits an enzyme that reduces folic acid, which is needed for nucleic acid synthesis in all cells; specific to S phase of cell cycle; immunosuppressive</para>
			</section>
			<section type="uses" id="sidelem4x6510">
				<sec_title>Uses:</sec_title>
				<para>Acute lymphocytic leukemia; in combination for breast, lung, head, neck carcinoma; lymphoma, sarcoma, gestational choriocarcinoma, hydatidiform mole, psoriasis, RA, mycosis fungoides, osteosarcoma</para>
				<section type="none" id="sidelem4x6515">
					<section type="none" id="sidelem4x6516">
						<sec_title>Unlabeled uses:</sec_title>
						<para> Burkitt’s lymphoma, bladder or ovarian cancer, carcinomatous meningitis, desmoid tumor, fibromatosis, asthma, active Crohn’s disease, ulcerative colitis, GVHD prophylaxis, ectopic pregnancy, pregnancy termination, psoriatic arthritis, pruritus due to cholestasis or primary biliary cirrhosis, SLE, sarcoidosis</para>
					</section>
				</section>
			</section>
			<section type="contra" id="sidelem4x6521">
				<sec_title>Contraindications:</sec_title>
				<para>Hypersensitivity, leukopenia (&lt;3500/mm<emphasis style="sup">3</emphasis>), thrombocytopenia (&lt;100,000/mm<emphasis style="sup">3</emphasis>), anemia; psoriatic patients with severe renal disease, alcoholism, AIDS</para>
				<para>
					<bbw>Pregnancy (X), hepatic disease</bbw>
				</para>
				<section type="none" id="sidelem4x6544">
					<section type="none" id="sidelem4x6545">
						<sec_title>Precautions:</sec_title>
						<para> Breastfeeding, children</para>
						<para>
							<bbw>Renal disease, ascites, diarrhea, exfoliative dermatitis, infection, intrathecal administration, lymphoma, pleural effusion, pulmonary disease, radiation therapy, stomatitis, tumor lysis syndrome, renal impairment</bbw>
						</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x6560">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x6563">
					<section type="none" id="sidelem4x6564">
						<sec_title>Acute lymphocytic leukemia</sec_title>
						<section type="none" id="sidelem4x6572">
							<label>•</label>
							<sec_title>Adult and child<route> PO/IM/IV</route></sec_title>
							<para>
								<list id="lidelem4x6572">
									<item>
										<label>•</label>
										<para> 3.3 mg/m<emphasis style="sup">2</emphasis>/day × 4-6 wk or until remission, then 30 mg/m<emphasis style="sup">2</emphasis> weekly in 2 divided doses or 2.5 mg/kg  × q2 wk</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x6587">
						<sec_title>Choriocarcinoma</sec_title>
						<section type="none" id="sidelem4x6595">
							<label>•</label>
							<sec_title>Adult and child<route> PO/IM</route></sec_title>
							<para>
								<list id="lidelem4x6595">
									<item>
										<label>•</label>
										<para> 15-30 mg/day × 5 days, then off 1 wk; may repeat</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x6599">
						<sec_title>Meningeal leukemia</sec_title>
						<section type="none" id="sidelem4x6607">
							<label>•</label>
							<sec_title>Adult</sec_title>
							<para>
								<list id="lidelem4x6607">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Adult:</emphasis> 12 mg/m<emphasis style="sup">2</emphasis> q2-5days until CSF is normal, then 1 additional dose, max 15 mg</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x6619">
							<label>•</label>
							<sec_title>Child ≥3 yr</sec_title>
							<para>
								<list id="lidelem4x6619">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Child ≥3 yr:</emphasis> Intrathecally 12 mg q2-5days</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x6626">
							<label>•</label>
							<sec_title>Child 2-3 yr</sec_title>
							<para>
								<list id="lidelem4x6626">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Child 2-3 yr:</emphasis> 10 mg q2-5days</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x6633">
							<label>•</label>
							<sec_title>Child 1-2 yr</sec_title>
							<para>
								<list id="lidelem4x6633">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Child 1-2 yr:</emphasis> 8 mg q2-5days</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x6637">
						<sec_title>Osteosarcoma</sec_title>
						<section type="none" id="sidelem4x6645">
							<label>•</label>
							<sec_title>Adult and child<route> IV</route></sec_title>
							<para>
								<list id="lidelem4x6645">
									<item>
										<label>•</label>
										<para> 12 g/m<emphasis style="sup">2</emphasis> given over 4 hr, then leucovorin rescue</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x6652">
						<sec_title>Mycosis fungoides</sec_title>
						<section type="none" id="sidelem4x6660">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x6660">
									<item>
										<label>•</label>
										<para> 5-50 mg weekly or 15-37.5 mg twice weekly;  50 mg weekly or 15-37.5 mg twice weekly</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x6667">
						<sec_title>Psoriasis</sec_title>
						<section type="none" id="sidelem4x6675">
							<label>•</label>
							<sec_title>Adult<route> PO/IM/IV</route></sec_title>
							<para>
								<list id="lidelem4x6675">
									<item>
										<label>•</label>
										<para> 10-25 mg/wk or 2.5 mg  q12hr × 3 doses/wk, may increase to 25 mg/wk, max 30 mg/wk</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x6682">
						<sec_title>Breast cancer</sec_title>
						<section type="none" id="sidelem4x6690">
							<label>•</label>
							<sec_title>Adult<route> IV</route></sec_title>
							<para>
								<list id="lidelem4x6690">
									<item>
										<label>•</label>
										<para> 40-60 mg/m<emphasis style="sup">2</emphasis> on day 1 of every 21-28 days with other antineoplastics</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x6697">
						<sec_title>Epidermal head/neck cancer</sec_title>
						<section type="none" id="sidelem4x6705">
							<label>•</label>
							<sec_title>Adult/child<route> IV</route></sec_title>
							<para>
								<list id="lidelem4x6705">
									<item>
										<label>•</label>
										<para> 40 mg/m<emphasis style="sup">2</emphasis> on days 1 and 15, q21days alone or in combination with bleomycin, CISplatin</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x6715">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x6715">
									<item>
										<label>•</label>
										<para> 25-50 mg/m<emphasis style="sup">2</emphasis> q7days</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x6725">
							<label>•</label>
							<sec_title>Child<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x6725">
									<item>
										<label>•</label>
										<para> 7.5-30 mg/m<emphasis style="sup">2</emphasis> q7-14days</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x6732">
						<sec_title>Rheumatoid arthritis</sec_title>
						<section type="none" id="sidelem4x6740">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x6740">
									<item>
										<label>•</label>
										<para> 7.5 mg/wk or in divided doses of 2.5 mg q12hr × 3 doses once a wk; max 20 mg/wk</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x6744">
						<sec_title>Polyarticular-course juvenile RA</sec_title>
						<section type="none" id="sidelem4x6752">
							<label>•</label>
							<sec_title>Child<route> PO/IM</route></sec_title>
							<para>
								<list id="lidelem4x6752">
									<item>
										<label>•</label>
										<para> 10 mg/m<emphasis style="sup">2</emphasis>/wk</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x6759">
						<sec_title>Burkitt’s lymphoma (stages I, II, III)</sec_title>
						<section type="none" id="sidelem4x6767">
							<label>•</label>
							<sec_title>Adult/adolescent/child<route> IV</route></sec_title>
							<para>
								<list id="lidelem4x6767">
									<item>
										<label>•</label>
										<para> 200 mg/m<emphasis style="sup">2</emphasis> days 8 and 15 q21days with bleomycin, cyclophosphamide, vinCRIStine, dexamethasone</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x6774">
						<sec_title>Bladder cancer (unlabeled)</sec_title>
						<section type="none" id="sidelem4x6782">
							<label>•</label>
							<sec_title>Adult<route> IV</route></sec_title>
							<para>
								<list id="lidelem4x6782">
									<item>
										<label>•</label>
										<para> 30 mg/m<emphasis style="sup">2</emphasis> on days 1, 15, 22 q28days in combination with vinBLAStine, DOXOrubicin, CISplatin (MVAC) regimen</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x6789">
						<sec_title>Active Crohn’s disease/ulcerative colitis (unlabeled)</sec_title>
						<section type="none" id="sidelem4x6797">
							<label>•</label>
							<sec_title>Adult<route> IM</route></sec_title>
							<para>
								<list id="lidelem4x6797">
									<item>
										<label>•</label>
										<para> 25 mg/wk;  15 mg/kg/wk × 16 wk</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x6804">
						<sec_title>GVHD prophylaxis (unlabeled)</sec_title>
						<section type="none" id="sidelem4x6812">
							<label>•</label>
							<sec_title>Adult and child<route> IV</route></sec_title>
							<para>
								<list id="lidelem4x6812">
									<item>
										<label>•</label>
										<para> 15 mg/m<emphasis style="sup">2</emphasis> on day 1 after transplant, then 10 mg/m<emphasis style="sup">2</emphasis> on days 3, 6, 11</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x6822">
						<sec_title>Ectopic pregnancy (unlabeled)</sec_title>
						<section type="none" id="sidelem4x6830">
							<label>•</label>
							<sec_title>Adult<route> IM</route></sec_title>
							<para>
								<list id="lidelem4x6830">
									<item>
										<label>•</label>
										<para> 50 mg/m<emphasis style="sup">2</emphasis> may be used in combination with mifepristone</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x6837">
						<sec_title>Pregnancy termination before 63rd day of pregnancy (unlabeled)</sec_title>
						<section type="none" id="sidelem4x6845">
							<label>•</label>
							<sec_title>Adult<route> IM</route></sec_title>
							<para>
								<list id="lidelem4x6845">
									<item>
										<label>•</label>
										<para> 50 mg/m<emphasis style="sup">2</emphasis>, then intravaginal misoprostol 5-7 days later</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x6852">
						<sec_title>Psoriatic arthritis (unlabeled)</sec_title>
						<section type="none" id="sidelem4x6860">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x6860">
									<item>
										<label>•</label>
										<para> 5-7.5 mg weekly</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x6864">
						<sec_title>Available forms:</sec_title>
						<para> Tabs 2.5, 5, 7.5, 10, 15 mg; inj 25 mg/ml (2, 4, 8, 10, 20, 40 ml vials); 25 mg/ml (2-, 10-ml vials with benzyl alcohol); powder for inj 1 g</para>
					</section>
					<section type="none" id="sidelem4x6869">
						<sec_title>Administer:</sec_title>
						<para>
							<list id="lidelem4x6873">
								<item>
									<label>•</label>
									<para>Using chemotherapeutic handling</para>
								</item>
								<item>
									<label>•</label>
									<para>Antiemetic 30-60 min before product</para>
								</item>
								<item>
									<label>•</label>
									<para>Allopurinol or sodium bicarbonate to reduce uric acid levels, alkalinization of urine (pH &gt;7.5), adequate fluids</para>
								</item>
								<item>
									<label>•</label>
									<para>Store in tightly closed container in cool environment; store injection, powder for inj in dark, dry area</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x6894">
							<sec_title>Direct IV route</sec_title>
							<para>
								<list id="lidelem4x6898">
									<item>
										<label>•</label>
										<para>After reconstituting to 5 mg/2ml of sterile water for inj; give through <emphasis style="sans-serif">Y</emphasis>-tube or 3-way stopcock</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x6908">
							<sec_title>Intermittent/Continuous IV INFUSION route</sec_title>
							<para>
								<list id="lidelem4x6913">
									<item>
										<label>•</label>
										<para>Further dilute in D<emphasis style="inf">5</emphasis>W, D<emphasis style="inf">5</emphasis>NS, NS, before infusion check patency of vein; flush with 5-10 ml of D<emphasis style="inf">5</emphasis>W, NS; infuse at 4-20 mg/hr or prescribed rate</para>
									</item>
								</list>
							</para>
							<para>
								<list id="lidelem4x6928">
									<item>
										<para>
											<emphasis alert="nurse">Leucovorin rescue: leucovorin calcium within 24-48 hr of product to prevent tissue damage; check agency policy; continue until methotrexate level &lt;10<emphasis style="sup">−8</emphasis> m</emphasis>
										</para>
									</item>
								</list>
							</para>
							<para>
								<emphasis style="bold">IV INFUSION intermediate or high dose (500 mg/m<emphasis style="sup">2</emphasis> over &lt;4 hr or &gt;1 g/m<emphasis style="sup">2</emphasis> over &gt;4 hr):</emphasis> confirm WBC &gt;1500/mm<emphasis style="sup">3</emphasis>, neutrophils &gt;200/mm<emphasis style="sup">3</emphasis>, platelets &gt;75,000/mm<emphasis style="sup">3</emphasis>, serum bilirubin &lt;1.2 mg/dl, serum creatinine WNL, SGPT &lt;450 U, creatinine clearance &gt;60 ml/min</para>
							<para>
								<emphasis alert="nurse">Give sodium bicarbonate tabs or IV fluids to prevent precipitation of product at high doses; urine pH should be &gt;7; may need to reduce dosage if BUN 20-30 mg/dl or creatinine is 1.2-2 mg/dl; stop product if BUN &gt;30 mg/dl or creatinine &gt;2 mg/dl</emphasis>
							</para>
							<para>
								<emphasis style="bold">Additive compatibilities:</emphasis> Cephalothin, cyclophosphamide, cytarabine, fluorouracil, hydrOXYzine, mercaptopurine, ondansetron, sodium bicarbonate, vinCRIStine</para>
							<para>
								<emphasis style="bold">Solution compatibilities:</emphasis> Amino acids, 4.25%/D<emphasis style="inf">25</emphasis>, D<emphasis style="inf">5</emphasis>W, sodium bicarbonate 0.05 mol/L, sodium chloride 0.9%</para>
							<para>
								<emphasis style="bold">Y-site compatibilities:</emphasis> Acyclovir, alemtuzumab, alfentanil, allopurinol, amifostine, aminophylline, amphotericin B cholesteryl, asparaginase, aztreonam, bleomycin, cefepime, cefTRIAXone, cimetidine, CISplatin, cyclophosphamide, cytarabine, DAUNOrubicin, dexchlorpheniramine, diphenhydrAMINE, doripenem, DOXOrubicin, DOXOrubicin liposome, etoposide, famotidine, filgrastim, fludarabine, fluorouracil, furosemide, gallium, ganciclovir, graniset-ron, heparin, HYDROmorphone, imipenem-cilastatin, leucovorin, LORazepam, melphalan, mesna, methylPREDNISolone, metoclopramide, mitoMYcin, morphine, ondansetron, oxacillin, PACLitaxel, piperacillin/tazobactam, prochlorperazine, ranitidine, sargramostim, teniposide, thiotepa, vinBLAStine, vinCRIStine, vinorelbine, zoledronic acid</para>
						</section>
						<section type="none" id="sidelem4x6978">
							<sec_title>Intrathecal route</sec_title>
							<para>
								<bbw>Use preservative-free sol, reconstitute with NS; dose should be drawn into 5- to 10-ml syringe after LP, vol of CSF should be withdrawn equal to vol of methotrexate; allow CSF to flow into syringe and mix, inject over 15-30 sec with bevel of needle upward</bbw>
							</para>
						</section>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x6991">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x6994">
					<section type="none" id="sidelem4x6995">
						<sec_title>CNS:</sec_title>
						<para> Dizziness, <emphasis style="bold">seizures, leukoencephalopathy,</emphasis> headache, confusion, <emphasis style="bold">encephalopathy,</emphasis> hemiparesis, malaise, fatigue, chills, fever; <emphasis style="bold">arachnoiditis</emphasis> (intrathecal)</para>
					</section>
					<section type="none" id="sidelem4x7009">
						<sec_title>EENT:</sec_title>
						<para> Blurred vision, optic neuropathy</para>
					</section>
					<section type="none" id="sidelem4x7014">
						<sec_title>GI:</sec_title>
						<para> <emphasis style="italic">Nausea, vomiting, anorexia, diarrhea, ulcerative stomatitis,</emphasis><emphasis style="bold">hepatotoxicity,</emphasis> cramps, ulcer, gastritis, <emphasis style="bold">GI hemorrhage,</emphasis> abdominal pain, hematemesis, <emphasis style="bold">hepatic fibrosis, acute toxicity</emphasis></para>
					</section>
					<section type="none" id="sidelem4x7029">
						<sec_title>GU:</sec_title>
						<para> Urinary retention, <emphasis style="bold">renal failure,</emphasis> menstrual irregularities, defective spermatogenesis, <emphasis style="bold">hematuria, azotemia, uric acid nephropathy</emphasis></para>
					</section>
					<section type="none" id="sidelem4x7039">
						<sec_title>HEMA:</sec_title>
						<para> <emphasis style="bold">Leukopenia, thrombocytopenia, myelosuppression, anemia</emphasis></para>
					</section>
					<section type="none" id="sidelem4x7046">
						<sec_title>INTEG:</sec_title>
						<para> <emphasis style="italic">Rash, alopecia,</emphasis> dry skin, urticaria, photosensitivity, folliculitis, vasculitis, petechiae, ecchymosis, acne, alopecia, <emphasis style="bold">severe fatal skin reaction</emphasis></para>
					</section>
					<section type="none" id="sidelem4x7056">
						<sec_title>RESP:</sec_title>
						<para> <emphasis style="bold">Methotrexate-induced lung disease</emphasis></para>
					</section>
					<section type="none" id="sidelem4x7063">
						<sec_title>SYST:</sec_title>
						<para> <emphasis style="bold">Sudden death,</emphasis><emphasis style="italic">Pneumocystis jiroveci,</emphasis><emphasis style="bold">tumor lysis syndrome, secondary malignancy</emphasis></para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x7074">
				<sec_title>Pharmacokinetics</sec_title>
				<para>Not metabolized; excreted in urine (unchanged); crosses placenta, blood-brain barrier; 50% plasma protein bound; terminal half-life 10-12 hr</para>
				<section type="none" id="sidelem4x7079">
					<section type="none" id="sidelem4x7080">
						<sec_title>PO:</sec_title>
						<para> Readily absorbed</para>
					</section>
					<section type="none" id="sidelem4x7085">
						<sec_title>PO/IM/IV:</sec_title>
						<para> Onset, duration unknown</para>
					</section>
					<section type="none" id="sidelem4x7090">
						<sec_title>IT:</sec_title>
						<para> Onset, peak, duration unknown</para>
					</section>
				</section>
			</section>
			<section type="interactions" id="sidelem4x7096">
				<sec_title>Interactions</sec_title>
				<para>
					<emphasis alert="lifethreat">Do not use with proton pump inhibitors</emphasis>
				</para>
				<para>
					<emphasis alert="lifethreat">Increase: toxicity—salicylates, sulfa products, other antineoplastics, radiation, alcohol, probenecid, NSAIDs, phenylbutazone, theophylline, penicillins</emphasis>
				</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> hypoprothrombinemia—oral anticoagulants</para>
				<para>
					<emphasis alert="lifethreat">Increase: hepatitis—acitretin; avoid concurrent use</emphasis>
				</para>
				<para>
					<emphasis style="bold">Decrease:</emphasis> effect of oral digoxin, vaccines, phenytoin, fosphenytoin</para>
				<para>
					<emphasis style="bold">Decrease:</emphasis> antibody response—live-virus vaccines</para>
				<para>
					<emphasis style="bold">Decrease:</emphasis> effect of methotrexate—folic acid supplements, asparaginase</para>
			</section>
			<section type="considerations" id="sidelem4x7124">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x7127">
					<section type="none" id="sidelem4x7128">
						<sec_title>Assess:</sec_title>
						<section type="none" id="sidelem4x7136">
							<para>
								<list id="lidelem4x7136">
									<item>
										<label>•</label>
										<para>Make sure product is taken weekly in RA, JRA
<bbw>
												<emphasis alert="lifethreat">Infection:</emphasis> those with active infections should be treated for infection before product use; monitor temperature, fever may indicate beginning of infection</bbw>
</para>
									</item>
								</list>
							</para>
						</section>
						<para>
							<list id="lidelem4x7149">
								<item>
									<label>•</label>
									<para>Make sure drug–drug interacting products are discontinued before therapy, and do not resume until methotrexate level is safe</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x7155">
								<item>
									<para>
										<emphasis alert="nurse">CBC, differential, platelet count weekly; avoid use until WBC is &gt;1500/mm<emphasis style="sup">3</emphasis> or platelet count is &gt;75,000/mm<emphasis style="sup">3</emphasis>, neutrophils &gt;200/mm<emphasis style="sup">3</emphasis>; notify prescriber; WBC, platelet nadirs occur on day 7; monitor</emphasis>
<bbw>
											<emphasis alert="lifethreat">Renal disease:</emphasis> avoid use in renal failure, BUN, serum uric acid, urine CCr, electrolytes before, during therapy; I&amp;O ratio; report fall in urine output to &lt;30 ml/hr</bbw>
</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x7180">
								<item>
									<label>•</label>
									<para>Bleeding time, coagulation time during treatment; bleeding: hematuria, guaiac, bruising, or petechiae in mucosa or orifices</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x7188">
							<para>
								<list id="lidelem4x7188">
									<item>
										<label>•</label>
										<para>Effects of alopecia on body image; discuss feelings about body changes
<bbw>
												<emphasis alert="lifethreat">Pulmonary toxicity:</emphasis> those with ascites or pleural effusion at greater risk for toxicity; fluid should be removed before treatment; monitor plasma methotrexate levels</bbw>

<bbw>
												<emphasis alert="lifethreat">Tumor lysis syndrome:</emphasis> hyperkalemia, hyperphosphatemia, hyperuricemia, hypocalcemia, decreased urine output; use aggressive hydration, allopurinol to correct severe electrolyte imbalances, renal toxicity</bbw>

<bbw>
												<emphasis alert="lifethreat">Hepatotoxicity:</emphasis> jaundiced skin and sclera, dark urine, clay-colored stools, pruritus, abdominal pain, fever, diarrhea, hepatic studies before and during therapy: bilirubin, alk phos, AST, ALT; liver biopsy should be done before start of therapy (psoriasis)</bbw>
</para>
									</item>
								</list>
							</para>
						</section>
						<para>
							<list id="lidelem4x7223">
								<item>
									<label>•</label>
									<para>Monitor methotrexate levels, adjust leucovorin dose based on level</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x7231">
							<para>
								<list id="lidelem4x7231">
									<item>
										<label>•</label>
										<para>Buccal cavity for dryness, sores, ulceration, white patches, oral pain, bleeding, dysphagia
<bbw>
												<emphasis alert="lifethreat">Serious skin reaction:</emphasis> Stevens-Johnson syndrome, exfoliate dermatitis, skin necrosis, erythema multiform may occur within days of receiving product by any route; product should be discontinued</bbw>
</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x7247">
							<label>•</label>
							<sec_title>Strokelike encephalopathy<route> common in high-dose therapy; assess for confusion, hemiparesis, seizures, coma; usually transient</route></sec_title>
						</section>
						<section type="none" id="sidelem4x7253">
							<label>•</label>
							<sec_title>Rheumatoid arthritis</sec_title>
							<para>
								<list id="lidelem4x7253">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Rheumatoid arthritis:</emphasis> ROM, pain, joint swelling before, during treatment</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x7260">
							<label>•</label>
							<sec_title>Psoriasis</sec_title>
							<para>
								<list id="lidelem4x7260">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Psoriasis:</emphasis> skin lesions before, during treatment</para>
									</item>
								</list>
							</para>
						</section>
						<para>
							<list id="lidelem4x7264">
								<item>
									<label>•</label>
									<para>Increased fluid intake to 2-3 L/day to prevent urate deposits, calculi formation unless contraindicated</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x7269">
								<item>
									<label>•</label>
									<para>Rinsing of mouth tid-qid with water, club soda; brushing of teeth bid-tid with soft brush or cotton-tipped applicators for stomatitis; use unwaxed dental floss</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x7275">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x7279">
								<item>
									<label>•</label>
									<para>Therapeutic response: decreased tumor size, spread of malignancy; decreased joint inflammation, pain in RA</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x7285">
						<sec_title>Teach patient/family:</sec_title>
						<para>
							<bbw>To report any complaints, side effects to nurse or prescriber: black tarry stools, chills, fever, sore throat, bleeding, bruising, cough, SOB, dark or bloody urine, seizures</bbw>
						</para>
						<para>
							<list id="lidelem4x7298">
								<item>
									<label>•</label>
									<para>That hair may be lost during treatment; that wig or hairpiece may make patient feel better; that new hair may be different in color, texture (alopecia rare)</para>
								</item>
								<item>
									<label>•</label>
									<para>To avoid foods with citric acid, hot or rough texture if stomatitis is present</para>
								</item>
								<item>
									<label>•</label>
									<para>To report stomatitis and any bleeding, white spots, ulcerations in mouth to prescriber; to examine mouth daily; to report symptoms to nurse; to use good oral hygiene</para>
								</item>
							</list>
						</para>
						<para>
							<bbw>That contraceptive measures are recommended during therapy and for at least 8 wk after cessation of therapy for women and men; to discontinue breastfeeding; that toxicity to infant may occur; pregnancy (X)</bbw>
						</para>
						<para>
							<list id="lidelem4x7324">
								<item>
									<label>•</label>
									<para>To drink 10-12 glasses of fluid/day</para>
								</item>
								<item>
									<label>•</label>
									<para>To avoid alcohol, salicylates, live vaccines</para>
								</item>
								<item>
									<label>•</label>
									<para>To avoid use of razors, commercial mouthwash</para>
								</item>
								<item>
									<label>•</label>
									<para>To use sunblock to prevent burns</para>
								</item>
								<item>
									<label>•</label>
									<para>To use good dental care to prevent overgrowth of infection in the mouth</para>
								</item>
								<item>
									<label>•</label>
									<para>How to use this product with leucovorin rescue</para>
								</item>
								<item>
									<label>•</label>
									<para>To continue leucovorin until told it is safe to stop</para>
								</item>
								<item>
									<label>•</label>
									<para>To report CNS symptoms, vision changes</para>
								</item>
								<item>
									<label>•</label>
									<para>To report fever, other symptoms of infection</para>
								</item>
								<item>
									<label>•</label>
									<para>To report decreased urine output</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
		</monograph>
<monograph id="19" status="active" ha="yes">
			<mono_name> methyldopa/methyldopate (Rx)</mono_name>
			<info>
				<pronunciation>(meth-ill-doe′pa)</pronunciation>
				<class type="func"> Antihypertensive</class>
				<class type="chem"> Centrally acting α-adrenergic inhibitor</class>
				<class type="preg">Pregnancy category <preg cat="B">B</preg></class>
			</info>
			<section type="confusion" id="sidelem4x7390">
				<para>
					<confusion>
						<tradename id="tnidelem4x73900">methyldopa</tradename>
						<drug type="generic" refid="idelem4x73900"/>
					</confusion>
				</para>
			</section>
			<section type="actions" id="sidelem4x7397">
				<sec_title>Action:</sec_title>
				<para>Stimulates central inhibitory α-adrenergic receptors or acts as false transmitter, resulting in reduction of arterial pressure</para>
			</section>
			<section type="uses" id="sidelem4x7402">
				<sec_title>Uses:</sec_title>
				<para>Hypertension, hypertensive crisis</para>
			</section>
			<section type="contra" id="sidelem4x7407">
				<sec_title>Contraindications:</sec_title>
				<para>Active hepatic disease, hypersensitivity, MAOI therapy</para>
				<section type="none" id="sidelem4x7412">
					<section type="none" id="sidelem4x7413">
						<sec_title>Precautions:</sec_title>
						<para> Pregnancy (<preg cat="B">B</preg>), geriatric patients, cardiac disease, autoimmune disease, depression, dialysis, hemolytic anemia, Parkinson’s disease, pheochromocytoma, sulfite hypersensitivity</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x7418">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x7426">
					<label>•</label>
					<sec_title>Adult<route> PO</route></sec_title>
					<para>
						<list id="lidelem4x7426">
							<item>
								<label>•</label>
								<para> 250-500 mg bid or tid, then adjusted q2days as needed, 0.5-2 g/day in 2-4 divided doses (maintenance), max 3 g/day;  250-500 mg in 100 ml D<emphasis style="inf">5</emphasis>W q6hr, run over 30-60 min, max 1 g q6hr; switch to oral as soon as possible</para>
							</item>
						</list>
					</para>
				</section>
				<section type="none" id="sidelem4x7439">
					<label>•</label>
					<sec_title>Child<route> PO</route></sec_title>
					<para>
						<list id="lidelem4x7439">
							<item>
								<label>•</label>
								<para> 10 mg/kg/day in 2-4 divided doses, max 65 mg/kg or 3 g/day, whichever is less;  20-40 mg/kg/day in 4 divided doses, max 65 mg/kg or 3 g, whichever is less</para>
							</item>
						</list>
					</para>
				</section>
				<section type="none" id="sidelem4x7446">
					<section type="none" id="sidelem4x7447">
						<sec_title>Renal dose</sec_title>
						<section type="none" id="sidelem4x7455">
							<label>•</label>
							<sec_title>Adult<route> PO CCr 10-50 ml/min dose q8-12hr; CCr &lt;10 ml/min dose q12-24hr</route></sec_title>
						</section>
					</section>
					<section type="none" id="sidelem4x7458">
						<sec_title>Available forms:</sec_title>
						<para> <emphasis style="italic">Methyldopa:</emphasis> tabs 250, 500 mg; <emphasis style="italic">methyldopate:</emphasis> inj 50 mg/ml</para>
					</section>
					<section type="none" id="sidelem4x7470">
						<sec_title>Administer:</sec_title>
						<section type="none" id="sidelem4x7473">
							<sec_title>PO route</sec_title>
							<para>
								<list id="lidelem4x7477">
									<item>
										<label>•</label>
										<para>Increase in dose should be done in the evening to minimize drowsiness</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x7483">
							<sec_title>Intermittent IV INFUSION route</sec_title>
							<para>
								<list id="lidelem4x7487">
									<item>
										<label>•</label>
										<para>After diluting with 100 ml D<emphasis style="inf">5</emphasis>W; run over <emphasis style="sup">1</emphasis>/<emphasis style="inf">2</emphasis>-1 hr</para>
									</item>
								</list>
							</para>
							<para>
								<emphasis style="bold">Y-site compatibilities:</emphasis> Alemtuzumab, alfentanil, amikacin, aminophylline, anidulafungin, ascorbic acid, atenolol, atracurium, atropine, aztreonam, benztropine, bivalirudin, bleomycin, bumetanide, buprenorphine, butorphanol, calcium chloride/gluconate, caspofungin, cefamandole, ceFAZolin, cefmetazole, cefonicid, cefotaxime, cefoTEtan, cefOXitin, cefTAZidime, ceftizoxime, cefTRIAXone, cefuroxime, cephalothin, chlorproMAZINE, cimetidine, clindamycin, cyanocobalamin, cycloSPORINE, DACTINomycin, DAPTOmycin, dexamethasone, digoxin, diltiazem, diphenhydrAMINE, DOCEtaxel, DOPamine, doxycycline, enalaprilat, ePHEDrine, EPINEPHrine, epoetin alfa, ertapenem, erythromycin, esmolol, etoposide, etoposide phosphate, famotidine, fenoldopam, fentaNYL, fluconazole, fludarabine, gatifloxacin, gemcitabine, gentamicin, glycopyrrolate, granisetron, heparin, hydrocortisone, HYDROmorphone, hydrOXYzine, IDArubicin, insulin (regular), irinotecan, isoproterenol, labetalol, lidocaine, linezolid, LORazepam, magnesium sulfate, mannitol, mechlorethamine, meperidine, metaraminol, methicillin, methoxamine, methylPREDNISolone, metoclopramide, metoprolol, metroNIDAZOLE, mezlocillin, miconazole, midazolam, milrinone, minocycline, mitoXANtrone, morphine, moxalactam, multiple vitamins, mycophenolate mofetil, nafcillin, nalbuphine, naloxone, netilmicin, nitroglycerin, nitroprusside, norepinephrine, octreotide, ondansetron, oxacillin, oxaliplatin, oxytocin, PACLitaxel, palonosetron, pamidronate, pancuronium, pantoprazole, papaverine, PEMEtrexed, penicillin G potassium/sodium, pentazocine, phentolamine, phenylephrine, phytonadione, piperacillin, polymyxin B, potassium chloride, procainamide, prochlorperazine, promethazine, propranolol, protamine, pyridoxine, quiNIDine, ranitidine, ritodrine, sodium bicarbonate, succinylcholine, SUFentanil, tacrolimus, teniposide, theophylline, thiamine, thiotepa, ticarcillin, ticarcillin-clavulanate, tigecycline, tirofiban, tobramycin, tolazoline, trimetaphan, urokinase, vancomycin, vasopressin, vecuronium, verapamil, vinorelbine, voriconazole, zoledronic acid</para>
						</section>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x7506">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x7509">
					<section type="none" id="sidelem4x7510">
						<sec_title>CNS:</sec_title>
						<para> <emphasis style="italic">Drowsiness, weakness, dizziness, sedation, headache,</emphasis> depression, psychosis, paresthesias, parkinsonism, Bell’s palsy, nightmares, <emphasis style="bold">drug fever</emphasis></para>
					</section>
					<section type="none" id="sidelem4x7520">
						<sec_title>CV:</sec_title>
						<para> Bradycardia, <emphasis style="bold">myocarditis,</emphasis> orthostatic hypotension, angina, edema, weight gain, <emphasis style="bold">CHF,</emphasis> paradoxic pressor response (IV)</para>
					</section>
					<section type="none" id="sidelem4x7531">
						<sec_title>EENT:</sec_title>
						<para> Nasal congestion</para>
					</section>
					<section type="none" id="sidelem4x7536">
						<sec_title>ENDO:</sec_title>
						<para> Breast enlargement, gynecomastia, amenorrhea</para>
					</section>
					<section type="none" id="sidelem4x7541">
						<sec_title>GI:</sec_title>
						<para> Nausea, vomiting, diarrhea, constipation, <emphasis style="bold">hepatic dysfunction,</emphasis> sore or “black” tongue, <emphasis style="bold">pancreatitis,</emphasis> colitis, flatulence</para>
					</section>
					<section type="none" id="sidelem4x7552">
						<sec_title>GU:</sec_title>
						<para> Impotence, failure to ejaculate</para>
					</section>
					<section type="none" id="sidelem4x7557">
						<sec_title>HEMA:</sec_title>
						<para> <emphasis style="bold">Leukopenia, thrombocytopenia, hemolytic anemia, granulocytopenia,</emphasis> positive Coombs’ test</para>
					</section>
					<section type="none" id="sidelem4x7565">
						<sec_title>INTEG:</sec_title>
						<para> Rash, <emphasis style="bold">toxic epidermal necrolysis,</emphasis> lupuslike syndrome</para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x7573">
				<sec_title>Pharmacokinetics</sec_title>
				<section type="none" id="sidelem4x7576">
					<section type="none" id="sidelem4x7577">
						<sec_title>PO:</sec_title>
						<para> Onset 4-6 hr, duration 24-48 hr</para>
					</section>
					<section type="none" id="sidelem4x7582">
						<sec_title>IV:</sec_title>
						<para> Onset 4-6 hr, duration 10-16 hr</para>
						<para>Metabolized by liver, excreted in urine, half-life 2 hr</para>
					</section>
				</section>
			</section>
			<section type="interactions" id="sidelem4x7589">
				<sec_title>Interactions</sec_title>
				<section type="none" id="sidelem4x7597">
					<label>•</label>
					<sec_title>Lithium toxicity<route> lithium</route></sec_title>
				</section>
				<para>
					<list id="lidelem4x7601">
						<item>
							<para>
								<emphasis alert="nurse">Increase: pressor effect—sympathomimetic amines, MAOIs; do not use concurrently with MAOIs</emphasis>
							</para>
						</item>
					</list>
				</para>
				<para>
					<emphasis alert="lifethreat">Increase: hypotension, CNS toxicity—levodopa</emphasis>
				</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> hypotension—diuretics, other antihypertensives</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> psychosis—haloperidol</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> CNS depression—alcohol, antihistamines, antidepressants, analgesics, sedative/hypnotics</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> B/P—phenothiazines, β-blockers, amphetamines, NSAIDs, tricyclics, barbiturates</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> hypoglycemia—TOLBUTamide</para>
				<para>
					<emphasis style="bold">Decrease:</emphasis> methyldopa absorption—iron</para>
				<section type="none" id="sidelem4x7634">
					<section type="none" id="sidelem4x7635">
						<sec_title>Drug/Lab Test</sec_title>
						<para>
							<emphasis style="bold">Increase:</emphasis> creatinine, LFTs</para>
						<para>
							<emphasis style="bold">Decrease:</emphasis> platelets, WBC, Hgb/HcT</para>
						<para>
							<emphasis style="bold">Interference:</emphasis> urinary uric acid, serum creatinine, AST</para>
						<para>
							<emphasis style="bold">False increase:</emphasis> urinary catecholamines</para>
					</section>
				</section>
			</section>
			<section type="considerations" id="sidelem4x7654">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x7657">
					<section type="none" id="sidelem4x7658">
						<sec_title>Assess:</sec_title>
						<para>
							<list id="lidelem4x7663">
								<item>
									<label>•</label>
									<para>Blood studies: neutrophils, decreased platelets, CBC</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x7671">
							<label>•</label>
							<sec_title>Hemolytic anemia<route> Direct Coombs’ test before, after 6, 12 mo of therapy; a positive test may indicate hemolytic anemia; usually reverses within weeks to months after discontinuing treatment; monitor Hgb/HcT and RBC; do not start therapy in those with hemolytic anemia</route></sec_title>
						</section>
						<para>
							<list id="lidelem4x7674">
								<item>
									<label>•</label>
									<para>Baselines of renal, hepatic studies before therapy begins</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x7682">
							<label>•</label>
							<sec_title>Drug-induced hepatitis/drug fever<route> Usually subsides within 3 months of discontinuing therapy</route></sec_title>
						</section>
						<section type="none" id="sidelem4x7688">
							<label>•</label>
							<sec_title>Hypertension</sec_title>
							<para>
								<list id="lidelem4x7688">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Hypertension:</emphasis> B/P when beginning treatment, periodically thereafter; report significant changes</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x7695">
							<label>•</label>
							<sec_title>Allergic reaction</sec_title>
							<para>
								<list id="lidelem4x7695">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Allergic reaction:</emphasis> rash, fever, pruritus, urticaria; product should be discontinued if antihistamines fail to help</para>
									</item>
								</list>
							</para>
						</section>
						<para>
							<list id="lidelem4x7699">
								<item>
									<label>•</label>
									<para>CNS symptoms, especially in geriatric patients; depression, change in mental status</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x7707">
							<label>•</label>
							<sec_title>CHF</sec_title>
							<para>
								<list id="lidelem4x7707">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">CHF:</emphasis> edema, dyspnea, wet crackles, B/P</para>
									</item>
								</list>
							</para>
						</section>
						<para>
							<list id="lidelem4x7711">
								<item>
									<label>•</label>
									<para>Renal symptoms: polyuria, oliguria, urinary frequency; I&amp;O ratio, weight; report weight gain &gt;5 lb</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x7719">
							<label>•</label>
							<sec_title>Product tolerance</sec_title>
							<para>
								<list id="lidelem4x7719">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Product tolerance:</emphasis> may occur within 3 mo of starting treatment; a dosage change and other products may be needed</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x7723">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x7727">
								<item>
									<label>•</label>
									<para>Therapeutic response: decrease in B/P</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x7733">
						<sec_title>Teach patient/family:</sec_title>
						<para>
							<list id="lidelem4x7738">
								<item>
									<label>•</label>
									<para>To avoid hazardous activities</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x7743">
								<item>
									<label>•</label>
									<para>Not to discontinue product abruptly because withdrawal symptoms may occur: anxiety, increased B/P, headache, insomnia, increased pulse, tremors, nausea, sweating</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x7748">
								<item>
									<label>•</label>
									<para>To rise slowly to sitting or standing position to minimize orthostatic hypotension</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x7756">
							<label>•</label>
							<sec_title>
								<route>To notify prescriber of mouth sores, sore throat, fever, swelling of hands or feet, irregular heartbeat, chest pain, signs of angioedema</route>
							</sec_title>
						</section>
						<para>
							<list id="lidelem4x7759">
								<item>
									<label>•</label>
									<para>That excessive perspiration, dehydration, vomiting, diarrhea may lead to fall in B/P; to consult prescriber</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x7764">
								<item>
									<label>•</label>
									<para>That dizziness, fainting, lightheadedness may occur during first few days of therapy</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x7769">
								<item>
									<label>•</label>
									<para>Not to use OTC (cough, cold, allergy) products unless directed by prescriber; that compliance is necessary; not to skip or stop product unless directed by prescriber</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x7774">
								<item>
									<label>•</label>
									<para>That product may cause skin rash or impaired perspiration</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
		</monograph>
<monograph id="20" status="active">
			<mono_name>methylergonovine (Rx)</mono_name>
			<info>
				<pronunciation>(meth-ill-er-goe-noe′veen)</pronunciation>
				<class type="func"> Oxytocic</class>
				<class type="chem"> Ergot alkaloid</class>
			</info>
			<section type="actions" id="sidelem4x7797">
				<sec_title>Action:</sec_title>
				<para>Stimulates uterine, vascular, and smooth muscle, thereby causing contractions; decreases bleeding; arterial vasoconstriction</para>
			</section>
			<section type="uses" id="sidelem4x7802">
				<sec_title>Uses:</sec_title>
				<para>Prevention, treatment of hemorrhage postpartum or postabortion, uterine contractions</para>
			</section>
			<section type="contra" id="sidelem4x7807">
				<sec_title>Contraindications:</sec_title>
				<para>Pregnancy (other than obstetric delivery/abortion), hypertension, preeclampsia, eclampsia, elective induction of labor, hypersensitivity to ergot preparations</para>
				<section type="none" id="sidelem4x7814">
					<section type="none" id="sidelem4x7815">
						<sec_title>Precautions:</sec_title>
						<para> Severe renal/hepatic disease, jaundice, diabetes mellitus, seizure disorders, sepsis, CAD, last stage of labor</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x7820">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x7828">
					<label>•</label>
					<sec_title>Adult<route> PO</route></sec_title>
					<para>
						<list id="lidelem4x7828">
							<item>
								<label>•</label>
								<para> 200 mcg tid-qid × ≤7 days;  200 mcg q2-4hr × 1-5 doses</para>
							</item>
						</list>
					</para>
				</section>
				<section type="none" id="sidelem4x7835">
					<section type="none" id="sidelem4x7836">
						<sec_title>Available forms:</sec_title>
						<para> Inj 200 mcg/ml; tabs 200 mcg</para>
					</section>
					<section type="none" id="sidelem4x7841">
						<sec_title>Administer:</sec_title>
						<section type="none" id="sidelem4x7844">
							<sec_title>PO route</sec_title>
							<para>
								<list id="lidelem4x7849">
									<item>
										<label>•</label>
										<para>Do not exceed dosage limits</para>
									</item>
								</list>
							</para>
							<para>
								<list id="lidelem4x7854">
									<item>
										<label>•</label>
										<para>Store tabs at room temperature</para>
									</item>
								</list>
							</para>
							<para>
								<list id="lidelem4x7859">
									<item>
										<label>•</label>
										<para>Give with water</para>
									</item>
								</list>
							</para>
							<section type="none" id="sidelem4x7867">
								<label>•</label>
								<sec_title>
									<route>Only during 4th stage of labor; not to be used to augment labor</route>
								</sec_title>
							</section>
						</section>
						<section type="none" id="sidelem4x7870">
							<sec_title>IM route</sec_title>
							<para>
								<list id="lidelem4x7874">
									<item>
										<label>•</label>
										<para>Protect from light</para>
									</item>
									<item>
										<label>•</label>
										<para>IM in deep muscle mass; rotate inj sites for additional doses, aspirate</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x7885">
							<sec_title>Direct IV route</sec_title>
							<para>
								<list id="lidelem4x7889">
									<item>
										<label>•</label>
										<para>Undiluted through <emphasis style="sans-serif">Y</emphasis>-tube or 3-way stopcock; give ≤0.2 mg/min or diluted in 5 ml 0.9% NaCl given through <emphasis style="sans-serif">Y</emphasis>-site</para>
									</item>
									<item>
										<label>•</label>
										<para>With crash cart available on unit; IV route used only in emergencies</para>
									</item>
									<item>
										<label>•</label>
										<para>Refrigerated storage of ampules; protect from light; give only if solution is clear; colorless</para>
									</item>
								</list>
							</para>
							<para>
								<emphasis style="bold">Y-site compatibilities:</emphasis> Heparin, hydrocortisone sodium succinate, potassium chloride, vit B/C</para>
						</section>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x7915">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x7918">
					<section type="none" id="sidelem4x7919">
						<sec_title>CNS:</sec_title>
						<para> <emphasis style="italic">Headache, dizziness,</emphasis><emphasis style="bold">seizures, hallucinations; stroke (IV)</emphasis></para>
					</section>
					<section type="none" id="sidelem4x7928">
						<sec_title>CV:</sec_title>
						<para> <emphasis style="bold">Hypotension,</emphasis> chest pain, palpitation, <emphasis style="bold">hypertension, dysrhythmias, CVA (IV)</emphasis></para>
					</section>
					<section type="none" id="sidelem4x7938">
						<sec_title>EENT:</sec_title>
						<para> Tinnitus</para>
					</section>
					<section type="none" id="sidelem4x7943">
						<sec_title>GI:</sec_title>
						<para> <emphasis style="italic">Nausea, vomiting</emphasis></para>
					</section>
					<section type="none" id="sidelem4x7950">
						<sec_title>GU:</sec_title>
						<para> Cramping</para>
					</section>
					<section type="none" id="sidelem4x7955">
						<sec_title>INTEG:</sec_title>
						<para> Sweating, rash, allergic reactions</para>
					</section>
					<section type="none" id="sidelem4x7960">
						<sec_title>MS:</sec_title>
						<para> Leg cramps</para>
					</section>
					<section type="none" id="sidelem4x7965">
						<sec_title>RESP:</sec_title>
						<para> Dyspnea</para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x7970">
				<sec_title>Pharmacokinetics</sec_title>
				<para>Metabolized in liver, excreted in urine</para>
				<section type="none" id="sidelem4x7975">
					<section type="none" id="sidelem4x7976">
						<sec_title>PO:</sec_title>
						<para> Onset 5-15 min, duration 3 hr</para>
					</section>
					<section type="none" id="sidelem4x7981">
						<sec_title>IM:</sec_title>
						<para> Onset 2-5 min, duration 3 hr</para>
					</section>
					<section type="none" id="sidelem4x7986">
						<sec_title>IV:</sec_title>
						<para> Onset immediate, duration 45 min- 3 hr</para>
					</section>
				</section>
			</section>
			<section type="interactions" id="sidelem4x7991">
				<sec_title>Interactions</sec_title>
				<para>
					<emphasis style="bold">Increase:</emphasis> vasoconstriction—DOPamine, ergots, anesthetics (regional), vasopressors, nicotine</para>
				<para>
					<emphasis alert="lifethreat">Increase: ergot toxicity—CYP3A4 inhibitors, do not use together</emphasis>
				</para>
			</section>
			<section type="considerations" id="sidelem4x8001">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x8004">
					<section type="none" id="sidelem4x8005">
						<sec_title>Assess:</sec_title>
						<para>
							<list id="lidelem4x8010">
								<item>
									<label>•</label>
									<para>B/P, pulse, character and amount of vaginal bleeding; watch for indications of hemorrhage</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x8015">
								<item>
									<label>•</label>
									<para>Uterine relaxation; observe for severe cramping</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x8021">
								<item>
									<para>
										<emphasis alert="nurse">Ergot toxicity: tinnitus, hypertension, palpitations, chest pain, nausea, vomiting, weakness; cold, numb extremities</emphasis>
									</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x8026">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x8030">
								<item>
									<label>•</label>
									<para>Therapeutic response: absence of hemorrhage</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x8036">
						<sec_title>Teach patient/family:</sec_title>
						<section type="none" id="sidelem4x8044">
							<label>•</label>
							<sec_title>
								<route>To report increased blood loss, severe abdominal cramps, fever, or foul-smelling lochia</route>
							</sec_title>
						</section>
					</section>
				</section>
			</section>
		</monograph>
<monograph id="21" status="active">
			<mono_name>methylnaltrexone (Rx)</mono_name>
			<info>
				<pronunciation>(meth-il-nal-trex′one)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x80520">Relistor</tradename>
				</tradenames>
				<class type="preg">Pregnancy category <preg cat="B">B</preg></class>
			</info>
			<section type="actions" id="sidelem4x8058">
				<sec_title>Action:</sec_title>
				<para>Peripheral μ-opioid receptor antagonist that reduces constipation associated with opiate agonists</para>
			</section>
			<section type="uses" id="sidelem4x8063">
				<sec_title>Uses:</sec_title>
				<para>Treatment of opioid-induced constipation in patients with advanced illness who are receiving palliative care when response to laxative therapy has been insufficient</para>
				<section type="none" id="sidelem4x8068">
					<section type="none" id="sidelem4x8069">
						<sec_title>Unlabeled uses:</sec_title>
						<para> Pruritus; nausea, vomiting related to morphine; urinary retention from opioids</para>
					</section>
				</section>
			</section>
			<section type="contra" id="sidelem4x8075">
				<sec_title>Contraindications:</sec_title>
				<para>Hypersensitivity, GI obstruction, IV route</para>
				<section type="none" id="sidelem4x8080">
					<section type="none" id="sidelem4x8081">
						<sec_title>Precautions:</sec_title>
						<para> Pregnancy (<preg cat="B">B</preg>), breastfeeding, children, geriatric patients, renal disease, diarrhea, driving, operating machinery, neoplastic disease, Crohn’s disease, peptic ulcer, ulcerative colitis</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x8086">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x8089">
					<section type="none" id="sidelem4x8090">
						<sec_title>Opiate-agonist–induced constipation</sec_title>
						<section type="none" id="sidelem4x8098">
							<label>•</label>
							<sec_title>Adult &gt;114 kg<route> SUBCUT</route></sec_title>
							<para>
								<list id="lidelem4x8098">
									<item>
										<label>•</label>
										<para> 0.15 mg/kg every other day prn</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x8105">
							<label>•</label>
							<sec_title>Adult 62-114 kg<route> SUBCUT</route></sec_title>
							<para>
								<list id="lidelem4x8105">
									<item>
										<label>•</label>
										<para> 12 mg every other day prn, max 12 mg/24 hr</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x8112">
							<label>•</label>
							<sec_title>Adult 38-&lt;62 kg<route> SUBCUT</route></sec_title>
							<para>
								<list id="lidelem4x8112">
									<item>
										<label>•</label>
										<para> 8 mg every other day prn, max 8 mg/24 hr</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x8119">
							<label>•</label>
							<sec_title>Adult &lt;38 kg<route> SUBCUT</route></sec_title>
							<para>
								<list id="lidelem4x8119">
									<item>
										<label>•</label>
										<para> 0.15 mg/kg every other day prn, max 0.15 mg/kg/24 hr</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x8123">
						<sec_title>Renal dose</sec_title>
						<section type="none" id="sidelem4x8131">
							<label>•</label>
							<sec_title>Adult<route> SUBCUT CCr &lt;30 ml/min, reduce normal adult dose by 50%</route></sec_title>
						</section>
					</section>
					<section type="none" id="sidelem4x8134">
						<sec_title>Available forms:</sec_title>
						<para> Sol for inj 12 mg/0.6 ml, 8 mg/0.4 ml</para>
					</section>
					<section type="none" id="sidelem4x8139">
						<sec_title>Administer:</sec_title>
						<para>
							<list id="lidelem4x8143">
								<item>
									<label>•</label>
									<para>SUBCUT only; oral dose investigational, not currently available</para>
								</item>
								<item>
									<label>•</label>
									<para>Do not give IV; IV dosing for urinary retention investigational</para>
								</item>
								<item>
									<label>•</label>
									<para>Store at 59° F-86° F (15° C-30° C); do not freeze</para>
								</item>
								<item>
									<label>•</label>
									<para>Store away from light</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x8164">
							<sec_title>SUBCUT route</sec_title>
							<para>
								<list id="lidelem4x8168">
									<item>
										<label>•</label>
										<para>Inspect sol before use; should be clear, colorless to pale yellow aqueous sol; do not use if particulate matter or discoloration are present</para>
									</item>
									<item>
										<label>•</label>
										<para>Withdraw needed amount of sol into sterile syringe; if immediate administration is impossible, syringe may be kept at room temperature for ≤24 hr; syringe does not need to be kept away from light during the 24-hr period; immediately discard any unused portion in vial; no preservatives are present</para>
									</item>
									<item>
										<label>•</label>
										<para>Administer into upper arm, abdomen, or thigh ≤1×/24 hr; rotate inj sites; do not inject same spot each time; do not inject into areas where skin is tender, bruised, red, or hard; avoid areas with scars or stretch marks</para>
									</item>
									<item>
										<label>•</label>
										<para>If using with retractable needle, slowly push down on plunger past resistance point until the syringe is empty and click is heard</para>
									</item>
								</list>
							</para>
						</section>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x8189">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x8192">
					<section type="none" id="sidelem4x8193">
						<sec_title>CNS:</sec_title>
						<para> Dizziness</para>
					</section>
					<section type="none" id="sidelem4x8198">
						<sec_title>GI:</sec_title>
						<para> Nausea, vomiting, diarrhea, flatulence, abdominal pain, <emphasis style="bold">GI perforation</emphasis></para>
					</section>
					<section type="none" id="sidelem4x8205">
						<sec_title>INTEG:</sec_title>
						<para> Hyperhidrosis</para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x8210">
				<sec_title>Pharmacokinetics</sec_title>
				<para>Terminal half-life 8 hr, protein binding 11%-15.3%; renal impairment has marked effect on renal excretion of methylnaltrexone; dose adjustment is required for patients with CCr &lt;30 ml/min; renal clearance decreased and total systemic exposure increased in patients with severe renal impairment who receive single SUBCUT dose of 0.3 mg/kg</para>
				<section type="none" id="sidelem4x8215">
					<section type="none" id="sidelem4x8216">
						<sec_title>SUBCUT:</sec_title>
						<para> Peak 30 min</para>
					</section>
				</section>
			</section>
			<section type="considerations" id="sidelem4x8221">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x8224">
					<section type="none" id="sidelem4x8225">
						<sec_title>Assess:</sec_title>
						<para>
							<list id="lidelem4x8230">
								<item>
									<label>•</label>
									<para>Serum creatinine</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x8238">
							<label>•</label>
							<sec_title>Opioid-induced constipation</sec_title>
							<para>
								<list id="lidelem4x8238">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Opioid-induced constipation:</emphasis> stool characteristics, bowel sounds during treatment</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x8242">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x8246">
								<item>
									<label>•</label>
									<para>Therapeutic response: decreasing constipation</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x8252">
						<sec_title>Teach patient/family:</sec_title>
						<para>
							<list id="lidelem4x8256">
								<item>
									<label>•</label>
									<para>That, after 30 min, to remain near toilet facilities because bowel relaxation occurs; not to use more than 1 dose in 24 hr</para>
								</item>
								<item>
									<label>•</label>
									<para>To notify prescriber of abdominal pain, continuous or severe diarrhea, nausea, vomiting</para>
								</item>
								<item>
									<label>•</label>
									<para>To avoid use in pregnancy unless absolutely necessary; avoid in breastfeeding</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
		</monograph>
<monograph id="22" status="active">
			<mono_name>methylphenidate (Rx)</mono_name>
			<info>
				<pronunciation>(meth-ill-fen′i-date)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x82789">
						<country code="CAN">Biphentin </country>
					</tradename>
					<tradename id="tnidelem4x82788">Concerta</tradename>
					<tradename id="tnidelem4x82787">Daytrana</tradename>
					<tradename id="tnidelem4x82786">Metadate CD</tradename>
					<tradename id="tnidelem4x82785">Metadate ER</tradename>
					<tradename id="tnidelem4x82784">Methylin</tradename>
					<tradename id="tnidelem4x82783">Quillivant XR</tradename>
					<tradename id="tnidelem4x82782">Ritalin</tradename>
					<tradename id="tnidelem4x82781">Ritalin LA</tradename>
					<tradename id="tnidelem4x82780">Ritalin SR</tradename>
				</tradenames>
				<class type="func"> Cerebral stimulant</class>
				<class type="chem"> Piperidine derivative</class>
				<class type="preg">Pregnancy category <preg cat="C">C</preg></class>
				<class type="schedule">Controlled Substance Schedule <schedule num="2">II</schedule></class>
			</info>
			<section type="confusion" id="sidelem4x8294">
				<para>
					<confusion>
						<tradename id="tnidelem4x82940">methylphenidate</tradename>
						<drug type="generic" refid="idelem4x82940">methadone</drug>
					</confusion>
				</para>
			</section>
			<section type="actions" id="sidelem4x8298">
				<sec_title>Action:</sec_title>
				<para>Increases release of norepinephrine, DOPamine in cerebral cortex to reticular activating system; exact action not known</para>
			</section>
			<section type="uses" id="sidelem4x8303">
				<sec_title>Uses:</sec_title>
				<para>Attention deficit disorder (ADD), attention-deficit/hyperactivity disorder (ADHD); narcolepsy (except Concerta, Metadate CD, Ritalin LA)</para>
			</section>
			<section type="contra" id="sidelem4x8308">
				<sec_title>Contraindications:</sec_title>
				<para>Children &lt;6 yr, hypersensitivity, anxiety, history of Gilles de la Tourette’s syndrome; glaucoma, anorexia nervosa, tartrazine dye hypersensitivity</para>
				<section type="none" id="sidelem4x8313">
					<section type="none" id="sidelem4x8314">
						<sec_title>Precautions:</sec_title>
						<para> Pregnancy (<preg cat="C">C</preg>), breastfeeding, hypertension, depression, seizures</para>
						<para>
							<bbw>Substance abuse</bbw>
						</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x8329">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x8332">
					<section type="none" id="sidelem4x8333">
						<sec_title>Attention-deficit/hyperactivity disorder (ADHD) initial treatment, not currently on methylphenidate</sec_title>
						<para/>
					</section>
				</section>
				<section type="none" id="sidelem4x8337">
					<sec_title>
						<emphasis style="italic">Regular release: Ritalin, Methylin, Methylin oral sol, Methylin chew tabs</emphasis>
					</sec_title>
					<section type="none" id="sidelem4x8346">
						<label>•</label>
						<sec_title>Adult<route> PO</route></sec_title>
						<para>
							<list id="lidelem4x8346">
								<item>
									<label>•</label>
									<para> 20-30 mg/day, range 10-60 mg/day in 2-3 divided doses, 30-45 min before meals</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x8353">
						<label>•</label>
						<sec_title>Child ≥6 yr<route> PO</route></sec_title>
						<para>
							<list id="lidelem4x8353">
								<item>
									<label>•</label>
									<para> 5 mg bid initially, increase 5-10 mg/day weekly, usual dose 0.3-2 mg/kg/day, max 60 mg/day</para>
								</item>
							</list>
						</para>
					</section>
				</section>
				<section type="none" id="sidelem4x8359">
					<sec_title>
						<emphasis style="italic">Extended release: Ritalin SR, Metadate ER, Methylin ER</emphasis>
					</sec_title>
					<section type="none" id="sidelem4x8368">
						<label>•</label>
						<sec_title>Adult/adolescent/child ≥6 yr<route> PO</route></sec_title>
						<para>
							<list id="lidelem4x8368">
								<item>
									<label>•</label>
									<para> max 20-30 mg tid</para>
								</item>
							</list>
						</para>
					</section>
				</section>
				<section type="none" id="sidelem4x8372">
					<sec_title>
						<emphasis style="italic">Extended-release once-daily tabs: Concerta</emphasis>
					</sec_title>
					<section type="none" id="sidelem4x8381">
						<label>•</label>
						<sec_title>Adult<route> PO</route></sec_title>
						<para>
							<list id="lidelem4x8381">
								<item>
									<label>•</label>
									<para> 18-36 mg/day initially, then adjust by 18 mg/wk, max 72 mg/day</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x8388">
						<label>•</label>
						<sec_title>Adolescent<route> PO</route></sec_title>
						<para>
							<list id="lidelem4x8388">
								<item>
									<label>•</label>
									<para> 18 mg/day initially, then adjust by 18 mg/wk, max 72 mg/day</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x8395">
						<label>•</label>
						<sec_title>Child ≥6 yr<route> PO</route></sec_title>
						<para>
							<list id="lidelem4x8395">
								<item>
									<label>•</label>
									<para> 18 mg/day initially, then adjust by 18 mg/wk, max 54 mg/day</para>
								</item>
							</list>
						</para>
					</section>
				</section>
				<section type="none" id="sidelem4x8399">
					<sec_title>
						<emphasis style="italic">Extended-release once-daily capsules: Ritalin LA</emphasis>
					</sec_title>
					<section type="none" id="sidelem4x8408">
						<label>•</label>
						<sec_title>Adult/adolescent/child ≥6 yr<route> PO</route></sec_title>
						<para>
							<list id="lidelem4x8408">
								<item>
									<label>•</label>
									<para> 10-20 mg daily in <emphasis style="smallcaps">am</emphasis> initially, adjust by 10 mg/wk, max 60 mg/day</para>
								</item>
							</list>
						</para>
					</section>
				</section>
				<section type="none" id="sidelem4x8415">
					<sec_title>
						<emphasis style="italic">Extended-release once-daily capsules: Metadate CD</emphasis>
					</sec_title>
					<section type="none" id="sidelem4x8424">
						<label>•</label>
						<sec_title>Adult/adolescent/child ≥6 yr<route> PO</route></sec_title>
						<para>
							<list id="lidelem4x8424">
								<item>
									<label>•</label>
									<para> 20 mg/day in <emphasis style="smallcaps">am</emphasis>, adjust by 10-20 mg/wk, max 60 mg/day</para>
								</item>
							</list>
						</para>
					</section>
				</section>
				<section type="none" id="sidelem4x8431">
					<sec_title>
						<emphasis style="italic">Transdermal: Daytrana</emphasis>
					</sec_title>
					<section type="none" id="sidelem4x8440">
						<label>•</label>
						<sec_title>Adolescent/child ≥6 yr<route> TD</route></sec_title>
						<para>
							<list id="lidelem4x8440">
								<item>
									<label>•</label>
									<para> wk 1: 10 mg/day (9-hr patch); wk 2: 15 mg/day (9-hr patch); wk 3: 20 mg/day (9-hr patch); wk 4: 30 mg/day (9-hr patch)</para>
								</item>
							</list>
						</para>
					</section>
				</section>
				<section type="none" id="sidelem4x8444">
					<sec_title>Conversion to once-daily treatment from other forms for ADHD</sec_title>
					<para/>
				</section>
				<section type="none" id="sidelem4x8448">
					<sec_title>Extended-release once-daily capsules: Metadate CD</sec_title>
					<section type="none" id="sidelem4x8456">
						<label>•</label>
						<sec_title>Adult/adolescent/child ≥6 yr<route> PO</route></sec_title>
						<para>
							<list id="lidelem4x8456">
								<item>
									<label>•</label>
									<para> give no more than total daily dose of other forms, may adjust by 20 mg/wk, max 60 mg/day</para>
								</item>
							</list>
						</para>
					</section>
				</section>
				<section type="none" id="sidelem4x8460">
					<sec_title>
						<emphasis style="italic">Extended-release once-daily capsules: Ritalin LA</emphasis>
					</sec_title>
					<section type="none" id="sidelem4x8469">
						<label>•</label>
						<sec_title>Adult/adolescent/child ≥6 yr<route> PO</route></sec_title>
						<para>
							<list id="lidelem4x8469">
								<item>
									<label>•</label>
									<para> give no more than total daily dose of other forms, may adjust by 10 mg/wk, max 60 mg/day</para>
								</item>
							</list>
						</para>
					</section>
				</section>
				<section type="none" id="sidelem4x8473">
					<sec_title>
						<emphasis style="italic">Extended-release once-daily tablets: Concerta</emphasis>
					</sec_title>
					<section type="none" id="sidelem4x8482">
						<label>•</label>
						<sec_title>Adult/adolescent/child ≥6 yr (currently on 10-15 mg/day)<route> PO</route></sec_title>
						<para>
							<list id="lidelem4x8482">
								<item>
									<label>•</label>
									<para> 18 mg every <emphasis style="smallcaps">am</emphasis> initially, adjust by 18 mg/wk, max 72 mg/day (adult); max 72 mg/day, 2 mg/kg/day (adolescent); 54 mg/day (child) mg/day</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x8494">
						<label>•</label>
						<sec_title>Adult/adolescent/child ≥6 yr (currently receiving 20-30 mg/day)<route> PO</route></sec_title>
						<para>
							<list id="lidelem4x8494">
								<item>
									<label>•</label>
									<para> 36 mg every <emphasis style="smallcaps">am</emphasis>, adjust by 18 mg/wk, max 72 mg/day (adult); 72 mg/day, 2 mg/kg/day (adolescent); 54 mg/day (child)</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x8504">
						<label>•</label>
						<sec_title>Adult/adolescent/child ≥6 yr (currently receiving 30-45 mg/day)<route> PO</route></sec_title>
						<para>
							<list id="lidelem4x8504">
								<item>
									<label>•</label>
									<para> 54 mg every <emphasis style="smallcaps">am</emphasis>, adjust by 18 mg/wk, max 72 mg/day (adult); 72 mg/day, 2 mg/kg/day (adolescent); 54 mg/day (child)</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x8514">
						<label>•</label>
						<sec_title>Adult/adolescent/child ≥6 yr (currently receiving 40-60 mg/day)<route> PO</route></sec_title>
						<para>
							<list id="lidelem4x8514">
								<item>
									<label>•</label>
									<para> 72 mg every <emphasis style="smallcaps">am</emphasis>, 72 mg/day</para>
								</item>
							</list>
						</para>
					</section>
				</section>
				<section type="none" id="sidelem4x8521">
					<sec_title>
						<emphasis style="italic">Extended-release once-daily suspension: Quillivant XR</emphasis>
					</sec_title>
					<section type="none" id="sidelem4x8530">
						<label>•</label>
						<sec_title>Adolescents/child ≥6 yr<route> PO</route></sec_title>
						<para>
							<list id="lidelem4x8530">
								<item>
									<label>•</label>
									<para> give 20 mg in <emphasis style="smallcaps">am</emphasis>, increase in 10-20 mg increments weekly</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x8537">
						<sec_title>Narcolepsy</sec_title>
						<para/>
					</section>
				</section>
				<section type="none" id="sidelem4x8541">
					<sec_title>
						<emphasis style="italic">Immediate release: Ritalin, Methylin oral sol, Methylin chew tabs</emphasis>
					</sec_title>
					<section type="none" id="sidelem4x8550">
						<label>•</label>
						<sec_title>Adult<route> PO</route></sec_title>
						<para>
							<list id="lidelem4x8550">
								<item>
									<label>•</label>
									<para> 20-30 mg/day, range 10-60 mg/day in 2-3 divided doses</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x8557">
						<label>•</label>
						<sec_title>Child ≥6 yr<route> PO</route></sec_title>
						<para>
							<list id="lidelem4x8557">
								<item>
									<label>•</label>
									<para> 5 mg bid, may increase by 5-10 mg/wk, max 60 mg/day</para>
								</item>
							</list>
						</para>
					</section>
				</section>
				<section type="none" id="sidelem4x8561">
					<sec_title>
						<emphasis style="italic">Extended-release tabs: Ritalin SR, Metadate ER</emphasis>
					</sec_title>
					<section type="none" id="sidelem4x8570">
						<label>•</label>
						<sec_title>Adult/adolescent/child ≥6 yr<route> PO</route></sec_title>
						<para>
							<list id="lidelem4x8570">
								<item>
									<label>•</label>
									<para> max 20 mg tid</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x8581">
						<label>•</label>
						<sec_title>Adult and geriatric<route> PO</route></sec_title>
						<para>
							<list id="lidelem4x8581">
								<item>
									<label>•</label>
									<para> (immediate rel tabs) 2.5 mg morning/noon, may increase by 2.5-5 mg q2-3days</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x8585">
						<sec_title>Available forms:</sec_title>
						<para> Tabs 5, 10, 20 mg; ext rel tabs 10, 20, mg; ext rel tabs (Concerta) 18, 27, 36, 54 mg; ext rel caps 10, 20, 30, 40 mg; oral sol 5 mg, 10 mg/ml; chew tabs (Methylin) 2.5, 5, 10 mg; transdermal patch 12.5 cm<emphasis style="sup">2</emphasis> (10 mg), 18.75 cm<emphasis style="sup">2</emphasis> (15 mg), 25 cm<emphasis style="sup">2</emphasis> (20 mg), 37.5 cm<emphasis style="sup">2</emphasis> (30 mg); ext rel oral susp 300 mg/60 ml, 600 mg/120 ml, 750 mg/150 ml, 900 mg/180 ml</para>
					</section>
					<section type="none" id="sidelem4x8602">
						<sec_title>Administer:</sec_title>
						<section type="none" id="sidelem4x8605">
							<sec_title>PO route</sec_title>
							<para>
								<list id="lidelem4x8610">
									<item>
										<label>•</label>
										<para>Do not crush, chew ext rel product; caps may be opened, beads sprinkled over spoonful of applesauce; give without regard to meals</para>
									</item>
								</list>
							</para>
							<para>
								<list id="lidelem4x8615">
									<item>
										<label>•</label>
										<para>Gum, hard candy, frequent sips of water for dry mouth</para>
									</item>
								</list>
							</para>
							<para>
								<list id="lidelem4x8620">
									<item>
										<label>•</label>
										<para>Give immediate rel dose 30-45 min before meals</para>
									</item>
								</list>
							</para>
							<section type="none" id="sidelem4x8628">
								<label>•</label>
								<sec_title>
									<route>Chew tab</route>
								</sec_title>
								<para>
									<list id="lidelem4x8628">
										<item>
											<label>•</label>
											<para> with adequate water to prevent choking; contains phenylalanine</para>
										</item>
									</list>
								</para>
							</section>
							<para>
								<list id="lidelem4x8632">
									<item>
										<label>•</label>
										<para>Avoid metadate CD on day of surgery</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x8637">
							<sec_title>Extended release oral suspension (Quillivant XR)</sec_title>
							<para>
								<list id="lidelem4x8641">
									<item>
										<label>•</label>
										<para>Shake bottle well; use calibrated dosing dispenser provided; give in <emphasis style="smallcaps">am</emphasis> without regard to meals; reconstitute as per manufacturer</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x8650">
							<sec_title>Transdermal route</sec_title>
							<para>
								<list id="lidelem4x8654">
									<item>
										<label>•</label>
										<para>Place on clean, dry area of hip; avoid waist; remove 9 hr after application; fold after removal; flush down toilet</para>
									</item>
									<item>
										<label>•</label>
										<para>If patch falls off, apply new patch to different site; total wear time should be 9 hr</para>
									</item>
								</list>
							</para>
						</section>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x8665">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x8668">
					<section type="none" id="sidelem4x8669">
						<sec_title>CNS:</sec_title>
						<para> <emphasis style="italic">Hyperactivity, insomnia, restlessness, talkativeness,</emphasis> dizziness, drowsiness, toxic psychosis, headache, akathisia, dyskinesia, masking or worsening of Tourette’s syndrome, <emphasis style="bold">seizures,</emphasis> hallucinations, <emphasis style="bold">malignant neuroleptic syndrome,</emphasis> aggression; <emphasis style="bold">cerebral vasculitis, hemorrhage, stroke (rare)</emphasis></para>
					</section>
					<section type="none" id="sidelem4x8685">
						<sec_title>CV:</sec_title>
						<para> <emphasis style="italic">Palpitations, tachycardia,</emphasis> B/P changes, angina, <emphasis style="bold">dysrhythmias</emphasis></para>
					</section>
					<section type="none" id="sidelem4x8695">
						<sec_title>ENDO:</sec_title>
						<para> Growth retardation</para>
					</section>
					<section type="none" id="sidelem4x8700">
						<sec_title>GI:</sec_title>
						<para> Nausea, anorexia, dry mouth, weight loss, abdominal pain</para>
					</section>
					<section type="none" id="sidelem4x8705">
						<sec_title>HEMA:</sec_title>
						<para> <emphasis style="bold">Leukopenia, anemia, thrombocytopenic purpura</emphasis></para>
					</section>
					<section type="none" id="sidelem4x8712">
						<sec_title>INTEG:</sec_title>
						<para> <emphasis style="bold">Exfoliative dermatitis,</emphasis> urticaria, rash, erythema multiforme, <emphasis style="bold">hypersensitivity reactions; patch: permanent loss of skin color</emphasis></para>
					</section>
					<section type="none" id="sidelem4x8722">
						<sec_title>MISC:</sec_title>
						<para> Fever, arthralgia, scalp hair loss, <emphasis style="bold">rhabdomyolysis</emphasis></para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x8729">
				<sec_title>Pharmacokinetics</sec_title>
				<section type="none" id="sidelem4x8732">
					<section type="none" id="sidelem4x8733">
						<sec_title>PO:</sec_title>
						<para> Varies with formulation, metabolized by liver, excreted by kidneys, half-life 3-4 hr</para>
					</section>
				</section>
			</section>
			<section type="interactions" id="sidelem4x8739">
				<sec_title>Interactions</sec_title>
				<section type="none" id="sidelem4x8747">
					<label>•</label>
					<sec_title>Hypertensive crisis<route> MAOIs or within 14 days of MAOIs, vasopressors</route></sec_title>
				</section>
				<para>
					<emphasis style="bold">Increase:</emphasis> effects of tricyclics, SSRIs, anticonvulsants, SNRIs, CNS stimulants</para>
				<para>
					<emphasis style="bold">Decrease:</emphasis> effect of antihypertensives</para>
				<section type="none" id="sidelem4x8758">
					<section type="none" id="sidelem4x8759">
						<sec_title>Drug/Herb</sec_title>
						<para>
							<emphasis style="bold">Increase:</emphasis> CNS stimulation—cola nut, guarana, horsetail, yerba maté, yohimbe</para>
					</section>
					<section type="none" id="sidelem4x8766">
						<sec_title>Drug/Food</sec_title>
						<para>
							<emphasis style="bold">Increase:</emphasis> stimulation—caffeine</para>
					</section>
				</section>
			</section>
			<section type="considerations" id="sidelem4x8773">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x8776">
					<section type="none" id="sidelem4x8777">
						<sec_title>Assess:</sec_title>
						<section type="none" id="sidelem4x8785">
							<label>•</label>
							<sec_title>ADHD</sec_title>
							<para>
								<list id="lidelem4x8785">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">ADHD:</emphasis> attention span, decreased hyperactivity
<bbw>Substance abuse: there is a high potential for abuse; use caution in those with history of substance abuse</bbw>
</para>
									</item>
								</list>
							</para>
						</section>
						<para>
							<list id="lidelem4x8798">
								<item>
									<label>•</label>
									<para>VS, B/P; may reverse antihypertensives; check patients with cardiac disease more often for increased B/P</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x8803">
								<item>
									<label>•</label>
									<para>CBC with differential, platelets, LFTs, urinalysis; in diabetes: blood glucose, urine glucose; insulin changes may have to be made because eating will decrease</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x8808">
								<item>
									<label>•</label>
									<para>Height, growth rate q3mo in children; growth rate may be decreased, but normal growth will resume when product is discontinued</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x8813">
								<item>
									<label>•</label>
									<para>Mental status: mood, sensorium, affect, stimulation, insomnia, aggressiveness</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x8819">
								<item>
									<para>
										<emphasis alert="nurse">Withdrawal symptoms: headache, nausea, vomiting, muscle pain, weakness, usually not associated with drug holidays</emphasis>
									</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x8824">
								<item>
									<label>•</label>
									<para>Appetite, sleep, speech patterns</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x8832">
							<label>•</label>
							<sec_title>Narcolepsy</sec_title>
							<para>
								<list id="lidelem4x8832">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Narcolepsy:</emphasis> identify frequency, length of narcoleptic episodes</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x8836">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x8840">
								<item>
									<label>•</label>
									<para>Therapeutic response: decreased hyperactivity (ADHD); increased ability to stay awake (narcolepsy)</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x8846">
						<sec_title>Teach patient/family:</sec_title>
						<para>
							<list id="lidelem4x8851">
								<item>
									<label>•</label>
									<para>To decrease caffeine consumption (coffee, tea, cola, chocolate), may increase irritability, stimulation; not to use guarana, yerba maté, cola nut</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x8856">
								<item>
									<label>•</label>
									<para>To avoid OTC preparations unless approved by prescriber</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x8861">
								<item>
									<label>•</label>
									<para>To taper off product over several weeks because depression, increased sleeping, lethargy will occur</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x8866">
								<item>
									<label>•</label>
									<para>To avoid driving, hazardous activities if dizziness, blurred vision occur</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x8871">
								<item>
									<label>•</label>
									<para>To avoid alcohol</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x8876">
								<item>
									<label>•</label>
									<para>To avoid hazardous activities until stabilized on medication</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x8881">
								<item>
									<label>•</label>
									<para>To get needed rest; patients will feel more tired at end of day</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x8886">
								<item>
									<label>•</label>
									<para>That shell of Concerta tab may appear in stools</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x8891">
								<item>
									<label>•</label>
									<para>To take regular tab at least 6 hr before sleep, 10 hr for ext rel, use dosing syringe to measure liquid; not to use household teaspoon</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x8899">
							<label>•</label>
							<sec_title>Transdermal</sec_title>
							<para>
								<list id="lidelem4x8899">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Transdermal:</emphasis> after tray is opened, use within 2 mo; do not store patches without protective patch; notify prescriber if skin irritation or rash occurs</para>
									</item>
								</list>
							</para>
						</section>
					</section>
				</section>
			</section>
		</monograph>
<monograph id="23" status="active">
			<mono_name>methylPREDNISolone (Rx)</mono_name>
			<info>
				<pronunciation>(meth-il-pred-niss′oh-lone)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x89133">A-Methapred</tradename>
					<tradename id="tnidelem4x89132">Depo-Medrol</tradename>
					<tradename id="tnidelem4x89131">Medrol</tradename>
					<tradename id="tnidelem4x89130">Solu-MEDROL</tradename>
				</tradenames>
				<class type="func"> Corticosteroid, synthetic</class>
				<class type="chem"> Glucocorticoid, immediate acting</class>
				<class type="preg">Pregnancy category <preg cat="C">C</preg></class>
			</info>
			<section type="confusion" id="sidelem4x8923">
				<para>
					<confusion>
						<tradename id="tnidelem4x89230">methylPREDNISolone</tradename>
						<drug type="generic" refid="idelem4x89230">predniSONE/medroxyPROGESTERone/methylTESTOSTERone</drug>
					</confusion>
				</para>
			</section>
			<section type="actions" id="sidelem4x8927">
				<sec_title>Action:</sec_title>
				<para>Decreases inflammation by suppression of migration of polymorphonuclear leukocytes, fibroblasts; reversal of increased capillary permeability and lysosomal stabilization</para>
			</section>
			<section type="uses" id="sidelem4x8933">
				<sec_title>Uses:</sec_title>
				<para>Severe inflammation, shock, adrenal insufficiency, collagen disorders, management of acute spinal cord injury, multiple sclerosis</para>
				<section type="none" id="sidelem4x8938">
					<section type="none" id="sidelem4x8939">
						<sec_title>Unlabeled uses:</sec_title>
						<para> Multiple myeloma, bronchospasm prophylaxis, airway-obstructing hemangioma, noncardiogenic pulmonary edema, idiopathic pulmonary fibrosis, carpal tunnel syndrome, temporal arteritis, Churg-Strauss syndrome, mixed connective-tissue disease, polyarteritis nodosa, relapsing polychondritis, polymyalgia rheumatica, vasculitis, Weg-ener’s granulomatosis, <emphasis style="italic">Pneumocystis jiroveci</emphasis> pneumonia in AIDS patients, acute spinal cord injury, severe acute res-piratory syndrome (SARS), acute interstitial nephritis</para>
					</section>
				</section>
			</section>
			<section type="contra" id="sidelem4x8947">
				<sec_title>Contraindications:</sec_title>
				<para>Hypersensitivity, intrathecal use, neonates</para>
				<section type="none" id="sidelem4x8952">
					<section type="none" id="sidelem4x8953">
						<sec_title>Precautions:</sec_title>
						<para> Pregnancy (<preg cat="C">C</preg>), breastfeeding, diabetes mellitus, glaucoma, osteoporosis, seizure disorders, ulcerative colitis, CHF, myasthenia gravis, renal disease, esophagitis, peptic ulcer, tartrazine, benzyl alcohol, corticosteroid hypersensitivity, viral infection, TB, traumatic brain injury, Cushing syndrome, measles, varicella, fungal infections</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x8958">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x8961">
					<section type="none" id="sidelem4x8962">
						<sec_title>Adrenal insufficiency/inflammation</sec_title>
						<section type="none" id="sidelem4x8970">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x8970">
									<item>
										<label>•</label>
										<para> 4-48 mg in 4 divided doses;  10-120 mg (acetate);  10-40 mg (succinate);  4-80 mg (acetate)</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x8986">
							<label>•</label>
							<sec_title>Child<route> IV</route></sec_title>
							<para>
								<list id="lidelem4x8986">
									<item>
										<label>•</label>
										<para> 0.5-1.7 mg/kg in 3-4 divided doses (succinate)</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x8990">
						<sec_title>Multiple sclerosis</sec_title>
						<section type="none" id="sidelem4x8998">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x8998">
									<item>
										<label>•</label>
										<para> 160 mg/day × 1 wk, then 64 mg every other day × 30 days</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x9002">
						<sec_title>Multiple myeloma/temporal arteritis/Churg-Strauss syndrome/mixed connective-tissue disease/polyarteritis nodosa/relapsing polychondritis/polymyalgia rheumatica/vasculitis/Wegener’s granulomatosis (unlabeled)</sec_title>
						<section type="none" id="sidelem4x9010">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x9010">
									<item>
										<label>•</label>
										<para> 4-48 mg/day in 4 divided doses;  10-120 mg (acetate);  10-40 mg over several min (sodium succinate)</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x9023">
							<label>•</label>
							<sec_title>Child<route> PO/IM</route></sec_title>
							<para>
								<list id="lidelem4x9023">
									<item>
										<label>•</label>
										<para> 0.5-1.7 mg/kg or 5-25 mg/m<emphasis style="sup">2</emphasis>/day in divided doses q6-12hr</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x9030">
						<sec_title>Bronchospasm prophylaxis (unlabeled)</sec_title>
						<section type="none" id="sidelem4x9038">
							<label>•</label>
							<sec_title>Adult and adolescent<route> PO/IV</route></sec_title>
							<para>
								<list id="lidelem4x9038">
									<item>
										<label>•</label>
										<para> 40-80 mg/day in 1-2 divided doses</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x9045">
							<label>•</label>
							<sec_title>Child<route> PO/IV</route></sec_title>
							<para>
								<list id="lidelem4x9045">
									<item>
										<label>•</label>
										<para> 1 mg/kg in 2 divided doses (max 60 mg)</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x9049">
						<sec_title>Airway-obstructing hemangioma (unlabeled)</sec_title>
						<section type="none" id="sidelem4x9057">
							<label>•</label>
							<sec_title>Child<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x9057">
									<item>
										<label>•</label>
										<para> 0.5-1.7 mg/kg or 5-25 mg/m<emphasis style="sup">2</emphasis>/day in divided doses q6-12hr</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x9064">
						<sec_title>Idiopathic pulmonary fibrosis (unlabeled)</sec_title>
						<section type="none" id="sidelem4x9072">
							<label>•</label>
							<sec_title>Adult<route> IV</route></sec_title>
							<para>
								<list id="lidelem4x9072">
									<item>
										<label>•</label>
										<para> 1-2 g/wk or every other week</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x9076">
						<sec_title>Carpal tunnel syndrome (unlabeled)</sec_title>
						<section type="none" id="sidelem4x9084">
							<label>•</label>
							<sec_title>Adult<route> INJ</route></sec_title>
							<para>
								<list id="lidelem4x9084">
									<item>
										<label>•</label>
										<para> (local) 40-80 mg as a single inj</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x9088">
						<sec_title>Available forms:</sec_title>
						<para> Tabs 2, 4, 8, 16, 32 mg; inj 20, 40, 80 mg/ml acetate; inj 40, 125, 500, 1000, 2000 mg/vial succinate</para>
					</section>
					<section type="none" id="sidelem4x9093">
						<sec_title>Administer:</sec_title>
						<para>
							<list id="lidelem4x9097">
								<item>
									<label>•</label>
									<para>Titrated dose; use lowest effective dose</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x9103">
							<sec_title>PO route</sec_title>
							<para>
								<list id="lidelem4x9107">
									<item>
										<label>•</label>
										<para>With food or milk to decrease GI symptoms (PO)</para>
									</item>
									<item>
										<label>•</label>
										<para>Once-a-day dose should be given in <emphasis style="smallcaps">am</emphasis> to coincide with body’s normal cortisol secretion</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x9121">
							<sec_title>IM route</sec_title>
							<para>
								<list id="lidelem4x9126">
									<item>
										<label>•</label>
										<para>IM inj deep in large muscle mass; rotate sites; avoid deltoid; use 21-G needle; after shaking suspension (parenteral); inj-site reaction may occur (induration, pain at site, atrophy)</para>
									</item>
								</list>
							</para>
							<para>
								<list id="lidelem4x9131">
									<item>
										<label>•</label>
										<para>In one dose in <emphasis style="smallcaps">am</emphasis> to prevent adrenal suppression; avoid SUBCUT administration; may damage tissue</para>
									</item>
								</list>
							</para>
							<para>
								<list id="lidelem4x9140">
									<item>
										<para>
											<emphasis alert="nurse">Do not give Solu-MEDROL intrathecally</emphasis>
										</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x9145">
							<sec_title>IV route</sec_title>
							<section type="none" id="sidelem4x9153">
								<label>•</label>
								<sec_title>
									<route>Use only Solu-MEDROL; never use acetate product</route>
								</sec_title>
							</section>
						</section>
						<section type="none" id="sidelem4x9156">
							<sec_title>Direct IV route</sec_title>
							<section type="none" id="sidelem4x9164">
								<label>•</label>
								<sec_title>
									<route>Use only methylPREDNISolone sodium succinate (Solu-MEDROL) IV; never use methylPREDNISolone acetate suspension IV</route>
								</sec_title>
							</section>
							<para>
								<list id="lidelem4x9167">
									<item>
										<label>•</label>
										<para>After diluting with diluent provided; agitate slowly; give ≤500 mg/≥1 min directly over 3-15 min; doses ≥2 mg/kg or 250 mg should be given by intermittent IV infusion unless potential benefits outweigh risks</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x9174">
							<sec_title>Intermittent/continuous INFUSION route</sec_title>
							<para>
								<list id="lidelem4x9178">
									<item>
										<label>•</label>
										<para>Dilute further in D5W, NS, D5NS; haze may form; give over 15-60 min; large dose (≥500 mg) should be given over 30-60 min</para>
									</item>
								</list>
							</para>
							<para>
								<emphasis style="bold">Y-site compatibilities:</emphasis> Acetaminophen, acyclovir, amifostine, amphotericin B cholesteryl, amrinone, aztreonam, cefepime, CISplatin, cladribine, cyclophosphamide, cytarabine, DOPamine, DOXOrubicin, enalaprilat, famotidine, fludarabine, grani-setron, heparin, melphalan, meperidine, methotrexate, metroNIDAZOLE, midazolam, morphine, piperacillin/tazobactam, remifentanil, sodium bicarbonate, tacrolimus, teniposide, theophylline, thiotepa</para>
						</section>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x9188">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x9191">
					<section type="none" id="sidelem4x9192">
						<sec_title>CNS:</sec_title>
						<para> Depression, flushing, sweating, headache, mood changes</para>
					</section>
					<section type="none" id="sidelem4x9197">
						<sec_title>CV:</sec_title>
						<para> Hypertension, <emphasis style="bold">circulatory collapse, thrombophlebitis, embolism,</emphasis> tachycardia</para>
					</section>
					<section type="none" id="sidelem4x9205">
						<sec_title>EENT:</sec_title>
						<para> Fungal infections, increased intraocular pressure, blurred vision, cataracts</para>
					</section>
					<section type="none" id="sidelem4x9210">
						<sec_title>GI:</sec_title>
						<para> Diarrhea, nausea, abdominal distention, <emphasis style="bold">GI hemorrhage,</emphasis> increased appetite, pancreatitis</para>
					</section>
					<section type="none" id="sidelem4x9218">
						<sec_title>HEMA:</sec_title>
						<para> <emphasis style="bold">Thrombocytopenia</emphasis></para>
					</section>
					<section type="none" id="sidelem4x9225">
						<sec_title>INTEG:</sec_title>
						<para> Acne, poor wound healing, ecchymosis, petechiae</para>
					</section>
					<section type="none" id="sidelem4x9230">
						<sec_title>MS:</sec_title>
						<para> Fractures, osteoporosis, weakness</para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x9235">
				<sec_title>Pharmacokinetics</sec_title>
				<para>Half-life &gt;3<emphasis style="sup">1</emphasis>/<emphasis style="inf">2</emphasis> hr (plasma), 18-36 hr (tissue); crosses placenta, enters breast milk in small amounts; metabolized in liver; excreted by kidneys (unchanged)</para>
				<section type="none" id="sidelem4x9246">
					<section type="none" id="sidelem4x9247">
						<sec_title>PO:</sec_title>
						<para> Peak 1-2 hr, duration 1<emphasis style="sup">1</emphasis>/<emphasis style="inf">2</emphasis> days, well absorbed</para>
					</section>
					<section type="none" id="sidelem4x9258">
						<sec_title>IM:</sec_title>
						<para> Peak 4-8 days, duration 1-4 wk, well absorbed</para>
					</section>
					<section type="none" id="sidelem4x9263">
						<sec_title>Intraarticular:</sec_title>
						<para> Peak 1 wk</para>
					</section>
				</section>
			</section>
			<section type="interactions" id="sidelem4x9268">
				<sec_title>Interactions</sec_title>
				<para>
					<emphasis style="bold">Increase:</emphasis> side effects—amphotericin B, diuretics</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> methylPREDNISolone action—oral contraceptives, estrogens</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> adrenal suppression—CYP3A4 inhibitors (aprepitant, antiretroviral protease inhibitors, clarithromycin, danazol, delavirdine, diltiazem, erythromycin, fluconazole, FLUoxetine, fluvoxaMINE, imatinib, ketoconazole, mibefradil, nefazodone, telithromycin, voriconazole)</para>
				<para>
					<emphasis style="bold">Decrease:</emphasis> methylPREDNISolone effect—CYP3A4 inducers (barbiturates, bosentan, carBAMazepine, efavirenz, phenytoins, nevirapine, rifabutin, rifampin)</para>
				<para>
					<emphasis style="bold">Decrease:</emphasis> effects of antidiabetics, vaccines, somatrem</para>
				<section type="none" id="sidelem4x9291">
					<section type="none" id="sidelem4x9292">
						<sec_title>Drug/Herb</sec_title>
						<para>
							<list id="lidelem4x9296">
								<item>
									<label>•</label>
									<para>Avoid use with St. John’s wort</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x9302">
						<sec_title>Drug/Food</sec_title>
						<section type="none" id="sidelem4x9310">
							<label>•</label>
							<sec_title>
								<route>Do not use with grapefruit juice; level of methylPREDNISolone will be increased</route>
							</sec_title>
						</section>
					</section>
					<section type="none" id="sidelem4x9313">
						<sec_title>Drug/Lab Test</sec_title>
						<para>
							<emphasis style="bold">Increase:</emphasis> cholesterol, blood glucose</para>
						<para>
							<emphasis style="bold">Decrease:</emphasis> calcium, potassium, T<emphasis style="inf">4</emphasis>, T<emphasis style="inf">3</emphasis>, thyroid <emphasis style="sup">131</emphasis>I uptake test, urine 17-OHCS, 17-KS</para>
						<para>
							<emphasis style="bold">False negative:</emphasis> skin allergy tests</para>
					</section>
				</section>
			</section>
			<section type="considerations" id="sidelem4x9337">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x9340">
					<section type="none" id="sidelem4x9341">
						<sec_title>Assess:</sec_title>
						<section type="none" id="sidelem4x9349">
							<label>•</label>
							<sec_title>Potassium depletion</sec_title>
							<para>
								<list id="lidelem4x9349">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Potassium depletion:</emphasis> parethesias, fatigue, nausea, vomiting, depression, polyuria, dysrhythmias, weakness</para>
									</item>
								</list>
							</para>
						</section>
						<para>
							<list id="lidelem4x9353">
								<item>
									<label>•</label>
									<para>Edema, hypertension, cardiac symptoms</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x9358">
								<item>
									<label>•</label>
									<para>Mental status: affect, mood, behavioral changes, aggression</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x9363">
								<item>
									<label>•</label>
									<para>Potassium, blood glucose, urine glucose while receiving long-term therapy; hypokalemia and hyperglycemia</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x9368">
								<item>
									<label>•</label>
									<para>Joint mobility, pain, edema if product given intraarticularly</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x9373">
								<item>
									<label>•</label>
									<para>B/P q4hr, pulse; notify prescriber of chest pain, crackles</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x9378">
								<item>
									<label>•</label>
									<para>I&amp;O ratio; be alert for decreasing urinary output, increasing edema; weight daily; notify prescriber of weekly gain &gt;5 lb</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x9385">
								<item>
									<para>
										<emphasis alert="nurse">Adrenal insufficiency: weight loss, nausea, vomiting, confusion, anxiety, hypotension, weakness; plasma cortisol levels during long-term therapy (normal level: 138-635 nmol/L SI units when drawn at 8 <emphasis style="smallcaps">am</emphasis>)</emphasis>
									</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x9393">
								<item>
									<label>•</label>
									<para>Growth in children receiving long-term treatment</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x9401">
							<label>•</label>
							<sec_title>Infection</sec_title>
							<para>
								<list id="lidelem4x9401">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Infection:</emphasis> increased temperature, WBC, even after withdrawal of product; product masks infection</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x9405">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x9409">
								<item>
									<label>•</label>
									<para>Therapeutic response: ease of respirations, decreased inflammation; decreased symptoms of adrenal insufficiency</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x9415">
						<sec_title>Teach patient/family:</sec_title>
						<para>
							<list id="lidelem4x9420">
								<item>
									<label>•</label>
									<para>To increase intake of potassium, calcium, protein</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x9425">
								<item>
									<label>•</label>
									<para>To carry emergency ID as corticosteroid user</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x9430">
								<item>
									<label>•</label>
									<para>To notify prescriber if therapeutic response decreases; that dosage adjustment may be needed</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x9436">
								<item>
									<para>
										<emphasis alert="nurse">Not to discontinue abruptly because adrenal crisis can result</emphasis>
									</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x9441">
								<item>
									<label>•</label>
									<para>To take PO with food, milk to decrease GI symptoms</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x9446">
								<item>
									<label>•</label>
									<para>To avoid OTC products: salicylates, alcohol in cough products, cold preparations unless directed by prescriber; to avoid vaccinations because immunosuppression occurs</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x9454">
							<label>•</label>
							<sec_title>Adrenal insufficiency</sec_title>
							<para>
								<list id="lidelem4x9454">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Adrenal insufficiency:</emphasis> nausea, anorexia, fatigue, dizziness, dyspnea, weakness, joint pain</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x9461">
							<label>•</label>
							<sec_title>Cushingoid symptoms</sec_title>
							<para>
								<list id="lidelem4x9461">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Cushingoid symptoms:</emphasis> buffalo hump, moon face, rapid weight gain, excess sweating</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x9468">
							<label>•</label>
							<sec_title>Infection</sec_title>
							<para>
								<list id="lidelem4x9468">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Infection:</emphasis> to avoid persons with known infections; corticosteroids can mask symptoms of infection</para>
									</item>
								</list>
							</para>
						</section>
					</section>
				</section>
			</section>
		</monograph>
<monograph id="24" status="active">
			<mono_name>metipranolol ophthalmic</mono_name>
			<section type="none" id="sidelem4x9475">
				<para>See <see refid="tra">Appendix B</see></para>
			</section>
		</monograph>
<monograph id="25" status="active">
			<mono_name>metoclopramide (Rx)</mono_name>
			<info>
				<pronunciation>(met-oh-kloe-pra′mide)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x94842">
						<country code="CAN">Apo-Metoclop </country>
					</tradename>
					<tradename id="tnidelem4x94841">Metozolv ODT</tradename>
					<tradename id="tnidelem4x94840">Reglan</tradename>
				</tradenames>
				<class type="func"> Cholinergic, antiemetic</class>
				<class type="chem"> Central dopamine receptor antagonist</class>
				<class type="preg">Pregnancy category <preg cat="B">B</preg></class>
			</info>
			<section type="confusion" id="sidelem4x9497">
				<para>
					<confusion>
						<tradename id="tnidelem4x94970">metoclopramide</tradename>
						<drug type="generic" refid="idelem4x94970">metolazone</drug>
					</confusion>
				</para>
			</section>
			<section type="actions" id="sidelem4x9504">
				<sec_title>Action:</sec_title>
				<para>Enhances response to acetylcholine of tissue in upper GI tract, which causes the contraction of gastric muscle; relaxes pyloric, duodenal segments; increases peristalsis without stimulating secretions; blocks dopamine in chemoreceptor trigger zone of CNS</para>
			</section>
			<section type="uses" id="sidelem4x9509">
				<sec_title>Uses:</sec_title>
				<para>Prevention of nausea, vomiting induced by chemotherapy, radiation, delayed gastric emptying, gastroesophageal reflux</para>
				<section type="none" id="sidelem4x9514">
					<section type="none" id="sidelem4x9515">
						<sec_title>Unlabeled uses:</sec_title>
						<para> Hiccups, migraines, breastfeeding induction, lung cancer</para>
					</section>
				</section>
			</section>
			<section type="contra" id="sidelem4x9520">
				<sec_title>Contraindications:</sec_title>
				<para>Hypersensitivity to this product, procaine, or procainamide; seizure disorder, pheochromocytoma, breast cancer (prolactin dependent), GI obstruction</para>
				<section type="none" id="sidelem4x9525">
					<section type="none" id="sidelem4x9526">
						<sec_title>Precautions:</sec_title>
						<para> Pregnancy (<preg cat="B">B</preg>), breastfeeding, GI hemorrhage, CHF, Parkinson’s disease</para>
						<para>
							<bbw>Tardive dyskinesia</bbw>
						</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x9541">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x9544">
					<section type="none" id="sidelem4x9545">
						<sec_title>Nausea/vomiting (chemotherapy)</sec_title>
						<section type="none" id="sidelem4x9553">
							<label>•</label>
							<sec_title>Adult<route> IV</route></sec_title>
							<para>
								<list id="lidelem4x9553">
									<item>
										<label>•</label>
										<para> 1-2 mg/kg 30 min before administration of chemotherapy, then q2hr × 2 doses, then q3hr × 3 doses</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x9561">
							<label>•</label>
							<sec_title>Child (unlabeled)<route> IV</route></sec_title>
							<para>
								<list id="lidelem4x9561">
									<item>
										<label>•</label>
										<para> 1-2 mg/kg/dose</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x9565">
						<sec_title>Facilitate small-bowel intubation for radiologic exams</sec_title>
						<section type="none" id="sidelem4x9573">
							<label>•</label>
							<sec_title>Adult and child &gt;14 yr<route> IV</route></sec_title>
							<para>
								<list id="lidelem4x9573">
									<item>
										<label>•</label>
										<para> 10 mg over 1-2 min</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x9580">
							<label>•</label>
							<sec_title>Child &lt;6 yr<route> IV</route></sec_title>
							<para>
								<list id="lidelem4x9580">
									<item>
										<label>•</label>
										<para> 0.1 mg/kg</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x9587">
							<label>•</label>
							<sec_title>Child 6-14 yr<route> IV</route></sec_title>
							<para>
								<list id="lidelem4x9587">
									<item>
										<label>•</label>
										<para> 2.5-5 mg</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x9591">
						<sec_title>Diabetic gastroparesis</sec_title>
						<section type="none" id="sidelem4x9599">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x9599">
									<item>
										<label>•</label>
										<para> 10 mg 30 min before meals, at bedtime × 2-8 wk</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x9606">
							<label>•</label>
							<sec_title>Geriatric<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x9606">
									<item>
										<label>•</label>
										<para> 5 mg 30 min before meals, at bedtime, increase to 10 mg if needed</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x9610">
						<sec_title>Gastroesophageal reflux</sec_title>
						<section type="none" id="sidelem4x9618">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x9618">
									<item>
										<label>•</label>
										<para> 10-15 mg qid 30 min before meals and at bedtime</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x9625">
							<label>•</label>
							<sec_title>Child<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x9625">
									<item>
										<label>•</label>
										<para> 0.4-0.8 mg/kg/day in 4 divided doses</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x9629">
						<sec_title>Renal dose</sec_title>
						<section type="none" id="sidelem4x9637">
							<label>•</label>
							<sec_title>Adult</sec_title>
							<para>
								<list id="lidelem4x9637">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Adult:</emphasis> CCr &lt;40 ml/min 50% of dose</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x9641">
						<sec_title>Lactation induction (unlabeled)</sec_title>
						<section type="none" id="sidelem4x9649">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x9649">
									<item>
										<label>•</label>
										<para> 10 mg bid-tid, may increase to 20-45 mg/day in divided doses</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x9653">
						<sec_title>Non–small-cell lung cancer (NSCLC) radiation sensitizer (unlabeled)</sec_title>
						<section type="none" id="sidelem4x9661">
							<label>•</label>
							<sec_title>Adult<route> IV</route></sec_title>
							<para>
								<list id="lidelem4x9661">
									<item>
										<label>•</label>
										<para> (Sensamide IV) 2 mg/kg given 1 hr before radiation therapy 3×/wk</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x9665">
						<sec_title>Hiccups (unlabeled)</sec_title>
						<section type="none" id="sidelem4x9673">
							<label>•</label>
							<sec_title>Adult<route> PO/IM/IV</route></sec_title>
							<para>
								<list id="lidelem4x9673">
									<item>
										<label>•</label>
										<para> 10 mg q6hr</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x9677">
						<sec_title>Available forms:</sec_title>
						<para> Tabs 5, 10 mg; syr 5 mg/5 ml; inj 5 mg/ml; oral sol 5 mg/5 ml; orally disintegrating tab 5, 10 mg</para>
					</section>
					<section type="none" id="sidelem4x9682">
						<sec_title>Administer:</sec_title>
						<section type="none" id="sidelem4x9685">
							<sec_title>PO route</sec_title>
							<para>
								<list id="lidelem4x9690">
									<item>
										<label>•</label>
										<para>
											<emphasis style="sup">1</emphasis>/<emphasis style="inf">2</emphasis>-1 hr before meals for better absorption</para>
									</item>
								</list>
							</para>
							<para>
								<list id="lidelem4x9700">
									<item>
										<label>•</label>
										<para>Gum, hard candy, frequent rinsing of mouth for dry oral cavity</para>
									</item>
								</list>
							</para>
							<section type="none" id="sidelem4x9708">
								<label>•</label>
								<sec_title>Oral disintegrating</sec_title>
								<para>
									<list id="lidelem4x9708">
										<item>
											<label>•</label>
											<para>
												<emphasis style="bold">Oral disintegrating:</emphasis> place on tongue, allow to dissolve, swallow, remove from bottle immediately before use</para>
										</item>
									</list>
								</para>
							</section>
						</section>
						<section type="none" id="sidelem4x9712">
							<sec_title>IM route</sec_title>
							<para>
								<list id="lidelem4x9716">
									<item>
										<label>•</label>
										<para>Give for postoperative nausea, vomiting before end of surgery</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x9722">
							<sec_title>Direct IV route</sec_title>
							<para>
								<list id="lidelem4x9726">
									<item>
										<label>•</label>
										<para>DiphenhydrAMINE IV or benztropine IM for EPS</para>
									</item>
									<item>
										<label>•</label>
										<para>Undiluted if dose ≤10 mg; give over 2 min</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x9737">
							<sec_title>Intermittent IV INFUSION route</sec_title>
							<para>
								<list id="lidelem4x9741">
									<item>
										<label>•</label>
										<para>&gt;10 mg may be diluted in ≥50 ml D<emphasis style="inf">5</emphasis>W, NaCl, Ringer’s, LR, given over ≥15 min</para>
									</item>
								</list>
							</para>
							<para>
								<list id="lidelem4x9751">
									<item>
										<label>•</label>
										<para>Protect from light with aluminum foil during infusion</para>
									</item>
									<item>
										<label>•</label>
										<para>Discard open ampules</para>
									</item>
								</list>
							</para>
							<para>
								<emphasis style="bold">Y-site compatibilities:</emphasis> Acetaminophen, alfentanil, amifostine, amikacin, aminophylline, ascorbic acid, atracurium, atropine, azaTHIOprine, aztreonam, bivalirudin, bleomycin, bumetanide, buprenorphine, butorphanol, calcium chloride/gluconate, CARBOplatin, caspofungin, ceFAZolin, cefonicid, cefoperazone, cefotaxime, cefoTEtan, cefOXitin, cefTAZidime, ceftizoxime, cefTRIAXone, cefuroxime, chloramphenicol, chlorproMAZINE, cimetidine, ciprofloxacin, cisatracurium, CISplatin, cladribine, clindamycin, cyanocobalamin, cyclophosphamide, cycloSPORINE, cytarabine, DACTINomycin, DAPTOmycin, dexamethasone, dexmedetomidine, digoxin, diltiazem, diphenhydrAMINE, DOBUTamine, DOCEtaxel, DOPamine, doripenem, doxapram, DOXOrubicin hydrochloride, doxycycline, droperidol, enalaprilat, ePHEDrine, EPINEPHrine, epirubicin, epoetin alfa, ertapenem, erythromycin, esmolol, etoposide, etoposide phosphate, famotidine, fenoldopam, fentaNYL, filgrastim, fluconazole, fludarabine, folic acid, foscarnet, gallium nitrate, gemcitabine, gentamicin, glycopyrrolate, granisetron, heparin, hydrocortisone, HYDROmorphone, IDArubicin, ifosfamide, imipenem/cilastatin, indomethacin, insulin, isoproterenol, ketorolac, labetalol, leucovorin, levofloxacin, lidocaine, linezolid, LORazepam, magnesium sulfate, mannitol, mechlorethamine, melphalan, meperidine, meropenem, metaraminol, methadone, methotrexate, methoxamine, methyldopate, methylPREDNISolone, metoprolol, metroNIDAZOLE, miconazole, midazolam, milrinone, minocycline, mitoMYcin, morphine, moxalactam, multiple vitamins, nafcillin, nalbuphine, naloxone, nesiritide, nitroglycerin, nitroprusside, norepinephrine, octreotide, ondansetron, oxaliplatin, oxytocin, PACLitaxel, palonosetron, pantoprazole, papaverine, PEMEtrexed, penicillin G, pentamidine, pentazocine, PENTobarbital, PHENobarbital, phentolamine, phenylephrine, phytonadione, piperacillin/tazobactam, potassium chloride, procainamide, prochlorperazine, promethazine, propranolol, protamine, pyridoxine, quinupristin/dalfopristin, ranitidine, remi-fentanil, riTUXimab, rocuronium, sargramostim, sodium acetate/bicarbonate, succinylcholine, SUFentanil, tacrolimus, teniposide, theophylline, thiamine, thiotepa, ticarcillin/clavulanate, tigecycline, tirofiban, tobramycin, tolazoline, topotecan, trastuzumab, trimethaphan, urokinase, vancomycin, vasopressin, vecuronium, verapamil, vinBLAStine, vinCRIStine, vinorelbine, voriconazole, zidovudine</para>
						</section>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x9768">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x9771">
					<section type="none" id="sidelem4x9772">
						<sec_title>CNS:</sec_title>
						<para> <emphasis style="italic">Sedation, fatigue, restlessness, headache, sleeplessness, dystonia,</emphasis> dizziness, drowsiness, <emphasis style="bold">suicidal ideation, seizures,</emphasis> EPS, <emphasis style="bold">neuroleptic malignant syndrome; tardive dyskinesia (&gt;3 mo, high doses)</emphasis></para>
					</section>
					<section type="none" id="sidelem4x9785">
						<sec_title>CV:</sec_title>
						<para> Hypotension, supraventricular tachycardia</para>
					</section>
					<section type="none" id="sidelem4x9790">
						<sec_title>GI:</sec_title>
						<para> Dry mouth, constipation, nausea, anorexia, vomiting, diarrhea</para>
					</section>
					<section type="none" id="sidelem4x9795">
						<sec_title>GU:</sec_title>
						<para> Decreased libido, prolactin secretion, amenorrhea, galactorrhea</para>
					</section>
					<section type="none" id="sidelem4x9800">
						<sec_title>HEMA:</sec_title>
						<para> <emphasis style="bold">Neutropenia, leukopenia, agranulocytosis</emphasis></para>
					</section>
					<section type="none" id="sidelem4x9807">
						<sec_title>INTEG:</sec_title>
						<para> Urticaria, rash</para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x9812">
				<sec_title>Pharmacokinetics</sec_title>
				<para>Metabolized by liver, excreted in urine, half-life 2<emphasis style="sup">1</emphasis>/<emphasis style="inf">2</emphasis>-6 hr</para>
				<section type="none" id="sidelem4x9823">
					<section type="none" id="sidelem4x9824">
						<sec_title>PO:</sec_title>
						<para> Onset <emphasis style="sup">1</emphasis>/<emphasis style="inf">2</emphasis>-1 hr, duration 1-2 hr</para>
					</section>
					<section type="none" id="sidelem4x9835">
						<sec_title>IM:</sec_title>
						<para> Onset 10-15 min, duration 1-2 hr</para>
					</section>
					<section type="none" id="sidelem4x9840">
						<sec_title>IV:</sec_title>
						<para> Onset 1-3 min, duration 1-2 hr</para>
					</section>
				</section>
			</section>
			<section type="interactions" id="sidelem4x9845">
				<sec_title>Interactions</sec_title>
				<para>
					<list id="lidelem4x9849">
						<item>
							<label>•</label>
							<para>Avoid use with MAOIs</para>
						</item>
					</list>
				</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> sedation—alcohol, other CNS depressants</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> risk for EPS—haloperidol, phenothiazines</para>
				<para>
					<emphasis style="bold">Decrease:</emphasis> action of metoclopramide—anticholinergics, opiates</para>
				<section type="none" id="sidelem4x9867">
					<section type="none" id="sidelem4x9868">
						<sec_title>Drug/Lab Test</sec_title>
						<para>
							<emphasis style="bold">Increase:</emphasis> prolactin, aldosterone, thyrotropin</para>
					</section>
				</section>
			</section>
			<section type="considerations" id="sidelem4x9875">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x9878">
					<section type="none" id="sidelem4x9879">
						<sec_title>Assess:</sec_title>
						<para>
							<bbw>EPS, tardive dyskinesia; more likely to occur in treatment &gt;3 mo, geriatric patients and may be irreversible; assess for involuntary movements often</bbw>
						</para>
						<section type="none" id="sidelem4x9896">
							<label>•</label>
							<sec_title>Neuroleptic malignant syndrome<route> hyperthermia, change in B/P, pulse, tachycardia, sweating, rigidity, altered consciousness (rare)</route></sec_title>
						</section>
						<para>
							<list id="lidelem4x9899">
								<item>
									<label>•</label>
									<para>Mental status: depression, anxiety, irritability</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x9904">
								<item>
									<label>•</label>
									<para>GI complaints: nausea, vomiting, anorexia, constipation</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x9909">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x9913">
								<item>
									<label>•</label>
									<para>Therapeutic response: absence of nausea, vomiting, anorexia, fullness</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x9919">
						<sec_title>Teach patient/family:</sec_title>
						<para>
							<list id="lidelem4x9923">
								<item>
									<label>•</label>
									<para>To avoid driving, other hazardous activities until stabilized on product</para>
								</item>
								<item>
									<label>•</label>
									<para>To avoid alcohol, other CNS depressants that will enhance sedating properties of this product</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
		</monograph>
<monograph id="26" status="active">
			<mono_name>metolazone (Rx)</mono_name>
			<info>
				<pronunciation>(me-tole′a-zone)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x99390">Zaroxolyn</tradename>
				</tradenames>
				<class type="func"> Diuretic, antihypertensive</class>
				<class type="chem"> Thiazide-like quinazoline derivative</class>
				<class type="preg">Pregnancy category <preg cat="D">D</preg> <preg cat="B">B</preg></class>
			</info>
			<section type="confusion" id="sidelem4x9949">
				<para>
					<confusion>
						<tradename id="tnidelem4x99490">metolazone</tradename>
						<drug type="generic" refid="idelem4x99490">methotrexate/metoclopramide</drug>
					</confusion>
				</para>
			</section>
			<section type="actions" id="sidelem4x9953">
				<sec_title>Action:</sec_title>
				<para>Acts on distal tubule by increasing excretion of water, sodium, chloride, potassium, magnesium, bicarbonate; decreases GFR</para>
			</section>
			<section type="uses" id="sidelem4x9960">
				<sec_title>Uses:</sec_title>
				<para>Edema, hypertension</para>
				<section type="none" id="sidelem4x9965">
					<section type="none" id="sidelem4x9966">
						<sec_title>Unlabeled uses:</sec_title>
						<para> Heart failure, nephrotic syndrome</para>
					</section>
				</section>
			</section>
			<section type="contra" id="sidelem4x9971">
				<sec_title>Contraindications:</sec_title>
				<para>Pregnancy (<preg cat="D">D</preg>) (preeclampsia, intrauterine growth retardation), hypersensitivity to thiazides, sulfonamides; anuria, coma, hepatic encephalopathy</para>
				<section type="none" id="sidelem4x9976">
					<section type="none" id="sidelem4x9977">
						<sec_title>Precautions:</sec_title>
						<para> Pregnancy (<preg cat="B">B</preg>), breastfeeding, geriatric patients, hypokalemia, renal/hepatic disease, gout, COPD, lupus erythematosus, diabetes mellitus, hypotension, history of pancreatitis; hypersensitivity to sulfonamides, thiazides; electrolyte imbalance</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x9982">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x9985">
					<section type="none" id="sidelem4x9986">
						<sec_title>Edema</sec_title>
						<section type="none" id="sidelem4x9994">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x9994">
									<item>
										<label>•</label>
										<para> 5-10 mg/day; max 20 mg/day</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x9998">
						<sec_title>Hypertension</sec_title>
						<section type="none" id="sidelem4x10006">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x10006">
									<item>
										<label>•</label>
										<para> 2.5-5 mg/day</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x10013">
							<label>•</label>
							<sec_title>Child<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x10013">
									<item>
										<label>•</label>
										<para> 0.2-0.4 mg/kg/day in divided doses q12-24hr</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x10017">
						<sec_title>Available forms:</sec_title>
						<para> Tabs 2.5, 5, 10 mg</para>
					</section>
					<section type="none" id="sidelem4x10022">
						<sec_title>Administer:</sec_title>
						<para>
							<list id="lidelem4x10026">
								<item>
									<label>•</label>
									<para>In <emphasis style="smallcaps">am</emphasis> to avoid interference with sleep if using product as diuretic</para>
								</item>
								<item>
									<label>•</label>
									<para>Potassium replacement if potassium &lt;3 mg/dl</para>
								</item>
								<item>
									<label>•</label>
									<para>With food if nausea occurs; absorption may be decreased slightly</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x10045">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x10048">
					<section type="none" id="sidelem4x10049">
						<sec_title>CNS:</sec_title>
						<para> Anxiety, depression, <emphasis style="italic">headache, dizziness, fatigue, weakness</emphasis></para>
					</section>
					<section type="none" id="sidelem4x10056">
						<sec_title>CV:</sec_title>
						<para> <emphasis style="italic">Orthostatic hypotension,</emphasis> palpitations, volume depletion, hypotension, chest pain</para>
					</section>
					<section type="none" id="sidelem4x10064">
						<sec_title>EENT:</sec_title>
						<para> Blurred vision</para>
					</section>
					<section type="none" id="sidelem4x10069">
						<sec_title>ELECT:</sec_title>
						<para> <emphasis style="italic">Hypokalemia,</emphasis> hypercalcemia, hyponatremia</para>
					</section>
					<section type="none" id="sidelem4x10077">
						<sec_title>GI:</sec_title>
						<para> <emphasis style="italic">Nausea, vomiting, anorexia,</emphasis> constipation, diarrhea, cramps, pancreatitis, GI irritation, dry mouth, jaundice, <emphasis style="bold">hepatitis</emphasis></para>
					</section>
					<section type="none" id="sidelem4x10087">
						<sec_title>GU:</sec_title>
						<para> <emphasis style="italic">Urinary frequency,</emphasis> polyuria, <emphasis style="bold">uremia, glucosuria,</emphasis> nocturia, impotence</para>
					</section>
					<section type="none" id="sidelem4x10098">
						<sec_title>HEMA:</sec_title>
						<para> <emphasis style="bold">Aplastic anemia, hemolytic anemia, leukopenia, agranulocytosis, neutropenia</emphasis></para>
					</section>
					<section type="none" id="sidelem4x10105">
						<sec_title>INTEG:</sec_title>
						<para> <emphasis style="italic">Rash,</emphasis> urticaria, purpura, photosensitivity, fever, dry skin, <emphasis style="bold">toxic epidermal necrolysis, Stevens-Johnson syndrome</emphasis></para>
					</section>
					<section type="none" id="sidelem4x10115">
						<sec_title>META:</sec_title>
						<para> <emphasis style="italic">Hyperglycemia,</emphasis> increased creatinine, BUN</para>
					</section>
					<section type="none" id="sidelem4x10123">
						<sec_title>MS:</sec_title>
						<para> Muscle cramps, joint pain, swelling</para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x10128">
				<sec_title>Pharmacokinetics</sec_title>
				<para>Protein binding 33%, peak 8 hr, duration 12-24 hr, excreted unchanged by kidneys, crosses placenta, enters breast milk, half-life 14 hr</para>
			</section>
			<section type="interactions" id="sidelem4x10133">
				<sec_title>Interactions</sec_title>
				<para>
					<emphasis style="bold">Increase:</emphasis> hyperglycemia—antidiabetics</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> hypokalemia—mezlocillin, piperacillin, amphotericin B, glucocorticoids, digoxin, stimulant laxatives</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> hypotension—alcohol (large amounts), nitrates, antihypertensives, barbiturates, opioids</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> toxicity—lithium</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> metolazone effects—loop diuretics</para>
				<para>
					<emphasis style="bold">Decrease:</emphasis> action of metolazone—NSAIDs, salicylates</para>
				<section type="none" id="sidelem4x10160">
					<section type="none" id="sidelem4x10161">
						<sec_title>Drug/Food</sec_title>
						<para>
							<emphasis style="bold">Increase:</emphasis> severe hypokalemia—licorice</para>
					</section>
					<section type="none" id="sidelem4x10168">
						<sec_title>Drug/Herb</sec_title>
						<para>
							<emphasis style="bold">Decrease:</emphasis> antihypertensive effect—ephedra (Ma huang)</para>
						<para>
							<emphasis style="bold">Increase:</emphasis> antihypertensive effect—hawthorn</para>
					</section>
					<section type="none" id="sidelem4x10179">
						<sec_title>Drug/Lab Test</sec_title>
						<para>
							<emphasis style="bold">Increase:</emphasis> calcium, cholesterol, glucose, triglycerides</para>
						<para>
							<emphasis style="bold">Decrease:</emphasis> potassium, sodium, chloride, magnesium</para>
					</section>
				</section>
			</section>
			<section type="considerations" id="sidelem4x10190">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x10193">
					<section type="none" id="sidelem4x10194">
						<sec_title>Assess:</sec_title>
						<para>
							<list id="lidelem4x10199">
								<item>
									<label>•</label>
									<para>Weight, I&amp;O daily to determine fluid loss; effect of product may be decreased if used daily</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x10207">
							<label>•</label>
							<sec_title>CHF</sec_title>
							<para>
								<list id="lidelem4x10207">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">CHF:</emphasis> improvement in edema of feet, legs, sacral area daily if product being used</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x10215">
							<label>•</label>
							<sec_title>Hypertension</sec_title>
							<para>
								<list id="lidelem4x10215">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Hypertension:</emphasis> B/P lying, standing; postural hypotension may occur</para>
									</item>
								</list>
							</para>
						</section>
						<para>
							<list id="lidelem4x10219">
								<item>
									<label>•</label>
									<para>Electrolytes: potassium, magnesium, sodium, chloride; include BUN, blood glucose, CBC, serum creatinine, blood pH, ABGs, uric acid, calcium</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x10227">
							<label>•</label>
							<sec_title>Hypokalemia</sec_title>
							<para>
								<list id="lidelem4x10227">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Hypokalemia:</emphasis> postural hypotension, malaise, fatigue, tachycardia, leg cramps, weakness</para>
									</item>
								</list>
							</para>
						</section>
						<para>
							<list id="lidelem4x10231">
								<item>
									<label>•</label>
									<para>Rashes, fever daily</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x10239">
							<para>
								<list id="lidelem4x10239">
									<item>
										<label>•</label>
										<para>Confusion, especially among geriatric patients; take safety precautions if needed
<bbw>
												<emphasis alert="lifethreat">Hepatic encephalopathy:</emphasis> do not use in hepatic coma or precoma; fluctuations in electrolytes can occur rapidly and precipitate hepatic coma; use caution in patients with im-paired hepatic function</bbw>
</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x10252">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x10256">
								<item>
									<label>•</label>
									<para>Therapeutic response: decreased edema, B/P</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x10262">
						<sec_title>Teach patient/family:</sec_title>
						<para>
							<list id="lidelem4x10266">
								<item>
									<label>•</label>
									<para>To increase fluid intake to 2-3 L/day unless contraindicated; to rise slowly from lying or sitting position</para>
								</item>
								<item>
									<label>•</label>
									<para>To notify prescriber of muscle weakness, cramps, nausea, dizziness</para>
								</item>
								<item>
									<label>•</label>
									<para>That product may be taken with food or milk</para>
								</item>
								<item>
									<label>•</label>
									<para>To use sunscreen for photosensitivity</para>
								</item>
								<item>
									<label>•</label>
									<para>That blood glucose may be increased in diabetics</para>
								</item>
								<item>
									<label>•</label>
									<para>To take early in day to avoid nocturia</para>
								</item>
								<item>
									<label>•</label>
									<para>To avoid alcohol</para>
								</item>
								<item>
									<label>•</label>
									<para>To avoid sodium foods; to increase potassium foods in diet</para>
								</item>
								<item>
									<label>•</label>
									<para>Not to stop product abruptly</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
		</monograph>
<monograph id="27" status="active">
			<mono_name>metoprolol (Rx)</mono_name>
			<info>
				<pronunciation>(meh-toe′proe-lole)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x103222">Lopressor</tradename>
					<tradename id="tnidelem4x103221">
						<country code="CAN">Nu-Metop </country>
					</tradename>
					<tradename id="tnidelem4x103220">Toprol-XL</tradename>
				</tradenames>
				<class type="func"> Antihypertensive, antianginal</class>
				<class type="chem"> β-Blocker</class>
				<class type="preg">Pregnancy category <preg cat="C">C</preg></class>
			</info>
			<section type="confusion" id="sidelem4x10338">
				<para>
					<confusion>
						<tradename id="tnidelem4x103380">metoprolol</tradename>
						<drug type="generic" refid="idelem4x103380">misoprostol</drug>
					</confusion>
				</para>
			</section>
			<section type="actions" id="sidelem4x10342">
				<sec_title>Action:</sec_title>
				<para>Lowers B/P by β-blocking effects; reduces elevated renin plasma levels; blocks β<emphasis style="inf">2</emphasis>-adrenergic receptors in bronchial, vascular smooth muscle only at high doses; negative chronotropic effect</para>
			</section>
			<section type="uses" id="sidelem4x10350">
				<sec_title>Uses:</sec_title>
				<para>Mild to moderate hypertension, acute MI to reduce cardiovascular mortality, angina pectoris, NYHA class II, III heart failure, cardiomyopathy</para>
				<section type="none" id="sidelem4x10355">
					<section type="none" id="sidelem4x10356">
						<sec_title>Unlabeled uses:</sec_title>
						<para> Migraine prevention, heart rate control for atrial fibrillation/flutter without accessory pathway, essential tremor, unstable angina</para>
					</section>
				</section>
			</section>
			<section type="contra" id="sidelem4x10361">
				<sec_title>Contraindications:</sec_title>
				<para>Hypersensitivity to β-blockers, cardiogenic shock, heart block (2nd, 3rd degree), sinus bradycardia, pheochromocytoma, sick sinus syndrome</para>
				<section type="none" id="sidelem4x10366">
					<section type="none" id="sidelem4x10367">
						<sec_title>Precautions:</sec_title>
						<para> Pregnancy (<preg cat="C">C</preg>), breastfeeding, geriatric patients, major surgery, diabetes mellitus, thyroid/renal/hepatic disease, COPD, CAD, nonallergic bronchospasm, bronchial asthma, CVA, children, depression, vasospastic angina</para>
						<para>
							<bbw>Abrupt discontinuation</bbw>
						</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x10382">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x10385">
					<section type="none" id="sidelem4x10386">
						<sec_title>Hypertension</sec_title>
						<section type="none" id="sidelem4x10394">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x10394">
									<item>
										<label>•</label>
										<para> 50 mg bid or 100 mg/day; may give up to 100-450 mg in divided doses;  25-100 mg daily, titrate at weekly intervals; max 400 mg/day</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x10405">
							<label>•</label>
							<sec_title>Geriatric<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x10405">
									<item>
										<label>•</label>
										<para> 25 mg/day initially, increase weekly as needed</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x10412">
							<label>•</label>
							<sec_title>Child and adolescent 6-16 yr<route> PO ER</route></sec_title>
							<para>
								<list id="lidelem4x10412">
									<item>
										<label>•</label>
										<para> 1 mg/kg up to 50 mg daily</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x10416">
						<sec_title>Myocardial infarction</sec_title>
						<section type="none" id="sidelem4x10424">
							<label>•</label>
							<sec_title>Adult<route> IV BOL</route></sec_title>
							<para>
								<list id="lidelem4x10424">
									<item>
										<label>•</label>
										<para> (early treatment) 5 mg q2min × 3, then 50 mg  15 min after last dose and q6hr × 48 hr; (late treatment)  maintenance 50-100 mg bid for 1-3 yr</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x10434">
						<sec_title>Heart failure (NYHA class II/III)</sec_title>
						<section type="none" id="sidelem4x10442">
							<label>•</label>
							<sec_title>Adult<route> PO EXT REL</route></sec_title>
							<para>
								<list id="lidelem4x10442">
									<item>
										<label>•</label>
										<para> 25 mg daily × 2 wk (class II); 12.5 mg daily (class III)</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x10446">
						<sec_title>Angina</sec_title>
						<section type="none" id="sidelem4x10454">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x10454">
									<item>
										<label>•</label>
										<para> 100 mg/day as a single dose or in 2 divided doses, increase weekly prn or 100 mg  daily, max 400 mg/day ext rel</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x10461">
						<sec_title>Migraine prevention (unlabeled)</sec_title>
						<section type="none" id="sidelem4x10469">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x10469">
									<item>
										<label>•</label>
										<para> 25-100 mg bid; 50-200 mg daily (XL)</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x10473">
						<sec_title>Heart rate control for atrial fibrillation/flutter without accessory pathway (unlabeled)</sec_title>
						<section type="none" id="sidelem4x10481">
							<label>•</label>
							<sec_title>Adult<route> IV BOL</route></sec_title>
							<para>
								<list id="lidelem4x10481">
									<item>
										<label>•</label>
										<para> (acute setting) 2.5-5 mg over 2 min, may repeat dose × 3;  (nonacute setting) 25-100 mg bid</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x10488">
						<sec_title>Essential tremor (unlabeled)</sec_title>
						<section type="none" id="sidelem4x10496">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x10496">
									<item>
										<label>•</label>
										<para> 50 mg/day, may increase, max 300 mg/day in divided doses;  100 mg/day, max 400 mg/day</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x10503">
						<sec_title>Available forms:</sec_title>
						<para> Tabs 25, 50, 100 mg; inj 1 mg/ml; ext rel tab (succinate) (XL) 25, 50, 100, 200 mg; ext rel tabs, tartrate: 100 mg</para>
					</section>
					<section type="none" id="sidelem4x10508">
						<sec_title>Administer:</sec_title>
						<section type="none" id="sidelem4x10511">
							<sec_title>PO route</sec_title>
							<para>
								<list id="lidelem4x10515">
									<item>
										<label>•</label>
										<para>Do not break, crush, or chew ext rel tabs</para>
									</item>
									<item>
										<label>•</label>
										<para>Regular release tab after meals, at bedtime; tab may be crushed or swallowed whole; take at same time each day</para>
									</item>
									<item>
										<label>•</label>
										<para>Store in dry area at room temperature; do not freeze</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x10531">
							<sec_title>Direct IV route</sec_title>
							<section type="none" id="sidelem4x10539">
								<label>•</label>
								<sec_title>
									<route>PO</route>
								</sec_title>
								<para>
									<list id="lidelem4x10539">
										<item>
											<label>•</label>
											<para>IV, undiluted, give over 1 min × 3 doses at 2- to 5-min intervals; start  15 min after last IV dose</para>
										</item>
									</list>
								</para>
							</section>
							<para>
								<emphasis style="bold">Y-site compatibilities:</emphasis> Abciximab, acyclovir, alemtuzumab, alfentanil, alteplase, amikacin, aminophylline, amiodarone, amphotericin B liposome, anidulafungin, argatroban, ascorbic acid, atracurium, atropine, azaTHIOprine, aztreonam, benztropine, bivalirudin, bleomycin, bumetanide, buprenorphine, butorphanol, calcium chloride/gluconate, CARBOplatin, caspofungin, ceFAZolin, cefonicid, cefoperazone, cefotaxime, cefoTEtan, cefOXitin, cefTAZidime, ceftizoxime, cefTRIAXone, cefuroxime, chloramphenicol, chlorproMAZINE, cimetidine, CISplatin, clindamycin, cyanocobalamin, cyclophosphamide, cycloSPORINE, cytarabine, DACTINomycin, DAPTOmycin, dexamethasone, dexmedetomidine, digoxin, diltiazem, diphenhydrAMINE, DOBUTamine, DOCEtaxel, DOPamine, doxacurium, DOXOrubicin, doxycycline, enalaprilat, ePHEDrine, EPINEPHrine, epirubicin, epoetin alfa, eptifibatide, esmolol, etoposide, etoposide phosphate, famotidine, fenoldopam, fentaNYL, fluconazole, fludarabine, fluorouracil, folic acid, furosemide, ganciclovir, gemcitabine, gentamicin, glycopyrrolate, granisetron, heparin, hydrocortisone, HYDROmorphone, IDArubicin, ifosfamide, imipenem/cilastatin, indomethacin, insulin, isoproterenol, ketorolac, labetalol, linezolid, LORazepam, magnesium sulfate, mannitol, mechlorethamine, meperidine, metaraminol, methotrexate, methoxamine, methyldopate, methylPREDNISolone, metoclopramide, metroNIDAZOLE, midazolam, milrinone, mitoXANtrone, morphine, multivitamins, nafcillin, nalbuphine, naloxone, nitroprusside, norepinephrine, octreotide, ondansetron, oxacillin, oxaliplatin, oxytocin, PACLitaxel, palonosetron, pancuronium, papaverine, PEMEtrexed, penicillin G, pentamidine, pentazocine, PENTobarbital, PHENobarbital, phentolamine, phenylephrine, phytonadione, piperacillin/tazobactam, potassium chloride, procainamide, prochlorperazine, promethazine, propranolol, protamine, pyridoxime, quinupristin/dalfopristin, ranitidine, rocuronium, sodium bicarbonate, succinylcholine, SUFentanil, tacrolimus, teniposide, theophylline, thiamine, thiotepa, ticarcillin/clavulanate, tigecycline, tirofiban, tobramycin, tolazoline, trimetaphan, urokinase, vancomycin, vasopressin, vecuronium, verapamil, vinCRIStine, vinorelbine, voriconazole</para>
						</section>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x10550">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x10553">
					<section type="none" id="sidelem4x10554">
						<sec_title>CNS:</sec_title>
						<para> <emphasis style="italic">Insomnia, dizziness,</emphasis> mental changes, hallucinations, depression, anxiety, headaches, nightmares, confusion, fatigue</para>
					</section>
					<section type="none" id="sidelem4x10562">
						<sec_title>CV:</sec_title>
						<para> <emphasis style="italic">Hypotension,</emphasis><emphasis style="bold">bradycardia,</emphasis> CHF, <emphasis style="italic">palpitations,</emphasis> dysrhythmias, <emphasis style="bold">cardiac arrest, AV block, pulmonary/peripheral edema, chest pain</emphasis></para>
					</section>
					<section type="none" id="sidelem4x10577">
						<sec_title>EENT:</sec_title>
						<para> Sore throat; dry, burning eyes</para>
					</section>
					<section type="none" id="sidelem4x10582">
						<sec_title>GI:</sec_title>
						<para> <emphasis style="italic">Nausea, vomiting,</emphasis> colitis, cramps, <emphasis style="italic">diarrhea,</emphasis> constipation, flatulence, dry mouth, <emphasis style="italic">hiccups</emphasis></para>
					</section>
					<section type="none" id="sidelem4x10595">
						<sec_title>GU:</sec_title>
						<para> Impotence</para>
					</section>
					<section type="none" id="sidelem4x10600">
						<sec_title>HEMA:</sec_title>
						<para> <emphasis style="bold">Agranulocytosis, eosinophilia, thrombocytopenia, purpura</emphasis></para>
					</section>
					<section type="none" id="sidelem4x10607">
						<sec_title>INTEG:</sec_title>
						<para> Rash, purpura, alopecia, dry skin, urticaria, pruritus</para>
					</section>
					<section type="none" id="sidelem4x10612">
						<sec_title>RESP:</sec_title>
						<para> <emphasis style="bold">Bronchospasm,</emphasis> dyspnea, wheezing</para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x10620">
				<sec_title>Pharmacokinetics</sec_title>
				<para>Half-life 3-4 hr, metabolized in liver (metabolites), excreted in urine, crosses placenta, enters breast milk</para>
				<section type="none" id="sidelem4x10625">
					<section type="none" id="sidelem4x10626">
						<sec_title>PO:</sec_title>
						<para> Peak 2-4 hr, duration 13-19 hr</para>
					</section>
					<section type="none" id="sidelem4x10631">
						<sec_title>PO-ER:</sec_title>
						<para> Peak 6-12 hr, duration 24 hr</para>
					</section>
					<section type="none" id="sidelem4x10636">
						<sec_title>IV:</sec_title>
						<para> Onset immediate, peak 20 min, duration 6-8 hr</para>
					</section>
				</section>
			</section>
			<section type="interactions" id="sidelem4x10641">
				<sec_title>Interactions</sec_title>
				<section type="none" id="sidelem4x10649">
					<label>•</label>
					<sec_title>
						<route>Do not use with MAOIs</route>
					</sec_title>
				</section>
				<para>
					<emphasis style="bold">Increase:</emphasis> hypotension, bradycardia—reserpine, hydrALAZINE, methyldopa, prazosin, amphetamines, EPINEPHrine, H<emphasis style="inf">2</emphasis>-antagonists, calcium channel blockers</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> hypoglycemic effects—insulin, oral antidiabetics</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> metoprolol level—cimetidine</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> effects of benzodiazepines</para>
				<para>
					<emphasis style="bold">Decrease:</emphasis> antihypertensive effect—salicylates, NSAIDs</para>
				<para>
					<emphasis style="bold">Decrease:</emphasis> metoprolol level—barbiturates</para>
				<para>
					<emphasis style="bold">Decrease:</emphasis> effects of—xanthines</para>
				<section type="none" id="sidelem4x10683">
					<section type="none" id="sidelem4x10684">
						<sec_title>Drug/Food</sec_title>
						<para>
							<emphasis style="bold">Increase:</emphasis> absorption with food</para>
					</section>
					<section type="none" id="sidelem4x10691">
						<sec_title>Drug/Lab Test</sec_title>
						<para>
							<emphasis style="bold">Increase:</emphasis> BUN, potassium, ANA titer, serum lipoprotein, triglycerides, uric acid, alk phos, LDH, AST, ALT</para>
					</section>
				</section>
			</section>
			<section type="considerations" id="sidelem4x10698">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x10701">
					<section type="none" id="sidelem4x10702">
						<sec_title>Assess:</sec_title>
						<para>
							<bbw>Abrupt withdrawal: may cause MI, ventricular dysrhythmias, myocardial ischemia; taper dose over 7-14 days</bbw>
						</para>
						<section type="none" id="sidelem4x10719">
							<label>•</label>
							<sec_title>Hypertension/angina</sec_title>
							<para>
								<list id="lidelem4x10719">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Hypertension/angina:</emphasis> ECG directly when giving IV during initial treatment</para>
									</item>
								</list>
							</para>
						</section>
						<para>
							<list id="lidelem4x10723">
								<item>
									<label>•</label>
									<para>I&amp;O, weight daily; check for CHF (weight gain, jugular venous distention, crackles, edema, dyspnea)</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x10728">
								<item>
									<label>•</label>
									<para>Monitor B/P during initial treatment, periodically thereafter; pulse q4hr; note rate, rhythm, quality; apical/radial pulse before administration; notify prescriber of any significant changes or pulse &lt;60 bpm</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x10733">
								<item>
									<label>•</label>
									<para>Baselines of renal, hepatic studies before therapy begins</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x10738">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x10742">
								<item>
									<label>•</label>
									<para>Therapeutic response: decreased B/P after 1-2 wk, decreased anginal pain</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x10748">
						<sec_title>Teach patient/family:</sec_title>
						<para>
							<list id="lidelem4x10752">
								<item>
									<label>•</label>
									<para>To take immediately after meals; to take medication at bedtime to prevent effect of orthostatic hypotension
<bbw>Not to discontinue product abruptly; to taper over 2 wk; may cause angina</bbw>
</para>
								</item>
								<item>
									<label>•</label>
									<para>Not to use OTC products containing α-adrenergic stimulants (nasal decongestants, OTC cold preparations) unless directed by prescriber; to avoid alcohol, smoking, sodium intake</para>
								</item>
								<item>
									<label>•</label>
									<para>To report bradycardia, dizziness, confusion, depression, fever, sore throat, SOB, decreased vision to prescriber</para>
								</item>
								<item>
									<label>•</label>
									<para>To take pulse, B/P at home; when to notify prescriber</para>
								</item>
								<item>
									<label>•</label>
									<para>To comply with weight control, dietary adjustments, modified exercise program</para>
								</item>
								<item>
									<label>•</label>
									<para>To carry emergency ID to identify product, allergies</para>
								</item>
								<item>
									<label>•</label>
									<para>To monitor blood glucose closely if diabetic</para>
								</item>
								<item>
									<label>•</label>
									<para>To avoid hazardous activities if dizziness is present</para>
								</item>
								<item>
									<label>•</label>
									<para>To report symptoms of CHF: difficult breathing, especially on exertion or when lying down; night cough; swelling of extremities</para>
								</item>
								<item>
									<label>•</label>
									<para>To wear support hose to minimize effects of orthostatic hypotension</para>
								</item>
								<item>
									<label>•</label>
									<para>To report Raynaud’s symptoms</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
		</monograph>
<monograph id="28" status="active">
			<mono_name>metroNIDAZOLE (Rx)</mono_name>
			<info>
				<pronunciation>(me-troe-ni′da-zole)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x108315">Flagyl</tradename>
					<tradename id="tnidelem4x108314">Flagyl ER</tradename>
					<tradename id="tnidelem4x108313">Flagyl IV</tradename>
					<tradename id="tnidelem4x108312">Flagyl IV RTU</tradename>
					<tradename id="tnidelem4x108311">
						<country code="CAN">Florazone ER </country>
					</tradename>
					<tradename id="tnidelem4x108310">
						<country code="CAN">Novo-Nidazol </country>
					</tradename>
				</tradenames>
				<class type="func"> Antiinfective—miscellaneous</class>
				<class type="chem"> Nitroimidazole derivative</class>
				<class type="preg">Pregnancy category <preg cat="B">B</preg></class>
			</info>
			<section type="actions" id="sidelem4x10846">
				<sec_title>Action:</sec_title>
				<para>Direct-acting amebicide/trichomonacide binds and disrupts DNA structure, thereby inhibiting bacterial nucleic acid synthesis</para>
			</section>
			<section type="uses" id="sidelem4x10851">
				<sec_title>Uses:</sec_title>
				<para>Intestinal amebiasis, amebic abscess, trichomoniasis, refractory trichomoniasis, bacterial anaerobic infections, giardiasis, septicemia, endocarditis; bone, joint, lower respiratory tract infections; rosacea</para>
				<section type="none" id="sidelem4x10856">
					<section type="none" id="sidelem4x10857">
						<sec_title>Unlabeled uses:</sec_title>
						<para> Crohn’s disease, urethritis, amebiasis due to <emphasis style="italic">Dientamoeba fragilis, Entamoeba polecki,</emphasis> giardiasis, pruritus; gastric ulcer, dyspepsia <emphasis style="italic">(H. pylori),</emphasis> pseudomembranous colitis, guinea worm disease, periodontitis</para>
					</section>
				</section>
			</section>
			<section type="contra" id="sidelem4x10868">
				<sec_title>Contraindications:</sec_title>
				<para>Pregnancy 1st trimester, breastfeeding, hypersensitivity to this product</para>
				<section type="none" id="sidelem4x10873">
					<section type="none" id="sidelem4x10874">
						<sec_title>Precautions:</sec_title>
						<para> Pregnancy (<preg cat="B">B</preg>) 2nd/3rd trimesters, geriatric patients, <emphasis style="italic">Candida</emphasis> infections, heart failure, fungal infection, dental disease, bone marrow suppression, hematologic disease, GI/renal/hepatic disease, contracted visual or color fields, blood dyscrasias, CNS disorders</para>
						<para>
							<bbw>Secondary malignancy</bbw>
						</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x10892">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x10895">
					<section type="none" id="sidelem4x10896">
						<sec_title>Trichomoniasis</sec_title>
						<section type="none" id="sidelem4x10904">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x10904">
									<item>
										<label>•</label>
										<para> 500 mg bid × 7 days or 2 g as single dose; do not repeat treatment for 4-6 wk</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x10911">
							<label>•</label>
							<sec_title>Child ≥45 kg (unlabeled)<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x10911">
									<item>
										<label>•</label>
										<para> 2 g once</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x10918">
							<label>•</label>
							<sec_title>Child &lt;45 kg (unlabeled)<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x10918">
									<item>
										<label>•</label>
										<para> 15 mg/kg/day in 3 divided doses × 7-10 days</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x10925">
							<label>•</label>
							<sec_title>Infant (unlabeled)<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x10925">
									<item>
										<label>•</label>
										<para> 15 mg/kg/day divided in 3 doses × 7 days</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x10929">
						<sec_title>Amebic hepatic abscess</sec_title>
						<section type="none" id="sidelem4x10937">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x10937">
									<item>
										<label>•</label>
										<para> 750 mg tid × 7-10 days</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x10944">
							<label>•</label>
							<sec_title>Child<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x10944">
									<item>
										<label>•</label>
										<para> 35-50 mg/kg/day in 3 divided doses × 7-10 days</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x10948">
						<sec_title>Intestinal amebiasis</sec_title>
						<section type="none" id="sidelem4x10956">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x10956">
									<item>
										<label>•</label>
										<para> 750 mg tid × 7-10 days</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x10963">
							<label>•</label>
							<sec_title>Child<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x10963">
									<item>
										<label>•</label>
										<para> 35-50 mg/kg/day in 3 divided doses × 7-10 days, then oral iodoquinol</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x10967">
						<sec_title>Anaerobic bacterial infections</sec_title>
						<section type="none" id="sidelem4x10975">
							<label>•</label>
							<sec_title>Adult<route> IV INFUSION</route></sec_title>
							<para>
								<list id="lidelem4x10975">
									<item>
										<label>•</label>
										<para> 15 mg/kg over 1 hr, then 7.5 mg/kg  or  q6hr, not to exceed 4 g/day; 1st maintenance dose should be administered 6 hr after loading dose</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x10985">
						<sec_title>Bacterial vaginosis</sec_title>
						<section type="none" id="sidelem4x10993">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x10993">
									<item>
										<label>•</label>
										<para> regular rel 500 mg bid or 250 mg tid × 7 days; ext rel 750 mg/day × 7 days</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x10997">
						<sec_title>Persistent urethritis (unlabeled)</sec_title>
						<section type="none" id="sidelem4x11005">
							<label>•</label>
							<sec_title>Adult and adolescent<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x11005">
									<item>
										<label>•</label>
										<para> 2 g as single dose with azithromycin</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x11009">
						<sec_title>
							<emphasis style="bold">
								<emphasis style="italic">Dientamoeba fragilis</emphasis>
							</emphasis> (unlabeled)</sec_title>
						<section type="none" id="sidelem4x11020">
							<label>•</label>
							<sec_title>Child<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x11020">
									<item>
										<label>•</label>
										<para> 250 mg tid × 7 days</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x11024">
						<sec_title>
							<emphasis style="bold">
								<emphasis style="italic">Entamoeba polecki</emphasis>
							</emphasis> (unlabeled)</sec_title>
						<section type="none" id="sidelem4x11035">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x11035">
									<item>
										<label>•</label>
										<para> 750 mg tid × 10 days, then diloxanide furoate (500 mg tid × 10 days</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x11043">
							<label>•</label>
							<sec_title>Child<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x11043">
									<item>
										<label>•</label>
										<para> 30-50 mg/kg/day in 3 divided doses × 5-10 days</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x11047">
						<sec_title>Crohn’s disease (unlabeled)</sec_title>
						<section type="none" id="sidelem4x11055">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x11055">
									<item>
										<label>•</label>
										<para> 250 mg tid-qid</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x11059">
						<sec_title>Giardiasis (unlabeled)</sec_title>
						<section type="none" id="sidelem4x11067">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x11067">
									<item>
										<label>•</label>
										<para> 250 mg tid × 5-7 days</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x11074">
							<label>•</label>
							<sec_title>Child<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x11074">
									<item>
										<label>•</label>
										<para> 15 mg/kg/day in 3 divided doses × 5 days</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x11078">
						<sec_title>Antibiotic-associated pseudomembranous colitis (unlabeled)</sec_title>
						<section type="none" id="sidelem4x11086">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x11086">
									<item>
										<label>•</label>
										<para> 500 mg/day × 10-14 days;  500 mg q8hr</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x11096">
							<label>•</label>
							<sec_title>Child<route> PO/IV</route></sec_title>
							<para>
								<list id="lidelem4x11096">
									<item>
										<label>•</label>
										<para> 30 mg/kg/day (max 2 g) divided q6hr × 10 days</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x11100">
						<sec_title>Available forms:</sec_title>
						<para> Tabs 250, 500 mg; ext rel tab (ER) 750 mg; caps 375 mg; injection solution 5 mg/ml</para>
					</section>
					<section type="none" id="sidelem4x11105">
						<sec_title>Administer:</sec_title>
						<para>
							<list id="lidelem4x11109">
								<item>
									<label>•</label>
									<para>Store in light-resistant container; do not refrigerate</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x11115">
							<sec_title>PO route</sec_title>
							<para>
								<list id="lidelem4x11119">
									<item>
										<label>•</label>
										<para>Do not break, crush, or chew ext rel product, give on empty stomach</para>
									</item>
									<item>
										<label>•</label>
										<para>PO with or after meals to avoid GI symptoms, metallic taste; crush tabs if needed</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x11130">
							<sec_title>IV route</sec_title>
							<para/>
						</section>
						<section type="none" id="sidelem4x11134">
							<sec_title>Intermittent INFUSION ([Flagyl] IV RTU)</sec_title>
							<para>
								<list id="lidelem4x11138">
									<item>
										<label>•</label>
										<para>Prediluted, ready to use; infusion over 30-60 min</para>
									</item>
									<item>
										<label>•</label>
										<para>Lyophilized vials: dilute with 4.4 ml sterile water, 0.9% NaCl; must be diluted further with ≤8 mg/ml with 0.9% NaCl, D<emphasis style="inf">5</emphasis>W, or LR; must neutralize with 5 mEq NaCO<emphasis style="inf">3</emphasis>/500 mg; CO<emphasis style="inf">2</emphasis> gas will be generated and may require venting; run over ≥1 hr; primary IV must be discontinued; may be given as cont infusion; do not use aluminum products; IV may require venting</para>
									</item>
									<item>
										<label>•</label>
										<para>Do not use aluminum needles or other products to prepare product</para>
									</item>
								</list>
							</para>
							<para>
								<emphasis style="bold">Y-site compatibilities:</emphasis> Acyclovir, alemtuzumab, alfentanil, allopurinol, amifostine, amikacin, aminophylline, amiodarone, ampicillin, ampicillin/sulbactam, anidulafungin, atracurium, bivalirudin, bumetanide, buprenorphine, busulfan, butorphanol, calcium acetate/chloride/gluconate, CARBOplatin, ceFAZolin, cefepime, cefoperazone, cefotaxime, cefoTEtan, cefTRIAXone, cefuroxime, chloramphenicol, chlorproMAZINE, cimetidine, ciprofloxacin, cisatracurium, CISplatin, clindamycin, codeine, cyclophosphamide, cycloSPORINE, cytarabine, DACTINomycin, dexamethasone, dexmedetomidine, dexrazoxane, digoxin, diltiazem, dimenhyDRINATE, diphenhydrAMINE, DOBUTamine, DOCEtaxel, DOPamine, doripenem, doxacurium, doxapram, DOXOrubicin, DOXOrubicin liposome, doxycycline, droperidol, enalaprilat, ePHEDrine, EPINEPHrine, epirubicin, eptifibatide, ertapenem, erythromycin, esmolol, etoposide, etoposide phosphate, famotidine, fenoldopam, fentaNYL, fluconazole, fludarabine, fluorouracil, foscarnet, fosphenytoin, furosemide, gemcitabine, gentamicin, glycopyrrolate, granisetron, haloperidol, heparin, hydrALAZINE, hydrocortisone, HYDROmorphone, IDArubicin, ifosfamide, imipenem/cilastatin, inamrinone, insulin, isoproterenol, ketorolac, labetalol, leucovorin, levofloxacin, lidocaine, linezolid, LORazepam, magnesium sulfate, mannitol, mechlorethamine, melphalan, meperidine, meropenem, mesna, metaraminol, methotrexate, methyldopate, methylPREDNISolone, metoclopramide, metoprolol, midazolam, milrinone, mitoXANtrone, morphine, nafcillin, nalbuphine, naloxone, nesiritide, niCARdipine, nitroglycerin, nitroprusside, norepinephrine, octreotide, ondansetron, oxaliplatin, oxytocin, PACLitaxel, palonosetron, pancuronium, pentamidine, pentazocine, PENTobarbital, perphenazine, PHENobarbital, phentolamine, phenylephrine, piperacillin/tazobactam, potassium chloride/phosphates, prochlorperazine, promethazine, propranolol, ranitidine, remifentanil, riTUXimab, rocuronium, sargramostim, sodium acetate/bicarbonate/phosphates, streptozocin, succinylcholine, SUFentanil, tacrolimus, teniposide, theophylline, thiopental, thiotepa, ticarcillin/clavulanate, tigecycline, tirofiban, tobramycin, trastuzumab, trimethobenzamide, trimethoprim/sulfamethoxazole, vancomycin, vasopressin, vecuronium, verapamil, vinCRIStine, vinorelbine, voriconazole, zidovudine, zoledronic acid</para>
						</section>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x11169">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x11172">
					<section type="none" id="sidelem4x11173">
						<sec_title>CNS:</sec_title>
						<para> <emphasis style="italic">Headache, dizziness,</emphasis> confusion, irritability, restlessness, ataxia, depression, fatigue, drowsiness, insomnia, paresthesia, peripheral neuropathy, <emphasis style="bold">seizures,</emphasis> incoordination, depression, encephalopathy, <emphasis style="bold">aseptic meningitis</emphasis></para>
					</section>
					<section type="none" id="sidelem4x11186">
						<sec_title>CV:</sec_title>
						<para> Flattening of <emphasis style="sans-serif">T</emphasis> waves</para>
					</section>
					<section type="none" id="sidelem4x11194">
						<sec_title>EENT:</sec_title>
						<para> Blurred vision, sore throat, retinal edema, dry mouth, metallic taste, furry tongue, glossitis, stomatitis, photophobia, optic neuritis</para>
					</section>
					<section type="none" id="sidelem4x11199">
						<sec_title>GI:</sec_title>
						<para> <emphasis style="italic">Nausea, vomiting, diarrhea,</emphasis> epigastric distress, <emphasis style="italic">anorexia,</emphasis> constipation, <emphasis style="italic">abdominal cramps,</emphasis><emphasis style="bold">pseudomembranous colitis,</emphasis> xerostomia, metallic taste, abdominal pain, <emphasis style="bold">pancreatitis</emphasis></para>
					</section>
					<section type="none" id="sidelem4x11217">
						<sec_title>GU:</sec_title>
						<para> Darkened urine, vaginal dryness, polyuria, <emphasis style="bold">albuminuria,</emphasis> dysuria, cystitis, decreased libido, <emphasis style="bold">nephrotoxicity,</emphasis> incontinence, dyspareunia, candidiasis, increased urinary frequency</para>
					</section>
					<section type="none" id="sidelem4x11228">
						<sec_title>HEMA:</sec_title>
						<para> <emphasis style="bold">Leukopenia, bone marrow, depression, aplasia, thrombocytopenia</emphasis></para>
					</section>
					<section type="none" id="sidelem4x11235">
						<sec_title>INTEG:</sec_title>
						<para> Rash, pruritus, urticaria, flushing, <emphasis style="bold">Stevens-Johnson syndrome, phlebitis at injection site, toxic epidermal necrolysis</emphasis></para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x11242">
				<sec_title>Pharmacokinetics</sec_title>
				<para>Crosses placenta, enters breast milk, metabolized by liver 30%-60%, excreted in urine (60%-80%), half-life 6-8 hr</para>
				<section type="none" id="sidelem4x11247">
					<section type="none" id="sidelem4x11248">
						<sec_title>PO:</sec_title>
						<para> Peak 2 hr, absorbed 80%-85%</para>
					</section>
					<section type="none" id="sidelem4x11253">
						<sec_title>IV:</sec_title>
						<para> Onset immediate, peak end of infusion</para>
					</section>
				</section>
			</section>
			<section type="interactions" id="sidelem4x11258">
				<sec_title>Interactions</sec_title>
				<para>
					<list id="lidelem4x11263">
						<item>
							<label>•</label>
							<para>Avoid use with zalcitabine, bortezomib, norfloxacin, disulfiram</para>
						</item>
					</list>
				</para>
				<section type="none" id="sidelem4x11271">
					<label>•</label>
					<sec_title>
						<route>Do not use with amprenavir</route>
					</sec_title>
				</section>
				<para>
					<emphasis style="bold">Decrease:</emphasis> metroNIDAZOLE half-life—barbiturates</para>
				<para>
					<emphasis style="bold">Decrease:</emphasis> metroNIDAZOLE—cholestyramine</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> disulfiram reaction—alcohol, oral ritonavir, any product with alcohol</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> busulfan toxicity—busulfan; avoid concurrent use</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> metroNIDAZOLE level, toxicity—cimetidine</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> lithium, CYP3A4 substrates</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> action of warfarin, phenytoin, lithium, fosphenytoin</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> leukopenia—azaTHIOprine, fluorouracil</para>
				<section type="none" id="sidelem4x11306">
					<section type="none" id="sidelem4x11307">
						<sec_title>Drug/Lab Test</sec_title>
						<para>
							<emphasis style="bold">Altered:</emphasis> AST, ALT, LDH</para>
						<para>
							<emphasis style="bold">Decrease:</emphasis> WBC, neutrophils</para>
						<para>
							<emphasis style="bold">False decrease:</emphasis> triglycerides</para>
					</section>
				</section>
			</section>
			<section type="considerations" id="sidelem4x11322">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x11325">
					<section type="none" id="sidelem4x11326">
						<sec_title>Assess:</sec_title>
						<section type="none" id="sidelem4x11334">
							<label>•</label>
							<sec_title>Infection</sec_title>
							<para>
								<list id="lidelem4x11334">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Infection:</emphasis> WBC, wound symptoms, fever, skin or vaginal secretions; start treatment after C&amp;S; for opportunistic fungal infections; superinfection: fever, monilial growth, fatigue, malaise</para>
									</item>
								</list>
							</para>
						</section>
						<para>
							<list id="lidelem4x11338">
								<item>
									<label>•</label>
									<para>Stools during entire treatment; should be clear at end of therapy; stools should be free of parasites for 1 yr before patient considered cured (amebiasis)</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x11343">
								<item>
									<label>•</label>
									<para>Vision by ophthalmic exam during, after therapy; vision problems often occur</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x11349">
								<item>
									<para>
										<emphasis alert="nurse">Neurotoxicity: peripheral neuropathy, seizures, dizziness, uncoordination, pruritus, joint pain; product may be discontinued</emphasis>
									</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x11357">
							<label>•</label>
							<sec_title>Allergic reaction</sec_title>
							<para>
								<list id="lidelem4x11357">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Allergic reaction:</emphasis> fever, rash, itching, chills; product should be discontinued if these occur</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x11364">
							<para>
								<list id="lidelem4x11364">
									<item>
										<label>•</label>
										<para>Renal, reproductive dysfunction: dysuria, polyuria, impotence, dyspareunia, decreased libido, I&amp;O; weight daily
<bbw>
												<emphasis alert="lifethreat">Secondary malignancy:</emphasis> use only when indicated; avoid unnecessary use</bbw>
</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x11377">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x11381">
								<item>
									<label>•</label>
									<para>Therapeutic response: decreased symptoms of infection</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x11387">
						<sec_title>Teach patient/family:</sec_title>
						<para>
							<list id="lidelem4x11391">
								<item>
									<label>•</label>
									<para>That urine may turn dark reddish brown; that product may cause metallic taste</para>
								</item>
								<item>
									<label>•</label>
									<para>About proper hygiene after bowel movement; handwashing technique</para>
								</item>
								<item>
									<label>•</label>
									<para>To notify physician about numbness or tingling of extremities</para>
								</item>
								<item>
									<label>•</label>
									<para>To avoid hazardous activities because dizziness can occur</para>
								</item>
								<item>
									<label>•</label>
									<para>About need for compliance with dosage schedule, duration of treatment</para>
								</item>
								<item>
									<label>•</label>
									<para>To use condoms if treatment for trichomoniasis or cross-contamination may occur; to notify prescriber if pregnant or planning to become pregnant; that treatment of both partners is necessary for trichomoniasis</para>
								</item>
								<item>
									<label>•</label>
									<para>To use frequent sips of water, sugarless gum, candy for dry mouth</para>
								</item>
								<item>
									<label>•</label>
									<para>Not to drink alcohol or use preparations containing alcohol during use or for 48 hr after use of product; disulfiram-like reaction can occur</para>
								</item>
								<item>
									<label>•</label>
									<para>To notify if pregnancy is planned or suspected, pregnancy (B) 2nd/3rd trimester in trichomoniasis</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
		</monograph>
<monograph id="29" status="active">
			<mono_name>metroNIDAZOLE (topical, vaginal)</mono_name>
			<info>
				<pronunciation>(met-roe-ni′da-zole)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x114437">MetroCream</tradename>
					<tradename id="tnidelem4x114436">MetroGel</tradename>
					<tradename id="tnidelem4x114435">MetroGel Vaginal</tradename>
					<tradename id="tnidelem4x114434">MetroLotion</tradename>
					<tradename id="tnidelem4x114433">Noritate</tradename>
					<tradename id="tnidelem4x114432">
						<country code="CAN">Rosasol</country>
					</tradename>
					<tradename id="tnidelem4x114431">Rosadan</tradename>
					<tradename id="tnidelem4x114430">Vandazole</tradename>
				</tradenames>
				<class type="func"> Antiprotozoal, antibacterial</class>
				<class type="chem"> Nitroimidazole</class>
			</info>
			<section type="actions" id="sidelem4x11456">
				<sec_title>Action:</sec_title>
				<para>Antibacterial and antiprotozoal activity may result from interacting with DNA</para>
			</section>
			<section type="uses" id="sidelem4x11461">
				<sec_title>Uses:</sec_title>
				<para>Acne rosacea, bacterial vaginosis</para>
			</section>
			<section type="contra" id="sidelem4x11466">
				<sec_title>Contraindications:</sec_title>
				<para>Hypersensitivity to this product or nitroimidazoles, parabens</para>
				<section type="none" id="sidelem4x11471">
					<section type="none" id="sidelem4x11472">
						<sec_title>Precautions:</sec_title>
						<para> Hepatic disease, blood dyscrasias; CNS conditions (vaginal), children</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x11477">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x11480">
					<section type="none" id="sidelem4x11481">
						<sec_title>Acne rosacea</sec_title>
						<section type="none" id="sidelem4x11489">
							<label>•</label>
							<sec_title>Adult<route> TOP</route></sec_title>
							<para>
								<list id="lidelem4x11489">
									<item>
										<label>•</label>
										<para> apply to affected areas bid (0.75%) daily (1%); adjust therapy based on response</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x11493">
						<sec_title>Bacterial vaginosis</sec_title>
						<section type="none" id="sidelem4x11501">
							<label>•</label>
							<sec_title>Adult<route> VAG</route></sec_title>
							<para>
								<list id="lidelem4x11501">
									<item>
										<label>•</label>
										<para> 1 applicatorful daily × 5 days</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x11505">
						<sec_title>Available forms:</sec_title>
						<para> Topical cream 0.75%, 1%; gel 0.75%, 1%; lotion 0.75%; vaginal gel 0.75%</para>
					</section>
					<section type="none" id="sidelem4x11510">
						<sec_title>Administer:</sec_title>
						<section type="none" id="sidelem4x11513">
							<sec_title>Topical route</sec_title>
							<para>
								<list id="lidelem4x11518">
									<item>
										<label>•</label>
										<para>Topical skin products are not for intravaginal therapy and are for external use only; do not use skin products near the eyes, nose, or mouth</para>
									</item>
								</list>
							</para>
							<para>
								<list id="lidelem4x11523">
									<item>
										<label>•</label>
										<para>Wash hands before and after use; wash affected area and gently pat dry</para>
									</item>
								</list>
							</para>
							<section type="none" id="sidelem4x11531">
								<label>•</label>
								<sec_title>Cream/Gel/Lotion</sec_title>
								<para>
									<list id="lidelem4x11531">
										<item>
											<label>•</label>
											<para>
												<emphasis style="bold">Cream/Gel/Lotion:</emphasis> Apply a thin film to the cleansed affected area; massage gently into affected areas</para>
										</item>
									</list>
								</para>
							</section>
						</section>
						<section type="none" id="sidelem4x11535">
							<sec_title>Intravaginal route</sec_title>
							<para>
								<list id="lidelem4x11540">
									<item>
										<label>•</label>
										<para>Only use dosage formulations specified for intravaginal use; intravaginal dosage forms are not for topical therapy; do not ingest</para>
									</item>
								</list>
							</para>
							<para>
								<list id="lidelem4x11545">
									<item>
										<label>•</label>
										<para>Avoid vaginal intercourse during treatment</para>
									</item>
								</list>
							</para>
							<section type="none" id="sidelem4x11553">
								<label>•</label>
								<sec_title>Cream</sec_title>
								<para>
									<list id="lidelem4x11553">
										<item>
											<label>•</label>
											<para>
												<emphasis style="bold">Cream:</emphasis> Use applicator(s) supplied by the manufacturer</para>
										</item>
									</list>
								</para>
							</section>
						</section>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x11557">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x11560">
					<section type="none" id="sidelem4x11561">
						<sec_title>GU:</sec_title>
						<para> Vaginitis, cervicitis; nausea, vomiting, cramping</para>
					</section>
					<section type="none" id="sidelem4x11566">
						<sec_title>INTEG:</sec_title>
						<para> Redness, burning, dermatitis, rash, pruritus</para>
					</section>
				</section>
			</section>
			<section type="interactions" id="sidelem4x11571">
				<sec_title>Interactions</sec_title>
				<para>
					<list id="lidelem4x11575">
						<item>
							<label>•</label>
							<para>MetroNIDAZOLE may increase warfarin anticoagulant effect</para>
						</item>
						<item>
							<label>•</label>
							<para>Caution with drinking alcohol or using disulfiram while using metroNIDAZOLE products(vaginal gel)</para>
						</item>
						<item>
							<label>•</label>
							<para>Possible lithium toxicity (vaginal gel)</para>
						</item>
					</list>
				</para>
			</section>
			<section type="considerations" id="sidelem4x11591">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x11594">
					<section type="none" id="sidelem4x11595">
						<sec_title>Assess:</sec_title>
						<section type="none" id="sidelem4x11603">
							<label>•</label>
							<sec_title>Allergic reaction</sec_title>
							<para>
								<list id="lidelem4x11603">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Allergic reaction:</emphasis> assess for hypersensitivity; product may need to be discontinued</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x11610">
							<label>•</label>
							<sec_title>Infection</sec_title>
							<para>
								<list id="lidelem4x11610">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Infection:</emphasis> assess for number of lesions and severity of acne rosacea, itching in vaginosis</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x11614">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x11618">
								<item>
									<label>•</label>
									<para>Decreased severity of acne rosacea, infection in vaginosis</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x11625">
						<sec_title>Teach patient/family:</sec_title>
						<para>
							<list id="lidelem4x11630">
								<item>
									<label>•</label>
									<para>That topical skin products are not for intravaginal therapy and are for external use only; not to use skin products near the eyes, nose, or mouth</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x11635">
								<item>
									<label>•</label>
									<para>To wash hands before and after use; to wash affected area and gently pat dry</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x11643">
							<label>•</label>
							<sec_title>Cream/Gel/Lotion</sec_title>
							<para>
								<list id="lidelem4x11643">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Cream/Gel/Lotion:</emphasis> to apply a thin film to the cleansed affected area and massage gently into affected areas</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x11650">
							<label>•</label>
							<sec_title>Intravaginal route</sec_title>
							<para>
								<list id="lidelem4x11650">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Intravaginal route:</emphasis> to use only dosage formulations specified for intravaginal use; not to ingest intravaginal dosage forms because these are not for topical therapy; to avoid vaginal intercourse during treatment</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x11657">
							<label>•</label>
							<sec_title>Cream</sec_title>
							<para>
								<list id="lidelem4x11657">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Cream:</emphasis> to use applicator(s) supplied by the manufacturer</para>
									</item>
								</list>
							</para>
						</section>
					</section>
				</section>
			</section>
		</monograph>
<monograph id="30" status="active">
			<mono_name>micafungin (Rx)</mono_name>
			<info>
				<pronunciation>(my-ca-fun′gin)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x116660">Mycamine</tradename>
				</tradenames>
				<class type="func"> Antifungal, systemic</class>
				<class type="chem"> Echinocandin</class>
				<class type="preg">Pregnancy category <preg cat="C">C</preg></class>
			</info>
			<section type="actions" id="sidelem4x11676">
				<sec_title>Action:</sec_title>
				<para>Inhibits an essential component of fungal cell walls; causes direct damage to fungal cell wall</para>
			</section>
			<section type="uses" id="sidelem4x11681">
				<sec_title>Uses:</sec_title>
				<para>Treatment of esophageal candidiasis; prophylaxis for <emphasis style="italic">Candida</emphasis> infections in patients undergoing hematopoietic stem-cell transplantation (HSCT); susceptible <emphasis style="italic">Candida</emphasis> sp.: <emphasis style="italic">C. albicans, C. glabrata, C. krusei, C. parapsilosis, C. tropicalis</emphasis></para>
				<section type="none" id="sidelem4x11694">
					<section type="none" id="sidelem4x11695">
						<sec_title>Unlabeled uses:</sec_title>
						<para> <emphasis style="italic">Aspergillus</emphasis> sp., pediatrics to prevent candidiasis, endocarditis, endophthalmitis, infectious arthritis, myocarditis, osteomyelitis, pericarditis, pneumonia, sinusitis, tracheobronchitis, prophylaxis of HIV-related esophageal candidiasis</para>
					</section>
				</section>
			</section>
			<section type="contra" id="sidelem4x11703">
				<sec_title>Contraindications:</sec_title>
				<para>Hypersensitivity to this product or other echinocandins</para>
				<section type="none" id="sidelem4x11708">
					<section type="none" id="sidelem4x11709">
						<sec_title>Precautions:</sec_title>
						<para> Pregnancy (<preg cat="C">C</preg>), breastfeeding, children, geriatric patients, severe hepatic disease, renal impairment, hemolytic anemia</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x11714">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x11717">
					<section type="none" id="sidelem4x11718">
						<sec_title>Esophageal candidiasis</sec_title>
						<section type="none" id="sidelem4x11726">
							<label>•</label>
							<sec_title>Adult<route> IV INFUSION</route></sec_title>
							<para>
								<list id="lidelem4x11726">
									<item>
										<label>•</label>
										<para> 150 mg/day given over 1 hr</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x11730">
						<sec_title>Candidemia/acute disseminated candidiasis, abscess/peritonitis</sec_title>
						<section type="none" id="sidelem4x11738">
							<label>•</label>
							<sec_title>Adult<route> IV</route></sec_title>
							<para>
								<list id="lidelem4x11738">
									<item>
										<label>•</label>
										<para> 100 mg/day over 1 hr</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x11742">
						<sec_title>Prophylaxis for <emphasis style="bold">
								<emphasis style="italic">Candida</emphasis>
							</emphasis> infections</sec_title>
						<section type="none" id="sidelem4x11754">
							<label>•</label>
							<sec_title>Adult<route> IV INFUSION</route></sec_title>
							<para>
								<list id="lidelem4x11754">
									<item>
										<label>•</label>
										<para> 50 mg/day given over 1 hr</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x11761">
							<label>•</label>
							<sec_title>Adolescent/child/infant ≥6 mo (unlabeled)<route> IV INFUSION</route></sec_title>
							<para>
								<list id="lidelem4x11761">
									<item>
										<label>•</label>
										<para> 1 mg/kg/day, max 50 mg/day</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x11765">
						<sec_title>
							<emphasis style="bold">
								<emphasis style="italic">Aspergillus</emphasis>
							</emphasis> sp. (unlabeled)</sec_title>
						<section type="none" id="sidelem4x11776">
							<label>•</label>
							<sec_title>Adult<route> IV INFUSION</route></sec_title>
							<para>
								<list id="lidelem4x11776">
									<item>
										<label>•</label>
										<para> 100-150 mg/day × ≥30 days</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x11780">
						<sec_title>Available forms:</sec_title>
						<para> Powder for inj 50 mg, in single-dose vials 50-, 100-mg vial</para>
					</section>
					<section type="none" id="sidelem4x11785">
						<sec_title>Administer:</sec_title>
						<para>
							<list id="lidelem4x11789">
								<item>
									<label>•</label>
									<para>Do not use if cloudy or precipitated; do not admix; by IV infusion only; product diluted, solution protected from light</para>
								</item>
								<item>
									<label>•</label>
									<para>Store at room temperature, away from light, do not freeze; discard unused sol</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x11800">
							<sec_title>IV route</sec_title>
							<para>
								<list id="lidelem4x11805">
									<item>
										<label>•</label>
										<para>Flush line before and after use with 0.9% NaCl</para>
									</item>
								</list>
							</para>
							<section type="none" id="sidelem4x11813">
								<label>•</label>
								<sec_title>For Candida prevention</sec_title>
								<para>
									<list id="lidelem4x11813">
										<item>
											<label>•</label>
											<para>
												<emphasis style="bold">For <emphasis style="italic">Candida</emphasis> prevention:</emphasis> reconstitute with provided diluent 0.9% NaCl without bacteriostatic product; 50-mg vial/5 ml (10 mg/ml), swirl to dissolve, do not shake; further dilute with 100 ml 0.9% NaCl only; run over 1 hr</para>
										</item>
									</list>
								</para>
							</section>
							<section type="none" id="sidelem4x11823">
								<label>•</label>
								<sec_title>For Candida infection</sec_title>
								<para>
									<list id="lidelem4x11823">
										<item>
											<label>•</label>
											<para>
												<emphasis style="bold">For <emphasis style="italic">Candida</emphasis> infection:</emphasis> reconstitute with provided diluent 50 mg/5 ml (10 mg/ml); further dilute 3 reconstituted vials in 100 ml 0.9% NaCl, run over 1 hr</para>
										</item>
									</list>
								</para>
							</section>
							<para>
								<emphasis style="bold">Y-site compatibilities:</emphasis> Aminophylline, bumetanide, calcium chloride/gluconate, cycloSPORINE, DOPamine, eptifibatide, esmolol, fenoldopam, furosemide, heparin, HYDROmorphone, lidocaine, LORazepam, magnesium sulfate, milrinone, nitroglycerin, nitroprusside, norepinephrine, phenylephrine, potassium chloride, potassium phosphate, tacrolimus, vasopressin</para>
						</section>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x11835">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x11838">
					<section type="none" id="sidelem4x11839">
						<sec_title>CNS:</sec_title>
						<para> <emphasis style="bold">Seizures,</emphasis> dizziness, <emphasis style="italic">headache, somnolence,</emphasis> fever, anxiety</para>
					</section>
					<section type="none" id="sidelem4x11850">
						<sec_title>CV:</sec_title>
						<para> Flushing, hypertension, phlebitis, tachycardia, <emphasis style="bold">atrial fibrillation</emphasis></para>
					</section>
					<section type="none" id="sidelem4x11857">
						<sec_title>GI:</sec_title>
						<para> Abdominal pain, <emphasis style="italic">nausea, anorexia, vomiting, diarrhea, hyperbilirubinemia,</emphasis><emphasis style="bold">hepatitis</emphasis></para>
					</section>
					<section type="none" id="sidelem4x11866">
						<sec_title>GU:</sec_title>
						<para> <emphasis style="bold">Renal failure</emphasis></para>
					</section>
					<section type="none" id="sidelem4x11873">
						<sec_title>HEMA:</sec_title>
						<para> <emphasis style="bold">Neutropenia, thrombocytopenia, leukopenia, coagulopathy, anemia, hemolytic anemia</emphasis></para>
					</section>
					<section type="none" id="sidelem4x11880">
						<sec_title>INTEG:</sec_title>
						<para> <emphasis style="italic">Rash, pruritus, inj-site pain</emphasis></para>
					</section>
					<section type="none" id="sidelem4x11887">
						<sec_title>META:</sec_title>
						<para> Hypokalemia, hypocalcemia, hypomagnesemia</para>
					</section>
					<section type="none" id="sidelem4x11892">
						<sec_title>MS:</sec_title>
						<para> <emphasis style="italic">Rigors</emphasis></para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x11899">
				<sec_title>Pharmacokinetics</sec_title>
				<para>Metabolized in liver; excreted in feces, urine; terminal half-life 14-17.2 hr; protein binding 99%</para>
			</section>
			<section type="interactions" id="sidelem4x11904">
				<sec_title>Interactions</sec_title>
				<para>
					<emphasis style="bold">Increase:</emphasis> plasma concentrations—itraconazole, sirolimus, NIFEdipine; may need dosage reduction</para>
				<section type="none" id="sidelem4x11911">
					<section type="none" id="sidelem4x11912">
						<sec_title>Drug/Lab Test</sec_title>
						<para>
							<emphasis style="bold">Increase:</emphasis> ALT/AST, alk phos, bilirubin, potassium, sodium</para>
						<para>
							<emphasis style="bold">Decrease:</emphasis> blood glucose</para>
					</section>
				</section>
			</section>
			<section type="considerations" id="sidelem4x11923">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x11926">
					<section type="none" id="sidelem4x11927">
						<sec_title>Assess:</sec_title>
						<section type="none" id="sidelem4x11935">
							<label>•</label>
							<sec_title>
								<route>Infection,</route>
							</sec_title>
							<para>
								<list id="lidelem4x11935">
									<item>
										<label>•</label>
										<para> clearing of cultures during treatment; obtain culture at baseline and during treatment; product may be started as soon as culture is taken (esophageal candidiasis); monitor cultures during HSCT for prevention of <emphasis style="italic">Candida</emphasis> infections</para>
									</item>
								</list>
							</para>
						</section>
						<para>
							<list id="lidelem4x11942">
								<item>
									<label>•</label>
									<para>CBC (RBC, Hct, Hgb), differential, platelet count periodically; notify prescriber of results</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x11947">
								<item>
									<label>•</label>
									<para>Renal studies: BUN, urine CCr, electrolytes before and during therapy</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x11952">
								<item>
									<label>•</label>
									<para>Hepatic studies before and during treatment: bilirubin, AST, ALT, alk phos as needed</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x11960">
							<label>•</label>
							<sec_title>Bleeding</sec_title>
							<para>
								<list id="lidelem4x11960">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Bleeding:</emphasis> hematuria, heme-positive stools, bruising, or petechiae, mucosa or orifices; blood dyscrasias can occur</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x11967">
							<label>•</label>
							<sec_title>For hypersensitivity</sec_title>
							<para>
								<list id="lidelem4x11967">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">For hypersensitivity:</emphasis> rash, pruritus, facial swelling, phlebitis</para>
									</item>
								</list>
							</para>
						</section>
						<para>
							<list id="lidelem4x11971">
								<item>
									<label>•</label>
									<para>For hemolytic anemia</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x11979">
							<label>•</label>
							<sec_title>GI symptoms</sec_title>
							<para>
								<list id="lidelem4x11979">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">GI symptoms:</emphasis> frequency of stools, cramping; if severe diarrhea occurs, electrolytes may need to be given</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x11983">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x11987">
								<item>
									<label>•</label>
									<para>Therapeutic response: prevention of <emphasis style="italic">Candida</emphasis> infection with HSCT or decreased symptoms of <emphasis style="italic">Candida</emphasis> infection, negative culture</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x11999">
						<sec_title>Teach patient/family:</sec_title>
						<para>
							<list id="lidelem4x12003">
								<item>
									<label>•</label>
									<para>To notify prescriber if pregnancy is suspected or planned</para>
								</item>
								<item>
									<label>•</label>
									<para>To avoid breastfeeding while taking this product</para>
								</item>
								<item>
									<label>•</label>
									<para>To inform prescriber of kidney or liver disease</para>
								</item>
								<item>
									<label>•</label>
									<para>To report bleeding, facial swelling, wheezing, difficulty breathing, itching, rash, hives, increasing warmth, flushing</para>
								</item>
								<item>
									<label>•</label>
									<para>To report signs of infection: increased temperature, sore throat, flulike symptoms</para>
								</item>
								<item>
									<label>•</label>
									<para>To notify prescriber of nausea, vomiting, diarrhea, jaundice, anorexia, clay-colored stools, dark urine; heptatotoxicity may occur</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
		</monograph>
<monograph id="31" status="active">
			<mono_name>miconazole</mono_name>
			<info>
				<pronunciation>(mi-kon′a-zole)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x120390">Oravig</tradename>
				</tradenames>
			</info>
		</monograph>
<monograph id="32" status="active">
			<mono_name>miconazole nitrate</mono_name>
			<info>
				<tradenames>
					<tradename id="tnidelem4x1204410">Desenex</tradename>
					<tradename id="tnidelem4x120449">Femizol-M</tradename>
					<tradename id="tnidelem4x120448">Fungoid</tradename>
					<tradename id="tnidelem4x120447">Lotrimin AF</tradename>
					<tradename id="tnidelem4x120446">Micatin</tradename>
					<tradename id="tnidelem4x120445">
						<country code="CAN">Micozole</country>
					</tradename>
					<tradename id="tnidelem4x120444">Monistat-1</tradename>
					<tradename id="tnidelem4x120443">Monistat-3</tradename>
					<tradename id="tnidelem4x120442">Monistat-7</tradename>
					<tradename id="tnidelem4x120441">M-Zole 3</tradename>
					<tradename id="tnidelem4x120440">Vagistat-3</tradename>
				</tradenames>
				<class type="func"> Antifungal</class>
				<class type="chem"> Imidazole</class>
			</info>
			<section type="confusion" id="sidelem4x12057">
				<para>
					<confusion>
						<tradename id="tnidelem4x120570">miconazole</tradename>
						<drug type="generic" refid="idelem4x120570">clotrimazole/metroNIDAZOLE</drug>
					</confusion>
				</para>
			</section>
			<section type="actions" id="sidelem4x12061">
				<sec_title>Action:</sec_title>
				<para>Antifungal activity results from disruption of cell membrane permeability</para>
			</section>
			<section type="uses" id="sidelem4x12067">
				<sec_title>Uses:</sec_title>
				<para>Treatment of topical fungal infection, vulvovaginal candidiasis; athlete’s foot (tinea pedis), jock itch (tinea cruris), and ringworm (tinea corporis)</para>
			</section>
			<section type="contra" id="sidelem4x12072">
				<sec_title>Contraindications:</sec_title>
				<para>Hypersensitivity to this product or imidazoles; pregnancy first trimester (vaginal)</para>
				<section type="none" id="sidelem4x12077">
					<section type="none" id="sidelem4x12078">
						<sec_title>Precautions:</sec_title>
						<para> Breastfeeding, children</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x12083">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x12086">
					<section type="none" id="sidelem4x12087">
						<sec_title>Oropharyngeal candidiasis (thrush)</sec_title>
						<section type="none" id="sidelem4x12095">
							<label>•</label>
							<sec_title>Adult/adolescent ≥16 yr<route> BUCCAL</route></sec_title>
							<para>
								<list id="lidelem4x12095">
									<item>
										<label>•</label>
										<para> apply 1 tab (50 mg) to upper gum region, just above incisor daily × 14 days</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x12099">
						<sec_title>Tinea corporis, cruris, pedis; cutaneous candidiasis</sec_title>
						<section type="none" id="sidelem4x12107">
							<label>•</label>
							<sec_title>Adult/child &gt;2 yr<route> TOP</route></sec_title>
							<para>
								<list id="lidelem4x12107">
									<item>
										<label>•</label>
										<para> apply bid × 2-4 wk</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x12111">
						<sec_title>Tinea versicolor</sec_title>
						<section type="none" id="sidelem4x12119">
							<label>•</label>
							<sec_title>Adult/child &gt;2 yr<route> TOP</route></sec_title>
							<para>
								<list id="lidelem4x12119">
									<item>
										<label>•</label>
										<para> use bid × 2 wk, apply sparingly every day</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x12123">
						<sec_title>Vulvovaginal candidiasis</sec_title>
						<section type="none" id="sidelem4x12131">
							<label>•</label>
							<sec_title>Adult/child ≥12 yr<route> VAG</route></sec_title>
							<para>
								<list id="lidelem4x12131">
									<item>
										<label>•</label>
										<para> 1 applicatorful of Monistat-7 (100 mg) or 1 supp (100 mg) at bedtime × 7 days, repeat if needed, or Monistat-3 (200 mg) × 3 days or a 1200 mg supp × 1 day</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x12135">
						<sec_title>Available forms:</sec_title>
						<para> Topical cream, ointment, solution, lotion, powder, aerosol, powder 2%; aerosol spray 2%; vag cream 2, 4%; vag supp 100, 200, 1200 mg; buccal tab 50 mg</para>
					</section>
					<section type="none" id="sidelem4x12140">
						<sec_title>Administer:</sec_title>
						<section type="none" id="sidelem4x12143">
							<sec_title>Transmucosal use (adhesive buccal tablet)</sec_title>
							<para>
								<list id="lidelem4x12147">
									<item>
										<label>•</label>
										<para>Apply tab in the morning after brushing the teeth, use dry hands</para>
									</item>
									<item>
										<label>•</label>
										<para>Place the rounded surface of the tab against the upper gum just above the incisor tooth, hold in place with slight pressure over the upper lip for 30 sec to assure adhesion</para>
									</item>
									<item>
										<label>•</label>
										<para>Although the tab is rounded on one side for comfort, the flat side may also be applied to the gum</para>
									</item>
									<item>
										<label>•</label>
										<para>The tab will gradually dissolve</para>
									</item>
									<item>
										<label>•</label>
										<para>Administration of subsequent tab should be made to alternate sides of the mouth</para>
									</item>
									<item>
										<label>•</label>
										<para>Before applying the next tab, clear away any remaining tab material</para>
									</item>
									<item>
										<label>•</label>
										<para>Do not crush, chew, or swallow; food and drink can be taken normally; avoid chewing gum</para>
									</item>
									<item>
										<label>•</label>
										<para>If tab does not adhere or falls off within the first 6 hr, the same tab should be repositioned immediately; if the tab still does not adhere, a new tab should be used</para>
									</item>
									<item>
										<label>•</label>
										<para>If the tab falls off or is swallowed after it was in place for 6 hr or more, a new tab should not be applied until the next regularly scheduled dose</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x12193">
							<sec_title>Topical route</sec_title>
							<para>
								<list id="lidelem4x12198">
									<item>
										<label>•</label>
										<para>Topical skin products are not for intravaginal therapy and are for external use only; do not use skin products near the eyes, nose, or mouth</para>
									</item>
								</list>
							</para>
							<para>
								<list id="lidelem4x12203">
									<item>
										<label>•</label>
										<para>Wash hands before and after use; wash affected area and gently pat dry</para>
									</item>
								</list>
							</para>
							<section type="none" id="sidelem4x12211">
								<label>•</label>
								<sec_title>Cream/ointment/lotion/solution</sec_title>
								<para>
									<list id="lidelem4x12211">
										<item>
											<label>•</label>
											<para>
												<emphasis style="bold">Cream/ointment/lotion/solution:</emphasis> apply a thin film to the cleansed affected area; massage gently into affected areas</para>
										</item>
									</list>
								</para>
							</section>
							<section type="none" id="sidelem4x12218">
								<label>•</label>
								<sec_title>Solution formulations</sec_title>
								<para>
									<list id="lidelem4x12218">
										<item>
											<label>•</label>
											<para>
												<emphasis style="bold">Solution formulations:</emphasis> apply a thin film to the cleansed affected area; massage gently into affected areas; if using a solution-soaked pledget, patient may use more than 1 pledget per application as needed to treat affected areas, but each pledget should be used only once and then discarded</para>
										</item>
									</list>
								</para>
							</section>
							<section type="none" id="sidelem4x12225">
								<label>•</label>
								<sec_title>Intravaginal route</sec_title>
								<para>
									<list id="lidelem4x12225">
										<item>
											<label>•</label>
											<para>
												<emphasis style="bold">Intravaginal route:</emphasis> only use dosage formulations specified for intravaginal use; intravaginal dosage forms are not for topical therapy; do not ingest</para>
										</item>
									</list>
								</para>
							</section>
							<section type="none" id="sidelem4x12232">
								<label>•</label>
								<sec_title>Suppository</sec_title>
								<para>
									<list id="lidelem4x12232">
										<item>
											<label>•</label>
											<para>
												<emphasis style="bold">Suppository:</emphasis> unwrap vaginal ovule (suppository) before insertion; use applicator(s) supplied by the manufacturer</para>
										</item>
									</list>
								</para>
							</section>
							<section type="none" id="sidelem4x12239">
								<label>•</label>
								<sec_title>Cream</sec_title>
								<para>
									<list id="lidelem4x12239">
										<item>
											<label>•</label>
											<para>
												<emphasis style="bold">Cream:</emphasis> use applicator(s) supplied by the manufacturer</para>
										</item>
									</list>
								</para>
							</section>
						</section>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x12243">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x12246">
					<section type="none" id="sidelem4x12247">
						<sec_title>CNS:</sec_title>
						<para> Headache</para>
					</section>
					<section type="none" id="sidelem4x12252">
						<sec_title>GI:</sec_title>
						<para> Diarrhea, nausea</para>
					</section>
					<section type="none" id="sidelem4x12257">
						<sec_title>GU:</sec_title>
						<para> Pruritus, irritation, vaginal burning</para>
					</section>
					<section type="none" id="sidelem4x12262">
						<sec_title>INTEG:</sec_title>
						<para> Burning, dermatitis, rash</para>
					</section>
				</section>
			</section>
			<section type="considerations" id="sidelem4x12267">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x12270">
					<section type="none" id="sidelem4x12271">
						<sec_title>Assess:</sec_title>
						<section type="none" id="sidelem4x12274">
							<sec_title>Allergic reaction:</sec_title>
							<para>
								<list id="lidelem4x12278">
									<item>
										<label>•</label>
										<para>Assess for hypersensitivity; product may need to be discontinued</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x12285">
							<sec_title>Infection:</sec_title>
							<para>
								<list id="lidelem4x12289">
									<item>
										<label>•</label>
										<para>Assess for severity of infection</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x12295">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x12299">
								<item>
									<label>•</label>
									<para>Decreasing severity of infection</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x12305">
						<sec_title>Teach patient/family:</sec_title>
						<section type="none" id="sidelem4x12308">
							<sec_title>Topical route</sec_title>
							<para>
								<list id="lidelem4x12313">
									<item>
										<label>•</label>
										<para>That topical skin products are not for intravaginal therapy and are for external use only; not to use skin products near the eyes, nose, or mouth</para>
									</item>
								</list>
							</para>
							<para>
								<list id="lidelem4x12318">
									<item>
										<label>•</label>
										<para>To wash hands before and after use; wash affected area and gently pat dry</para>
									</item>
								</list>
							</para>
							<section type="none" id="sidelem4x12326">
								<label>•</label>
								<sec_title>Cream/ointment/lotion/solution</sec_title>
								<para>
									<list id="lidelem4x12326">
										<item>
											<label>•</label>
											<para>
												<emphasis style="bold">Cream/ointment/lotion/solution:</emphasis> to apply a thin film to the cleansed affected area and massage gently into affected areas</para>
										</item>
									</list>
								</para>
							</section>
							<section type="none" id="sidelem4x12333">
								<label>•</label>
								<sec_title>Solution formulations</sec_title>
								<para>
									<list id="lidelem4x12333">
										<item>
											<label>•</label>
											<para>
												<emphasis style="bold">Solution formulations:</emphasis> to shake well before use, apply a thin film to the cleansed affected area, and massage gently into affected areas</para>
										</item>
									</list>
								</para>
							</section>
						</section>
						<section type="none" id="sidelem4x12337">
							<sec_title>Intravaginal route</sec_title>
							<para>
								<list id="lidelem4x12342">
									<item>
										<label>•</label>
										<para>To only use dosage formulations specified for intravaginal use; not to ingest intravaginal dosage forms; not to use tampons, douches, spermicides; not to engage in sexual activity; product may damage condoms, diaphragms, cervical caps</para>
									</item>
								</list>
							</para>
							<section type="none" id="sidelem4x12350">
								<label>•</label>
								<sec_title>Suppository</sec_title>
								<para>
									<list id="lidelem4x12350">
										<item>
											<label>•</label>
											<para>
												<emphasis style="bold">Suppository:</emphasis> to unwrap vaginal ovule (suppository) before inserting; to use applicator(s) supplied by the manufacturer</para>
										</item>
									</list>
								</para>
							</section>
							<section type="none" id="sidelem4x12357">
								<label>•</label>
								<sec_title>Cream</sec_title>
								<para>
									<list id="lidelem4x12357">
										<item>
											<label>•</label>
											<para>
												<emphasis style="bold">Cream:</emphasis> to use applicator(s) supplied by the manufacturer</para>
										</item>
									</list>
								</para>
							</section>
						</section>
					</section>
				</section>
			</section>
		</monograph>
<monograph id="33" status="active" ha="yes">
			<mono_name> midazolam (Rx)</mono_name>
			<info>
				<pronunciation>(mid′ay-zoe-lam)</pronunciation>
				<class type="func"> Sedative, hypnotic, antianxiety</class>
				<class type="chem"> Benzodiazepine, short-acting</class>
				<class type="preg">Pregnancy category <preg cat="D">D</preg></class>
				<class type="schedule">Controlled Substance Schedule <schedule num="4">IV</schedule></class>
			</info>
			<section type="actions" id="sidelem4x12378">
				<sec_title>Action:</sec_title>
				<para>Depresses subcortical levels in CNS; may act on limbic system, reticular formation; may potentiate γ-aminobutyric acid (GABA) by binding to specific benzodiazepine receptors</para>
			</section>
			<section type="uses" id="sidelem4x12383">
				<sec_title>Uses:</sec_title>
				<para>Preoperative sedation, general anesthesia induction, sedation for diagnostic endoscopic procedures, intubation, anxiety</para>
				<section type="none" id="sidelem4x12388">
					<section type="none" id="sidelem4x12389">
						<sec_title>Unlabeled uses:</sec_title>
						<para> Refractory status epilepticus, alcohol withdrawal, agitation</para>
					</section>
				</section>
			</section>
			<section type="contra" id="sidelem4x12394">
				<sec_title>Contraindications:</sec_title>
				<para>Pregnancy (<preg cat="D">D</preg>), hypersensitivity to benzodiazepines, acute closed-angle glaucoma, epidural/intrathecal use</para>
				<section type="none" id="sidelem4x12399">
					<section type="none" id="sidelem4x12400">
						<sec_title>Precautions:</sec_title>
						<para> Breastfeeding, children, geriatric patients, COPD, CHF, chronic renal failure, chills, debilitated, hepatic disease, shock, coma, alcohol intoxication, status asthmaticus</para>
						<para>
							<bbw>Neonates (contains benzyl alcohol), IV administration, respiratory depression/insufficiency, specialized care setting, experienced clinician</bbw>
						</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x12415">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x12418">
					<section type="none" id="sidelem4x12419">
						<sec_title>Preoperative sedation/amnesia induction</sec_title>
						<section type="none" id="sidelem4x12427">
							<label>•</label>
							<sec_title>Adult and child ≥12 yr<route> IM</route></sec_title>
							<para>
								<list id="lidelem4x12427">
									<item>
										<label>•</label>
										<para> 0.07-0.08 mg/kg <emphasis style="sup">1</emphasis>/<emphasis style="inf">2</emphasis>-1 hr before general anesthesia</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x12440">
							<label>•</label>
							<sec_title>Child 6 yr-12 yr<route> IV</route></sec_title>
							<para>
								<list id="lidelem4x12440">
									<item>
										<label>•</label>
										<para> 0.025-0.05 mg/kg; total dose of 0.4 mg/kg may be necessary</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x12447">
							<label>•</label>
							<sec_title>Child 6 mo-5 yr<route> IV</route></sec_title>
							<para>
								<list id="lidelem4x12447">
									<item>
										<label>•</label>
										<para> 0.05-0.1 mg/kg; total dose of 0.6 mg/kg may be necessary</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x12451">
						<sec_title>Induction of general anesthesia</sec_title>
						<section type="none" id="sidelem4x12459">
							<label>•</label>
							<sec_title>Adult &gt;55 yr</sec_title>
							<para>
								<list id="lidelem4x12459">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Adult &gt;55 yr:</emphasis> (ASA I/II)  150-300 mcg/kg over 30 sec; (ASA III/IV) limit dose to 250 mcg/kg (nonpremedicated) or 150 mcg/kg (premedicated)</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x12469">
							<label>•</label>
							<sec_title>Adult &lt;55 yr<route> IV</route></sec_title>
							<para>
								<list id="lidelem4x12469">
									<item>
										<label>•</label>
										<para> 200-350 mcg/kg over 20-30 sec; if patient has not received premedication, may repeat by giving 20% of original dose; if patient has received premedication, reduce dose by 50 mcg/kg</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x12476">
							<label>•</label>
							<sec_title>Child</sec_title>
							<para>
								<list id="lidelem4x12476">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Child:</emphasis> no safe and effective dose established; however, doses of 50-200 mcg/kg  have been used</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x12483">
						<sec_title>Continuous infusion for mechanical ventilation (critical care)</sec_title>
						<section type="none" id="sidelem4x12491">
							<label>•</label>
							<sec_title>Adult<route> IV</route></sec_title>
							<para>
								<list id="lidelem4x12491">
									<item>
										<label>•</label>
										<para> 0.01-0.05 mg/kg over several min; repeat at 10- to 15-min intervals until adequate sedation, then 0.02-0.10 mg/kg/hr maintenance; adjust as needed</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x12499">
							<label>•</label>
							<sec_title>Child<route> IV</route></sec_title>
							<para>
								<list id="lidelem4x12499">
									<item>
										<label>•</label>
										<para> 0.05-0.2 mg/kg over 2-3 min then 0.06-0.12 mg/kg/hr by cont infusion; adjust as needed</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x12506">
							<label>•</label>
							<sec_title>Neonate<route> IV</route></sec_title>
							<para>
								<list id="lidelem4x12506">
									<item>
										<label>•</label>
										<para> 0.03 mg/kg/hr, titrate using lowest dose</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x12510">
						<sec_title>Status epilepticus (unlabeled)</sec_title>
						<section type="none" id="sidelem4x12518">
							<label>•</label>
							<sec_title>Child and infant &gt;2 mo<route> IV</route></sec_title>
							<para>
								<list id="lidelem4x12518">
									<item>
										<label>•</label>
										<para> 0.15 mg/kg then  1 mcg/kg/min, titrate upward q5min until seizures controlled</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x12525">
						<sec_title>Alcohol withdrawal (unlabeled)</sec_title>
						<section type="none" id="sidelem4x12533">
							<label>•</label>
							<sec_title>Adult<route> IV</route></sec_title>
							<para>
								<list id="lidelem4x12533">
									<item>
										<label>•</label>
										<para> 1-5 mg q1-2hr (mild-moderate symptoms);  1-20 mg q1-2hr (delirium tremens)</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x12540">
						<sec_title>Available forms:</sec_title>
						<para> Inj 1, 5 mg/ml, 25 mg/5 ml, 50 mg/10 ml; syr 2 mg/ml</para>
					</section>
					<section type="none" id="sidelem4x12545">
						<sec_title>Administer:</sec_title>
						<para>
							<list id="lidelem4x12549">
								<item>
									<label>•</label>
									<para>Store at room temperature; protect from light</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x12555">
							<sec_title>PO route</sec_title>
							<para>
								<list id="lidelem4x12559">
									<item>
										<label>•</label>
										<para>Remove cap of press-in bottle adaptor, push adaptor into neck of bottle; close with cap; remove cap, insert tip of dispenser, insert into adaptor; turn upside-down, withdraw correct dose; place in mouth</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x12565">
							<sec_title>IM route</sec_title>
							<para>
								<list id="lidelem4x12569">
									<item>
										<label>•</label>
										<para>IM deep into large muscle mass</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x12575">
							<sec_title>IV route</sec_title>
							<para>
								<list id="lidelem4x12579">
									<item>
										<label>•</label>
										<para>May be given diluted or undiluted</para>
									</item>
									<item>
										<label>•</label>
										<para>After diluting with D<emphasis style="inf">5</emphasis>W or 0.9% NaCl to 0.25 mg/ml; give over 2 min (conscious sedation) or over 30 sec (anesthesia induction)</para>
									</item>
								</list>
							</para>
							<para>
								<emphasis style="bold">Y-site compatibilities:</emphasis> Abciximab, acetaminophen, alemtuzumab, alfentamil, amikacin, amiodarone, anidulafungin, argatroban, atracurium, atropine, aztreonam, benzotropine, calcium gluconate, ceFAZolin, cefotaxime, cefOXitine, cefTRIAXone, cimetidine, ciprofloxacin, CISplatin, clindamycin, cloNIDine, cyanocobalamin, cycloSPORINE, DACTINomycin, digoxin, diltiazem, diphenhydrAMINE, DOCEtaxal, DOPamine, doxycyclin, enalaprilat, EPINEPHrine, erythromycin, esmolol, etomidate, etoposide, famotidine, fentaNYL, fluconazole, folic acid, gatifloxacin, gemcitabine, gentamicin, glycopyrrolate, granisetron, heparin, hetastarch, HYDROmorphone, hydrOXYzine, inamrinone, isoproterenol, labetalol, lactated Ringer’s, levofloxacin, lidocaine, linezolid, LORazepam, magnesium, mannitol, meperdine, methadone, methyldopa, methylPREDNISolone, metoclopromide, metomolol, metroNIDAZOLE, milrinone, morphine, nalbuphine, naloxone, niCARdipine, nitroglycerin, nitroprusside, norepinephrine, ondansetron, oxacillin, oxytocin, PACLitaxel, palonasetron, pancuronium, papaverin, phytonadione, piperacillin, potassium chloride, propanolol, protamine, pyridoxine, ranitidine, remifentanil, sodium nitroprusside, succinylcholine, SUFentanil, teniposide, theophylline, thiotepa, ticarcillin, tobramycin, vancomycin, vasopressin, vecuronium, verap-amil, voriconazole, zoledronic acid</para>
						</section>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x12597">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x12600">
					<section type="none" id="sidelem4x12601">
						<sec_title>CNS:</sec_title>
						<para> Retrograde amnesia, euphoria, confusion, headache, anxiety, insomnia, slurred speech, paresthesia, tremors, weakness, chills, agitation, paradoxic reactions</para>
					</section>
					<section type="none" id="sidelem4x12606">
						<sec_title>CV:</sec_title>
						<para> Hypotension, PVCs, tachycardia, bigeminy, nodal rhythm, <emphasis style="bold">cardiac arrest</emphasis></para>
					</section>
					<section type="none" id="sidelem4x12613">
						<sec_title>EENT:</sec_title>
						<para> Blurred vision, nystagmus, diplopia, loss of balance</para>
					</section>
					<section type="none" id="sidelem4x12618">
						<sec_title>GI:</sec_title>
						<para> <emphasis style="italic">Nausea, vomiting,</emphasis> increased salivation, hiccups</para>
					</section>
					<section type="none" id="sidelem4x12626">
						<sec_title>INTEG:</sec_title>
						<para> Urticaria; pain, swelling, pruritus at inj site; rash</para>
					</section>
					<section type="none" id="sidelem4x12631">
						<sec_title>RESP:</sec_title>
						<para> Coughing, <emphasis style="bold">apnea, bronchospasm, laryngospasm,</emphasis> dyspnea, <emphasis style="bold">respiratory depression</emphasis></para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x12641">
				<sec_title>Pharmacokinetics</sec_title>
				<para>Protein binding 97%; half-life 1-5 hr, metabolized in liver; by CYP3A4 to metabolites excreted in urine; crosses placenta, blood-brain barrier</para>
				<section type="none" id="sidelem4x12646">
					<section type="none" id="sidelem4x12647">
						<sec_title>PO:</sec_title>
						<para> Onset 10-30 min</para>
					</section>
					<section type="none" id="sidelem4x12652">
						<sec_title>IM:</sec_title>
						<para> Onset 15 min, peak <emphasis style="sup">1</emphasis>/<emphasis style="inf">2</emphasis>-1 hr, duration 2-3 hr</para>
					</section>
					<section type="none" id="sidelem4x12663">
						<sec_title>IV:</sec_title>
						<para> Onset 1.5-5 min, onset of anesthesia 1<emphasis style="sup">1</emphasis>/<emphasis style="inf">2</emphasis>-2<emphasis style="sup">1</emphasis>/<emphasis style="inf">2</emphasis> min, duration 2 hr</para>
					</section>
				</section>
			</section>
			<section type="interactions" id="sidelem4x12680">
				<sec_title>Interactions</sec_title>
				<para>
					<emphasis style="bold">Increase:</emphasis> hypotension—antihypertensives, opiates, alcohol, nitrates</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> extended half-life—CYP3A4 inhibitors (cimetidine, erythromycin, ranitidine)</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> respiratory depression—other CNS depressants, alcohol, barbiturates, opiate analgesics, verapamil, ritonavir, indinavir, fluvoxaMINE, protease inhibitors</para>
				<para>
					<emphasis style="bold">Decrease:</emphasis> midazolam metabolism—CYP3A4 inducers (azole antifungals, theophylline)</para>
				<section type="none" id="sidelem4x12700">
					<section type="none" id="sidelem4x12701">
						<sec_title>Drug/Herb</sec_title>
						<para>
							<emphasis style="bold">Increase:</emphasis> sedation—kava, valerian</para>
						<para>
							<emphasis style="bold">Decrease:</emphasis> midazolam effect—St. John’s wort</para>
					</section>
					<section type="none" id="sidelem4x12712">
						<sec_title>Drug/Food</sec_title>
						<para>
							<emphasis style="bold">Increase:</emphasis> (PO) midazolam effect—grapefruit juice</para>
					</section>
				</section>
			</section>
			<section type="considerations" id="sidelem4x12719">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x12722">
					<section type="none" id="sidelem4x12723">
						<sec_title>Assess:</sec_title>
						<para>
							<list id="lidelem4x12728">
								<item>
									<label>•</label>
									<para>B/P, pulse, respirations during IV; emergency equipment should be nearby</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x12733">
								<item>
									<label>•</label>
									<para>Inj site for redness, pain, swelling</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x12738">
								<item>
									<label>•</label>
									<para>Degree of amnesia in geriatric patients; may be increased</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x12743">
								<item>
									<label>•</label>
									<para>Anterograde amnesia</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x12751">
							<para>
								<list id="lidelem4x12751">
									<item>
										<label>•</label>
										<para>Vital signs for recovery period in obese patients; half-life may be extended
<bbw>
												<emphasis alert="lifethreat">Respiratory depression insufficiency:</emphasis> apnea, respiratory depression that may be increased in geriatric patients</bbw>
</para>
									</item>
								</list>
							</para>
						</section>
						<para>
							<list id="lidelem4x12764">
								<item>
									<label>•</label>
									<para>Assistance with ambulation until drowsy period ends</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x12772">
							<label>•</label>
							<sec_title>
								<route>Immediate availability of resuscitation equipment, O</route>
							</sec_title>
						</section>
					</section>
					<section type="none" id="sidelem4x12779">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x12783">
								<item>
									<label>•</label>
									<para>Therapeutic response: induction of sedation, general anesthesia</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x12789">
						<sec_title>Teach patient/family:</sec_title>
						<para>
							<list id="lidelem4x12793">
								<item>
									<label>•</label>
									<para>That amnesia occurs; that events may not be remembered</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
		</monograph>
<monograph id="34" status="active">
			<mono_name>miglitol (Rx)</mono_name>
			<info>
				<pronunciation>(mig′lih-tol)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x128110">Glyset</tradename>
				</tradenames>
				<class type="func"> Oral hypoglycemic</class>
				<class type="chem"> α-Glucosidase inhibitor</class>
				<class type="preg">Pregnancy category <preg cat="B">B</preg></class>
			</info>
			<section type="actions" id="sidelem4x12821">
				<sec_title>Action:</sec_title>
				<para>Delays digestion and absorption of ingested carbohydrates, which results in a smaller rise in blood glucose after meals; does not increase insulin production</para>
			</section>
			<section type="uses" id="sidelem4x12826">
				<sec_title>Uses:</sec_title>
				<para>Type 2 diabetes mellitus</para>
				<section type="none" id="sidelem4x12831">
					<section type="none" id="sidelem4x12832">
						<sec_title>Unlabeled uses:</sec_title>
						<para> Type 1 diabetes mellitus</para>
					</section>
				</section>
			</section>
			<section type="contra" id="sidelem4x12837">
				<sec_title>Contraindications:</sec_title>
				<para>Hypersensitivity, diabetic ketoacidosis, cirrhosis, inflammatory bowel disease, colonic ulceration, partial intestinal obstruction, chronic intestinal disease, ileus</para>
				<section type="none" id="sidelem4x12842">
					<section type="none" id="sidelem4x12843">
						<sec_title>Precautions:</sec_title>
						<para> Pregnancy (<preg cat="B">B</preg>), breastfeeding, children, diarrhea, hiatal hernia, hypoglycemia, renal disease, type 1 diabetes, vomiting</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x12848">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x12856">
					<label>•</label>
					<sec_title>Adult<route> PO</route></sec_title>
					<para>
						<list id="lidelem4x12856">
							<item>
								<label>•</label>
								<para> 25 mg tid initially, with 1st bite of meal; maintenance dose may be increased to 50 mg tid; may be increased to 100 mg tid if needed with dosage adjustment at 4- to 8-wk intervals</para>
							</item>
						</list>
					</para>
				</section>
				<section type="none" id="sidelem4x12860">
					<section type="none" id="sidelem4x12861">
						<sec_title>Available forms:</sec_title>
						<para> Tabs 25, 50, 100 mg</para>
					</section>
					<section type="none" id="sidelem4x12866">
						<sec_title>Administer:</sec_title>
						<para>
							<list id="lidelem4x12870">
								<item>
									<label>•</label>
									<para>Tid with first bite of each meal</para>
								</item>
								<item>
									<label>•</label>
									<para>Store in tight container at room temperature</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x12881">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x12884">
					<section type="none" id="sidelem4x12885">
						<sec_title>GI:</sec_title>
						<para> <emphasis style="italic">Abdominal pain, diarrhea, flatulence,</emphasis><emphasis style="bold">hepatotoxicity</emphasis></para>
					</section>
					<section type="none" id="sidelem4x12894">
						<sec_title>HEMA:</sec_title>
						<para> Low iron</para>
					</section>
					<section type="none" id="sidelem4x12899">
						<sec_title>INTEG:</sec_title>
						<para> Rash</para>
					</section>
					<section type="none" id="sidelem4x12904">
						<sec_title>RESP:</sec_title>
						<para> Pneumatosis cystoides, intestinalis</para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x12909">
				<sec_title>Pharmacokinetics</sec_title>
				<para>Peak 2-3 hr, not metabolized, excreted in urine as unchanged product, half-life 2 hr</para>
			</section>
			<section type="interactions" id="sidelem4x12915">
				<sec_title>Interactions</sec_title>
				<para>
					<emphasis style="bold">Decrease:</emphasis> levels of digoxin, propranolol, ranitidine</para>
				<para>
					<emphasis style="bold">Decrease:</emphasis> miglitol levels—digestive enzymes, intestinal adsorbents; do not use together</para>
				<section type="none" id="sidelem4x12926">
					<section type="none" id="sidelem4x12927">
						<sec_title>Drug/Food</sec_title>
						<para>
							<emphasis style="bold">Increase:</emphasis> diarrhea—carbohydrates</para>
					</section>
				</section>
			</section>
			<section type="considerations" id="sidelem4x12934">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x12937">
					<section type="none" id="sidelem4x12938">
						<sec_title>Assess:</sec_title>
						<section type="none" id="sidelem4x12946">
							<label>•</label>
							<sec_title>
								<route>Hypo/hyperglycemia;</route>
							</sec_title>
							<para>
								<list id="lidelem4x12946">
									<item>
										<label>•</label>
										<para> even though product does not cause hypoglycemia, if patient receiving sulfonylureas or insulin, hypoglycemia may be additive (rare)</para>
									</item>
								</list>
							</para>
						</section>
						<para>
							<list id="lidelem4x12950">
								<item>
									<label>•</label>
									<para>Blood glucose levels, hemoglobin, A1c, LFTs; if hypoglycemia occurs with monotherapy, treat with glucose</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x12955">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x12959">
								<item>
									<label>•</label>
									<para>Therapeutic response: decreased signs, symptoms of diabetes mellitus (polyuria, polydipsia, polyphagia; clear sensorium, absence of dizziness; stable gait); improved blood glucose, A1c</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x12965">
						<sec_title>Teach patient/family:</sec_title>
						<para>
							<list id="lidelem4x12969">
								<item>
									<label>•</label>
									<para>About the symptoms of hypo/hyperglycemia; what to do about each; that, during periods of stress, infection, or surgery, insulin may be required</para>
								</item>
								<item>
									<label>•</label>
									<para>That medication must be taken as prescribed; about consequences of discontinuing medication abruptly</para>
								</item>
								<item>
									<label>•</label>
									<para>To avoid OTC medications unless approved by health care provider</para>
								</item>
								<item>
									<label>•</label>
									<para>That diabetes is lifelong; that product is not a cure</para>
								</item>
								<item>
									<label>•</label>
									<para>To carry ID for emergency purposes</para>
								</item>
								<item>
									<label>•</label>
									<para>That diet and exercise regimen must be followed</para>
								</item>
								<item>
									<label>•</label>
									<para>About GI side effects</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
		</monograph>
<monograph id="35" status="active" ha="yes">
			<mono_name> milrinone (Rx)</mono_name>
			<info>
				<pronunciation>(mill′rih-nohn)</pronunciation>
				<class type="func"> Inotropic/vasodilator agent with phosphodiesterase activity</class>
				<class type="chem"> Bipyridine derivative</class>
				<class type="preg">Pregnancy category <preg cat="C">C</preg></class>
			</info>
			<section type="actions" id="sidelem4x13020">
				<sec_title>Action:</sec_title>
				<para>Positive inotropic agent; increases contractility of cardiac muscle with vasodilator properties; reduces preload and afterload by direct relaxation on vascular smooth muscle</para>
			</section>
			<section type="uses" id="sidelem4x13025">
				<sec_title>Uses:</sec_title>
				<para>Short-term management of advanced heart failure that has not responded to other medication</para>
				<section type="none" id="sidelem4x13030">
					<section type="none" id="sidelem4x13031">
						<sec_title>Unlabeled uses:</sec_title>
						<para> Adolescents, children, infants</para>
					</section>
				</section>
			</section>
			<section type="contra" id="sidelem4x13036">
				<sec_title>Contraindications:</sec_title>
				<para>Hypersensitivity to this product, severe aortic disease, severe pulmonic valvular disease, acute MI</para>
				<section type="none" id="sidelem4x13041">
					<section type="none" id="sidelem4x13042">
						<sec_title>Precautions:</sec_title>
						<para> Pregnancy (<preg cat="C">C</preg>), breastfeeding, children, geriatric patients, renal/hepatic disease, atrial flutter/fibrillation</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x13047">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x13055">
					<label>•</label>
					<sec_title>Adult<route> IV BOL</route></sec_title>
					<para>
						<list id="lidelem4x13055">
							<item>
								<label>•</label>
								<para> 50 mcg/kg given over 10 min; start infusion of 0.375-0.75 mcg/kg/min</para>
							</item>
						</list>
					</para>
				</section>
				<section type="none" id="sidelem4x13062">
					<label>•</label>
					<sec_title>Adolescent/child/infant (unlabeled)<route> IV</route></sec_title>
					<para>
						<list id="lidelem4x13062">
							<item>
								<label>•</label>
								<para> 50 mcg/kg over 10-60 min, then 0.5-0.75 mcg/kg/min</para>
							</item>
						</list>
					</para>
				</section>
				<section type="none" id="sidelem4x13066">
					<section type="none" id="sidelem4x13067">
						<sec_title>Renal dose</sec_title>
						<section type="none" id="sidelem4x13075">
							<label>•</label>
							<sec_title>Adult<route> IV CCr 41-50 ml/min, 0.43 mcg/kg/min, titrate up; CCr 31-40 ml/min, 0.38 mcg/kg/min, titrate up; CCr 21-30 ml/min, 0.33 mcg/kg/min, titrate up; CCr 11-20 ml/min, 0.28 mcg/kg/min; CCr 6-10 ml/min, 0.23 mcg/kg/min; CCr ≤5 ml/min, 0.20 mcg/kg/min; max for all doses 0.75 mcg/kg/min</route></sec_title>
						</section>
					</section>
					<section type="none" id="sidelem4x13078">
						<sec_title>Available forms:</sec_title>
						<para> Inj 1 mg/ml; premixed inj 200 mcg/ml in D<emphasis style="inf">5</emphasis>W</para>
					</section>
					<section type="none" id="sidelem4x13086">
						<sec_title>Administer:</sec_title>
						<para>
							<list id="lidelem4x13090">
								<item>
									<label>•</label>
									<para>Potassium supplements if ordered for potassium levels &lt;3 mg/dl</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x13097">
							<sec_title>Direct IV route</sec_title>
							<para>
								<list id="lidelem4x13101">
									<item>
										<label>•</label>
										<para>Give IV loading dose undiluted over 10 min, use infusion device</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x13107">
							<sec_title>Continuous IV route</sec_title>
							<para>
								<list id="lidelem4x13111">
									<item>
										<label>•</label>
										<para>Dilute 20-mg vial with 80, 113, 180 ml of 0.45% NaCl, 0.9% NaCl, or D<emphasis style="inf">5</emphasis>W to a concentration of 200, 150, 100 mcg/ml, respectively</para>
									</item>
									<item>
										<label>•</label>
										<para>Titrate rate based on hemodynamic and clinical response, use infusion device</para>
									</item>
									<item>
										<label>•</label>
										<para>Precipitation will form when furosemide is injected into line with milrinone</para>
									</item>
								</list>
							</para>
							<para>
								<emphasis style="bold">Y-site compatibilities:</emphasis> Acyclovir, alfentanil, allopurinol, amifostine, amikacin, aminocaproic acid, aminophylline, amiodarone, amphotericin B liposome, ampicillin, ampicillin-sulbactam, anidulafungin, argatroban, atenolol, atracurium, aztreonam, bivalirudin, bleomycin, bumetanide, buprenorphine, busulfan, butorphanol, calcium chloride/gluconate, CARBOplatin, caspofungin, ceFAZolin, cefepime, cefotaxime, cefoTEtan, cefOXitin, cefTAZidime, ceftizoxime, cefTRIAXone, cefuroxime, chloramphenicol, chlorproMAZINE, cimetidine, ciprofloxacin, cisatracurium, CISplatin, clindamycin, cyclophosphamide, cycloSPORINE, cytarabine, DACTINomycin, DAPTOmycin, dexamethasone, digoxin, diltiazem, DOBUTamine, DOCEtaxel, DOPamine, doripenem, doxacurium, DOXOrubicin, doxycycline, droperidol, enalaprilat, ePHEDrine, EPINEPHrine, epirubicin, eptifibatide, ertapenem, erythromycin, etoposide, famotidine, fenoldopam, fentaNYL, fluconazole, fludarabine, fluorouracil, gallium, ganciclovir, gatifloxacin, gemcitabine, gentamicin, glycopyrrolate, granisetron, haloperidol, heparin, hydrALAZINE, hydrocortisone, HYDROmorphone, IDArubicin, ifosfamide, insulin (regular), irinotecan, isoproterenol, ketorolac, labetalol, levofloxacin, linezolid, LORazepam, magnesium sulfate, mannitol, mechlorethamine, melphalan, meperidine, meropenem, methohexital, methotrexate, methyldopate, methylPREDNISolone, metoclopramide, metoprolol, metroNIDAZOLE, micafungin, midazolam, mitoXANtrone, morphine, mycophenolate, nafcillin, nalbuphine, naloxone, nesiritide, niCARdipine, nitroglycerin, nitroprusside, norepinephrine, octreotide, oxacillin, oxaliplatin, oxytocin, PACLitaxel, palonosetron, pamidronate, pancuronium, PEMEtrexed, pentamidine, pentazocine, PENTobarbital, PHENobarbital, phenylephrine, piperacillin, piperacillin-tazobactam, polymyxin B, potassium chloride/phosphates, prochlorperazine, promethazine, propofol, propranolol, quiNIDine, quinupristin-dalfopristin, ranitidine, remifentanil, rocuronium, sodium acetate/bicarbonate/phosphates, streptozocin, succinylcholine, SUFentanil, sulfamethoxazole-trimethoprim, tacrolimus, teniposide, theophylline, thiopental, thiotepa, ticarcillin, ticarcillin-clavulanate, tigecycline, tirofiban, tobramycin, torsemide, vancomycin, vasopressin, vecuronium, verapamil, vinCRIStine, vinorelbine, voriconazole, zidovudine, zoledronic acid</para>
						</section>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x13134">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x13137">
					<section type="none" id="sidelem4x13138">
						<sec_title>CV:</sec_title>
						<para> <emphasis style="bold">Dysrhythmias,</emphasis> hypotension, chest pain, <emphasis style="italic">PVCs</emphasis></para>
					</section>
					<section type="none" id="sidelem4x13148">
						<sec_title>GI:</sec_title>
						<para> Nausea, vomiting, anorexia, abdominal pain, <emphasis style="bold">hepatotoxicity, jaundice</emphasis></para>
					</section>
					<section type="none" id="sidelem4x13155">
						<sec_title>HEMA:</sec_title>
						<para> <emphasis style="bold">Thrombocytopenia</emphasis></para>
					</section>
					<section type="none" id="sidelem4x13162">
						<sec_title>MISC:</sec_title>
						<para> Headache, hypokalemia, tremor, inj site reactions</para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x13167">
				<sec_title>Pharmacokinetics</sec_title>
				<section type="none" id="sidelem4x13170">
					<section type="none" id="sidelem4x13171">
						<sec_title>IV:</sec_title>
						<para> Onset 2-5 min, peak 10 min, duration variable; terminal half-life 2.3 hr; metabolized in liver; excreted in urine as product (83%), metabolites (12%)</para>
					</section>
				</section>
			</section>
			<section type="interactions" id="sidelem4x13176">
				<sec_title>Interactions</sec_title>
				<para>
					<emphasis style="bold">Increase:</emphasis> effects of antihypertensives, diuretics</para>
			</section>
			<section type="considerations" id="sidelem4x13183">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x13186">
					<section type="none" id="sidelem4x13187">
						<sec_title>Assess:</sec_title>
						<para>
							<list id="lidelem4x13193">
								<item>
									<para>
										<emphasis alert="nurse">ECG continuously during IV; ventricular dysrhythmia can occur</emphasis>
									</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x13198">
								<item>
									<label>•</label>
									<para>B/P, pulse q5min during infusion; if B/P drops 30 mm Hg, stop infusion, call prescriber</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x13204">
								<item>
									<label>•</label>
									<para>Electrolytes: potassium, sodium, chloride, calcium; renal studies: BUN, creatinine; blood studies: platelet count</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x13209">
								<item>
									<label>•</label>
									<para>ALT, AST, bilirubin daily</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x13214">
								<item>
									<label>•</label>
									<para>I&amp;O ratio, weight daily; diuresis should increase with continuing therapy</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x13219">
								<item>
									<label>•</label>
									<para>If platelets are &lt;150,000/mm<emphasis style="sup">3</emphasis>, product is usually discontinued and another product started</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x13227">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x13231">
								<item>
									<label>•</label>
									<para>Therapeutic response: increased cardiac output, decreased PCWP, adequate CVP; decreased dyspnea, fatigue, edema, ECG</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x13237">
						<sec_title>Teach patient/family:</sec_title>
						<para>
							<list id="lidelem4x13241">
								<item>
									<label>•</label>
									<para>To report angina immediately during infusion</para>
								</item>
								<item>
									<label>•</label>
									<para>To report headache, which can be treated with analgesics</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
		</monograph>
<monograph id="36" status="active">
			<mono_name>minocycline (Rx)</mono_name>
			<info>
				<pronunciation>(min-oh-sye′kleen)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x132623">Arestin</tradename>
					<tradename id="tnidelem4x132622">Dynacin</tradename>
					<tradename id="tnidelem4x132621">Minocin</tradename>
					<tradename id="tnidelem4x132620">Solodyn</tradename>
				</tradenames>
				<class type="func"> Broad-spectrum antiinfective</class>
				<class type="chem"> Tetracycline</class>
				<class type="preg">Pregnancy category <preg cat="D">D</preg></class>
			</info>
			<section type="actions" id="sidelem4x13272">
				<sec_title>Action:</sec_title>
				<para>Inhibits protein synthesis, phosphorylation in microorganisms by binding to ribosomal subunits, reversibly binding to ribosomal subunits; bacteriostatic</para>
			</section>
			<section type="uses" id="sidelem4x13277">
				<sec_title>Uses:</sec_title>
				<para>Syphilis, <emphasis style="italic">Chlamydia trachomatis,</emphasis> gonorrhea, lymphogranuloma venereum, rickettsial infections, inflammatory acne, <emphasis style="italic">Neisseria meningitidis, Neisseria gonorrhoeae, Treponema pallidum, Chlamydia trachomatis, Ureaplasma urealyticum, Mycoplasma pneumoniae, Nocardia,</emphasis> periodontitis, methicillin-resistant <emphasis style="italic">S. aureus</emphasis> (MRSA) infection, nonnodular moderate to severe acne vulgaris, <emphasis style="italic">Rickettsia</emphasis> sp.</para>
				<section type="none" id="sidelem4x13294">
					<section type="none" id="sidelem4x13295">
						<sec_title>Unlabeled uses:</sec_title>
						<para> Rheumatoid arthritis, bullous pemphigoid, dental infection, prostatis, pleural effusion</para>
					</section>
				</section>
			</section>
			<section type="contra" id="sidelem4x13300">
				<sec_title>Contraindications:</sec_title>
				<para>Pregnancy (<preg cat="D">D</preg>), children &lt;8 yr, hypersensitivity to tetracyclines</para>
				<section type="none" id="sidelem4x13305">
					<section type="none" id="sidelem4x13306">
						<sec_title>Precautions:</sec_title>
						<para> Hepatic disease, breastfeeding</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x13311">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x13319">
					<label>•</label>
					<sec_title>Adult<route> PO/IV</route></sec_title>
					<para>
						<list id="lidelem4x13319">
							<item>
								<label>•</label>
								<para> 200 mg, then 100 mg q12hr, max 400 mg/24 hr  inserted into periodontal pocket</para>
							</item>
						</list>
					</para>
				</section>
				<section type="none" id="sidelem4x13329">
					<label>•</label>
					<sec_title>Child &gt;8 yr<route> PO/IV</route></sec_title>
					<para>
						<list id="lidelem4x13329">
							<item>
								<label>•</label>
								<para> 4 mg/kg, then 4 mg/kg/day  in divided doses q12hr</para>
							</item>
						</list>
					</para>
				</section>
				<section type="none" id="sidelem4x13336">
					<section type="none" id="sidelem4x13337">
						<sec_title>Rickettsial infections</sec_title>
						<section type="none" id="sidelem4x13345">
							<label>•</label>
							<sec_title>Adult<route> PO/IV</route></sec_title>
							<para>
								<list id="lidelem4x13345">
									<item>
										<label>•</label>
										<para> 200 mg, then 100 mg q12hr</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x13352">
							<label>•</label>
							<sec_title>Child ≥8 yr/adolescent<route> PO/IV</route></sec_title>
							<para>
								<list id="lidelem4x13352">
									<item>
										<label>•</label>
										<para> 4 mg/kg, then 2 mg/kg q12hr, max adult dose</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x13356">
						<sec_title>Gonorrhea</sec_title>
						<section type="none" id="sidelem4x13364">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x13364">
									<item>
										<label>•</label>
										<para> 200 mg, then 100 mg q12hr × ≥4 days</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x13368">
						<sec_title>Syphilis</sec_title>
						<section type="none" id="sidelem4x13376">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x13376">
									<item>
										<label>•</label>
										<para> 200 mg, then 100 mg q12hr × 10-15 days</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x13380">
						<sec_title>Uncomplicated gonococcal urethritis in men</sec_title>
						<section type="none" id="sidelem4x13388">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x13388">
									<item>
										<label>•</label>
										<para> 100 mg q12hr × 5 days</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x13392">
						<sec_title>Acne vulgaris (Solodyn only)</sec_title>
						<section type="none" id="sidelem4x13400">
							<label>•</label>
							<sec_title>Adult/adolescent/child ≥12 yr</sec_title>
							<para>
								<list id="lidelem4x13400">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Adult/adolescent/child ≥12 yr:</emphasis> ext rel 1 mg/kg/day × 12 wk or those weighing 126-136 kg—135 mg/day; 111-125 kg—115 mg/day; 97-110 kg—105 mg/day; 85-96 kg—90 mg/day; 72-84 kg—80 mg/day; 60-71 kg—65 mg/day; 50-59 kg—55 mg/day; 45-49 kg—45 mg/day</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x13404">
						<sec_title>Acne vulgaris (all except Solodyn)</sec_title>
						<section type="none" id="sidelem4x13412">
							<label>•</label>
							<sec_title>Adult/adolescent/child ≥12 yr</sec_title>
							<para>
								<list id="lidelem4x13412">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Adult/adolescent/child ≥12 yr:</emphasis> ext rel 1 mg/kg × 12 wk or 91-136 kg, 135 mg/day; 60-90 kg, 90 mg/day; 45-59 kg, 45 mg/day</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x13416">
						<sec_title>Rheumatoid arthritis (unlabeled)</sec_title>
						<section type="none" id="sidelem4x13424">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x13424">
									<item>
										<label>•</label>
										<para> 100 mg bid for ≤48 wk</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x13428">
						<sec_title>Bullous pemphigus (unlabeled)</sec_title>
						<section type="none" id="sidelem4x13436">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x13436">
									<item>
										<label>•</label>
										<para> 50 mg/day; may increase to 100 mg/day after 1-2 wk</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x13440">
						<sec_title>Available forms:</sec_title>
						<para> Caps 50, 75, 100 mg; powder for inj 100 mg; caps, pellet filled 50, 100 mg; tabs 50, 75, 100 mg; ext rel tabs 45, 55, 65, 80, 90, 105, 115, 135 mg</para>
					</section>
					<section type="none" id="sidelem4x13445">
						<sec_title>Administer:</sec_title>
						<para>
							<list id="lidelem4x13449">
								<item>
									<label>•</label>
									<para>After C&amp;S obtained</para>
								</item>
								<item>
									<label>•</label>
									<para>Store in airtight, light-resistant container at room temperature</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x13461">
							<sec_title>PO route</sec_title>
							<para>
								<list id="lidelem4x13465">
									<item>
										<label>•</label>
										<para>With full glass of water; with food for GI symptoms</para>
									</item>
									<item>
										<label>•</label>
										<para>2 hr before or after laxative or ferrous products; 3 hr after antacid</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x13476">
							<sec_title>IV route</sec_title>
							<para>
								<list id="lidelem4x13480">
									<item>
										<label>•</label>
										<para>After diluting 100 mg/5 ml sterile water for inj; further dilute in 500-1000 ml of NaCl, dextrose sol, LR, Ringer’s sol; run 100 mg/6 hr</para>
									</item>
								</list>
							</para>
							<para>
								<emphasis style="bold">Y-site compatibilities:</emphasis> Alfentanil, amikacin, atracurium, benztropine, buprenorphine, butorphanol, calcium chloride, CARBOplatin, caspofungin, cefonicid, chlorproMAZINE, cimetidine, cisatracurium, codeine, cyclophosphamide, cycloSPORINE, cytarabine, DACTINomycin, dexmedetomidine, diltiazem, diphenhydrAMINE, DOBUTamine, DOCEtaxel, doxacurium, doxycycline, enalaprilat, ePHEDrine, EPINEPHrine, eptifibatide, etoposide, fenoldopam, fentaNYL, filgrastim, fludarabine, gatafloxacin, gemcitabine, gentamicin, glycopyrrolate, granisetron, heparin, hetastarch, IDArubicin, ifosfamide, inamrinone, isoproterenol, labetalol, levofloxacin, lidocaine, linezolid, LORazepam, magnesium sulfate, mannitol, melphalan, metaraminol, methotrexate, methyldopa, metoclopramide, metoprolol, midazolam, mitoXANtrone, nalbuphine, naloxone, perphenazine, potassium chloride, remifentanil, sargramostim, teniposide, vinorelbine, vit B/C</para>
						</section>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x13490">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x13493">
					<section type="none" id="sidelem4x13494">
						<sec_title>CNS:</sec_title>
						<para> <emphasis style="italic">Dizziness</emphasis>, fever, lightheadedness, vertigo, <emphasis style="bold">seizures, increased intracranial pressure</emphasis></para>
					</section>
					<section type="none" id="sidelem4x13504">
						<sec_title>CV:</sec_title>
						<para> Pericarditis</para>
					</section>
					<section type="none" id="sidelem4x13509">
						<sec_title>EENT:</sec_title>
						<para> Dysphagia, glossitis, decreased calcification of deciduous teeth, permanent discoloration of teeth, oral candidiasis</para>
					</section>
					<section type="none" id="sidelem4x13514">
						<sec_title>GI:</sec_title>
						<para> <emphasis style="italic">Nausea,</emphasis> abdominal pain, <emphasis style="italic">vomiting, diarrhea,</emphasis> anorexia, enterocolitis, <emphasis style="bold">hepatotoxicity,</emphasis> flatulence, abdominal cramps, epigastric burning, stomatitis, <emphasis style="bold">pseudomembranous colitis</emphasis></para>
					</section>
					<section type="none" id="sidelem4x13530">
						<sec_title>GU:</sec_title>
						<para> <emphasis style="italic">Increased BUN,</emphasis> polyuria, polydipsia, <emphasis style="bold">renal failure, nephrotoxicity</emphasis></para>
					</section>
					<section type="none" id="sidelem4x13540">
						<sec_title>HEMA:</sec_title>
						<para> <emphasis style="bold">Eosinophilia, neutropenia, thrombocytopenia, hemolytic anemia, pancytopenia</emphasis></para>
					</section>
					<section type="none" id="sidelem4x13547">
						<sec_title>INTEG:</sec_title>
						<para> <emphasis style="italic">Rash, urticaria, photosensitivity, increased pigmentation,</emphasis><emphasis style="bold">exfoliative dermatitis,</emphasis> pruritus, blue-gray color of skin, mucous membranes</para>
					</section>
					<section type="none" id="sidelem4x13557">
						<sec_title>MS:</sec_title>
						<para> Myalgia, arthritis, bone discoloration, joint stiffness</para>
					</section>
					<section type="none" id="sidelem4x13562">
						<sec_title>SYST:</sec_title>
						<para> <emphasis style="bold">Angioedema, Stevens-Johnson syndrome</emphasis></para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x13569">
				<sec_title>Pharmacokinetics</sec_title>
				<section type="none" id="sidelem4x13572">
					<section type="none" id="sidelem4x13573">
						<sec_title>PO:</sec_title>
						<para> Peak 1-4 hr, half-life 11-22 hr; excreted in urine, feces, breast milk; crosses placenta</para>
					</section>
				</section>
			</section>
			<section type="interactions" id="sidelem4x13578">
				<sec_title>Interactions</sec_title>
				<para>
					<emphasis style="bold">Increase:</emphasis> effect of warfarin, digoxin, insulin, oral anticoagulants, theophylline, neuromuscular blockers</para>
				<para>
					<emphasis alert="lifethreat">Increase: chance of pseudomotor cerebri—retinoids; do not use concurrently</emphasis>
				</para>
				<para>
					<emphasis style="bold">Decrease:</emphasis> effect of minocycline—antacids, sodium bicarbonate, alkali prod-ucts, iron, kaolin/pectin, cimetidine, quinapril, sucralfate</para>
				<para>
					<emphasis style="bold">Decrease:</emphasis> effect of barbiturates, carBAMazepine, phenytoin, penicillins, oral contraceptives, calcium</para>
				<section type="none" id="sidelem4x13596">
					<section type="none" id="sidelem4x13597">
						<sec_title>Drug/Lab Test</sec_title>
						<para>
							<emphasis style="bold">False negative:</emphasis> urine glucose with Clinistix or Tes-Tape</para>
					</section>
				</section>
			</section>
			<section type="considerations" id="sidelem4x13604">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x13607">
					<section type="none" id="sidelem4x13608">
						<sec_title>Assess:</sec_title>
						<para>
							<list id="lidelem4x13614">
								<item>
									<para>
										<emphasis alert="nurse">Pseudomembranous colitis: diarrhea, abdominal cramps, fever; may start up to 2 mo after treatment ends</emphasis>
									</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x13619">
								<item>
									<label>•</label>
									<para>I&amp;O ratio</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x13624">
								<item>
									<label>•</label>
									<para>Age and tooth development</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x13629">
								<item>
									<label>•</label>
									<para>Blood tests: PT, CBC, AST, ALT, BUN, creatinine</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x13634">
								<item>
									<label>•</label>
									<para>Signs of anemia: Hct, Hgb, fatigue</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x13640">
								<item>
									<para>
										<emphasis alert="nurse">Allergic reactions: rash, itching, pruritus, angioedema</emphasis>
									</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x13645">
								<item>
									<label>•</label>
									<para>Nausea, vomiting, diarrhea; administer antiemetic, antacids as ordered</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x13652">
								<item>
									<para>
										<emphasis alert="nurse">Overgrowth of infection: fever, malaise, redness, pain, swelling, drainage, perineal itching, diarrhea; changes in cough or sputum; black, furry tongue</emphasis>
									</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x13657">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x13661">
								<item>
									<label>•</label>
									<para>Therapeutic response: decreased temperature, absence of lesions, negative C&amp;S</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x13667">
						<sec_title>Teach patient/family:</sec_title>
						<para>
							<list id="lidelem4x13671">
								<item>
									<label>•</label>
									<para>To avoid sunlight, wear protective clothing; sunscreen does not seem to decrease photosensitivity</para>
								</item>
								<item>
									<label>•</label>
									<para>That all prescribed medication must be taken to prevent superinfection; not to use outdated product because Fanconi’s syndrome may occur</para>
								</item>
								<item>
									<label>•</label>
									<para>To avoid taking antacids, iron, cimetidine; use 2 hr before, 6 hr after this product; absorption may be decreased</para>
								</item>
								<item>
									<label>•</label>
									<para>That teeth discoloration, joint or muscle pain may occur</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
		</monograph>
<monograph id="37" status="active">
			<mono_name>minoxidil (Rx, <emphasis style="smallcaps">otc</emphasis>)</mono_name>
			<info>
				<pronunciation>(mi-nox′i-dill)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x137000">Rogaine (topical)</tradename>
				</tradenames>
				<class type="func"> Antihypertensive</class>
				<class type="chem"> Vasodilator, peripheral</class>
				<class type="preg">Pregnancy category <preg cat="C">C</preg></class>
			</info>
			<section type="confusion" id="sidelem4x13710">
				<para>
					<confusion>
						<tradename id="tnidelem4x137100">minoxidil</tradename>
						<drug type="generic" refid="idelem4x137100">Monopril</drug>
					</confusion>
				</para>
			</section>
			<section type="actions" id="sidelem4x13714">
				<sec_title>Action:</sec_title>
				<para>Directly relaxes arteriolar smooth muscle, causing vasodilation; reduces peripheral vascular resistance, decreases B/P</para>
			</section>
			<section type="uses" id="sidelem4x13719">
				<sec_title>Uses:</sec_title>
				<para>Severe hypertension unresponsive to other therapy (use with diuretic and β-blocker); topically to treat alopecia</para>
				<section type="none" id="sidelem4x13724">
					<section type="none" id="sidelem4x13725">
						<sec_title>Unlabeled uses:</sec_title>
						<para> Scleroderma renal crisis (SRC) to control hypertension, anal fissures</para>
					</section>
				</section>
			</section>
			<section type="contra" id="sidelem4x13730">
				<sec_title>Contraindications:</sec_title>
				<para>Dissecting aortic aneurysm, hypersensitivity, pheochromocytoma</para>
				<para>
					<bbw>Acute MI</bbw>
				</para>
				<section type="none" id="sidelem4x13745">
					<section type="none" id="sidelem4x13746">
						<sec_title>Precautions:</sec_title>
						<para> Pregnancy (<preg cat="C">C</preg>), breastfeeding, children, geriatric patients, renal disease, CVD</para>
						<para>
							<bbw>CAD, CHF, cardiac disease, cardiac tamponade, edema, hypotension, orthostatic hypotension, pericardial effusion</bbw>
						</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x13761">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x13764">
					<section type="none" id="sidelem4x13765">
						<sec_title>Severe hypertension</sec_title>
						<section type="none" id="sidelem4x13773">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x13773">
									<item>
										<label>•</label>
										<para> 5 mg/day in 1-2 divided doses; max 100 mg/day; usual range 10-40 mg/day divided in 1-2 doses</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x13780">
							<label>•</label>
							<sec_title>Geriatric<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x13780">
									<item>
										<label>•</label>
										<para> 2.5 mg/day, may be increased gradually</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x13787">
							<label>•</label>
							<sec_title>Child &lt;12 yr<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x13787">
									<item>
										<label>•</label>
										<para> (initial) 0.1-0.2 mg/kg/day; (effective range) 0.25-1 mg/kg/day; (max) 50 mg/day</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x13791">
						<sec_title>Alopecia</sec_title>
						<section type="none" id="sidelem4x13799">
							<label>•</label>
							<sec_title>Adult<route> TOP</route></sec_title>
							<para>
								<list id="lidelem4x13799">
									<item>
										<label>•</label>
										<para> 1 ml bid, rub into scalp daily, max 2 ml/day</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x13803">
						<sec_title>Renal dose</sec_title>
						<section type="none" id="sidelem4x13811">
							<label>•</label>
							<sec_title>Adult<route> PO CCr 10-15 ml/min extend interval to q24hr; CCr &lt;10 ml/min not recommended</route></sec_title>
						</section>
					</section>
					<section type="none" id="sidelem4x13814">
						<sec_title>Anal fissures (unlabeled)</sec_title>
						<section type="none" id="sidelem4x13822">
							<label>•</label>
							<sec_title>Adult/adolescent<route> TOP</route></sec_title>
							<para>
								<list id="lidelem4x13822">
									<item>
										<label>•</label>
										<para> (0.5% minoxidil in white paraffin base) 0.5 g each compounded minoxidil and lignocaine ointment q8hr</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x13826">
						<sec_title>Scleroderma renal crisis (unlabeled)</sec_title>
						<section type="none" id="sidelem4x13834">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x13834">
									<item>
										<label>•</label>
										<para> 5 mg/day in 1-2 divided doses, increase after 3 days by 10-20 mg/day to reach desired B/P, max 100 mg/day</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x13838">
						<sec_title>Available forms:</sec_title>
						<para> Tabs 2.5, 10 mg; topical 2%, 5% sol; topical foam 5%</para>
					</section>
					<section type="none" id="sidelem4x13843">
						<sec_title>Administer:</sec_title>
						<para>
							<list id="lidelem4x13847">
								<item>
									<label>•</label>
									<para>Store protected from light and heat</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x13853">
							<sec_title>PO route</sec_title>
							<para>
								<list id="lidelem4x13857">
									<item>
										<label>•</label>
										<para>Without regard to meals</para>
									</item>
									<item>
										<label>•</label>
										<para>With β-blocker and/or diuretic for hypertension</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x13868">
							<sec_title>Topical route</sec_title>
							<para>
								<list id="lidelem4x13872">
									<item>
										<label>•</label>
										<para>1 ml no matter how much balding has occurred; increasing dosage does not speed growth</para>
									</item>
								</list>
							</para>
						</section>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x13878">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x13881">
					<section type="none" id="sidelem4x13882">
						<sec_title>Systemic</sec_title>
						<para/>
					</section>
					<section type="none" id="sidelem4x13886">
						<sec_title>CNS:</sec_title>
						<para> Headache, fatigue</para>
					</section>
					<section type="none" id="sidelem4x13891">
						<sec_title>CV:</sec_title>
						<para> <emphasis style="italic">Severe rebound hypertension on withdrawal in children,</emphasis> tachycardia, angina, increased T wave, <emphasis style="bold">CHF, pulmonary edema, pericardial effusion,</emphasis> edema, sodium, water retention, <emphasis style="italic">hypotension</emphasis></para>
					</section>
					<section type="none" id="sidelem4x13906">
						<sec_title>GI:</sec_title>
						<para> Nausea, vomiting</para>
					</section>
					<section type="none" id="sidelem4x13911">
						<sec_title>GU:</sec_title>
						<para> Breast tenderness</para>
					</section>
					<section type="none" id="sidelem4x13916">
						<sec_title>HEMA:</sec_title>
						<para> Hct, Hgb; erythrocyte count may decrease initially, leukopenia</para>
					</section>
					<section type="none" id="sidelem4x13921">
						<sec_title>INTEG:</sec_title>
						<para> Pruritus, <emphasis style="bold">Stevens-Johnson syndrome,</emphasis> rash, hirsutism, contact dermatitis</para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x13929">
				<sec_title>Pharmacokinetics</sec_title>
				<section type="none" id="sidelem4x13932">
					<section type="none" id="sidelem4x13933">
						<sec_title>PO:</sec_title>
						<para> Onset 30 min, peak 2-3 hr, duration 48-120 hr; half-life 4.2 hr; metabolized in liver; metabolites excreted in urine, feces; protein binding minimal</para>
					</section>
				</section>
			</section>
			<section type="interactions" id="sidelem4x13938">
				<sec_title>Interactions</sec_title>
				<para>
					<emphasis style="bold">Increase:</emphasis> hypotension—antihypertensives, MAOIs</para>
				<para>
					<emphasis style="bold">Decrease:</emphasis> antihypertensive effect—NSAIDs, salicylates, estrogens</para>
				<section type="none" id="sidelem4x13949">
					<section type="none" id="sidelem4x13950">
						<sec_title>Drug/Herb</sec_title>
						<para>
							<emphasis style="bold">Increase:</emphasis> antihypertensive effect—hawthorn</para>
					</section>
					<section type="none" id="sidelem4x13957">
						<sec_title>Drug/Lab Test</sec_title>
						<para>
							<emphasis style="bold">Increase:</emphasis> renal studies</para>
						<para>
							<emphasis style="bold">Decrease:</emphasis> Hgb/Hct/RBC</para>
					</section>
				</section>
			</section>
			<section type="considerations" id="sidelem4x13968">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x13971">
					<section type="none" id="sidelem4x13972">
						<sec_title>Assess:</sec_title>
						<para>
							<list id="lidelem4x13976">
								<item>
									<para> Monitor closely; usually given with β-blocker to prevent tachycardia and increased myocardial workload; usually given with diuretic to prevent serious fluid accumulation; patient should be hospitalized during beginning treatment</para>
								</item>
								<item>
									<label>•</label>
									<para>Nausea, edema in feet, legs daily</para>
								</item>
								<item>
									<label>•</label>
									<para>Skin turgor, dryness of mucous membranes for hydration status</para>
								</item>
								<item>
									<label>•</label>
									<para>Crackles, dyspnea, orthopnea</para>
								</item>
								<item>
									<label>•</label>
									<para>Electrolytes: potassium, sodium, chloride, CO<emphasis style="inf">2</emphasis></para>
								</item>
								<item>
									<label>•</label>
									<para>Renal studies: catecholamines, BUN, creatinine</para>
								</item>
								<item>
									<label>•</label>
									<para>Hepatic studies: AST, ALT, alk phos</para>
								</item>
								<item>
									<label>•</label>
									<para>B/P, pulse</para>
								</item>
								<item>
									<label>•</label>
									<para>Weight daily, I&amp;O</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x14024">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x14028">
								<item>
									<label>•</label>
									<para>Therapeutic response: decreased B/P, increased hair growth</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x14034">
						<sec_title>Teach patient/family:</sec_title>
						<para>
							<list id="lidelem4x14038">
								<item>
									<label>•</label>
									<para>That body hair will increase but is reversible after discontinuing treatment</para>
								</item>
								<item>
									<label>•</label>
									<para>Not to discontinue product abruptly</para>
								</item>
								<item>
									<label>•</label>
									<para>To report pitting edema, dizziness, weight gain &gt;5 lb, SOB, bruising or bleeding, heart rate &gt;20 beats/min over normal, severe indigestion, dizziness, lightheadedness, panting, new or aggravated symptoms of angina</para>
								</item>
								<item>
									<label>•</label>
									<para>To take product exactly as prescribed because serious side effects may occur</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x14059">
						<sec_title>Topical</sec_title>
						<para>
							<list id="lidelem4x14063">
								<item>
									<label>•</label>
									<para>That for topical use, treatment must continue for the long term, or new hair will be lost</para>
								</item>
								<item>
									<label>•</label>
									<para>Not to use except on scalp; use on clean, dry scalp before styling aids; wash hands after each use</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
		</monograph>
<monograph id="38" status="active">
			<mono_name>mipomersen</mono_name>
			<info>
				<pronunciation>(mye′poe-mer-sen)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x140840">Kynamro</tradename>
				</tradenames>
				<class type="func"> Antilipemics</class>
				<class type="chem"> Antisense oligonucleotide</class>
				<class type="preg">Pregnancy category <preg cat="B">B</preg></class>
			</info>
			<section type="actions" id="sidelem4x14094">
				<sec_title>Action:</sec_title>
				<para>Inhibits synthesis of the principal apolipoprotein of LDL, VLDL, binds to messenger ribonucleic acid (mRNA)</para>
			</section>
			<section type="uses" id="sidelem4x14099">
				<sec_title>Uses:</sec_title>
				<para>Decreasing LDL, total cholesterol, apolipoprotein B, non-high density lipoprotein cholesterol to reduce LDL, total cholesterol, apolipoprotein B, non-high density lipoprotein cholesterol (homozygous familial hypercholesterolemia)</para>
			</section>
			<section type="contra" id="sidelem4x14104">
				<sec_title>Contraindications:</sec_title>
				<para>
					<bbw>Hepatic disease</bbw>
				</para>
				<section type="none" id="sidelem4x14117">
					<section type="none" id="sidelem4x14118">
						<sec_title>Precautions:</sec_title>
						<para> Pregnancy (<preg cat="B">B</preg>), breastfeeding, dialysis, alcohol ingestion, geriatric patients, proteinuria, renal disease, low density lipoprotein apheresis</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x14125">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x14128">
					<section type="none" id="sidelem4x14129">
						<sec_title>Homozygous familial hypercholesterolemia</sec_title>
						<section type="none" id="sidelem4x14137">
							<label>•</label>
							<sec_title>Adult<route> SUBCUT</route></sec_title>
							<para>
								<list id="lidelem4x14137">
									<item>
										<label>•</label>
										<para> 200 mg weekly</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x14141">
						<sec_title>Renal/hepatic dose</sec_title>
						<section type="none" id="sidelem4x14149">
							<label>•</label>
							<sec_title>Adult<route> SUBCUT do not use in severe renal, hepatic disease</route></sec_title>
						</section>
					</section>
					<section type="none" id="sidelem4x14152">
						<sec_title>Available forms:</sec_title>
						<para> Solution for injection 200 mg/ml</para>
					</section>
					<section type="none" id="sidelem4x14157">
						<sec_title>Administer:</sec_title>
						<para>
							<list id="lidelem4x14162">
								<item>
									<label>•</label>
									<para>Give on the same day weekly; if a dose is missed, give ≥3 days from the next weekly dose</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x14167">
								<item>
									<label>•</label>
									<para>Monitor ALT, AST, alkaline phosphatase, and total bilirubin before start of therapy; monitor lipid levels ≥q3-4mo for the first year</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x14172">
								<item>
									<label>•</label>
									<para>Monitor LDL-C level after 6 mo</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x14180">
							<label>•</label>
							<sec_title>
								<route>Dose adjustments for elevated transaminases during treatment</route>
							</sec_title>
						</section>
						<section type="none" id="sidelem4x14186">
							<label>•</label>
							<sec_title>ALT or AST ≥3× and &lt;5× ULN<route> confirm elevation with a repeat test within 1 wk; if confirmed, withhold product; obtain other tests if not already obtained (total bilirubin, alkaline phosphatase, INR) to identify the probable cause; if resuming product after transaminases resolve to &lt;3× ULN, consider monitor liver-related tests more frequently</route></sec_title>
						</section>
						<section type="none" id="sidelem4x14192">
							<label>•</label>
							<sec_title>ALT or AST ≥5× ULN<route> withhold, obtain additional liver-related tests if not already obtained (total bilirubin, alkaline phosphatase, INR), and identify the probable cause; if resuming product after transaminases resolve to &lt;3× ULN, monitor liver-related tests more frequently</route></sec_title>
						</section>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x14195">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x14198">
					<section type="none" id="sidelem4x14199">
						<sec_title>CNS:</sec_title>
						<para> Fatigue, headache, fever</para>
					</section>
					<section type="none" id="sidelem4x14204">
						<sec_title>CV:</sec_title>
						<para> Hypertension, palpitations</para>
					</section>
					<section type="none" id="sidelem4x14209">
						<sec_title>GI:</sec_title>
						<para> Abdominal pain, vomiting</para>
					</section>
					<section type="none" id="sidelem4x14214">
						<sec_title>GU:</sec_title>
						<para> <emphasis style="bold">Glomerulonephritis,</emphasis> proteinuria</para>
					</section>
					<section type="none" id="sidelem4x14222">
						<sec_title>MS:</sec_title>
						<para> Musculoskeletal pain</para>
					</section>
					<section type="none" id="sidelem4x14227">
						<sec_title>SYST:</sec_title>
						<para> <emphasis style="bold">Angioedema</emphasis></para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x14234">
				<sec_title>Pharmacokinetics</sec_title>
				<para>Half-life 1-2 mo protein binding &gt;90%</para>
			</section>
			<section type="interactions" id="sidelem4x14239">
				<sec_title>Interactions</sec_title>
				<para>
					<emphasis alert="lifethreat">Increase: hepatotoxicity risk—acetaminophen, methotrexate, tetracyclines, tamoxifen</emphasis>
				</para>
			</section>
			<section type="considerations" id="sidelem4x14245">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x14248">
					<section type="none" id="sidelem4x14249">
						<sec_title>Assess:</sec_title>
						<para>
							<list id="lidelem4x14253">
								<item>
									<label>•</label>
									<para>Determine if the LDL-C reduction achieved is sufficient to warrant the potential risk of liver toxicity</para>
								</item>
								<item>
									<label>•</label>
									<para>Assess geriatric patients: increased risk for hypertension, peripheral edema, hepatic steatosis</para>
								</item>
								<item>
									<label>•</label>
									<para>Hypercholesterolemia: diet history: fat content, lipid levels (triglycerides, LDL, HDL, cholesterol); LFTs are at baseline, periodically during treatment</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x14269">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x14273">
								<item>
									<label>•</label>
									<para>Therapeutic response: decreasing LDL, total cholesterol, apolipoprotein B, non-high density lipoprotein cholesterol</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x14279">
						<sec_title>Teach patient/family:</sec_title>
						<para>
							<list id="lidelem4x14283">
								<item>
									<label>•</label>
									<para>That compliance is needed</para>
								</item>
								<item>
									<label>•</label>
									<para>That risk factors should be decreased: high fat diet, smoking, alcohol consumption, absence of exercise</para>
								</item>
								<item>
									<label>•</label>
									<para>To notify prescriber if pregnancy is suspected, planned, or if breastfeeding</para>
								</item>
								<item>
									<label>•</label>
									<para>To notify prescriber of dietary/herbal supplements</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
		</monograph>
<monograph id="39" status="active">
			<mono_name>mirabegron</mono_name>
			<info>
				<pronunciation>(mir′a-beg′ron)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x143090">Myrbetriq</tradename>
				</tradenames>
				<class type="func"> Bladder antispasmodic</class>
				<class type="chem"> β-Adrenergic receptor agonist</class>
				<class type="preg">Pregnancy category <preg cat="C">C</preg></class>
			</info>
			<section type="actions" id="sidelem4x14322">
				<sec_title>Action:</sec_title>
				<para>Relaxes smooth muscles in urinary tract</para>
			</section>
			<section type="uses" id="sidelem4x14327">
				<sec_title>Uses:</sec_title>
				<para>Overactive bladder (urinary frequency, urgency), urinary incontinence</para>
			</section>
			<section type="contra" id="sidelem4x14332">
				<sec_title>Contraindications:</sec_title>
				<para>Hypersensitivity</para>
				<section type="none" id="sidelem4x14337">
					<section type="none" id="sidelem4x14338">
						<sec_title>Precautions:</sec_title>
						<para> Pregnancy (<preg cat="C">C</preg>), breastfeeding, children, kidney/liver disease, bladder obstruction, dialysis, hypertension</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x14344">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x14352">
					<label>•</label>
					<sec_title>Adult<route> PO</route></sec_title>
					<para>
						<list id="lidelem4x14352">
							<item>
								<label>•</label>
								<para> 25 mg/day, may increase to 50 mg/day if needed</para>
							</item>
						</list>
					</para>
				</section>
				<section type="none" id="sidelem4x14356">
					<section type="none" id="sidelem4x14357">
						<sec_title>Hepatic/renal dose</sec_title>
						<para>
							<list id="lidelem4x14363">
								<item>
									<para>
										<emphasis alert="nurse">PO Child–Pugh B or (CCr 15-29 ml/min, max 25 mg/day; Child–Pugh C or CCr &lt;15 ml/min, not recommended</emphasis>
									</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x14368">
						<sec_title>Available forms:</sec_title>
						<para> Tabs ext rel 25, 50 mg</para>
					</section>
					<section type="none" id="sidelem4x14373">
						<sec_title>Administer:</sec_title>
						<para>
							<list id="lidelem4x14377">
								<item>
									<label>•</label>
									<para>Give whole; take with liquids; do not crush, chew, or break ext rel product; use without regard to meals</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x14383">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x14386">
					<section type="none" id="sidelem4x14387">
						<sec_title>CNS:</sec_title>
						<para> Fatigue, dizziness, headache</para>
					</section>
					<section type="none" id="sidelem4x14392">
						<sec_title>CV:</sec_title>
						<para> Hypertension</para>
					</section>
					<section type="none" id="sidelem4x14397">
						<sec_title>EENT:</sec_title>
						<para> Xerophthalmia, blurred vision</para>
					</section>
					<section type="none" id="sidelem4x14402">
						<sec_title>GI:</sec_title>
						<para> Nausea, vomiting, anorexia, abdominal pain, constipation, diarrhea, dyspepsia</para>
					</section>
					<section type="none" id="sidelem4x14407">
						<sec_title>GU:</sec_title>
						<para> Dysuria, urinary retention, frequency, UTI, bladder discomfort</para>
					</section>
					<section type="none" id="sidelem4x14412">
						<sec_title>INTEG:</sec_title>
						<para> Rash, pruritus</para>
					</section>
					<section type="none" id="sidelem4x14417">
						<sec_title>MISC:</sec_title>
						<para> Arthralgia, back pain</para>
					</section>
					<section type="none" id="sidelem4x14422">
						<sec_title>RESP:</sec_title>
						<para> Pharyngitis</para>
					</section>
					<section type="none" id="sidelem4x14427">
						<sec_title>SYST:</sec_title>
						<para> <emphasis style="bold">Stevens–Johnson syndrome</emphasis></para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x14434">
				<sec_title>Pharmacokinetics</sec_title>
				<para>71% protein binding, excretion 25% unchanged in urine, terminal half-life 50 hr, peak 3.5 hr</para>
			</section>
			<section type="interactions" id="sidelem4x14439">
				<sec_title>Interactions</sec_title>
				<para>
					<emphasis style="bold">Increase:</emphasis> mirabegron effect—CYP3A4 inhibitors</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> effect of CYP2D6 substrates</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> effect of digoxin, warfarin, desipramine, thioridazine, flecainide, propafenone</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> risk of urinary retention with antimuscarinic agents (e.g., atropine, scopolamine)</para>
			</section>
			<section type="considerations" id="sidelem4x14458">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x14461">
					<section type="none" id="sidelem4x14462">
						<sec_title>Assess:</sec_title>
						<para>
							<list id="lidelem4x14466">
								<item>
									<label>•</label>
									<para>Urinary patterns: distention, nocturia, frequency, urgency, incontinence</para>
								</item>
								<item>
									<label>•</label>
									<para>LFTs at baseline, periodically</para>
								</item>
								<item>
									<label>•</label>
									<para>Monitor B/P</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x14482">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x14486">
								<item>
									<label>•</label>
									<para>Decreasing dysuria, frequency, nocturia, incontinence</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x14492">
						<sec_title>Teach patient/family:</sec_title>
						<para>
							<list id="lidelem4x14496">
								<item>
									<label>•</label>
									<para>To avoid hazardous activities; dizziness can occur</para>
								</item>
								<item>
									<label>•</label>
									<para>Not to drink liquids before bedtime</para>
								</item>
								<item>
									<label>•</label>
									<para>About the importance of bladder maintenance</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
		</monograph>
<monograph id="40" status="active">
			<mono_name>mirtazapine (Rx)</mono_name>
			<info>
				<pronunciation>(mer-ta′za-peen)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x145171">Remeron</tradename>
					<tradename id="tnidelem4x145170">Remeron Soltab</tradename>
				</tradenames>
				<class type="func"> Antidepressant</class>
				<class type="chem"> Tetracyclic</class>
				<class type="preg">Pregnancy category <preg cat="C">C</preg></class>
			</info>
			<section type="actions" id="sidelem4x14527">
				<sec_title>Action:</sec_title>
				<para>Blocks reuptake of norepinephrine and serotonin into nerve endings, thereby increasing action of norepinephrine and serotonin in nerve cells; antagonist of central α<emphasis style="inf">2</emphasis>-receptors; blocks histamine receptors</para>
			</section>
			<section type="uses" id="sidelem4x14535">
				<sec_title>Uses:</sec_title>
				<para>Depression; dysthymic disorder; bipolar disorder: depressed, agitated depression</para>
				<section type="none" id="sidelem4x14540">
					<section type="none" id="sidelem4x14541">
						<sec_title>Unlabeled uses:</sec_title>
						<para> Resting tremor, benign familial tremor, levodopa-induced dyskinesias, pruritus</para>
					</section>
				</section>
			</section>
			<section type="contra" id="sidelem4x14546">
				<sec_title>Contraindications:</sec_title>
				<para>Hypersensitivity to tricyclics, recovery phase of MI, agranulocytosis, jaundice</para>
				<section type="none" id="sidelem4x14551">
					<section type="none" id="sidelem4x14552">
						<sec_title>Precautions:</sec_title>
						<para> Pregnancy (<preg cat="C">C</preg>), geriatric patients, suicidal patients, severe depression, increased intraocular pressure, closed-angle glaucoma, urinary retention, cardiac/renal/hepatic disease, hypo/hyperthyroidism, electroshock therapy, elective surgery, seizure disorder, bone marrow suppression, thrombocytopenia</para>
						<para>
							<bbw>Suicidal ideation, children</bbw>
						</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x14567">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x14575">
					<label>•</label>
					<sec_title>Adult<route> PO</route></sec_title>
					<para>
						<list id="lidelem4x14575">
							<item>
								<label>•</label>
								<para> 15 mg/day at bedtime, maintenance to continue for 6 mo, titrate up to 45 mg/day;  tabs: open blister pack, place tab on tongue, allow to disintegrate, swallow</para>
							</item>
						</list>
					</para>
				</section>
				<section type="none" id="sidelem4x14587">
					<label>•</label>
					<sec_title>Geriatric<route> PO</route></sec_title>
					<para>
						<list id="lidelem4x14587">
							<item>
								<label>•</label>
								<para> 7.5 mg at bedtime, increase by 7.5 mg q1-2wk to desired dose, max 45 mg/day</para>
							</item>
						</list>
					</para>
				</section>
				<section type="none" id="sidelem4x14591">
					<section type="none" id="sidelem4x14592">
						<sec_title>Resting tremor/benign familial tremor/levodopa-induced dyskinesias (unlabeled)</sec_title>
						<section type="none" id="sidelem4x14600">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x14600">
									<item>
										<label>•</label>
										<para> titrate up to 30 mg at bedtime</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x14604">
						<sec_title>Pruritus (unlabeled)</sec_title>
						<section type="none" id="sidelem4x14612">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x14612">
									<item>
										<label>•</label>
										<para> 15-30 mg/day</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x14616">
						<sec_title>Available forms:</sec_title>
						<para> Tabs 7.5, 15, 30, 45 mg; orally disintegrating tab (Soltab) 15, 30, 45 mg</para>
					</section>
					<section type="none" id="sidelem4x14621">
						<sec_title>Administer:</sec_title>
						<para>
							<list id="lidelem4x14626">
								<item>
									<label>•</label>
									<para>Increased fluids, bulk in diet for constipation, especially for geriatric patients</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x14631">
								<item>
									<label>•</label>
									<para>Without regard to meals</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x14636">
								<item>
									<label>•</label>
									<para>Dosage at bedtime if oversedation occurs during day; may take entire dose at bedtime; geriatric patients may not tolerate once-daily dosing</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x14641">
								<item>
									<label>•</label>
									<para>Gum, hard candy, or frequent sips of water for dry mouth</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x14646">
								<item>
									<label>•</label>
									<para>Store in tight container at room temperature; do not freeze</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x14654">
							<label>•</label>
							<sec_title>Orally disintegrating tab</sec_title>
							<para>
								<list id="lidelem4x14654">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Orally disintegrating tab:</emphasis> no water needed; allow to dissolve on tongue, do not split; contains phenylalanine</para>
									</item>
								</list>
							</para>
						</section>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x14658">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x14661">
					<section type="none" id="sidelem4x14662">
						<sec_title>CNS:</sec_title>
						<para> <emphasis style="italic">Dizziness, drowsiness,</emphasis> confusion, headache, anxiety, tremors, stimulation, weakness, nightmares, EPS (geriatric patients), increased psychiatric symptoms, <emphasis style="bold">seizures,</emphasis> abnormal dreams</para>
					</section>
					<section type="none" id="sidelem4x14673">
						<sec_title>CV:</sec_title>
						<para> <emphasis style="italic">Orthostatic hypotension, ECG changes,</emphasis> tachycardia, <emphasis style="bold">hypertension,</emphasis> palpitations</para>
					</section>
					<section type="none" id="sidelem4x14684">
						<sec_title>EENT:</sec_title>
						<para> <emphasis style="italic">Blurred vision,</emphasis> tinnitus, mydriasis</para>
					</section>
					<section type="none" id="sidelem4x14692">
						<sec_title>GI:</sec_title>
						<para> <emphasis style="italic">Diarrhea, dry mouth,</emphasis> nausea, vomiting, <emphasis style="bold">paralytic ileus,</emphasis> increased appetite, cramps, epigastric distress, constipation, <emphasis style="bold">jaundice, hepatitis,</emphasis> stomatitis, weight gain</para>
					</section>
					<section type="none" id="sidelem4x14706">
						<sec_title>GU:</sec_title>
						<para> <emphasis style="italic">Urinary retention,</emphasis><emphasis style="bold">acute renal failure,</emphasis> urinary frequency</para>
					</section>
					<section type="none" id="sidelem4x14716">
						<sec_title>HEMA:</sec_title>
						<para> <emphasis style="bold">Agranulocytosis, thrombocytopenia, eosinophilia, leukopenia</emphasis></para>
					</section>
					<section type="none" id="sidelem4x14723">
						<sec_title>INTEG:</sec_title>
						<para> Rash, urticaria, sweating, pruritus, photosensitivity</para>
					</section>
					<section type="none" id="sidelem4x14728">
						<sec_title>MS:</sec_title>
						<para> Back pain, myalgia</para>
					</section>
					<section type="none" id="sidelem4x14733">
						<sec_title>RESP:</sec_title>
						<para> Cough</para>
					</section>
					<section type="none" id="sidelem4x14738">
						<sec_title>SYST:</sec_title>
						<para> Flulike symptoms, increased lipid levels</para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x14743">
				<sec_title>Pharmacokinetics</sec_title>
				<section type="none" id="sidelem4x14746">
					<section type="none" id="sidelem4x14747">
						<sec_title>PO:</sec_title>
						<para> Peak 2 hr, metabolized by CYP1A2, 2D6, 3A4 in liver; excreted in urine, feces; crosses placenta; half-life 20-40 hr, protein binding 85%</para>
					</section>
				</section>
			</section>
			<section type="interactions" id="sidelem4x14752">
				<sec_title>Interactions</sec_title>
				<para>
					<list id="lidelem4x14758">
						<item>
							<para>
								<emphasis alert="nurse">Increase: hyperpyretic crisis, seizures, hypertensive episode—MAOIs</emphasis>
							</para>
						</item>
					</list>
				</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> CNS depression—alcohol, barbiturates, benzodiazepines, other CNS depressants</para>
				<para>
					<emphasis alert="lifethreat">Increase: serotonin syndrome—SSRIs, SNRIs, serotonin-receptor agonists, fenfluramine, dexfenfluramine, sibutramine, nefazodone</emphasis>
				</para>
				<para>
					<emphasis style="bold">Decrease:</emphasis> effects of cloNIDine, indirect-acting sympathomimetics (ePHEDrine)</para>
				<section type="none" id="sidelem4x14774">
					<section type="none" id="sidelem4x14775">
						<sec_title>Drug/Herb</sec_title>
						<section type="none" id="sidelem4x14783">
							<label>•</label>
							<sec_title>Serotonin syndrome<route> St. John’s wort</route></sec_title>
						</section>
						<para>
							<emphasis style="bold">Increase:</emphasis> CNS depression—kava</para>
					</section>
					<section type="none" id="sidelem4x14790">
						<sec_title>Drug/Lab Test</sec_title>
						<para>
							<emphasis style="bold">Increase:</emphasis> serum bilirubin, blood glucose, alk phos</para>
						<para>
							<emphasis style="bold">Decrease:</emphasis> VMA, 5-HIAA</para>
						<para>
							<emphasis style="bold">False increase:</emphasis> urinary catecholamines</para>
					</section>
				</section>
			</section>
			<section type="considerations" id="sidelem4x14805">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x14808">
					<section type="none" id="sidelem4x14809">
						<sec_title>Assess:</sec_title>
						<para>
							<list id="lidelem4x14814">
								<item>
									<label>•</label>
									<para>B/P (lying, standing), pulse q4hr; if systolic B/P drops 20 mm Hg, hold product, notify prescriber; vital signs q4hr in patients with CV disease</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x14819">
								<item>
									<label>•</label>
									<para>Blood studies: CBC, leukocytes, differential, cardiac enzymes, lipid profile, blood glucose, LFTs, serum creatinine/BUN if patient is receiving long-term therapy</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x14824">
								<item>
									<label>•</label>
									<para>Weight weekly; appetite may increase with product</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x14833">
							<label>•</label>
							<sec_title>
								<route>ECG for flattening of T wave, bundle branch block, AV block, dysrhythmias in cardiac patients</route>
							</sec_title>
						</section>
						<para>
							<list id="lidelem4x14846">
								<item>
									<para>
										<emphasis alert="nurse">Serotonin syndrome: hyperthermia, hypertension, myoclonus, rigidity, delirium, coma; if using other serotonergic products</emphasis>
									</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x14851">
								<item>
									<label>•</label>
									<para>Alcohol consumption; if alcohol consumed, hold dose until morning</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x14856">
								<item>
									<label>•</label>
									<para>Assistance with ambulation during beginning therapy, since drowsiness, dizziness occurs</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x14861">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x14865">
								<item>
									<label>•</label>
									<para>Therapeutic response: decreased depression</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x14871">
						<sec_title>Teach patient/family:</sec_title>
						<para>
							<list id="lidelem4x14875">
								<item>
									<label>•</label>
									<para>That therapeutic effects may take 2-3 wk; to take at bedtime; that there is decreased sedation with increased doses; not to discontinue abruptly</para>
								</item>
								<item>
									<label>•</label>
									<para>To use caution when driving, performing other activities requiring alertness because of drowsiness, dizziness, blurred vision</para>
								</item>
								<item>
									<label>•</label>
									<para>To avoid alcohol, other CNS depressants</para>
								</item>
								<item>
									<label>•</label>
									<para>About how to take orally disintegrating tabs; dissolve on tongue, swallow</para>
								</item>
								<item>
									<label>•</label>
									<para>Not to use within 14 days of MAOIs
<bbw>To notify prescriber of suicidal thoughts, behavior</bbw>
</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
		</monograph>
<monograph id="41" status="active">
			<mono_name>misoprostol (Rx)</mono_name>
			<info>
				<pronunciation>(mye-soe-prost′ole)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x149200">Cytotec</tradename>
				</tradenames>
				<class type="func"> Gastric mucosa protectant, antiulcer</class>
				<class type="chem"> Prostaglandin E analog</class>
				<class type="preg">Pregnancy category <preg cat="X">X</preg></class>
			</info>
			<section type="confusion" id="sidelem4x14933">
				<para>
					<confusion>
						<tradename id="tnidelem4x149330">misoprostol</tradename>
						<drug type="generic" refid="idelem4x149330">metoprolol</drug>
					</confusion>
				</para>
			</section>
			<section type="actions" id="sidelem4x14940">
				<sec_title>Action:</sec_title>
				<para>Inhibits gastric acid secretion; may protect gastric mucosa; can increase bicarbonate, mucous production</para>
			</section>
			<section type="uses" id="sidelem4x14945">
				<sec_title>Uses:</sec_title>
				<para>Prevention of NSAID-induced gastric ulcers</para>
				<section type="none" id="sidelem4x14950">
					<section type="none" id="sidelem4x14951">
						<sec_title>Unlabeled uses:</sec_title>
						<para> Pregnancy termination, postpartum hemorrhage, cervical ripening/labor induction (vaginal), active duodenal/gastric ulcer, kidney transplant rejection prophylaxis</para>
					</section>
				</section>
			</section>
			<section type="contra" id="sidelem4x14956">
				<sec_title>Contraindications:</sec_title>
				<para>Hypersensitivity to this product or prostaglandins</para>
				<para>
					<bbw>Pregnancy (X), females</bbw>
				</para>
				<section type="none" id="sidelem4x14971">
					<section type="none" id="sidelem4x14972">
						<sec_title>Precautions:</sec_title>
						<para> Breastfeeding, children, geriatric patients, renal/CV disease, abnormal fetal position, cardiac/renal/inflammatory bowel disease, C-section, dehydration, diarrhea, fever, ectopic pregnancy, fetal distress, sepsis, vaginal bleeding</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x14977">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x14985">
					<label>•</label>
					<sec_title>Adult<route> PO</route></sec_title>
					<para>
						<list id="lidelem4x14985">
							<item>
								<label>•</label>
								<para> 200 mcg qid with food for duration of NSAID therapy, with last dose given at bedtime; if 200 mcg is not tolerated, 100 mcg may be given</para>
							</item>
						</list>
					</para>
				</section>
				<section type="none" id="sidelem4x14989">
					<section type="none" id="sidelem4x14990">
						<sec_title>Active duodenal/gastric ulcer (unlabeled)</sec_title>
						<section type="none" id="sidelem4x14998">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x14998">
									<item>
										<label>•</label>
										<para> 100-200 mcg qid with meals at bedtime × 4-8 wk</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x15002">
						<sec_title>Pregnancy termination before 63rd day (unlabeled)</sec_title>
						<section type="none" id="sidelem4x15010">
							<label>•</label>
							<sec_title>Adult<route> INTRAVAGINALLY</route></sec_title>
							<para>
								<list id="lidelem4x15010">
									<item>
										<label>•</label>
										<para> 800 mcg 5-7 days after methotrexate IM</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x15014">
						<sec_title>Cervical ripening induction for term pregnancy (unlabeled)</sec_title>
						<section type="none" id="sidelem4x15022">
							<label>•</label>
							<sec_title>Adult<route> INTRAVAGINALLY</route></sec_title>
							<para>
								<list id="lidelem4x15022">
									<item>
										<label>•</label>
										<para> 25 mcg q3-6hr</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x15026">
						<sec_title>Available forms:</sec_title>
						<para> Tabs 100, 200 mcg</para>
					</section>
					<section type="none" id="sidelem4x15031">
						<sec_title>Administer:</sec_title>
						<para>
							<list id="lidelem4x15035">
								<item>
									<label>•</label>
									<para>PO with meals for prolonged product effect; avoid use of magnesium antacids</para>
								</item>
								<item>
									<label>•</label>
									<para>Store at room temperature</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x15047">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x15050">
					<section type="none" id="sidelem4x15051">
						<sec_title>GI:</sec_title>
						<para> <emphasis style="italic">Diarrhea,</emphasis> nausea, vomiting, flatulence, constipation, dyspepsia, abdominal pain</para>
					</section>
					<section type="none" id="sidelem4x15059">
						<sec_title>GU:</sec_title>
						<para> Spotting, cramps, hypermenorrhea, menstrual disorders</para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x15064">
				<sec_title>Pharmacokinetics</sec_title>
				<section type="none" id="sidelem4x15067">
					<section type="none" id="sidelem4x15068">
						<sec_title>PO:</sec_title>
						<para> Peak 12 min, plasma steady-state achieved within 2 days, excreted in urine</para>
					</section>
				</section>
			</section>
			<section type="interactions" id="sidelem4x15073">
				<sec_title>Interactions</sec_title>
				<section type="none" id="sidelem4x15076">
					<section type="none" id="sidelem4x15077">
						<sec_title>Drug/Food</sec_title>
						<para>
							<emphasis style="bold">Decrease:</emphasis> maximum concentrations when taken with food</para>
					</section>
				</section>
			</section>
			<section type="considerations" id="sidelem4x15084">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x15087">
					<section type="none" id="sidelem4x15088">
						<sec_title>Assess:</sec_title>
						<section type="none" id="sidelem4x15096">
							<label>•</label>
							<sec_title>NSAID-induced ulcer prophylaxis</sec_title>
							<para>
								<list id="lidelem4x15096">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">NSAID-induced ulcer prophylaxis:</emphasis> monitor GI symptoms (hematemesis, occult or frank blood in stools, gastric aspirate, cramping, severe diarrhea)
<bbw>Pregnancy (X): Obtain a negative pregnancy test; miscarriages are common</bbw>
</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x15109">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x15113">
								<item>
									<label>•</label>
									<para>Therapeutic response: absence of pain or GI complaints; prevention of ulcers</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x15119">
						<sec_title>Teach patient/family:</sec_title>
						<para>
							<list id="lidelem4x15123">
								<item>
									<label>•</label>
									<para>To take only as directed; to read patient information leaflet
<bbw>Not to take if pregnant (can cause miscarriage) (X); not to become pregnant while taking product; if pregnancy occurs during therapy, discontinue product, notify prescriber; not to breastfeed</bbw>
</para>
								</item>
								<item>
									<label>•</label>
									<para>Not to give product to anyone else or to take for more than 4 wk unless directed by prescriber</para>
								</item>
								<item>
									<label>•</label>
									<para>To avoid OTC preparations: aspirin, cough, cold products; condition may worsen</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
		</monograph>
<monograph id="42" status="active" ha="yes">
			<mono_name> mitoMYcin (Rx)</mono_name>
			<info>
				<pronunciation>(mye-toe-mye′sin)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x151550">Mitosol</tradename>
				</tradenames>
				<class type="func"> Antineoplastic, antibiotic</class>
				<class type="preg">Pregnancy category <preg cat="D">D</preg></class>
			</info>
			<section type="confusion" id="sidelem4x15161">
				<para>
					<confusion>
						<tradename id="tnidelem4x151610">mitoMYcin</tradename>
						<drug type="generic" refid="idelem4x151610">mithramycin/mitotane/mitoXANtrone</drug>
					</confusion>
				</para>
			</section>
			<section type="actions" id="sidelem4x15165">
				<sec_title>Action:</sec_title>
				<para>Inhibits DNA synthesis, primarily; derived from <emphasis style="italic">Streptomyces caespitosus;</emphasis> appears to cause cross-linking of DNA; vesicant</para>
			</section>
			<section type="uses" id="sidelem4x15173">
				<sec_title>Uses:</sec_title>
				<para>Pancreatic, stomach, colorectal, bladder cancer</para>
				<section type="none" id="sidelem4x15178">
					<section type="none" id="sidelem4x15179">
						<sec_title>Unlabeled uses:</sec_title>
						<para> Palliative treatment of anal, bladder, head, neck, colon, breast, biliary, cervical, lung malignancies; bone marrow ablation, desmoid tumor, mesothelioma, stem cell transplant preparation</para>
					</section>
				</section>
			</section>
			<section type="contra" id="sidelem4x15184">
				<sec_title>Contraindications:</sec_title>
				<para>Pregnancy (<preg cat="D">D</preg>) 1st trimester, breastfeeding, hypersensitivity, as single agent, coagulation disorders</para>
				<para>
					<bbw>Thrombocytopenia</bbw>
				</para>
				<section type="none" id="sidelem4x15199">
					<section type="none" id="sidelem4x15200">
						<sec_title>Precautions:</sec_title>
						<para> Accidental exposure, acute bronchospasm, anemia, children, dental disease/work, extravasation, females, infection, radiation therapy, surgery, vaccines, renal/respiratory disease</para>
						<para>
							<bbw>Bone marrow suppression, hemolytic-uremic syndrome</bbw>
						</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x15215">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x15223">
					<label>•</label>
					<sec_title>Adult<route> IV</route></sec_title>
					<para>
						<list id="lidelem4x15223">
							<item>
								<label>•</label>
								<para> 20 mg/m<emphasis style="sup">2</emphasis> q6-8wk</para>
							</item>
						</list>
					</para>
				</section>
				<section type="none" id="sidelem4x15230">
					<section type="none" id="sidelem4x15231">
						<sec_title>Available forms:</sec_title>
						<para> Inj 5, 20, 40 mg/vial</para>
					</section>
					<section type="none" id="sidelem4x15236">
						<sec_title>Administer:</sec_title>
						<section type="none" id="sidelem4x15239">
							<sec_title>Direct IV route</sec_title>
							<para>
								<list id="lidelem4x15243">
									<item>
										<label>•</label>
										<para>Use port or central line if possible</para>
									</item>
									<item>
										<label>•</label>
										<para>Antiemetic 30-60 min before product to prevent vomiting</para>
									</item>
									<item>
										<label>•</label>
										<para>IV after diluting 5 mg/10 ml, 20 mg/ 40 ml, 40 mg/80 ml (0.5 mg/ml) sterile water for inj; shake, allow to stand, give through <emphasis style="sans-serif">Y</emphasis>-tube or 3-way stopcock; give slow IV push or infuse over 15-30 min; color of reconstituted sol is gray</para>
									</item>
									<item>
										<label>•</label>
										<para>Avoid excessive heat; store reconstituted product in refrigerator; discard after 2 wk; store unreconstituted product at room temperature</para>
									</item>
								</list>
							</para>
							<para>
								<emphasis style="bold">Y-site compatibilities:</emphasis> Amifostine, amphotericin B lipid complex, amphotericin B liposome, anidulafungin, argatroban, atenolol, bivalirudin, bleomycin, caspofungin, CISplatin, cyclophosphamide, DACTINomycin, dolasteron, DOXOrubicin, droperidol, epirubicin, ertapenem, fluorouracil, furosemide, granisetron, heparin, leucovorin, melphalan, methotrexate, metoclopramide, nesiritide, octreotide, ondansetron, oxaliplatin, PACLitaxel, palonosetron, PEMEtrexed, riTUXimab, teniposide, thiotepa, tigecycline, tirofiban, trastuzumab, vinBLAStine, vinCRIStine, voriconazole, zoledronic acid</para>
						</section>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x15272">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x15275">
					<section type="none" id="sidelem4x15276">
						<sec_title>CNS:</sec_title>
						<para> Fever, headache, confusion, drowsiness, syncope, fatigue</para>
					</section>
					<section type="none" id="sidelem4x15281">
						<sec_title>EENT:</sec_title>
						<para> Blurred vision</para>
					</section>
					<section type="none" id="sidelem4x15286">
						<sec_title>GI:</sec_title>
						<para> <emphasis style="italic">Nausea, vomiting, anorexia, stomatitis,</emphasis><emphasis style="bold">hepatotoxicity,</emphasis> diarrhea</para>
					</section>
					<section type="none" id="sidelem4x15296">
						<sec_title>GU:</sec_title>
						<para> Urinary retention, <emphasis style="bold">renal failure,</emphasis> edema</para>
					</section>
					<section type="none" id="sidelem4x15304">
						<sec_title>HEMA:</sec_title>
						<para> <emphasis style="bold">Thrombocytopenia, leukopenia, anemia</emphasis></para>
					</section>
					<section type="none" id="sidelem4x15311">
						<sec_title>INTEG:</sec_title>
						<para> <emphasis style="italic">Rash,</emphasis> alopecia, <emphasis style="bold">extravasation,</emphasis> nail discoloration</para>
					</section>
					<section type="none" id="sidelem4x15322">
						<sec_title>MISC:</sec_title>
						<para> <emphasis style="bold">Hemolytic uremic syndrome, CHF</emphasis></para>
					</section>
					<section type="none" id="sidelem4x15329">
						<sec_title>RESP:</sec_title>
						<para> <emphasis style="bold">Fibrosis, pulmonary infiltrate,</emphasis> dyspnea</para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x15337">
				<sec_title>Pharmacokinetics</sec_title>
				<para>Half-life 1 hr, metabolized in liver, 10% excreted in urine (unchanged)</para>
			</section>
			<section type="interactions" id="sidelem4x15342">
				<sec_title>Interactions</sec_title>
				<para>
					<emphasis alert="lifethreat">Increase: toxicity—other antineoplastics, radiation</emphasis>
				</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> bleeding risk—NSAIDs, anticoagulants<list id="lidelem4x15352">
						<item>
							<label>•</label>
							<para>Avoid use with vaccines</para>
						</item>
					</list></para>
				<section type="none" id="sidelem4x15358">
					<section type="none" id="sidelem4x15359">
						<sec_title>Drug/Herb</sec_title>
						<para>
							<list id="lidelem4x15363">
								<item>
									<label>•</label>
									<para>Avoid use with black cohosh</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
			<section type="considerations" id="sidelem4x15369">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x15372">
					<section type="none" id="sidelem4x15373">
						<sec_title>Assess:</sec_title>
						<para>
							<bbw>Bone marrow suppression: CBC, differential, platelet count weekly; withhold product if WBC is &lt;4000/mm3, serum creatinine &gt;1.7 mg/dl, or platelet count is &lt;100,000/mm3; notify prescriber; bleeding: hematuria, guaiac, bruising, petechiae, mucosa, or orifices</bbw>
						</para>
						<para>
							<bbw>
								<emphasis alert="lifethreat">Fatal hemolytic-uremic syndrome:</emphasis> hypertension, thrombocytopenia, microangiopathic hemolytic anemia; occurs in those receiving long-term therapy</bbw>
						</para>
						<para>
							<list id="lidelem4x15404">
								<item>
									<label>•</label>
									<para>Renal studies: BUN, serum uric acid, urine CCr, electrolytes before, during therapy, adjust dose based on renal function</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x15409">
								<item>
									<label>•</label>
									<para>I&amp;O ratio; report fall in urine output to &lt;30 ml/hr</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x15414">
								<item>
									<label>•</label>
									<para>Monitor temperature q4hr; fever may indicate beginning infection</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x15419">
								<item>
									<label>•</label>
									<para>Hepatic studies before, during therapy: bilirubin, AST, ALT, alk phos as needed or monthly; check for jaundiced skin and sclera, dark urine, clay-colored stools, itchy skin, abdominal pain, fever, diarrhea</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x15425">
								<item>
									<para>
										<emphasis alert="nurse">Pulmonary fibrosis: bronchospasm, dyspnea, crackles, unproductive cough; chest pain, tachypnea, fatigue, increased pulse, pallor, lethargy; pulmonary function tests; chest x-ray before, during therapy; chest x-ray should be obtained q2wk during treatment</emphasis>
									</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x15430">
								<item>
									<label>•</label>
									<para>Effects of alopecia on body image; discuss feelings about body changes</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x15435">
								<item>
									<label>•</label>
									<para>Buccal cavity q8hr for dryness, sores, ulceration, white patches, oral pain, bleeding, dysphagia</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x15440">
								<item>
									<label>•</label>
									<para>Local irritation, pain, burning at inj site</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x15446">
								<item>
									<label>•</label>
									<para>GI symptoms: frequency of stools, cramping</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x15451">
								<item>
									<label>•</label>
									<para>Adequate fluids 2-3 L/day unless contraindicated</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x15456">
								<item>
									<label>•</label>
									<para>Rinsing of mouth tid-qid with water; brushing of teeth with baking soda bid-tid with soft brush or cotton-tipped applicators for stomatitis; use unwaxed dental floss</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x15461">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x15465">
								<item>
									<label>•</label>
									<para>Therapeutic response: decreased tumor size, spread of malignancy</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x15471">
						<sec_title>Teach patient/family:</sec_title>
						<para>
							<list id="lidelem4x15476">
								<item>
									<label>•</label>
									<para>That hair may be lost during treatment; that wig or hairpiece may make patient feel better; that new hair may be different in color, texture</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x15481">
								<item>
									<label>•</label>
									<para>To avoid foods with citric acid, hot or rough texture</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x15486">
								<item>
									<label>•</label>
									<para>To report any bleeding, white spots, ulcerations in mouth; to examine mouth daily</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x15494">
							<label>•</label>
							<sec_title>
								<route>To report sign of IV-site reaction, redness, inflammation, burning, pain</route>
							</sec_title>
						</section>
						<para>
							<list id="lidelem4x15497">
								<item>
									<label>•</label>
									<para>To avoid crowds, persons with infections if granulocyte count is low</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x15505">
							<label>•</label>
							<sec_title>Infection<route> report fever, flulike symptoms, sore throat</route></sec_title>
						</section>
						<section type="none" id="sidelem4x15511">
							<label>•</label>
							<sec_title>
								<route>To immediately report urine retention, absence of urine, dyspnea, bleeding, jaundice, signs of pulmonary toxicity</route>
							</sec_title>
						</section>
						<section type="none" id="sidelem4x15517">
							<label>•</label>
							<sec_title>
								<route>To report if pregnancy is planned or suspected; pregnancy (D) 1st trimester, do not breastfeed</route>
							</sec_title>
						</section>
					</section>
				</section>
			</section>
		</monograph>
<monograph id="43" status="active" ha="yes">
			<mono_name> mitoXANtrone (Rx)</mono_name>
			<info>
				<pronunciation>(mye-toe-zan′trone)</pronunciation>
				<class type="func"> Antineoplastic, antiinfective, immunomodulator</class>
				<class type="chem"> Synthetic anthraquinone</class>
				<class type="preg">Pregnancy category <preg cat="D">D</preg></class>
			</info>
			<section type="confusion" id="sidelem4x15535">
				<para>
					<confusion>
						<tradename id="tnidelem4x155350">mitoXANtrone</tradename>
						<drug type="generic" refid="idelem4x155350">mitoMYcin/mithramycin/mitotane</drug>
					</confusion>
				</para>
			</section>
			<section type="actions" id="sidelem4x15539">
				<sec_title>Action:</sec_title>
				<para>DNA reactive agent; cytocidal effect on both proliferating and nonproliferating cells; topoisomerase II inhibitor (vesicant)</para>
			</section>
			<section type="uses" id="sidelem4x15544">
				<sec_title>Uses:</sec_title>
				<para>Acute myelogenous leukemia (adult), relapsed leukemia; used with steroids to treat bone pain (advanced prostate cancer), multiple sclerosis (MS)</para>
				<section type="none" id="sidelem4x15549">
					<section type="none" id="sidelem4x15550">
						<sec_title>Unlabeled uses:</sec_title>
						<para> Liver malignancies, non-Hodgkin’s lymphoma, breast cancer, ALL, bone marrow ablation, CLL, hepatocellular cancer, ovarian cancer, pleural effusion, stem cell transplant preparation</para>
					</section>
				</section>
			</section>
			<section type="contra" id="sidelem4x15555">
				<sec_title>Contraindications:</sec_title>
				<para>Pregnancy (<preg cat="D">D</preg>), hypersensitivity</para>
				<section type="none" id="sidelem4x15560">
					<section type="none" id="sidelem4x15561">
						<sec_title>Precautions:</sec_title>
						<para> Breastfeeding, children; myelosuppression, renal/cardiac/hepatic disease; gout</para>
						<para>
							<bbw>Secondary malignancy, neutropenia, intrathecal administration, extravasation, heart failure</bbw>
						</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x15576">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x15579">
					<section type="none" id="sidelem4x15580">
						<sec_title>Acute myelogenous leukemia/induction</sec_title>
						<section type="none" id="sidelem4x15588">
							<label>•</label>
							<sec_title>Adult<route> IV INFUSION</route></sec_title>
							<para>
								<list id="lidelem4x15588">
									<item>
										<label>•</label>
										<para> 12 mg/m<emphasis style="sup">2</emphasis>/day on days 1-3 and 100 mg/m<emphasis style="sup">2</emphasis> cytarabine × 7 days as continuous 24-hr infusion</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x15598">
						<sec_title>Consolidation</sec_title>
						<section type="none" id="sidelem4x15606">
							<label>•</label>
							<sec_title>Adult<route> IV</route></sec_title>
							<para>
								<list id="lidelem4x15606">
									<item>
										<label>•</label>
										<para> 12 mg/m<emphasis style="sup">2</emphasis> given as short 5- to 15-min infusion for 2 days with cytarabine × 5 days</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x15613">
						<sec_title>Advanced prostate cancer</sec_title>
						<section type="none" id="sidelem4x15621">
							<label>•</label>
							<sec_title>Adult<route> IV</route></sec_title>
							<para>
								<list id="lidelem4x15621">
									<item>
										<label>•</label>
										<para> 12-14 mg/m<emphasis style="sup">2</emphasis> as single dose or short infusion q21days</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x15628">
						<sec_title>Multiple sclerosis, relapsing</sec_title>
						<section type="none" id="sidelem4x15636">
							<label>•</label>
							<sec_title>Adult<route> IV INFUSION</route></sec_title>
							<para>
								<list id="lidelem4x15636">
									<item>
										<label>•</label>
										<para> 12 mg/m<emphasis style="sup">2</emphasis> as 5- to 15-min infusion q3mo, cumulative lifetime dose 140 mg/m<emphasis style="sup">2</emphasis></para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x15645">
						<sec_title>Available forms:</sec_title>
						<para> Inj 2, 10, 12.5, 15 mg/ml</para>
					</section>
					<section type="none" id="sidelem4x15650">
						<sec_title>Administer:</sec_title>
						<para>
							<list id="lidelem4x15654">
								<item>
									<label>•</label>
									<para>Other medications by oral route if possible; avoid IM, SUBCUT, IV routes</para>
								</item>
								<item>
									<label>•</label>
									<para>Antiemetic 30-60 min before product to prevent vomiting</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x15665">
							<sec_title>Direct IV route</sec_title>
							<para>
								<list id="lidelem4x15669">
									<item>
										<label>•</label>
										<para>IV after diluting with ≥50 ml NS or D<emphasis style="inf">5</emphasis>W; give over 3-5 min into running IV of D<emphasis style="inf">5</emphasis>W or NS; check for extravasation; do not give IM, SUBCUT, or intraarterially</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x15683">
							<sec_title>Intermittent IV INFUSION route</sec_title>
							<para>
								<list id="lidelem4x15687">
									<item>
										<label>•</label>
										<para>May be diluted further in D<emphasis style="inf">5</emphasis>W, NS, run over 15-30 min</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x15696">
							<sec_title>Continuous IV INFUSION route</sec_title>
							<para>
								<list id="lidelem4x15700">
									<item>
										<label>•</label>
										<para>Give over 24 hr</para>
									</item>
								</list>
							</para>
							<para>
								<emphasis style="bold">Y-site compatibilities:</emphasis> Acyclovir, alemtuzumab, alfentanil, allopurinol, amikacin, aminocaproic acid, aminophylline, amiodarone, anidulafungin, argatroban, arsenic trioxide, atracurium, bivalirudin, bleomycin, bretylium, bumetanide, buprenorphine, butorphanol, calcium chloride, calcium gluconate, CARBOplatin, carmustine, caspofungin, cefoTEtan, ceftizoxime, chloramphenicol, chlorproMAZINE, cimetidine, ciprofloxacin, cisatracurium, CISplatin, cladribine, codeine, cyclophosphamide, cycloSPORINE, cytarabine, DACTINomycin, DAPTOmycin, DAUNOrubicin citrate liposome, dexmedetomidine, dexrazoxane, diltiazem, diphenhydrAMINE, DOBUTamine, DOCEtaxel, dolasetron, DOPamine, doxacurium, doxycycline, droperidol, enalaprilat, ePHEDrine, EPINEPHrine, erythromycin, esmolol, etoposide, etoposide phosphate, famotidine, fenoldopam, fentaNYL, filgrastim, fluconazole, fludarabine, fluorouracil, ganciclovir, gatifloxacin, gemcitabine, gentamicin, glycopyrrolate, granisetron, haloperidol, hydrALAZINE, hydrocortisone sodium succinate, HYDROmorphone, hydrOXYzine, ifosfamide, imipenem-cilastatin, inamrinone, insulin regular, irinotecan, isoproterenol, ketorolac, labetalol, leucovorin, levofloxacin, levorphanol, lidocaine, linezolid, LORazepam, magnesium sulfate, mannitol, melphalan, meperidine, meropenem, mesna, metaraminol, methohexital, methotrexate, methyldopate, metoclopramide, metoprolol, metroNIDAZOLE, midazolam, milrinone, minocycline, mivacurium, morphine sulfate, nalbuphine, naloxone, nesiritide, niCARdipine, nitroglycerin, norepinephrine, octreotide, ondansetron, oxaliplatin, palonosetron, pamidronate, pancuronium, pentamidine, pentazocine, PENTObarbital, PHENObarbital, phentolamine, phenylephrine, polymyxin b, potassium acetate, potassium chloride, procainamide, prochlorperazine, promethazine hydrochloride, propranolol, quiNIDine gluconate, quinupristin-dalfopristin, ranitidine, remifentanil, riTUXimab, rocuronium, sargramostim, sodium acetate, sodium bicarbonate, succinylcholine, SUFentanil, sulfamethoxazole-trimethoprim, tacrolimus, teniposide, theophylline, thiopental, thiotepa, tigecycline, tirofiban, tobramycin, tolazoline, trastuzumab, trimethobenzamide, vancomycin, vasopressin, vecuronium, verapamil, vinCRIStine, vinorelbine, zidovudine, zoledronic acid</para>
						</section>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x15710">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x15713">
					<section type="none" id="sidelem4x15714">
						<sec_title>CNS:</sec_title>
						<para> Headache, <emphasis style="bold">seizures,</emphasis> fatigue</para>
					</section>
					<section type="none" id="sidelem4x15722">
						<sec_title>CV:</sec_title>
						<para> <emphasis style="bold">CHF, cardiopathy, dysrhythmias</emphasis></para>
					</section>
					<section type="none" id="sidelem4x15729">
						<sec_title>EENT:</sec_title>
						<para> Conjunctivitis, blue/green sclera, blurred vision</para>
					</section>
					<section type="none" id="sidelem4x15734">
						<sec_title>GI:</sec_title>
						<para> <emphasis style="italic">Nausea, vomiting, diarrhea, anorexia, mucositis,</emphasis><emphasis style="bold">hepatotoxicity,</emphasis> abdominal pain, constipation, jaundice</para>
					</section>
					<section type="none" id="sidelem4x15744">
						<sec_title>GU:</sec_title>
						<para> Amenorrhea, menstrual disorders</para>
					</section>
					<section type="none" id="sidelem4x15749">
						<sec_title>HEMA:</sec_title>
						<para> <emphasis style="bold">Thrombocytopenia, leukopenia, myelosuppression, anemia, secondary leukemia</emphasis></para>
					</section>
					<section type="none" id="sidelem4x15756">
						<sec_title>INTEG:</sec_title>
						<para> <emphasis style="italic">Rash, necrosis at inj site,</emphasis> dermatitis, thrombophlebitis at inj site, alopecia</para>
					</section>
					<section type="none" id="sidelem4x15764">
						<sec_title>MISC:</sec_title>
						<para> Fever, hyperuricemia, infections</para>
					</section>
					<section type="none" id="sidelem4x15769">
						<sec_title>RESP:</sec_title>
						<para> Cough, dyspnea</para>
					</section>
					<section type="none" id="sidelem4x15774">
						<sec_title>SYST:</sec_title>
						<para> <emphasis style="bold">Tumor lysis syndrome, sepsis</emphasis></para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x15781">
				<sec_title>Pharmacokinetics</sec_title>
				<para>Protein binding 78%; excreted via renal, hepatobiliary systems; half-life 23-215 hr</para>
			</section>
			<section type="interactions" id="sidelem4x15786">
				<sec_title>Interactions</sec_title>
				<para>
					<emphasis alert="lifethreat">Increase: bone marrow depression toxicity—radiation, other antineoplastics</emphasis>
				</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> adverse reactions—live virus vaccines, trastuzumab</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> bleeding risk—NSAIDs, anticoagulants</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> mitoXANtrone effects of—digoxin, phenytoin</para>
				<section type="none" id="sidelem4x15805">
					<section type="none" id="sidelem4x15806">
						<sec_title>Drug/Lab Test</sec_title>
						<para>
							<emphasis style="bold">Increase:</emphasis> LFTs, uric acid</para>
						<para>
							<emphasis style="bold">Decrease:</emphasis> HcT/Hgb, platelets, WBC</para>
					</section>
				</section>
			</section>
			<section type="considerations" id="sidelem4x15817">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x15820">
					<section type="none" id="sidelem4x15821">
						<sec_title>Assess:</sec_title>
						<para>
							<list id="lidelem4x15826">
								<item>
									<label>•</label>
									<para>CBC, differential, platelet count weekly; withhold product if WBC is &lt;1500/mm<emphasis style="sup">3</emphasis>; leukopenia, neutropenia, thrombocytopenia are expected, leukocyte nadir 10-14 days, recovers in 2-3 wk</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x15837">
							<label>•</label>
							<sec_title>Hepatotoxicity<route> hepatic studies before, during therapy</route></sec_title>
						</section>
						<para>
							<list id="lidelem4x15840">
								<item>
									<label>•</label>
									<para>Renal studies: BUN, serum uric acid, urine CCr, electrolytes before, during therapy</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x15848">
							<para>
								<list id="lidelem4x15848">
									<item>
										<label>•</label>
										<para>Bleeding, hematuria, guaiac, bruising or petechiae, mucosa or orifices q8hr
<bbw>ECG, ECHO, chest x-ray, MUGA, RAI angiography; assess ejection fraction before and during treatment; cardiotoxic may develop during treatment or months to years after treatment; use vigilant cardiac monitoring in MS</bbw>

<bbw>Secondary acute myelogenous leukemia (AML) that can develop after taking this product</bbw>

<bbw>
												<emphasis alert="lifethreat">Multiple sclerosis:</emphasis> obtain MUGA, LVEF baselines; repeat LVEF if symptoms of CHF occur or if cumulative dose is &gt;100 mg/m2; do not administer to patients who have received lifetime dose of ≥140 mg/m2 or if LVEF &lt;50% or significant LVEF</bbw>
</para>
									</item>
								</list>
							</para>
						</section>
						<para>
							<list id="lidelem4x15885">
								<item>
									<label>•</label>
									<para>Obtain pregnancy test for all women of childbearing age, even if birth control is used, pregnancy (D)</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x15890">
								<item>
									<label>•</label>
									<para>Rinsing of mouth tid-qid with water, club soda; brushing of teeth bid-qid with soft brush or cotton-tipped applicators for stomatitis; use unwaxed dental floss</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x15895">
								<item>
									<label>•</label>
									<para>Provide increased fluids to 2-3 L/day unless contraindicated</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x15900">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x15904">
								<item>
									<label>•</label>
									<para>Therapeutic response: decreased tumor size, spread of malignancy</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x15910">
						<sec_title>Teach patient/family:</sec_title>
						<para>
							<list id="lidelem4x15914">
								<item>
									<label>•</label>
									<para>To immediately report bleeding, dyspnea, possible infections, seizure, jaundice, fever, cough, or dyspnea</para>
								</item>
								<item>
									<label>•</label>
									<para>To avoid hot foods or those with citric acid, rough texture</para>
								</item>
								<item>
									<label>•</label>
									<para>To report any bleeding, white spots, ulcerations in mouth; to examine mouth daily</para>
								</item>
								<item>
									<label>•</label>
									<para>To avoid crowds, persons with infections</para>
								</item>
								<item>
									<label>•</label>
									<para>That sclera, urine may turn blue or green; that hair loss may occur</para>
								</item>
							</list>
						</para>
						<para>
							<bbw>To notify prescriber if pregnancy is suspected or planned; to use effective contraception</bbw>
						</para>
					</section>
				</section>
			</section>
		</monograph>
<monograph id="44" status="active">
			<mono_name>modafinil (Rx)</mono_name>
			<info>
				<pronunciation>(mo-daf′i-nil)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x159551">
						<country code="CAN">Alertec </country>
					</tradename>
					<tradename id="tnidelem4x159550">Provigil</tradename>
				</tradenames>
				<class type="func"> CNS stimulant</class>
				<class type="chem"> Racemic compound</class>
				<class type="preg">Pregnancy category <preg cat="C">C</preg></class>
			</info>
			<section type="actions" id="sidelem4x15970">
				<sec_title>Action:</sec_title>
				<para>Similar action as that of sympathomimetics; does not alter release of DOPamine, norepinephrine</para>
			</section>
			<section type="uses" id="sidelem4x15975">
				<sec_title>Uses:</sec_title>
				<para>Narcolepsy, shift-work sleep disturbance, obstructive sleep apnea</para>
				<section type="none" id="sidelem4x15980">
					<section type="none" id="sidelem4x15981">
						<sec_title>Unlabeled uses:</sec_title>
						<para> Fatigue in MS, ADHD, symptoms of major depression</para>
					</section>
				</section>
			</section>
			<section type="contra" id="sidelem4x15986">
				<sec_title>Contraindications:</sec_title>
				<para>Hypersensitivity, ischemic heart disease, left ventricular hypertrophy, chest pain, dysrhythmias</para>
				<section type="none" id="sidelem4x15991">
					<section type="none" id="sidelem4x15992">
						<sec_title>Precautions:</sec_title>
						<para> Pregnancy (<preg cat="C">C</preg>), breastfeeding, child &lt;16 yr, geriatric patients, unstable angina, history of MI, severe hepatic disease</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x15998">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x16001">
					<section type="none" id="sidelem4x16002">
						<sec_title>To improve wakefulness with daytime sleepiness</sec_title>
						<section type="none" id="sidelem4x16010">
							<label>•</label>
							<sec_title>Adult and adolescent ≥16 yr<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x16010">
									<item>
										<label>•</label>
										<para> 200 mg daily</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x16014">
						<sec_title>Hepatic dose (severe hepatic disease)</sec_title>
						<section type="none" id="sidelem4x16022">
							<label>•</label>
							<sec_title>Adult<route> PO 100 mg daily</route></sec_title>
						</section>
					</section>
					<section type="none" id="sidelem4x16025">
						<sec_title>Multiple sclerosis/fatigue (unlabeled)</sec_title>
						<section type="none" id="sidelem4x16033">
							<label>•</label>
							<sec_title>Adult/geriatric/adolescents ≥6 yr<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x16033">
									<item>
										<label>•</label>
										<para> 200-400 mg daily in the <emphasis style="smallcaps">am</emphasis></para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x16039">
						<sec_title>Major depression symptoms (unlabeled)</sec_title>
						<section type="none" id="sidelem4x16047">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x16047">
									<item>
										<label>•</label>
										<para> 100 mg/day, max 400 mg/day</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x16051">
						<sec_title>Available forms:</sec_title>
						<para> Tabs 100, 200 mg</para>
					</section>
					<section type="none" id="sidelem4x16056">
						<sec_title>Administer:</sec_title>
						<para>
							<list id="lidelem4x16060">
								<item>
									<label>•</label>
									<para>Give 1 hr before start of shift work or in <emphasis style="smallcaps">am</emphasis> for those with narcolepsy or sleep apnea</para>
								</item>
								<item>
									<label>•</label>
									<para>Store at room temperature</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x16074">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x16077">
					<section type="none" id="sidelem4x16078">
						<sec_title>CNS:</sec_title>
						<para> <emphasis style="italic">Headache,</emphasis> anxiety, cataplexy, depression, dizziness, insomnia, amnesia, confusion, ataxia, tremors, paresthesia, dyskinesia, <emphasis style="bold">suicidal ideation</emphasis></para>
					</section>
					<section type="none" id="sidelem4x16088">
						<sec_title>CV:</sec_title>
						<para> Dysrhythmias, hypo/hypertension, chest pain, vasodilation</para>
					</section>
					<section type="none" id="sidelem4x16093">
						<sec_title>EENT:</sec_title>
						<para> Change in vision, <emphasis style="italic">rhinitis,</emphasis> pharyngitis, epistaxis</para>
					</section>
					<section type="none" id="sidelem4x16101">
						<sec_title>GI:</sec_title>
						<para> Nausea, vomiting, changes in LFTs, anorexia, diarrhea, thirst, mouth ulcers</para>
					</section>
					<section type="none" id="sidelem4x16106">
						<sec_title>GU:</sec_title>
						<para> Ejaculation disorder, urinary retention, albuminuria</para>
					</section>
					<section type="none" id="sidelem4x16111">
						<sec_title>HEMA:</sec_title>
						<para> Eosinophilia</para>
					</section>
					<section type="none" id="sidelem4x16116">
						<sec_title>INTEG:</sec_title>
						<para> Rash, dry skin, herpes simplex, <emphasis style="bold">Stevens-Johnson syndrome</emphasis></para>
					</section>
					<section type="none" id="sidelem4x16123">
						<sec_title>MISC:</sec_title>
						<para> Infection, hyperglycemia, neck pain</para>
					</section>
					<section type="none" id="sidelem4x16128">
						<sec_title>RESP:</sec_title>
						<para> <emphasis style="italic">Dyspnea</emphasis>, lung changes</para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x16136">
				<sec_title>Pharmacokinetics</sec_title>
				<para>Absorbed rapidly, 60% protein binding, metabolized by the liver (90%), half-life 15 hr, peak 2-4 hr</para>
			</section>
			<section type="interactions" id="sidelem4x16141">
				<sec_title>Interactions</sec_title>
				<para>
					<emphasis style="bold">Increase:</emphasis> altered levels of CYP3A4 inhibitors (azole antibiotics some SSRIs), reaction difficult to predict</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> levels of CYP2C19 substrates (diazepam, phenytoin some tricyclics)</para>
				<para>
					<emphasis style="bold">Decrease:</emphasis> effects of—cycloSPORINE, hormonal contraceptives, theophylline, estrogens</para>
				<para>
					<emphasis style="bold">Delayed effect modafinil by 1 hr:</emphasis> methylphenidate</para>
				<para>
					<emphasis style="bold">Altered:</emphasis> levels of CYP3A4 inducers (carBAMazepine, phenytoin, rifampin, cycloSPORINE, theophylline)</para>
				<section type="none" id="sidelem4x16164">
					<section type="none" id="sidelem4x16165">
						<sec_title>Drug/Herb</sec_title>
						<para>
							<emphasis style="bold">Increase:</emphasis> stimulation—cola nut, guarana, yerba maté, coffee, tea</para>
					</section>
					<section type="none" id="sidelem4x16172">
						<sec_title>Drug/Lab Test</sec_title>
						<para>
							<emphasis style="bold">Increase:</emphasis> LFTs, glucose, eosinophils</para>
					</section>
				</section>
			</section>
			<section type="considerations" id="sidelem4x16179">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x16182">
					<section type="none" id="sidelem4x16183">
						<sec_title>Assess:</sec_title>
						<para>
							<list id="lidelem4x16187">
								<item>
									<label>•</label>
									<para>Narcolepsy, shift work, history of sleep apnea</para>
								</item>
								<item>
									<label>•</label>
									<para>Depression, suicidal ideation</para>
								</item>
								<item>
									<label>•</label>
									<para>Monitor B/P in those with hypertension</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x16203">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x16207">
								<item>
									<label>•</label>
									<para>Ability to stay awake</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x16213">
						<sec_title>Teach patient/family:</sec_title>
						<para>
							<list id="lidelem4x16218">
								<item>
									<label>•</label>
									<para>To take only as directed; that product may be taken with/without food</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x16226">
							<label>•</label>
							<sec_title>
								<route>To use other form of contraception during and for ≥30 days after discontinuing medication if using hormonal birth control; to notify prescriber if pregnancy is planned or suspected or if breastfeeding</route>
							</sec_title>
						</section>
						<para>
							<list id="lidelem4x16229">
								<item>
									<label>•</label>
									<para>To notify prescriber of allergic reaction, tremors, confusion</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x16234">
								<item>
									<label>•</label>
									<para>To avoid all OTC medications unless approved by prescriber</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x16239">
								<item>
									<label>•</label>
									<para>To avoid hazardous activities until drug effect is known</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
		</monograph>
<monograph id="45" status="active">
			<mono_name>moexipril (Rx)</mono_name>
			<info>
				<pronunciation>(moe-ex′ih-prill)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x162490">Univasc</tradename>
				</tradenames>
				<class type="func"> Antihypertensive</class>
				<class type="chem"> Angiotensin-converting enzyme inhibitor</class>
				<class type="preg">Pregnancy category <preg cat="D">D</preg></class>
			</info>
			<section type="actions" id="sidelem4x16259">
				<sec_title>Action:</sec_title>
				<para>Selectively suppresses renin-angiotensin-aldosterone system; inhibits ACE; prevents conversion of angiotensin I to angiotensin II; results in dilation of arterial, venous vessels</para>
			</section>
			<section type="uses" id="sidelem4x16266">
				<sec_title>Uses:</sec_title>
				<para>Hypertension, alone or in combination with thiazide diuretics</para>
			</section>
			<section type="contra" id="sidelem4x16271">
				<sec_title>Contraindications:</sec_title>
				<para>Breastfeeding, children, hypersensitivity, heart block, bilateral renal stenosis, history of angioedema</para>
				<para>
					<bbw>Pregnancy (D)</bbw>
				</para>
				<section type="none" id="sidelem4x16285">
					<section type="none" id="sidelem4x16286">
						<sec_title>Precautions:</sec_title>
						<para> Dialysis patients, hypovolemia, leukemia, scleroderma, lupus erythematosus, blood dyscrasias, CHF, diabetes mellitus, thyroid/renal disease, COPD, asthma, potassium-sparing diuretics</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x16291">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x16299">
					<label>•</label>
					<sec_title>Adult<route> PO</route></sec_title>
					<para>
						<list id="lidelem4x16299">
							<item>
								<label>•</label>
								<para> 7.5 mg 1 hr before meals initially; may be increased or divided depending on B/P response; maintenance dosage 7.5-30 mg/day in 1-2 divided doses 1 hr before meals</para>
							</item>
						</list>
					</para>
				</section>
				<section type="none" id="sidelem4x16303">
					<section type="none" id="sidelem4x16304">
						<sec_title>Renal dose</sec_title>
						<section type="none" id="sidelem4x16312">
							<label>•</label>
							<sec_title>Adult<route> PO CCr &lt;40 ml/min, 3.75 mg/day; titrate to desired dose; max 15 mg/day</route></sec_title>
						</section>
					</section>
					<section type="none" id="sidelem4x16315">
						<sec_title>Available forms:</sec_title>
						<para> Tabs 7.5, 15 mg</para>
					</section>
					<section type="none" id="sidelem4x16320">
						<sec_title>Administer:</sec_title>
						<para>
							<list id="lidelem4x16325">
								<item>
									<label>•</label>
									<para>1 hr before meals</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x16333">
							<label>•</label>
							<sec_title>
								<route>Do not use with potassium-sparing diuretics, sympathomimetics, potassium supplements</route>
							</sec_title>
						</section>
						<para>
							<list id="lidelem4x16336">
								<item>
									<label>•</label>
									<para>Storage in tight container at ≤86° F (30° C)</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x16341">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x16344">
					<section type="none" id="sidelem4x16345">
						<sec_title>CNS:</sec_title>
						<para> Fever, chills, fatigue, headache</para>
					</section>
					<section type="none" id="sidelem4x16350">
						<sec_title>CV:</sec_title>
						<para> Hypotension, postural hypotension</para>
					</section>
					<section type="none" id="sidelem4x16355">
						<sec_title>GI:</sec_title>
						<para> Loss of taste, <emphasis style="bold">hepatic failure/necrosis, hepatitis</emphasis></para>
					</section>
					<section type="none" id="sidelem4x16362">
						<sec_title>GU:</sec_title>
						<para> Impotence, dysuria, nocturia, proteinuria, <emphasis style="bold">nephrotic syndrome,</emphasis> acute reversible renal failure, polyuria, oliguria, frequency</para>
					</section>
					<section type="none" id="sidelem4x16370">
						<sec_title>HEMA:</sec_title>
						<para> <emphasis style="bold">Neutropenia</emphasis></para>
					</section>
					<section type="none" id="sidelem4x16377">
						<sec_title>INTEG:</sec_title>
						<para> Rash, photosensitivity</para>
					</section>
					<section type="none" id="sidelem4x16382">
						<sec_title>META:</sec_title>
						<para> Hypokalemia, hyperkalemia, hyponatremia</para>
					</section>
					<section type="none" id="sidelem4x16387">
						<sec_title>MS:</sec_title>
						<para> Myalgia</para>
					</section>
					<section type="none" id="sidelem4x16392">
						<sec_title>RESP:</sec_title>
						<para> <emphasis style="bold">Bronchospasm,</emphasis> dyspnea, dry cough, pneumonitis</para>
					</section>
					<section type="none" id="sidelem4x16400">
						<sec_title>SYST:</sec_title>
						<para> <emphasis style="bold">Angioedema, anaphylaxis</emphasis></para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x16407">
				<sec_title>Pharmacokinetics</sec_title>
				<para>Peak 1.5 hr, metabolized by liver (metabolites); excreted in feces (52%), urine; crosses placenta, excreted in breast milk, protein binding 50%-70%, half-life 2-10 hr</para>
			</section>
			<section type="interactions" id="sidelem4x16412">
				<sec_title>Interactions</sec_title>
				<section type="none" id="sidelem4x16420">
					<label>•</label>
					<sec_title>
						<route>Do not use with potassium-sparing diuretics, sympathomimetics, potassium supplements</route>
					</sec_title>
				</section>
				<para>
					<emphasis style="bold">Increase:</emphasis> hypotension—diuretics, other antihypertensives, ganglionic blockers, adrenergic blockers, phenothiazines</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> toxicity—digoxin, lithium</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> hyperkalemia—cycloSPORINE, potassium-sparing diuretics</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> myelosuppression—azaTHIOprine</para>
				<para>
					<emphasis style="bold">Decrease:</emphasis> antihypertensive effect—NSAIDs</para>
				<section type="none" id="sidelem4x16443">
					<section type="none" id="sidelem4x16444">
						<sec_title>Drug/Herb</sec_title>
						<para>
							<emphasis style="bold">Increase:</emphasis> antihypertensive effect—hawthorn</para>
						<para>
							<emphasis style="bold">Decrease:</emphasis> antihypertensive effect—yohimbe</para>
					</section>
					<section type="none" id="sidelem4x16455">
						<sec_title>Drug/Lab Test</sec_title>
						<para>
							<emphasis style="bold">False positive:</emphasis> urine acetone</para>
					</section>
				</section>
			</section>
			<section type="considerations" id="sidelem4x16462">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x16465">
					<section type="none" id="sidelem4x16466">
						<sec_title>Assess:</sec_title>
						<para>
							<list id="lidelem4x16471">
								<item>
									<label>•</label>
									<para>Blood tests: neutrophils, decreased platelets</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x16476">
								<item>
									<label>•</label>
									<para>Renal studies: protein, BUN, creatinine; watch for increased levels that may indicate nephrotic syndrome</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x16481">
								<item>
									<label>•</label>
									<para>Baselines of renal, hepatic studies before therapy begins</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x16486">
								<item>
									<label>•</label>
									<para>Potassium levels, although hyperkalemia rarely occurs</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x16491">
								<item>
									<label>•</label>
									<para>Edema in feet, legs daily</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x16499">
							<label>•</label>
							<sec_title>Allergic reaction</sec_title>
							<para>
								<list id="lidelem4x16499">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Allergic reaction:</emphasis> rash, fever, pruritus, urticaria; product should be discontinued if antihistamines fail to help</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x16507">
							<label>•</label>
							<sec_title>
								<route>Symptoms of CHF;</route>
							</sec_title>
							<para>
								<list id="lidelem4x16507">
									<item>
										<label>•</label>
										<para> edema, dyspnea, wet crackles, B/P, difficulty breathing</para>
									</item>
								</list>
							</para>
						</section>
						<para>
							<list id="lidelem4x16511">
								<item>
									<label>•</label>
									<para>Renal symptoms: polyuria, oliguria, frequency</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x16516">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x16520">
								<item>
									<label>•</label>
									<para>Therapeutic response: decrease in B/P with hypertension</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x16526">
						<sec_title>Teach patient/family:</sec_title>
						<para>
							<list id="lidelem4x16530">
								<item>
									<label>•</label>
									<para>To take 1 hr before meals</para>
								</item>
								<item>
									<label>•</label>
									<para>Not to discontinue product abruptly</para>
								</item>
								<item>
									<label>•</label>
									<para>Not to use OTC (cough, cold, allergy) products unless directed by prescriber</para>
								</item>
								<item>
									<label>•</label>
									<para>To comply with dosage schedule even if feeling better</para>
								</item>
								<item>
									<label>•</label>
									<para>To rise slowly to sitting or standing position to minimize orthostatic hypotension</para>
								</item>
								<item>
									<label>•</label>
									<para>To notify prescriber of mouth sores, sore throat, fever, swelling of hands or feet, irregular heartbeat, chest pain, signs of angioedema</para>
								</item>
								<item>
									<label>•</label>
									<para>That excessive perspiration, dehydration, vomiting, diarrhea may lead to fall in B/P; to consult prescriber if these occur</para>
								</item>
								<item>
									<label>•</label>
									<para>That dizziness, fainting, lightheadedness may occur during 1st few days of therapy</para>
								</item>
								<item>
									<label>•</label>
									<para>That skin rash or impaired perspiration may occur</para>
								</item>
								<item>
									<label>•</label>
									<para>How to take B/P
<bbw>Notify prescriber if pregnancy is planned or suspected</bbw>
</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
		</monograph>
<monograph id="46" status="active">
			<mono_name>montelukast (Rx)</mono_name>
			<info>
				<pronunciation>(mon-teh-loo′kast)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x166000">Singulair</tradename>
				</tradenames>
				<class type="func"> Bronchodilator</class>
				<class type="chem"> Leukotriene receptor antagonist, cysteinyl</class>
				<class type="preg">Pregnancy category <preg cat="B">B</preg></class>
			</info>
			<section type="actions" id="sidelem4x16610">
				<sec_title>Action:</sec_title>
				<para>Inhibits leukotriene (LTD<emphasis style="inf">4</emphasis>) formation; leukotrienes exert their effects by increasing neutrophil, eosinophil migration; aggregation of neutrophils, monocytes; smooth muscle contraction, capillary permeability; these actions further lead to bronchoconstriction, inflammation, edema</para>
			</section>
			<section type="uses" id="sidelem4x16618">
				<sec_title>Uses:</sec_title>
				<para>Chronic asthma in adults and children, seasonal allergic rhinitis, bronchospasm prophylaxis</para>
			</section>
			<section type="contra" id="sidelem4x16623">
				<sec_title>Contraindications:</sec_title>
				<para>Hypersensitivity</para>
				<section type="none" id="sidelem4x16628">
					<section type="none" id="sidelem4x16629">
						<sec_title>Precautions:</sec_title>
						<para> Pregnancy (<preg cat="B">B</preg>), breastfeeding, children &lt;6 yr, acute attacks of asthma, alcohol consumption, severe hepatic disease, corticosteroid withdrawal, phenylketonuria, suicidal ideation, depression</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x16634">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x16642">
					<label>•</label>
					<sec_title>Adult and child ≥15 yr<route> PO</route></sec_title>
					<para>
						<list id="lidelem4x16642">
							<item>
								<label>•</label>
								<para> 10 mg/day in <emphasis style="smallcaps">pm</emphasis></para>
							</item>
						</list>
					</para>
				</section>
				<section type="none" id="sidelem4x16651">
					<label>•</label>
					<sec_title>Child 6-14 yr<route> PO</route></sec_title>
					<para>
						<list id="lidelem4x16651">
							<item>
								<label>•</label>
								<para> 5-mg chew tab/day in <emphasis style="smallcaps">pm</emphasis></para>
							</item>
						</list>
					</para>
				</section>
				<section type="none" id="sidelem4x16660">
					<label>•</label>
					<sec_title>Child 2-5 yr<route> PO</route></sec_title>
					<para>
						<list id="lidelem4x16660">
							<item>
								<label>•</label>
								<para> (chew tab/granules) 4 mg/day</para>
							</item>
						</list>
					</para>
				</section>
				<section type="none" id="sidelem4x16664">
					<section type="none" id="sidelem4x16665">
						<sec_title>Asthma</sec_title>
						<section type="none" id="sidelem4x16673">
							<label>•</label>
							<sec_title>Child 12-23 mo<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x16673">
									<item>
										<label>•</label>
										<para> 1 packet (4 mg) granules taken in <emphasis style="smallcaps">pm</emphasis></para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x16679">
						<sec_title>Exercise-induced bronchoconstriction</sec_title>
						<section type="none" id="sidelem4x16687">
							<label>•</label>
							<sec_title>Adult/child ≥6 yr<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x16687">
									<item>
										<label>•</label>
										<para> 10 mg 2 hr before exercise; do not take another dose within 24 hr</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x16691">
						<sec_title>Available forms:</sec_title>
						<para> Tabs 10 mg; chew tabs 4, 5 mg; oral granules 4 mg/packet</para>
					</section>
					<section type="none" id="sidelem4x16696">
						<sec_title>Administer:</sec_title>
						<section type="none" id="sidelem4x16699">
							<sec_title>PO route</sec_title>
							<para>
								<list id="lidelem4x16703">
									<item>
										<label>•</label>
										<para>In <emphasis style="smallcaps">pm</emphasis> daily for all uses except exercise-induced bronchoconstriction; then take 2 hr before exercise</para>
									</item>
									<item>
										<label>•</label>
										<para>Granules directly in mouth or mixed with spoonful of soft food (carrots, applesauce, ice cream, rice)</para>
									</item>
									<item>
										<label>•</label>
										<para>Do not open granules packet until ready to use; mix whole dose; give within 15 min</para>
									</item>
								</list>
							</para>
						</section>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x16722">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x16725">
					<section type="none" id="sidelem4x16726">
						<sec_title>CNS:</sec_title>
						<para> <emphasis style="italic">Dizziness, fatigue, headache,</emphasis> behavior changes, hallucinations, <emphasis style="bold">seizures,</emphasis>agitation, anxiety, depression, fever, drowsiness, <emphasis style="bold">suicidal ideation, memory impairment, hostility, somnambulism</emphasis></para>
					</section>
					<section type="none" id="sidelem4x16740">
						<sec_title>GI:</sec_title>
						<para> <emphasis style="italic">Abdominal pain,</emphasis> dyspepsia, nausea, vomiting, diarrhea, <emphasis style="bold">pancreatitis</emphasis></para>
					</section>
					<section type="none" id="sidelem4x16750">
						<sec_title>HEMA:</sec_title>
						<para> <emphasis style="bold">Thrombocytopenia</emphasis></para>
					</section>
					<section type="none" id="sidelem4x16757">
						<sec_title>INTEG:</sec_title>
						<para> Rash, pruritus, erythema</para>
					</section>
					<section type="none" id="sidelem4x16762">
						<sec_title>MS:</sec_title>
						<para> Asthenia, myalgia, muscle cramps</para>
					</section>
					<section type="none" id="sidelem4x16767">
						<sec_title>RESP:</sec_title>
						<para> <emphasis style="italic">Influenza, cough,</emphasis> nasal congestion</para>
					</section>
					<section type="none" id="sidelem4x16775">
						<sec_title>SYST:</sec_title>
						<para> <emphasis style="bold">Anaphylaxis, angioedema, Churg-Strauss syndrome, Stevens-Johnson syndrome, toxic epidermal necrolysis</emphasis></para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x16782">
				<sec_title>Pharmacokinetics</sec_title>
				<para>Rapidly absorbed; peak 3-4 hr, chew tab (5 mg) 2-2.5 hr; half-life 2.7-5.5 hr, extended in hepatic disease; protein binding 99%; metabolized by liver; excreted via bile</para>
			</section>
			<section type="interactions" id="sidelem4x16787">
				<sec_title>Interactions</sec_title>
				<para>
					<emphasis style="bold">Increase:</emphasis> adverse reactions of CYP2C8 substrates</para>
				<para>
					<emphasis style="bold">Decrease:</emphasis> montelukast levels—barbiturates, rifabutin, rifapentine, carBAMazepine, fosphenytoin, phenytoin, rifampin</para>
				<section type="none" id="sidelem4x16798">
					<section type="none" id="sidelem4x16799">
						<sec_title>Drug/Herb</sec_title>
						<para>
							<emphasis style="bold">Increase:</emphasis> stimulation—black, green tea, guarana</para>
					</section>
					<section type="none" id="sidelem4x16806">
						<sec_title>Drug/Lab Test</sec_title>
						<para>
							<emphasis style="bold">Increase:</emphasis> ALT, AST</para>
					</section>
				</section>
			</section>
			<section type="considerations" id="sidelem4x16813">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x16816">
					<section type="none" id="sidelem4x16817">
						<sec_title>Assess:</sec_title>
						<para>
							<list id="lidelem4x16823">
								<item>
									<para>
										<emphasis alert="nurse">Churg-Strauss syndrome: rare adult patients carefully for symptoms: eosinophilia, vasculitic rash, worsening pulmonary symptoms, cardiac complications, neuropathy</emphasis>
									</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x16828">
								<item>
									<label>•</label>
									<para>Allergic reactions: rash, urticaria; product should be discontinued</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x16834">
								<item>
									<para>
										<emphasis alert="nurse">For behavior changes and suicidal ideation, other neuropsychiatric reactions</emphasis>
									</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x16842">
							<label>•</label>
							<sec_title>Severe hepatic disease</sec_title>
							<para>
								<list id="lidelem4x16842">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Severe hepatic disease:</emphasis> use cautiously</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x16846">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x16850">
								<item>
									<label>•</label>
									<para>Therapeutic response: ability to breathe more easily</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x16856">
						<sec_title>Teach patient/family:</sec_title>
						<para>
							<list id="lidelem4x16861">
								<item>
									<label>•</label>
									<para>To check OTC medications, current prescription medications for ePHEDrine, which will increase stimulation; to avoid alcohol</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x16866">
								<item>
									<label>•</label>
									<para>To avoid hazardous activities; dizziness may occur</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x16871">
								<item>
									<label>•</label>
									<para>That product is not to be used for acute asthma attacks</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x16876">
								<item>
									<label>•</label>
									<para>If aspirin sensitivity is known, not to take NSAIDs while taking this product</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x16881">
								<item>
									<label>•</label>
									<para>To continue to use inhaled β-agonists if exercise-induced asthma occurs</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x16889">
							<label>•</label>
							<sec_title>Granules</sec_title>
							<para>
								<list id="lidelem4x16889">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Granules:</emphasis> to give directly in mouth or mixed in a spoonful of room temperature soft food (use only applesauce, carrots, rice, or ice cream); use within 15 min of opening packets; discard unused portions</para>
									</item>
								</list>
							</para>
						</section>
					</section>
				</section>
			</section>
		</monograph>
<monograph id="47" status="active" ha="yes">
			<mono_name> morphine (Rx)</mono_name>
			<info>
				<pronunciation>(mor′feen)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x169008">Astramorph PF</tradename>
					<tradename id="tnidelem4x169007">AVINza</tradename>
					<tradename id="tnidelem4x169006">Depo Dur</tradename>
					<tradename id="tnidelem4x169005">Infumorph PF</tradename>
					<tradename id="tnidelem4x169004">Kadian</tradename>
					<tradename id="tnidelem4x169003">
						<country code="CAN">M.O.S. </country>
					</tradename>
					<tradename id="tnidelem4x169002">MS Contin</tradename>
					<tradename id="tnidelem4x169001">
						<country code="CAN">MSIR </country>
					</tradename>
					<tradename id="tnidelem4x169000">Oramorph SR</tradename>
				</tradenames>
				<class type="func"> Opioid analgesic</class>
				<class type="chem"> Alkaloid</class>
				<class type="preg">Pregnancy category <preg cat="C">C</preg></class>
				<class type="schedule">Controlled Substance Schedule <schedule num="2">II</schedule></class>
			</info>
			<section type="confusion" id="sidelem4x16918">
				<para>
					<confusion>
						<tradename id="tnidelem4x169180">morphine</tradename>
						<drug type="generic" refid="idelem4x169180">HYDROmorphone</drug>
					</confusion>
				</para>
			</section>
			<section type="actions" id="sidelem4x16925">
				<sec_title>Action:</sec_title>
				<para>Depresses pain impulse transmission at the spinal cord level by interacting with opioid receptors</para>
			</section>
			<section type="uses" id="sidelem4x16930">
				<sec_title>Uses:</sec_title>
				<para>Moderate to severe pain</para>
				<section type="none" id="sidelem4x16935">
					<section type="none" id="sidelem4x16936">
						<sec_title>Unlabeled uses:</sec_title>
						<para> Agitation, bone/dental pain, dyspnea in end-stage cancer or pulmonary disease, sedation induction, rapid-sequence intubation</para>
					</section>
				</section>
			</section>
			<section type="contra" id="sidelem4x16941">
				<sec_title>Contraindications:</sec_title>
				<para>Hypersensitivity, addiction (opioid/alcohol), hemorrhage, bronchial asthma, increased intracranial pressure, paralytic ileus, hypovolemia, shock, MAOI therapy</para>
				<para>
					<bbw>Respiratory depression</bbw>
				</para>
				<section type="none" id="sidelem4x16957">
					<section type="none" id="sidelem4x16958">
						<sec_title>Precautions:</sec_title>
						<para> Pregnancy (<preg cat="C">C</preg>), breastfeeding, children &lt;18 yr, geriatric patients, addictive personality, acute MI, severe heart disease, renal/hepatic disease, bowel impaction, abrupt discontinuation, seizures</para>
						<para>
							<bbw>Accidental exposure, epidural/intrathecal/IM/subcut administration, opioid-naive patients, substance abuse</bbw>
						</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x16973">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x16976">
					<section type="none" id="sidelem4x16977">
						<sec_title>Acute moderate to severe pain</sec_title>
						<section type="none" id="sidelem4x16980">
							<sec_title>PO regular-release route</sec_title>
							<section type="none" id="sidelem4x16988">
								<label>•</label>
								<sec_title>Adult ≥50 kg</sec_title>
								<para>
									<list id="lidelem4x16988">
										<item>
											<label>•</label>
											<para>
												<emphasis style="bold">Adult ≥50 kg:</emphasis> initially, 10-30 mg every 3-4 hr as needed</para>
										</item>
									</list>
								</para>
							</section>
							<section type="none" id="sidelem4x16995">
								<label>•</label>
								<sec_title>Adult &lt;50 kg/geriatric patients</sec_title>
								<para>
									<list id="lidelem4x16995">
										<item>
											<label>•</label>
											<para>
												<emphasis style="bold">Adult &lt;50 kg/geriatric patients:</emphasis> might require lower doses and/or extended dosing intervals; doses should be titrated carefully</para>
										</item>
									</list>
								</para>
							</section>
							<section type="none" id="sidelem4x17002">
								<label>•</label>
								<sec_title>Child/infant ≥6 mo</sec_title>
								<para>
									<list id="lidelem4x17002">
										<item>
											<label>•</label>
											<para>
												<emphasis style="bold">Child/infant ≥6 mo:</emphasis> 0.2-0.5 mg/kg every 4-6 hr as needed</para>
										</item>
									</list>
								</para>
							</section>
							<section type="none" id="sidelem4x17009">
								<label>•</label>
								<sec_title>Infants &lt;6 mo/neonate<route> PO</route></sec_title>
								<para>
									<list id="lidelem4x17009">
										<item>
											<label>•</label>
											<para> 0.1 mg/kg every 3-4 hr</para>
										</item>
									</list>
								</para>
							</section>
						</section>
						<section type="none" id="sidelem4x17013">
							<sec_title>IV/IM/SUBCUT route</sec_title>
							<section type="none" id="sidelem4x17021">
								<label>•</label>
								<sec_title>Adult ≥50 kg</sec_title>
								<para>
									<list id="lidelem4x17021">
										<item>
											<label>•</label>
											<para>
												<emphasis style="bold">Adult ≥50 kg:</emphasis> 2.5-15 mg every 2-6 hr as needed, titrate; or a loading dose of 0.05-0.1 mg/kg IV, followed by 0.8-10 mg/hr IV, titrate</para>
										</item>
									</list>
								</para>
							</section>
							<section type="none" id="sidelem4x17028">
								<label>•</label>
								<sec_title>Adult &lt;50 kg/geriatric patients</sec_title>
								<para>
									<list id="lidelem4x17028">
										<item>
											<label>•</label>
											<para>
												<emphasis style="bold">Adult &lt;50 kg/geriatric patients:</emphasis> might require lower doses and/or extended dosing intervals 0.1 mg/kg every 3-4 hr, titrate</para>
										</item>
									</list>
								</para>
							</section>
							<section type="none" id="sidelem4x17035">
								<label>•</label>
								<sec_title>Child/infant ≥6 mo</sec_title>
								<para>
									<list id="lidelem4x17035">
										<item>
											<label>•</label>
											<para>
												<emphasis style="bold">Child/infant ≥6 mo:</emphasis> 0.05-0.2 mg/kg every 2-4 hr, titrate to relief; max initial dose 15 mg/dose, avoid IM when possible</para>
										</item>
									</list>
								</para>
							</section>
							<section type="none" id="sidelem4x17042">
								<label>•</label>
								<sec_title>Infants &lt;6 mo/neonate</sec_title>
								<para>
									<list id="lidelem4x17042">
										<item>
											<label>•</label>
											<para>
												<emphasis style="bold">Infants &lt;6 mo/neonate:</emphasis> 0.03-0.05 mg/kg every 3-8 hr, titrate to relief, avoid IM when possible</para>
										</item>
									</list>
								</para>
							</section>
						</section>
						<section type="none" id="sidelem4x17046">
							<sec_title>Epidural (morphine sulfate injection, but <emphasis style="bold">
									<emphasis style="italic">not</emphasis>
								</emphasis> DepoDur)</sec_title>
							<section type="none" id="sidelem4x17058">
								<label>•</label>
								<sec_title>Adult</sec_title>
								<para>
									<list id="lidelem4x17058">
										<item>
											<label>•</label>
											<para>
												<emphasis style="bold">Adult:</emphasis> initially, 5 mg in the lumbar region; if pain relief does not occur in 1 hr, give 1-2 mg epidurally; max 10 mg/24 hr;  2-4 mg/24 hr; may give another 1-2 mg</para>
										</item>
									</list>
								</para>
							</section>
						</section>
						<section type="none" id="sidelem4x17065">
							<sec_title>Intrathecal route (morphine sulfate injection, but <emphasis style="bold">
									<emphasis style="italic">not</emphasis>
								</emphasis> DepoDur)</sec_title>
							<para>
								<list id="lidelem4x17074">
									<item>
										<label>•</label>
										<para>Do not inject &gt;2 ml of the 0.5 mg/ml or 1 ml of the 1 mg/ml ampule</para>
									</item>
								</list>
							</para>
							<section type="none" id="sidelem4x17082">
								<label>•</label>
								<sec_title>Adult</sec_title>
								<para>
									<list id="lidelem4x17082">
										<item>
											<label>•</label>
											<para>
												<emphasis style="bold">Adult:</emphasis> 0.2-1 mg in the lumbar area as a single dose or to establish dosage for continuous intrathecal infusion; repeated injections are not recommended</para>
										</item>
									</list>
								</para>
							</section>
						</section>
						<section type="none" id="sidelem4x17086">
							<sec_title>Rectal route</sec_title>
							<section type="none" id="sidelem4x17094">
								<label>•</label>
								<sec_title>Adult<route> PR</route></sec_title>
								<para>
									<list id="lidelem4x17094">
										<item>
											<label>•</label>
											<para> 10-20 mg every 4 hr, as needed</para>
										</item>
									</list>
								</para>
							</section>
							<section type="none" id="sidelem4x17101">
								<label>•</label>
								<sec_title>Child</sec_title>
								<para>
									<list id="lidelem4x17101">
										<item>
											<label>•</label>
											<para>
												<emphasis style="bold">Child:</emphasis> Individualize</para>
										</item>
									</list>
								</para>
							</section>
						</section>
					</section>
					<section type="none" id="sidelem4x17105">
						<sec_title>Chronic moderate and severe pain:</sec_title>
						<para>
							<list id="lidelem4x17111">
								<item>
									<para>
										<emphasis alert="nurse">Do not use extended-release cap or tab as <emphasis style="smallcaps">prn</emphasis> analgesics, for acute pain, or if the pain is mild or not expected to persist for an extended period of time; use for postoperative pain only if the patient is receiving chronic opioid therapy before surgery or if the postoperative pain is expected to be moderate to severe and expected to persist for an extended period of time; do not use controlled-release tablets (MS Contin) immediately after surgery (for the first 24 hr) in patients not previously taking the drug</emphasis>
									</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x17120">
								<item>
									<para>
										<emphasis alert="nurse">Do not use in opioid-naïve patients: 90 mg, 120 mg morphine biphasic-release capsules (AVINza); 100 mg, 130 mg, 150 mg, 200 mg morphine extended-release capsules (Kadian), 100 mg, 200 mg morphine control-release tablets (MS Contin); patients considered opioid tolerant are those who are taking at least 60 mg/day oral morphine, 30 mg/day oral oxyCODONE, 8 mg/day oral HYDROmorphone, or an equal dose of another opioid, for 1 wk or longer</emphasis>
									</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x17125">
							<sec_title>PO (extended-release tab [MS Contin, Oramorph SR] or caps [Kadian, AVINza]) in opiate agonist naive patients</sec_title>
							<section type="none" id="sidelem4x17133">
								<label>•</label>
								<sec_title>Adult</sec_title>
								<para>
									<list id="lidelem4x17133">
										<item>
											<label>•</label>
											<para>
												<emphasis style="bold">Adult:</emphasis> 15-30 mg every 12 hr (tabs); 10 mg bid or 20 mg daily (Kadian); or 30 mg daily (AVINza), titrate; AVINza should be adjusted in increments ≤30 mg every 4 days; Kadian should be increased ≤20 mg every 1-2 days, taper gradually; to discontinue, gradually decrease AVINza and Kadian every 2-4 days</para>
										</item>
									</list>
								</para>
							</section>
							<section type="none" id="sidelem4x17140">
								<label>•</label>
								<sec_title>Child (unlabeled)</sec_title>
								<para>
									<list id="lidelem4x17140">
										<item>
											<label>•</label>
											<para>
												<emphasis style="bold">Child (unlabeled):</emphasis> 0.3-0.6 mg/kg every 12 hr (tabs)</para>
										</item>
									</list>
								</para>
							</section>
						</section>
						<section type="none" id="sidelem4x17145">
							<sec_title>IV/SUBCUT route (opiate)</sec_title>
							<section type="none" id="sidelem4x17153">
								<label>•</label>
								<sec_title>Adult<route> IV</route></sec_title>
								<para>
									<list id="lidelem4x17153">
										<item>
											<label>•</label>
											<para> 2-10 mg loading dose, then 0.8-10 mg/hour IV, titrate; maintenance 0.8-80 mg/hour IV</para>
										</item>
									</list>
								</para>
							</section>
							<section type="none" id="sidelem4x17160">
								<label>•</label>
								<sec_title>Children/infants ≥6 mo<route> IV</route></sec_title>
								<para>
									<list id="lidelem4x17160">
										<item>
											<label>•</label>
											<para> initially, 0.04-0.07 mg/kg/hr (range: 0.025-2.6 mg/kg/hr)</para>
										</item>
									</list>
								</para>
							</section>
							<section type="none" id="sidelem4x17167">
								<label>•</label>
								<sec_title>
									<route>Subcut infusion</route>
								</sec_title>
								<para>
									<list id="lidelem4x17167">
										<item>
											<label>•</label>
											<para> 0.025-1.79 mg/kg/hour</para>
										</item>
									</list>
								</para>
							</section>
							<section type="none" id="sidelem4x17174">
								<label>•</label>
								<sec_title>
									<route>IV</route>
								</sec_title>
								<para>
									<list id="lidelem4x17174">
										<item>
											<label>•</label>
											<para>Infants &lt;6 mo/neonate:  0.01 mg/kg/hour initially; infusion rates max 0.015-0.02 mg/kg/hour IV</para>
										</item>
									</list>
								</para>
							</section>
						</section>
					</section>
					<section type="none" id="sidelem4x17179">
						<sec_title>Breakthrough pain in patients receiving long-acting or continuous-infusion morphine</sec_title>
						<section type="none" id="sidelem4x17182">
							<sec_title>PO (regular-release) route</sec_title>
							<section type="none" id="sidelem4x17190">
								<label>•</label>
								<sec_title>Adult/child</sec_title>
								<para>
									<list id="lidelem4x17190">
										<item>
											<label>•</label>
											<para>
												<emphasis style="bold">Adult/child:</emphasis> the dose is usually <emphasis style="sup">1</emphasis>/<emphasis style="inf">4</emphasis> to <emphasis style="sup">1</emphasis>/<emphasis style="inf">3</emphasis> the 8- to 12-hour extended-release dose every 4-6 hr as needed</para>
										</item>
									</list>
								</para>
							</section>
							<section type="none" id="sidelem4x17209">
								<label>•</label>
								<sec_title>Adult/child</sec_title>
								<para>
									<list id="lidelem4x17209">
										<item>
											<label>•</label>
											<para>
												<emphasis style="bold">Adult/child:</emphasis> For PCA, intermittent dosage is usually 25%-30% of the hourly rate IV/SC every 6-15 min as needed; intermittent IV injection dosage is 25%-30% of the hourly rate given IV/SC every 1-2 hr as needed</para>
										</item>
									</list>
								</para>
							</section>
							<para>
								<emphasis style="bold">Available forms: HCL:</emphasis> suppositories 10, 20, 30 mg; syrup 1, 5, 10, 20, 50 mg/ml; tabs 10, 20, 40, 60 mg; <emphasis style="bold">Sulfate:</emphasis> caps ext rel microgranules 10, 15, 30, 60, 100, 200 mg; cap ext rel pellets (Avinza): 30, 45, 60, 75, 90, 120 mg; caps ext rel pellets (Kadian) 10, 20, 30, 40, 50, 60, 70, 80, 100, 130, 150, 200 mg; drops: 20, 50 mg/ml; injection epidural: 0.5, 1, 10, 15 mg/ml; injection (preservative): 0.5, 1, 2, 10, 15, 25, 50 mg/ml; injection (Corpuject/prefilled syringes): 2, 4, 8, 10, 15 mg/ml; oral solution 2 mg/5 ml, 10 mg/ml; suppositories 5, 10, 20, 30 mg; syrup 1, 5, 10 mg/ml; tab 5, 10, 15, 25, 30, 50 mg; tabs ext rel 15, 30, 60, 100, 200 mg</para>
						</section>
					</section>
					<section type="none" id="sidelem4x17220">
						<sec_title>Administer:</sec_title>
						<section type="none" id="sidelem4x17223">
							<sec_title>PO route</sec_title>
							<para>
								<list id="lidelem4x17228">
									<item>
										<label>•</label>
										<para>Give with food or milk to minimize GI effects</para>
									</item>
								</list>
							</para>
							<para>
								<list id="lidelem4x17233">
									<item>
										<label>•</label>
										<para>Begin with immediate-release products and titrate to correct dose and convert to a sustained-release product</para>
									</item>
								</list>
							</para>
							<section type="none" id="sidelem4x17241">
								<label>•</label>
								<sec_title>Immediate-release cap</sec_title>
								<para>
									<list id="lidelem4x17241">
										<item>
											<label>•</label>
											<para>
												<emphasis style="bold">Immediate-release cap:</emphasis> may swallow whole, or cap may be opened and contents sprinkled on cool food (pudding or applesauce) or added to juice; give immediately or delivered via gastric or NG tube by either adding to or following with liquid</para>
										</item>
									</list>
								</para>
							</section>
							<section type="none" id="sidelem4x17248">
								<label>•</label>
								<sec_title>Extended-release and controlled-release tabs</sec_title>
								<para>
									<list id="lidelem4x17248">
										<item>
											<label>•</label>
											<para>
												<emphasis style="bold">Extended-release and controlled-release tabs:</emphasis> swallow whole; do not crush, break, dissolve, or chew</para>
										</item>
									</list>
								</para>
							</section>
							<para>
								<list id="lidelem4x17252">
									<item>
										<label>•</label>
										<para>The use of MS Contin 100-mg or 200-mg tabs should be limited to opioid-tolerant patients requiring oral doses equivalent to ≥200 mg/day; use of the 100-mg or 200-mg tablet is only recommended for patients who have already been titrated to a stable analgesic regimen using lower strengths of MS Contin or other opioids</para>
									</item>
								</list>
							</para>
							<section type="none" id="sidelem4x17260">
								<label>•</label>
								<sec_title>Sustained-release caps</sec_title>
								<para>
									<list id="lidelem4x17260">
										<item>
											<label>•</label>
											<para>
												<emphasis style="bold">Sustained-release caps:</emphasis> swallow; do not chew, crush, or dissolve; caps may be opened and contents sprinkled on applesauce (at room temperature or cooler) immediately before ingestion; do not chew, crush, or dissolve the pellets/beads inside the cap; the applesauce should be swallowed without chewing; if the pellets/beads are chewed, an immediate release of a potentially fatal morphine dose may be delivered; rinse mouth to ensure all the pellets/beads have been swallowed; do not separate applesauce into separate doses; the entire portion should be taken; discard unused portion</para>
										</item>
									</list>
								</para>
							</section>
							<section type="none" id="sidelem4x17267">
								<label>•</label>
								<sec_title>Kadian caps</sec_title>
								<para>
									<list id="lidelem4x17267">
										<item>
											<label>•</label>
											<para>
												<emphasis style="bold">Kadian caps:</emphasis> may be given through a 16-F gastrostomy tube; flush with water, and sprinkle the cap contents into 10 ml of water; using a funnel and a swirling motion, pour the pellets and water into the tube; rinse the beaker with 10 ml of water, and pour the water into the funnel; repeat until no pellets remain in the beaker; </para>
										</item>
									</list>
								</para>
							</section>
							<section type="none" id="sidelem4x17280">
								<label>•</label>
								<sec_title>
									<route>Avoid concurrent administration of AVINza with prescription or nonprescription medications that contain alcohol; consumption of alcohol while taking the extended-release capsules can result in the rapid release and absorption of a potentially fatal dose of morphine</route>
								</sec_title>
							</section>
							<section type="none" id="sidelem4x17286">
								<label>•</label>
								<sec_title>
									<route>AVINza ≥90 mg or Kadian 100 mg, 130 mg, 150 mg, or 200 mg caps are given only to opioid-tolerant patients</route>
								</sec_title>
							</section>
						</section>
						<section type="none" id="sidelem4x17289">
							<sec_title>Oral liquid</sec_title>
							<para>
								<list id="lidelem4x17293">
									<item>
										<label>•</label>
										<para>Check dose before use because many concentrations of oral solution are available; may be diluted in fruit juice; protect from light</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x17299">
						<sec_title>Injectable administration</sec_title>
						<para>
							<list id="lidelem4x17303">
								<item>
									<label>•</label>
									<para>Visually inspect for particulate matter, discoloration before use; do not use if a precipitate is present after shaking; do not use the Duramorph solution if a precipitate is present or if the color is darker than pale yellow</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x17309">
							<sec_title>SUBCUT route</sec_title>
							<para>
								<list id="lidelem4x17314">
									<item>
										<label>•</label>
										<para>Inject, taking care not to inject intradermally</para>
									</item>
								</list>
							</para>
							<section type="none" id="sidelem4x17322">
								<label>•</label>
								<sec_title>Continuous SC infusion</sec_title>
								<para>
									<list id="lidelem4x17322">
										<item>
											<label>•</label>
											<para>
												<emphasis style="bold">Continuous SC infusion:</emphasis> morphine is not approved by the FDA for subcut use; dilute to an appropriate concentration in D<emphasis style="inf">5</emphasis>W; give using a portable, controlled, subcut device; adjust rate based on patient response and tolerance; max subcut rate is 2 ml/hour/site</para>
										</item>
									</list>
								</para>
							</section>
						</section>
						<section type="none" id="sidelem4x17329">
							<sec_title>Intrathecal/epidural route</sec_title>
							<para>
								<list id="lidelem4x17335">
									<item>
										<para>
											<emphasis alert="nurse">Morphine sulfate injection is not interchangeable with morphine sulfate extended-release liposome injection (DepoDur); DepoDur is only for epidural administration</emphasis>
										</para>
									</item>
								</list>
							</para>
							<para>
								<list id="lidelem4x17341">
									<item>
										<para>
											<emphasis alert="nurse">Do not use Infumorph (10 mg/ml or 25 mg/ml) for single-dose neuraxial injection because lower doses can be more reliably administered with Duramorph (0.5 mg/ml or 1 mg/ml</emphasis>
										</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x17346">
							<sec_title>Rectal route</sec_title>
							<para>
								<list id="lidelem4x17350">
									<item>
										<label>•</label>
										<para>Moisten the suppository with water before insertion; if suppository is too soft, chill in the refrigerator for 30 min or run cold water over it before removing the wrapper</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x17356">
							<sec_title>IV route</sec_title>
							<para>
								<list id="lidelem4x17361">
									<item>
										<label>•</label>
										<para>Before use, an opiate antagonist and emergency facilities should be available</para>
									</item>
								</list>
							</para>
							<para>
								<list id="lidelem4x17367">
									<item>
										<para>
											<emphasis alert="nurse">Do not use the highly concentrated morphine injections (i.e., 10-25 mg/ml) for IV, IM, or SC administration of single doses; these injection solutions are intended for use via continuous, controlled microinfusion devices</emphasis>
										</para>
									</item>
								</list>
							</para>
							<section type="none" id="sidelem4x17375">
								<label>•</label>
								<sec_title>Direct IV route</sec_title>
								<para>
									<list id="lidelem4x17375">
										<item>
											<label>•</label>
											<para>
												<emphasis style="bold">Direct IV route:</emphasis> dilute dose with ≥5 ml of sterile water for injection or NS injection; inject 2.5-15 mg directly into a vein or into the tubing of a freely flowing IV solution over 4-5 min; do not give rapidly</para>
										</item>
									</list>
								</para>
							</section>
							<section type="none" id="sidelem4x17382">
								<label>•</label>
								<sec_title>Continuous IV infusion</sec_title>
								<para>
									<list id="lidelem4x17382">
										<item>
											<label>•</label>
											<para>
												<emphasis style="bold">Continuous IV infusion:</emphasis> dilute in 5% dextrose; use a controlled-infusion device; adjust dosage and rate based on patient response</para>
										</item>
									</list>
								</para>
							</section>
							<section type="none" id="sidelem4x17389">
								<label>•</label>
								<sec_title>Patient-controlled analgesia (PCA)</sec_title>
								<para>
									<list id="lidelem4x17389">
										<item>
											<label>•</label>
											<para>
												<emphasis style="bold">Patient-controlled analgesia (PCA):</emphasis> a compatible patient-controlled infusion device must be used; dilute solutions to obtain a concentration of 1 or 10 mg/ml for ease in calculations and programming of PCA pumps; adjust dosage and rate based on patient response; consult the patient-controlled infusion device manual for directions on rate of infusion</para>
										</item>
									</list>
								</para>
							</section>
							<para>
								<emphasis style="bold">Y-site compatibilities:</emphasis> Acetaminophen, aldesleukin, allopurinol, amifostine, amikacin, aminophylline, amiodarone, amsacrine, atenolol, atracurium, aztreonam, bumetanide, calcium chloride, cefamandole, ceFAZolin, cefotaxime, cefoTEtan, cefOXitin, cefTAZidime, ceftizoxime, cefTRIAXone, cefuroxime, cephalothin, chloramphenicol, cisatracurium, cladribine, clindamycin, cyclophosphamide, cytarabine, dexamethasone, digoxin, diltiazem, DOBUTamine, DOPamine, doxycycline, enalaprilat, EPINEPHrine, erythromycin, esmolol, etomidate, famotidine, fentaNYL, filgrastim, fluconazole, fludarabine, foscarnet, gentamicin, granisetron, heparin, hydrocortisone, HYDROmorphone, kanamycin, labetalol, lidocaine, LORazepam, magnesium sulfate, melphalan, meropenem, methotrexate, methyldopate, methylPREDNISolone, metoclopramide, metoprolol, metroNIDAZOLE, midazolam, milrinone, nafcillin, niCARdipine, nitroglycerin, norepinephrine, ondansetron, oxacillin, oxytocin, PACLitaxel, pancuronium, penicillin G potassium, piperacillin, piperacillin/tazobactam, potassium chloride, propranolol, ranitidine, remifentanil, sodium bicarbonate, teniposide, thiotepa, ticarcillin, ticarcillin/clavulanate, tigecycline, tobramycin, vancomycin, vecuronium, vinorelbine, vit B/C, warfarin, zidovudine, zoledronic acid</para>
						</section>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x17399">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x17402">
					<section type="none" id="sidelem4x17403">
						<sec_title>CNS:</sec_title>
						<para> Drowsiness, dizziness, confusion, headache, sedation, euphoria, insomnia, <emphasis style="bold">seizures</emphasis></para>
					</section>
					<section type="none" id="sidelem4x17410">
						<sec_title>CV:</sec_title>
						<para> Palpitations, <emphasis style="bold">bradycardia,</emphasis> change in B/P, <emphasis style="bold">shock, cardiac arrest,</emphasis> chest pain, hypo/hypertension, edema, <emphasis style="bold">tachycardia</emphasis></para>
					</section>
					<section type="none" id="sidelem4x17423">
						<sec_title>EENT:</sec_title>
						<para> Blurred vision, miosis, diplopia</para>
					</section>
					<section type="none" id="sidelem4x17428">
						<sec_title>ENDO:</sec_title>
						<para> Gynecomastia</para>
					</section>
					<section type="none" id="sidelem4x17433">
						<sec_title>GI:</sec_title>
						<para> Nausea, vomiting, anorexia, constipation, cramps, biliary tract pressure</para>
					</section>
					<section type="none" id="sidelem4x17438">
						<sec_title>GU:</sec_title>
						<para> Urinary retention, impotence, gonadal suppression</para>
					</section>
					<section type="none" id="sidelem4x17443">
						<sec_title>HEMA:</sec_title>
						<para> <emphasis style="bold">Thrombocytopenia</emphasis></para>
					</section>
					<section type="none" id="sidelem4x17450">
						<sec_title>INTEG:</sec_title>
						<para> Rash, urticaria, bruising, flushing, diaphoresis, pruritus</para>
					</section>
					<section type="none" id="sidelem4x17455">
						<sec_title>RESP:</sec_title>
						<para> <emphasis style="bold">Respiratory depression, respiratory arrest, apnea</emphasis></para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x17462">
				<sec_title>Pharmacokinetics</sec_title>
				<section type="none" id="sidelem4x17465">
					<section type="none" id="sidelem4x17466">
						<sec_title>PO:</sec_title>
						<para> Onset variable, peak 60 min, duration 4-5 hr</para>
					</section>
					<section type="none" id="sidelem4x17471">
						<sec_title>IM:</sec_title>
						<para> Onset <emphasis style="sup">1</emphasis>/<emphasis style="inf">2</emphasis> hr, peak 30-60 min, duration 4-5 hr</para>
					</section>
					<section type="none" id="sidelem4x17482">
						<sec_title>SUBCUT:</sec_title>
						<para> Onset 15-20 min, peak 50-90 min, duration 4-5 hr</para>
					</section>
					<section type="none" id="sidelem4x17487">
						<sec_title>IV:</sec_title>
						<para> Peak 20 min, duration 4-5 hr</para>
					</section>
					<section type="none" id="sidelem4x17492">
						<sec_title>RECT:</sec_title>
						<para> Peak <emphasis style="sup">1</emphasis>/<emphasis style="inf">2</emphasis>-1 hr, duration 3-7 hr</para>
					</section>
					<section type="none" id="sidelem4x17503">
						<sec_title>Intrathecal:</sec_title>
						<para> Onset rapid, duration ≤24 hr</para>
						<para>Metabolized by liver, crosses placenta; excreted in urine, breast milk; half-life IM 3-4 hr; AVINza 24 hr; Kadian 11-13 hr</para>
					</section>
				</section>
			</section>
			<section type="interactions" id="sidelem4x17510">
				<sec_title>Interactions</sec_title>
				<section type="none" id="sidelem4x17518">
					<label>•</label>
					<sec_title>Unpredictable reaction, avoid use<route> MAOIs</route></sec_title>
				</section>
				<para>
					<emphasis style="bold">Increase:</emphasis> effects with other CNS depressants—alcohol, opiates, sedative/hypnotics, antipsychotics, skeletal muscle relaxants</para>
				<para>
					<emphasis style="bold">Decrease:</emphasis> morphine action—rifampin</para>
				<section type="none" id="sidelem4x17529">
					<section type="none" id="sidelem4x17530">
						<sec_title>Drug/Herb</sec_title>
						<para>
							<emphasis style="bold">Increase:</emphasis> CNS depression—chamomile, hops, kava, St. John’s wort, valerian</para>
					</section>
					<section type="none" id="sidelem4x17537">
						<sec_title>Drug/Lab Test</sec_title>
						<para>
							<emphasis style="bold">Increase:</emphasis> amylase</para>
					</section>
				</section>
			</section>
			<section type="considerations" id="sidelem4x17544">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x17547">
					<section type="none" id="sidelem4x17548">
						<sec_title>Assess:</sec_title>
						<section type="none" id="sidelem4x17556">
							<label>•</label>
							<sec_title>Pain</sec_title>
							<para>
								<list id="lidelem4x17556">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Pain:</emphasis> location, type, character; give dose before pain becomes severe</para>
									</item>
								</list>
							</para>
						</section>
						<para>
							<list id="lidelem4x17560">
								<item>
									<label>•</label>
									<para>Bowel status; constipation common, use stimulant laxative if needed</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x17565">
								<item>
									<label>•</label>
									<para>I&amp;O ratio; check for decreasing output; may indicate urinary retention; monitor serum sodium</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x17570">
								<item>
									<label>•</label>
									<para>B/P, pulse, respirations (character, depth, rate)</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x17575">
								<item>
									<label>•</label>
									<para>CNS changes: dizziness, drowsiness, hallucinations, euphoria, LOC, pupil reaction</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x17583">
							<label>•</label>
							<sec_title>Abrupt discontinuation<route> gradually taper to prevent withdrawal symptoms; decrease by 50% q1-2days; avoid use of narcotic antagonists</route></sec_title>
						</section>
						<section type="none" id="sidelem4x17589">
							<para>
								<list id="lidelem4x17589">
									<item>
										<label>•</label>
										<para>Allergic reactions: rash, urticaria
<bbw>
												<emphasis alert="lifethreat">Accidental exposure:</emphasis> if Duramorph or Infumorph gets on skin, remove contaminated clothing, rinse affected area with water</bbw>
</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x17606">
							<label>•</label>
							<sec_title>Respiratory dysfunction<route> depression, character, rate, rhythm; notify prescriber if respirations are &lt;12/min; accidental overdose has occurred with high-potency oral sols</route></sec_title>
						</section>
						<para>
							<list id="lidelem4x17609">
								<item>
									<label>•</label>
									<para>Gradual withdrawal after long-term use</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x17614">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x17618">
								<item>
									<label>•</label>
									<para>Therapeutic response; decrease in pain intensity</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x17624">
						<sec_title>Teach patient/family:</sec_title>
						<para>
							<list id="lidelem4x17628">
								<item>
									<label>•</label>
									<para>To change position slowly; orthostatic hypotension may occur</para>
								</item>
								<item>
									<label>•</label>
									<para>To report any symptoms of CNS changes, allergic reactions</para>
								</item>
								<item>
									<label>•</label>
									<para>That physical dependency may result from long-term use</para>
								</item>
								<item>
									<label>•</label>
									<para>To avoid use of alcohol, CNS depressants</para>
								</item>
								<item>
									<label>•</label>
									<para>That withdrawal symptoms may occur: nausea, vomiting, cramps, fever, faintness, anorexia</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
		</monograph>
<monograph id="48" status="active">
			<mono_name>moxifloxacin (Rx)</mono_name>
			<info>
				<tradenames>
					<tradename id="tnidelem4x176661">Avelox</tradename>
					<tradename id="tnidelem4x176660">Avelox IV</tradename>
				</tradenames>
				<class type="func"> Antiinfective</class>
				<class type="chem"> Fluoroquinolone</class>
				<class type="preg">Pregnancy category <preg cat="C">C</preg></class>
			</info>
			<section type="actions" id="sidelem4x17676">
				<sec_title>Action:</sec_title>
				<para>Interferes with conversion of intermediate DNA fragments into high-molecular-weight DNA in bacteria; DNA gyrase inhibitor</para>
			</section>
			<section type="uses" id="sidelem4x17681">
				<sec_title>Uses:</sec_title>
				<para>Acute bacterial sinusitis: <emphasis style="italic">Streptococcus pneumoniae, Haemophilus influenzae, Moraxella catarrhalis;</emphasis> acute bacterial exacerbation of chronic bronchitis: <emphasis style="italic">S. pneumoniae, H. influenzae, Haemophilus parainfluenzae, Klebsiella pneumoniae, Staphylococcus aureus, M. catarrhalis;</emphasis> community-acquired pneumonia: <emphasis style="italic">S. pneumoniae, H. influenzae, Mycoplasma pneumoniae, Chlamydia pneumoniae, M. catarrhalis;</emphasis> uncomplicated skin/skin-structure infections: <emphasis style="italic">S. aureus, Streptococcus pyogenes;</emphasis> complicated intraabdominal infections including polymicrobial infections: <emphasis style="italic">E. coli, Bacterioides fragilis, S. anginosus, S. constellatus, Enterococcus faecalis, Proteus mirabilis, Clostridium perfringens, Bacteroides thetaiotaomicron, Peptostreptococcus</emphasis> sp; complicated skin, skin-structure infections caused by methicillin-susceptible: <emphasis style="italic">S. aureus, E. coli, K. pneumoniae, Enterobacter cloacae</emphasis></para>
				<section type="none" id="sidelem4x17703">
					<section type="none" id="sidelem4x17704">
						<sec_title>Unlabeled uses:</sec_title>
						<para> Anthrax treatment/prophylaxis, gastroenteritis, MAC, non-gonococcal urethritis, shigellosis, surgical infection prophylaxis, TB</para>
					</section>
				</section>
			</section>
			<section type="contra" id="sidelem4x17709">
				<sec_title>Contraindications:</sec_title>
				<para>Hypersensitivity to quinolones</para>
				<section type="none" id="sidelem4x17714">
					<section type="none" id="sidelem4x17715">
						<sec_title>Precautions:</sec_title>
						<para> Pregnancy (<preg cat="C">C</preg>), breastfeeding, children, hepatic/cardiac/renal/GI disease, epilepsy, uncorrected hypokalemia, prolonged QT interval; patients receiving class IA, III antidysrhythmics; seizure disorder, pseudomembranous colitis, diabetes mellitus</para>
						<para>
							<bbw>Tendon pain, rupture; tendinitis, myasthenia gravis</bbw>
						</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x17730">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x17733">
					<section type="none" id="sidelem4x17734">
						<sec_title>Acute bacterial sinusitis</sec_title>
						<section type="none" id="sidelem4x17742">
							<label>•</label>
							<sec_title>Adult<route> PO/IV</route></sec_title>
							<para>
								<list id="lidelem4x17742">
									<item>
										<label>•</label>
										<para> 400 mg q24hr × 10 days</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x17746">
						<sec_title>Acute bacterial exacerbation of chronic bronchitis</sec_title>
						<section type="none" id="sidelem4x17754">
							<label>•</label>
							<sec_title>Adult<route> PO/IV</route></sec_title>
							<para>
								<list id="lidelem4x17754">
									<item>
										<label>•</label>
										<para> 400 mg q24hr × 5 days</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x17758">
						<sec_title>Community-acquired pneumonia</sec_title>
						<section type="none" id="sidelem4x17766">
							<label>•</label>
							<sec_title>Adult<route> PO/IV</route></sec_title>
							<para>
								<list id="lidelem4x17766">
									<item>
										<label>•</label>
										<para> 400 mg q24hr × 7-14 days</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x17770">
						<sec_title>Uncomplicated skin/skin-structure infections</sec_title>
						<section type="none" id="sidelem4x17778">
							<label>•</label>
							<sec_title>Adult<route> PO/IV</route></sec_title>
							<para>
								<list id="lidelem4x17778">
									<item>
										<label>•</label>
										<para> 400 mg q24hr × 7 days</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x17782">
						<sec_title>Complicated intraabdominal infections</sec_title>
						<section type="none" id="sidelem4x17790">
							<label>•</label>
							<sec_title>Adult<route> IV</route></sec_title>
							<para>
								<list id="lidelem4x17790">
									<item>
										<label>•</label>
										<para> 400 mg/day × 5-14 days</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x17794">
						<sec_title>Complicated skin, skin-structure infections</sec_title>
						<section type="none" id="sidelem4x17802">
							<label>•</label>
							<sec_title>Adult<route> PO/IV</route></sec_title>
							<para>
								<list id="lidelem4x17802">
									<item>
										<label>•</label>
										<para> 400 mg/day × 7-21 days</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x17806">
						<sec_title>Available forms:</sec_title>
						<para> Tabs 400 mg; inj premix 400 mg/250 ml</para>
					</section>
					<section type="none" id="sidelem4x17811">
						<sec_title>Administer:</sec_title>
						<section type="none" id="sidelem4x17814">
							<sec_title>PO route</sec_title>
							<para>
								<list id="lidelem4x17818">
									<item>
										<label>•</label>
										<para>4 hr before or 8 hr after antacids, zinc, iron, calcium</para>
									</item>
									<item>
										<label>•</label>
										<para>Without regard to food</para>
									</item>
									<item>
										<label>•</label>
										<para>Store at room temperature</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x17834">
							<sec_title>IV route</sec_title>
							<para>
								<list id="lidelem4x17838">
									<item>
										<label>•</label>
										<para>Discontinue primary IV while administering moxifloxacin, give over 60 min</para>
									</item>
									<item>
										<label>•</label>
										<para>Do not give SUBCUT, IM</para>
									</item>
									<item>
										<label>•</label>
										<para>Available as premixed sol; may be diluted at ratios from 1:10 to 10:1; do not refrigerate; give by direct infusion or through Y-type infusion set; do not add other medications to sol or infusion through same IV line at same time</para>
									</item>
									<item>
										<label>•</label>
										<para>Flush line with compatible sol before and after use</para>
									</item>
									<item>
										<label>•</label>
										<para>Do not admix</para>
									</item>
								</list>
							</para>
							<para>
								<emphasis style="bold">Solution compatibilities:</emphasis> 0.9% NaCl, D<emphasis style="inf">5</emphasis>, D<emphasis style="inf">10</emphasis>, LR, sterile water for inj</para>
						</section>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x17874">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x17877">
					<section type="none" id="sidelem4x17878">
						<sec_title>CNS:</sec_title>
						<para> <emphasis style="italic">Headache,</emphasis> dizziness, fatigue, insomnia, depression, <emphasis style="italic">restlessness,</emphasis><emphasis style="bold">seizures,</emphasis> confusion, <emphasis style="bold">increased intracranial pressure,</emphasis> peripheral neuropathy, <emphasis style="bold">pseudotumor cerebri,</emphasis> fever</para>
					</section>
					<section type="none" id="sidelem4x17898">
						<sec_title>CV:</sec_title>
						<para> <emphasis style="bold">Prolonged QT interval, dysrhythmias, torsades de pointes,</emphasis> tachycardia</para>
					</section>
					<section type="none" id="sidelem4x17906">
						<sec_title>EENT:</sec_title>
						<para> Blurred vision, tinnitus, taste changes</para>
					</section>
					<section type="none" id="sidelem4x17911">
						<sec_title>GI:</sec_title>
						<para> <emphasis style="italic">Nausea, diarrhea,</emphasis> increased ALT, AST, flatulence, heartburn, <emphasis style="italic">vomiting,</emphasis> oral candidiasis, dysphagia, <emphasis style="bold">pseudomembranous colitis,</emphasis> abdominal pain, dyspepsia, constipation, gastroenteritis, xerostomia</para>
					</section>
					<section type="none" id="sidelem4x17925">
						<sec_title>GU:</sec_title>
						<para> <emphasis style="bold">Renal failure</emphasis></para>
					</section>
					<section type="none" id="sidelem4x17932">
						<sec_title>INTEG:</sec_title>
						<para> <emphasis style="italic">Rash,</emphasis> pruritus, urticaria, photosensitivity, flushing, fever, chills, injection-site reactions</para>
					</section>
					<section type="none" id="sidelem4x17940">
						<sec_title>MISC:</sec_title>
						<para> Candidiasis vaginitis</para>
					</section>
					<section type="none" id="sidelem4x17945">
						<sec_title>MS:</sec_title>
						<para> Tremor, arthralgia, tendinitis, <emphasis style="bold">tendon rupture,</emphasis> myalgia</para>
					</section>
					<section type="none" id="sidelem4x17953">
						<sec_title>SYST:</sec_title>
						<para> <emphasis style="bold">Anaphylaxis, Stevens-Johnson syndrome, angioedema, toxic epidermal necrolysis</emphasis></para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x17960">
				<sec_title>Pharmacokinetics</sec_title>
				<para>Excreted in urine as active product, metabolites; parent product excreted in urine (20%), feces (25%); terminal half-life PO 12-16 hr, IV 8-15 hr</para>
			</section>
			<section type="interactions" id="sidelem4x17965">
				<sec_title>Interactions</sec_title>
				<para>
					<emphasis alert="lifethreat">Increase: QT prolongation—drugs that interval QT</emphasis>
				</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> moxifloxacin serum levels—probenecid</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> warfarin, cycloSPORINE effect</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> seizure risk—NSAIDs</para>
				<para>
					<bbw>
						<emphasis alert="lifethreat">Increase:</emphasis> tendon rupture—corticosteroids</bbw>
				</para>
				<para>
					<emphasis style="bold">Decrease:</emphasis> moxifloxacin absorption—magnesium antacids, aluminum hydroxide, zinc, iron, sucralfate, calcium, enteral feeding, didanosine</para>
				<section type="none" id="sidelem4x17999">
					<section type="none" id="sidelem4x18000">
						<sec_title>Drug/Lab Test</sec_title>
						<para>
							<emphasis style="bold">Increase:</emphasis> glucose, amylase, lipids, triglycerides, uric acid, LDH</para>
						<para>
							<emphasis style="bold">Decrease:</emphasis> potassium</para>
					</section>
				</section>
			</section>
			<section type="considerations" id="sidelem4x18011">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x18014">
					<section type="none" id="sidelem4x18015">
						<sec_title>Assess:</sec_title>
						<para>
							<list id="lidelem4x18020">
								<item>
									<label>•</label>
									<para>CNS symptoms: headache, dizziness, fatigue, insomnia, depression, seizures</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x18025">
								<item>
									<label>•</label>
									<para>Renal, hepatic studies: BUN, creatinine, AST, ALT, electrolytes</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x18030">
								<item>
									<label>•</label>
									<para>I&amp;O ratio, urine pH &lt;5.5 is ideal</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x18036">
								<item>
									<para>
										<emphasis alert="nurse">Allergic reactions, Stevens-Johnson syndrome, toxic epidermal necrolysis, anaphylaxis: fever, flushing, rash, urticaria, pruritus, sore throat, fatigue, ulcers, other lesions; keep EPINEPHrine, emergency equipment nearby for anaphylaxis</emphasis>
<bbw>Tendon pain, rupture, tendinitis; if tendon becomes inflamed, product should be discontinued; more common in Achilles tendon</bbw>
</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x18051">
								<item>
									<para>
										<emphasis alert="nurse">Cardiac status: prolonged QT or use of products that increase QT prolongation</emphasis>
									</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x18057">
								<item>
									<para>
										<emphasis alert="nurse">Pseudomembranous colitis: assess for diarrhea, abdominal pain, fever, fatigue, anorexia; possible anemia, elevated WBC, low serum albumin; stop product; usually either vancomycin or IV metroNIDAZOLE given</emphasis>
									</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x18062">
								<item>
									<label>•</label>
									<para>Increased fluids to 3 L/day to avoid crystallization in kidneys</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x18067">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x18071">
								<item>
									<label>•</label>
									<para>Therapeutic response: decreased pain, C&amp;S; absence of infection</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x18077">
						<sec_title>Teach patient/family:</sec_title>
						<para>
							<bbw>To notify prescriber of tendon pain, inflammation; stop drug</bbw>
						</para>
						<para>
							<list id="lidelem4x18091">
								<item>
									<label>•</label>
									<para>Not to take any products containing magnesium or calcium (such as antacids), iron, or aluminum with this product or 4 hr before or 8 hr after</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x18096">
								<item>
									<label>•</label>
									<para>That photosensitivity may occur; to avoid sunlight or use sunscreen to prevent burns</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x18101">
								<item>
									<label>•</label>
									<para>To use frequent rinsing of mouth, sugarless candy or gum for dry mouth</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x18106">
								<item>
									<label>•</label>
									<para>To take as prescribed; not to double or miss doses</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x18111">
								<item>
									<label>•</label>
									<para>If dizziness occurs, to ambulate, perform activities with assistance</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x18116">
								<item>
									<label>•</label>
									<para>To complete full course of product therapy</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x18125">
							<label>•</label>
							<sec_title>
								<route>To contact prescriber if abnormal heart rhythm or seizures occur</route>
							</sec_title>
						</section>
					</section>
				</section>
			</section>
		</monograph>
<monograph id="49" status="active">
			<mono_name>moxifloxacin (ophthalmic)</mono_name>
			<info>
				<pronunciation>(mocks-ih-floks′a-sin)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x181331">Vigamox</tradename>
					<tradename id="tnidelem4x181330">Moxeza</tradename>
				</tradenames>
				<class type="func"> Ophthalmic antiinfective</class>
				<class type="chem"> Fluoroquinolone</class>
				<class type="preg">Pregnancy category <preg cat="C">C</preg></class>
			</info>
			<section type="confusion" id="sidelem4x18143">
				<para>
					<confusion>
						<tradename id="tnidelem4x181430">ciprofloxacin</tradename>
						<drug type="generic" refid="idelem4x181430">gatifloxacin/levofloxacin</drug>
					</confusion>
				</para>
			</section>
			<section type="actions" id="sidelem4x18147">
				<sec_title>Action:</sec_title>
				<para>Inhibits DNA gyrase, thereby decreasing bacterial replication</para>
			</section>
			<section type="uses" id="sidelem4x18152">
				<sec_title>Uses:</sec_title>
				<para>Bacterial conjunctivitis (aerobic gram-positive/negative organisms), <emphasis style="italic">Chlamydia trachomatis</emphasis></para>
			</section>
			<section type="contra" id="sidelem4x18159">
				<sec_title>Contraindications:</sec_title>
				<para>Hypersensitivity to this product or fluoroquinolones</para>
				<section type="none" id="sidelem4x18164">
					<section type="none" id="sidelem4x18165">
						<sec_title>Precautions:</sec_title>
						<para> Pregnancy (<preg cat="C">C</preg>), breastfeeding</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x18170">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x18173">
					<section type="none" id="sidelem4x18174">
						<sec_title>Bacterial conjunctivitis</sec_title>
						<section type="none" id="sidelem4x18182">
							<label>•</label>
							<sec_title>Adult/adolescent/child ≥1 yr<route> ophthalmic SOL</route></sec_title>
							<para>
								<list id="lidelem4x18182">
									<item>
										<label>•</label>
										<para> 1 drop in affected eye(s) bid (Moxeza) or tid (Vigamox) × 7 days</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x18186">
						<sec_title>Available forms:</sec_title>
						<para> Ophthalmic solution 0.5%</para>
					</section>
					<section type="none" id="sidelem4x18191">
						<sec_title>Administer:</sec_title>
						<section type="none" id="sidelem4x18194">
							<sec_title>Ophthalmic route</sec_title>
							<para>
								<list id="lidelem4x18198">
									<item>
										<label>•</label>
										<para>Commercially available ophthalmic solutions are not for injection subconjunctivally or into the anterior chamber of the eye</para>
									</item>
									<item>
										<label>•</label>
										<para>Apply topically to the eye, taking care to avoid contamination</para>
									</item>
									<item>
										<label>•</label>
										<para>Do not touch the tip of the dropper to the eye, fingertips, or other surface</para>
									</item>
									<item>
										<label>•</label>
										<para>Apply pressure to lacrimal sac for 1 min after instillation</para>
									</item>
									<item>
										<label>•</label>
										<para>Avoid wearing contact lenses during treatment</para>
									</item>
								</list>
							</para>
						</section>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x18224">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x18227">
					<section type="none" id="sidelem4x18228">
						<sec_title>EENT:</sec_title>
						<para> Hypersensitivity, pruritus, blurred vision, tearing</para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x18233">
				<sec_title>Pharmacokinetics</sec_title>
				<para>Half-life 13 hr</para>
			</section>
			<section type="considerations" id="sidelem4x18238">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x18241">
					<section type="none" id="sidelem4x18242">
						<sec_title>Assess:</sec_title>
						<section type="none" id="sidelem4x18250">
							<label>•</label>
							<sec_title>Allergic reaction</sec_title>
							<para>
								<list id="lidelem4x18250">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Allergic reaction:</emphasis> assess for hypersensitivity, discontinue product</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x18254">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x18258">
								<item>
									<label>•</label>
									<para>Decreased ophthalmic infection</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x18264">
						<sec_title>Teach patient/family:</sec_title>
						<section type="none" id="sidelem4x18267">
							<sec_title>Ophthalmic route</sec_title>
							<para>
								<list id="lidelem4x18271">
									<item>
										<label>•</label>
										<para>To apply topically to the eye, taking care to avoid contamination</para>
									</item>
									<item>
										<label>•</label>
										<para>That product is for ophthalmic use only</para>
									</item>
									<item>
										<label>•</label>
										<para>Not to touch the tip of the dropper to the eye, fingertips, or other surface</para>
									</item>
									<item>
										<label>•</label>
										<para>To apply pressure to lacrimal sac for 1 min after installation</para>
									</item>
									<item>
										<label>•</label>
										<para>To avoid wearing contact lenses during treatment</para>
									</item>
								</list>
							</para>
						</section>
					</section>
				</section>
			</section>
		</monograph>
<monograph id="50" status="active">
			<mono_name>mupirocin (topical, nasal)</mono_name>
			<info>
				<pronunciation>(myoo-pihr′oh-sin)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x183021">Bactroban</tradename>
					<tradename id="tnidelem4x183020">Centany</tradename>
				</tradenames>
				<class type="func"> Topical antiinfective</class>
			</info>
			<section type="actions" id="sidelem4x18308">
				<sec_title>Action:</sec_title>
				<para>Antibacterial activity results from inhibition of protein synthesis; bacteriostatic at low concentration, bactericidal at high concentration</para>
			</section>
			<section type="uses" id="sidelem4x18313">
				<sec_title>Uses:</sec_title>
				<para>Impetigo, skin lesions <emphasis style="italic">(Staphylococcus aureus/Streptococcus pyogenes);</emphasis> nasal: methicillin-resistant <emphasis style="italic">S. aureus</emphasis></para>
			</section>
			<section type="contra" id="sidelem4x18323">
				<sec_title>Contraindications:</sec_title>
				<para>Hypersensitivity to this product</para>
				<section type="none" id="sidelem4x18328">
					<section type="none" id="sidelem4x18329">
						<sec_title>Precautions:</sec_title>
						<para> Open wounds, burns, severe kidney disease, children, pregnancy (B), breastfeeding</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x18334">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x18337">
					<section type="none" id="sidelem4x18338">
						<sec_title>Impetigo</sec_title>
						<section type="none" id="sidelem4x18346">
							<label>•</label>
							<sec_title>Adult/child<route> TOP</route></sec_title>
							<para>
								<list id="lidelem4x18346">
									<item>
										<label>•</label>
										<para> apply to affected area tid × 1-2 wk</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x18351">
						<sec_title>Skin lesions</sec_title>
						<section type="none" id="sidelem4x18359">
							<label>•</label>
							<sec_title>Adult/child<route> TOP</route></sec_title>
							<para>
								<list id="lidelem4x18359">
									<item>
										<label>•</label>
										<para> apply to affected area tid × 10 days</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x18363">
						<sec_title>Methicillin-resistant <emphasis style="bold">
								<emphasis style="italic">S. aureus</emphasis>
							</emphasis> in the nose</sec_title>
						<section type="none" id="sidelem4x18375">
							<label>•</label>
							<sec_title>Adult/child ≥12 yr<route> NASAL</route></sec_title>
							<para>
								<list id="lidelem4x18375">
									<item>
										<label>•</label>
										<para> divide ointment in single use tube in half; use in each nostril bid × 5 days</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x18379">
						<sec_title>Available forms:</sec_title>
						<para> Topical cream, ointment 2%; intranasal ointment 2%</para>
					</section>
					<section type="none" id="sidelem4x18384">
						<sec_title>Administer:</sec_title>
						<section type="none" id="sidelem4x18387">
							<sec_title>Topical route</sec_title>
							<para>
								<list id="lidelem4x18391">
									<item>
										<label>•</label>
										<para>Do not use skin products near the eyes, nose, or mouth</para>
									</item>
									<item>
										<label>•</label>
										<para>Wash hands before and after use; wash affected area and gently pat dry</para>
									</item>
									<item>
										<label>•</label>
										<para>May cover treated areas with gauze dressing</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x18407">
							<sec_title>Cream/ointment</sec_title>
							<para>
								<list id="lidelem4x18412">
									<item>
										<label>•</label>
										<para>Apply a thin film to the cleansed affected area; massage gently into affected areas, do not use near eyes, mouth</para>
									</item>
								</list>
							</para>
							<section type="none" id="sidelem4x18420">
								<label>•</label>
								<sec_title>Nasal</sec_title>
								<para>
									<list id="lidelem4x18420">
										<item>
											<label>•</label>
											<para>
												<emphasis style="bold">Nasal:</emphasis> Close nostrils by squeezing and releasing and gently massaging over 1 min</para>
										</item>
									</list>
								</para>
							</section>
						</section>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x18424">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x18427">
					<section type="none" id="sidelem4x18428">
						<sec_title>CNS:</sec_title>
						<para> Headache</para>
					</section>
					<section type="none" id="sidelem4x18433">
						<sec_title>EENT:</sec_title>
						<para> Burning, pharyngitis, rhinitis (nasal)</para>
					</section>
					<section type="none" id="sidelem4x18438">
						<sec_title>GI:</sec_title>
						<para> Taste change, nausea</para>
					</section>
					<section type="none" id="sidelem4x18443">
						<sec_title>INTEG:</sec_title>
						<para> Burning, rash, pruritus</para>
					</section>
				</section>
			</section>
			<section type="interactions" id="sidelem4x18448">
				<sec_title>Interactions</sec_title>
				<para>
					<emphasis style="bold">Decrease:</emphasis> Effect of other nasal products</para>
			</section>
			<section type="considerations" id="sidelem4x18455">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x18458">
					<section type="none" id="sidelem4x18459">
						<sec_title>Assess:</sec_title>
						<section type="none" id="sidelem4x18467">
							<label>•</label>
							<sec_title>Allergic reaction</sec_title>
							<para>
								<list id="lidelem4x18467">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Allergic reaction:</emphasis> assess for hypersensitivity; product may need to be discontinued</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x18474">
							<label>•</label>
							<sec_title>Infection</sec_title>
							<para>
								<list id="lidelem4x18474">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Infection:</emphasis> assess for number of lesions, severity in impetigo, other skin disorders</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x18478">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x18482">
								<item>
									<label>•</label>
									<para>Decreased lesions in impetigo, other skin disorders</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x18488">
						<sec_title>Teach patient/family:</sec_title>
						<section type="none" id="sidelem4x18491">
							<sec_title>Topical route</sec_title>
							<para>
								<list id="lidelem4x18496">
									<item>
										<label>•</label>
										<para>Not to use skin products near the eyes, nose, or mouth</para>
									</item>
								</list>
							</para>
							<para>
								<list id="lidelem4x18501">
									<item>
										<label>•</label>
										<para>To wash hands before and after use and to wash affected area and gently pat dry</para>
									</item>
								</list>
							</para>
							<section type="none" id="sidelem4x18509">
								<label>•</label>
								<sec_title>Cream/Ointment</sec_title>
								<para>
									<list id="lidelem4x18509">
										<item>
											<label>•</label>
											<para>
												<emphasis style="bold">Cream/Ointment:</emphasis> to apply a thin film to the cleansed affected area; to cover treated areas with gauze dressing if desired</para>
										</item>
									</list>
								</para>
							</section>
							<section type="none" id="sidelem4x18516">
								<label>•</label>
								<sec_title>Nasal</sec_title>
								<para>
									<list id="lidelem4x18516">
										<item>
											<label>•</label>
											<para>
												<emphasis style="bold">Nasal:</emphasis> to close nostrils by squeezing and releasing and gently massaging over 1 min</para>
										</item>
									</list>
								</para>
							</section>
						</section>
					</section>
				</section>
			</section>
		</monograph>
<monograph id="51" status="active">
			<mono_name>mycophenolate mofetil (Rx)</mono_name>
			<info>
				<pronunciation>(mye-koe-phen′oh-late)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x185251">CellCept</tradename>
					<tradename id="tnidelem4x185250">Myfortic</tradename>
				</tradenames>
				<class type="func"> Immunosuppressant</class>
				<class type="preg">Pregnancy category <preg cat="D">D</preg></class>
			</info>
			<section type="actions" id="sidelem4x18531">
				<sec_title>Action:</sec_title>
				<para>Inhibits inflammatory responses that are mediated by the immune system</para>
			</section>
			<section type="uses" id="sidelem4x18536">
				<sec_title>Uses:</sec_title>
				<para>Prophylaxis for organ rejection in allogenic cardiac, hepatic, renal transplants</para>
				<section type="none" id="sidelem4x18541">
					<section type="none" id="sidelem4x18542">
						<sec_title>Unlabeled uses:</sec_title>
						<para> Refractory uveitis, second-line therapy for Churg-Strauss syndrome, diffuse proliferative lupus nephritis (in combination), rheumatoid arthritis, psoriasis, GVHD, kidney disease, myasthenia gravis, atopic dermatitis</para>
					</section>
				</section>
			</section>
			<section type="contra" id="sidelem4x18547">
				<sec_title>Contraindications:</sec_title>
				<para>Hypersensitivity to this product or mycophenolic acid</para>
				<para>
					<bbw>Pregnancy (D)</bbw>
				</para>
				<section type="none" id="sidelem4x18562">
					<section type="none" id="sidelem4x18563">
						<sec_title>Precautions:</sec_title>
						<para> Breastfeeding, lymphomas, neutropenia, renal disease, accidental exposure, anemia</para>
						<para>
							<bbw>Infection, neoplastic disease</bbw>
						</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x18578">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x18581">
					<section type="none" id="sidelem4x18582">
						<sec_title>Renal transplant</sec_title>
						<para/>
					</section>
					<section type="none" id="sidelem4x18586">
						<sec_title>To prevent organ rejection</sec_title>
						<section type="none" id="sidelem4x18594">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x18594">
									<item>
										<label>•</label>
										<para> mycophenolate mofetil 1 g or 720 mg mycophenolate sodium; 1 g or 720 mg bid given to renal transplant patients in combination with corticosteroids, cycloSPORINE</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x18603">
							<label>•</label>
							<sec_title>Child<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x18603">
									<item>
										<label>•</label>
										<para> 600 mg bid (suspension) or  cap 750 mg bid body surface area (BSA) of 1.25 to 1.5 m<emphasis style="sup">2</emphasis> or 1 g bid BSA &gt;1.5 m<emphasis style="sup">2</emphasis></para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x18615">
						<sec_title>Renal dose</sec_title>
						<section type="none" id="sidelem4x18623">
							<label>•</label>
							<sec_title>Adult<route> PO/IV GFR &lt;25 ml/min, max 2 g/day</route></sec_title>
						</section>
					</section>
					<section type="none" id="sidelem4x18626">
						<sec_title>Cardiac transplant To prevent organ rejection</sec_title>
						<section type="none" id="sidelem4x18634">
							<label>•</label>
							<sec_title>Adult<route> PO/IV</route></sec_title>
							<para>
								<list id="lidelem4x18634">
									<item>
										<label>•</label>
										<para> 1.5 g bid,  can be started ≤24 hr after transplant, switch to  when able</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x18644">
						<sec_title>Hepatic transplant</sec_title>
						<para/>
					</section>
					<section type="none" id="sidelem4x18648">
						<sec_title>To prevent organ rejection</sec_title>
						<section type="none" id="sidelem4x18656">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x18656">
									<item>
										<label>•</label>
										<para> 1.5 g bid;  1 g over ≥2 hr</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x18663">
						<sec_title>Refractory acute kidney transplant rejection (unlabeled)</sec_title>
						<section type="none" id="sidelem4x18671">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x18671">
									<item>
										<label>•</label>
										<para> 1.5 g (Mofetil) bid</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x18675">
						<sec_title>Rheumatoid arthritis (unlabeled)</sec_title>
						<section type="none" id="sidelem4x18683">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x18683">
									<item>
										<label>•</label>
										<para> 250 mg-2 g/day (Mofetil)</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x18687">
						<sec_title>GVHD (unlabeled)</sec_title>
						<section type="none" id="sidelem4x18695">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x18695">
									<item>
										<label>•</label>
										<para> 2 g/day (Mofetil) with cycloSPORINE and prednisoLONE</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x18699">
						<sec_title>Diffuse proliferative lupus nephritis (unlabeled)</sec_title>
						<section type="none" id="sidelem4x18707">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x18707">
									<item>
										<label>•</label>
										<para> 1 g/day (Mofetil)</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x18711">
						<sec_title>Uveitis (unlabeled)</sec_title>
						<section type="none" id="sidelem4x18719">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x18719">
									<item>
										<label>•</label>
										<para> 1 g (Mofetil) bid × 6-41 mo</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x18723">
						<sec_title>Atopic dermatitis (unlabeled)</sec_title>
						<section type="none" id="sidelem4x18731">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x18731">
									<item>
										<label>•</label>
										<para> 1 g (Mofetil) bid × 4 wk, then 500 mg bid × 4 wk</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x18738">
							<label>•</label>
							<sec_title>Adolescent/child ≥2 yr<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x18738">
									<item>
										<label>•</label>
										<para> 30-50 mg/kg/day (Mofetil) in 2 divided doses</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x18742">
						<sec_title>Available forms:</sec_title>
						<para> Caps 250 mg; tabs 500 mg; inj (powder) 500 mg/20-ml vial; powder for oral susp 200 mg/ml; ext rel tab (Myfortic) 180, 360 mg</para>
					</section>
					<section type="none" id="sidelem4x18747">
						<sec_title>Administer:</sec_title>
						<para>
							<list id="lidelem4x18751">
								<item>
									<label>•</label>
									<para>May be given in combination with corticosteroids, cycloSPORINE</para>
								</item>
								<item>
									<label>•</label>
									<para>Del rel tab, cap, oral susp, tab are not interchangeable</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x18762">
							<sec_title>PO route</sec_title>
							<para>
								<list id="lidelem4x18767">
									<item>
										<label>•</label>
										<para>Do not break, crush, or chew tabs; do not open caps</para>
									</item>
								</list>
							</para>
							<para>
								<list id="lidelem4x18772">
									<item>
										<label>•</label>
										<para>Give at same time each day</para>
									</item>
								</list>
							</para>
							<section type="none" id="sidelem4x18780">
								<label>•</label>
								<sec_title>
									<route>Avoid inhalation or direct contact with skin, mucous membranes; teratogenic in animals</route>
								</sec_title>
							</section>
							<section type="none" id="sidelem4x18786">
								<label>•</label>
								<sec_title>Oral susp</sec_title>
								<para>
									<list id="lidelem4x18786">
										<item>
											<label>•</label>
											<para>
												<emphasis style="bold">Oral susp:</emphasis> tap closed bottle several times to loosen powder; use 94 ml of water in graduated cylinder; add <emphasis style="sup">1</emphasis>/<emphasis style="inf">2</emphasis> total amount of water for constitution and shake the closed bottle; add remaining water and shake again; remove child-resistant cap; push adapter into neck of bottle; close tightly</para>
										</item>
									</list>
								</para>
							</section>
							<para>
								<list id="lidelem4x18796">
									<item>
										<label>•</label>
										<para>Give alone for better absorption</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x18801">
							<sec_title>Intermittent IV INFUSION route</sec_title>
							<para>
								<list id="lidelem4x18805">
									<item>
										<label>•</label>
										<para>Reconstitute each vial with 14 ml D<emphasis style="inf">5</emphasis>W; shake gently; further dilute to 6 mg/ml; dilute 1 g/140 ml D<emphasis style="inf">5</emphasis>W, 1.5 g/210 ml D<emphasis style="inf">5</emphasis>W; give by slow IV infusion ≥2 hr; never give by bolus or rapid IV inj</para>
									</item>
									<item>
										<label>•</label>
										<para>Do not give with other medications or sol</para>
									</item>
								</list>
							</para>
							<para>
								<emphasis style="bold">Y-site compatibilities:</emphasis> Alemtuzumab, alfentanil, amikacin, anidulafungin, argatroban, bivalirudin, caspofungin, cefepime, DAPTOmycin, DOPamine, norepinephrine, octreotide, oxytocin, tacrolimus, tigecycline, tirofiban, vancomycin, zoledronic acid</para>
						</section>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x18829">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x18832">
					<section type="none" id="sidelem4x18833">
						<sec_title>CNS:</sec_title>
						<para> <emphasis style="italic">Tremor, dizziness, insomnia, headache, fever,</emphasis> anxiety, pain, <emphasis style="bold">progressive multifocal leukoencephalopathy,</emphasis> asthenia, paresthesia</para>
					</section>
					<section type="none" id="sidelem4x18844">
						<sec_title>CV:</sec_title>
						<para> <emphasis style="italic">Hypertension, chest pain,</emphasis> hypotension, edema</para>
					</section>
					<section type="none" id="sidelem4x18852">
						<sec_title>GI:</sec_title>
						<para> <emphasis style="italic">Diarrhea, constipation, nausea, vomiting,</emphasis> stomatitis, <emphasis style="bold">GI bleeding,</emphasis> abdominal pain, anorexia, dyspepsia</para>
					</section>
					<section type="none" id="sidelem4x18863">
						<sec_title>GU:</sec_title>
						<para> <emphasis style="italic">UTI, hematuria,</emphasis><emphasis style="bold">renal tubular necrosis, polyomavirus-associated nephropathy</emphasis></para>
					</section>
					<section type="none" id="sidelem4x18872">
						<sec_title>HEMA:</sec_title>
						<para> <emphasis style="bold">Leukopenia, thrombocytopenia, anemia, pancytopenia, pure red cell aplasia,</emphasis> neutropenia</para>
					</section>
					<section type="none" id="sidelem4x18880">
						<sec_title>INTEG:</sec_title>
						<para> <emphasis style="italic">Rash</emphasis></para>
					</section>
					<section type="none" id="sidelem4x18887">
						<sec_title>META:</sec_title>
						<para> <emphasis style="italic">Peripheral edema, hypercholesterolemia, hypophosphatemia, edema, hyperkalemia, hypokalemia, hyperglycemia,</emphasis> hypocalcemia, hypomagnesemia</para>
					</section>
					<section type="none" id="sidelem4x18895">
						<sec_title>MS:</sec_title>
						<para> Arthralgia, muscle wasting, back pain, weakness</para>
					</section>
					<section type="none" id="sidelem4x18901">
						<sec_title>RESP:</sec_title>
						<para> <emphasis style="italic">Dyspnea, respiratory infection, increased cough, pharyngitis, bronchitis, pneumonia,</emphasis><emphasis style="bold">plural effusion, pulmonary fibrosis</emphasis></para>
					</section>
					<section type="none" id="sidelem4x18910">
						<sec_title>SYST:</sec_title>
						<para> <emphasis style="bold">Lymphoma,</emphasis><emphasis style="italic">nonmelanoma skin carcinoma,</emphasis><emphasis style="bold">sepsis</emphasis></para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x18921">
				<sec_title>Pharmacokinetics</sec_title>
				<para>Rapidly and completely absorbed; metabolized to active metabolite (MPA); excreted in urine, feces; protein binding (MPA) 97%; half-life (MPA) 17.9 hr</para>
			</section>
			<section type="interactions" id="sidelem4x18926">
				<sec_title>Interactions</sec_title>
				<para>
					<emphasis style="bold">Increase:</emphasis> bone marrow suppression—azaTHIOprine<list id="lidelem4x18933">
						<item>
							<label>•</label>
							<para>Increased bleeding risk: anticoagulants, NSAIDs, thrombolytics, salicylates</para>
						</item>
					</list></para>
				<para>
					<emphasis alert="lifethreat">Increase: toxicity—acyclovir, ganciclovir, valacyclovir</emphasis>
				</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> effects of phenytoin, theophylline</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> mycophenolate levels—probenecid, immunosuppressives, salicylates</para>
				<para>
					<emphasis style="bold">Decrease:</emphasis> mycophenolate levels—antacids (magnesium, aluminum), cholestyramine, cycloSPORINE, rifamycin</para>
				<para>
					<emphasis style="bold">Decrease:</emphasis> protein binding of phenytoin, theophylline</para>
				<para>
					<emphasis style="bold">Decrease:</emphasis> effect of live attenuated vaccines, oral contraceptives</para>
				<section type="none" id="sidelem4x18962">
					<section type="none" id="sidelem4x18963">
						<sec_title>Drug/Herb</sec_title>
						<para>Interference with immunosuppression: astragalus, echinacea, melatonin</para>
					</section>
					<section type="none" id="sidelem4x18968">
						<sec_title>Drug/Food</sec_title>
						<para>
							<emphasis style="bold">Decrease:</emphasis> absorption if taken with food</para>
					</section>
					<section type="none" id="sidelem4x18975">
						<sec_title>Drug/Lab Test</sec_title>
						<para>
							<emphasis style="bold">Increase:</emphasis> serum creatitine, BUN<list id="lidelem4x18982">
								<item>
									<label>•</label>
									<para>Abnormal LFTs</para>
								</item>
							</list></para>
					</section>
				</section>
			</section>
			<section type="considerations" id="sidelem4x18988">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x18991">
					<section type="none" id="sidelem4x18992">
						<sec_title>Assess:</sec_title>
						<para>
							<list id="lidelem4x18998">
								<item>
									<para>
										<emphasis alert="nurse">Progressive multifocal leukoencephalopathy, may be fatal; ataxia, confusion, apathy, hemiparesis, visual problems, weakness; side effects should be reported to FDA</emphasis>
									</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x19003">
								<item>
									<label>•</label>
									<para>Blood studies: CBC during treatment monthly</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x19008">
								<item>
									<label>•</label>
									<para>Hepatic studies: alk phos, AST, ALT, bilirubin</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x19013">
								<item>
									<label>•</label>
									<para>Renal studies: BUN, CCr, electrolytes
<bbw>Pregnancy test within 1 wk before initiation of treatment; confirm negative pregnancy test</bbw>
</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x19027">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x19031">
								<item>
									<label>•</label>
									<para>Therapeutic response: absence of graft rejection</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x19037">
						<sec_title>Teach patient/family:</sec_title>
						<para>
							<list id="lidelem4x19041">
								<item>
									<label>•</label>
									<para>To report fever, rash, severe diarrhea, chills, sore throat, fatigue because serious infections may occur</para>
								</item>
								<item>
									<label>•</label>
									<para>To reduce risk of infection by avoiding crowds</para>
								</item>
								<item>
									<label>•</label>
									<para>About the need for repeated lab tests
<bbw>To use 2 forms of contraception before, during, and for 6 wk after therapy</bbw>
</para>
								</item>
								<item>
									<label>•</label>
									<para>To take at same time each day</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
		</monograph>
</alpha>
</drug_guide>